

Cochrane Database of Systematic Reviews

Chinese herbal medicines for treating osteoporosis (Review)

Liu Y, Liu JP, Xia Y

Liu Y, Liu JP, Xia Y. Chinese herbal medicines for treating osteoporosis. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD005467. DOI: 10.1002/14651858.CD005467.pub2.

www.cochranelibrary.com



TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	11
OBJECTIVES	12
METHODS	12
RESULTS	14
Figure 1	15
Figure 2	17
Figure 3	18
DISCUSSION	33
AUTHORS' CONCLUSIONS	34
ACKNOWLEDGEMENTS	34
REFERENCES	35
CHARACTERISTICS OF STUDIES	46
DATA AND ANALYSES	149
Analysis 1.1. Comparison 1 Chinese herbal medicines versus placebo, Outcome 1 New fractures.	150
Analysis 1.2. Comparison 1 Chinese herbal medicines versus placebo, Outcome 2 Bone mineral density (BMD).	151
Analysis 1.3. Comparison 1 Chinese herbal medicines versus placebo, Outcome 3 Oestradiol (E2).	151
Analysis 1.4. Comparison 1 Chinese herbal medicines versus placebo, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility.	151
Analysis 2.1. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 1 Bone mineral density (BMD)	153
Analysis 2.2. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 2 Oestradiol (E2).	154
Analysis 2.3. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 3 Bone Gla protein (BGP).	155
Analysis 3.1. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 1 New fractures.	171
Analysis 3.2. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 2 Bone mineral density (BMD)	172
Analysis 3.3. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 3 T score in BMD measurement	183
Analysis 3.4. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility.	184
Analysis 3.5. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 5 Oestradiol (E2).	186
Analysis 3.6. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 6 Serum calcium (Ca).	190
Analysis 3.7. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 7 Phosphorus (P)	193
Analysis 3.8. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 8 Alkaline phosphatase (ALP)	195
Analysis 3.9. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 9 Bone Gla protein (BGP)	200
Analysis 3.10. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 10 Interleukin-6 (IL-6).	201
Analysis 3.11. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 11 Parathyroid hormone (PTH)	202
Analysis 3.12. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 12 Computed tomography (CT)	204
Analysis 4.1. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 1 New fractures.	217
Analysis 4.2. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 2 Bone mineral density (BMD).	218
Analysis 4.3. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 3 T score in BMD measurement.	229
Analysis 4.4. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 4 Quality of life.	230
Analysis 4.5. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 5 Symptoms including pain, muscle fatigue and limited mobility.	230
Analysis 4.6. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 6 Oestradiol (E2).	231
Analysis 4.7. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 7 Serum calcium (Ca).	232
Analysis 4.8. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 8 Phosphorus	234
(P).	_01

Chinese herbal medicines for treating osteoporosis (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Analysis 4.9. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 9 Alkaline phosphatase (ALP).	235
Analysis 4.10. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 10 Bone Gla protein (BGP).	237
Analysis 4.11. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 11 Interleukin-6 (IL-6).	238
ADDITIONAL TABLES	239
APPENDICES	251
HISTORY	262
CONTRIBUTIONS OF AUTHORS	262
DECLARATIONS OF INTEREST	263
SOURCES OF SUPPORT	263
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	263
INDEX TERMS	263



[Intervention Review]

Chinese herbal medicines for treating osteoporosis

Yunxia Liu¹, Jian Ping Liu², Yun Xia³

¹Department of Epidemiology and Biostatistics, School of Public Health, Shandong University, Jinan, China. ²Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China. ³Science of Education, Beijing University of Chinese Medicine Subsidiary Dongfang Hospital, Beijing, China

Contact: Yunxia Liu, Department of Epidemiology and Biostatistics, School of Public Health, Shandong University, 44 Wenhua Xilu Road, Jinan, 250012, China. lyx7677@hotmail.com, yunxialiu@163.com.

Editorial group: Cochrane Musculoskeletal Group. **Publication status and date:** New, published in Issue 3, 2014.

Citation: Liu Y, Liu JP, Xia Y. Chinese herbal medicines for treating osteoporosis. *Cochrane Database of Systematic Reviews* 2014, Issue 3. Art. No.: CD005467. DOI: 10.1002/14651858.CD005467.pub2.

Copyright ${\ensuremath{\mathbb C}}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Chinese herbal medicines have been used for a long time to treat osteoporosis. The evidence of their benefits and harms needs to be systematically reviewed.

Objectives

To assess the beneficial and harmful effects of Chinese herbal medicines as a general experimental intervention for treating primary osteoporosis by comparing herbal treatments with placebo, no intervention and conventional medicine.

Search methods

We searched the following electronic databases to January 2013: the Specialised Register of the Cochrane Complementary Medicine Field, CENTRAL, MEDLINE, EMBASE, LILACS, JICST-E, AMED, Chinese Biomedical Database and CINAHL.

Selection criteria

Randomised controlled trials of Chinese herbal medicines compared with placebo, no intervention or conventional medicine were included.

Data collection and analysis

Two authors extracted data and assessed risk of bias independently. Disagreement was resolved by discussion.

Main results

One hundred and eight randomised trials involving 10,655 participants were included. Ninety-nine different Chinese herbal medicines were tested and compared with placebo (three trials), no intervention (five trials) or conventional medicine (61 trials), or Chinese herbal medicines plus western medicine were compared with western medicine (47 trials). The risk of bias across all studies was unclear for most domains primarily due to inadequate reporting of study design. Although we rated the risk of selective reporting for all studies as unclear, only a few studies contributed numerical data to the key outcomes.

Seven trials reported fracture incidence, but they were small in sample size, suffered from various biases and tested different Chinese herbal medicines. These trials compared Kanggusong capsules versus placebo, Kanggusong granule versus Caltrate or ipriflavone plus Caltrate, Yigu capsule plus calcium versus placebo plus calcium, Xianlinggubao capsule plus Caltrate versus placebo plus Caltrate, Bushen Zhuanggu granules plus Caltrate versus placebo granules plus Caltrate, Kanggusong soup plus Caltrate versus Caltrate, Zhuangguqiangjin tablets and Shujinbogu tablets plus calcitonin ampoule versus calcitonin ampoule. The results were inconsistent.



One trial showed that Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol had a better effect on quality of life score (scale 0 to 100, higher is better) than calcium carbonate tablets and alfacalcidol (mean difference (MD) 5.30; 95% confidence interval (CI) 3.67 to 6.93).

Compared with placebo in three separate trials, Chinese herbal medicines (Migu decoction, Bushen Yigu soft extract, Kanggusong capsules) showed a statistically significant increase in bone mineral density (BMD) (e.g. Kanggusong capsules, MD 0.06 g/cm³; 95% CI 0.02 to 0.10). Compared with no intervention in five trials, only two showed that Chinese herbal medicines had a statistically significant effect on increase in BMD (e.g. Shigu yin, MD 0.08 g/cm³; 95% CI 0.03 to 0.13). Compared with conventional medicine in 61 trials, 23 showed that Chinese herbal medicines had a statistically significant effect on increase in BMD. In 48 trials evaluating Chinese herbal medicines plus western medication against western medication, 26 showed better effects of the combination therapy on increase in BMD.

No trial reported death or serious adverse events of Chinese herbal medicines, while some trials reported minor adverse effects such as nausea, diarrhoea, etc.

Authors' conclusions

Current findings suggest that the beneficial effect of Chinese herbal medicines in improving BMD is still uncertain and more rigorous studies are warranted.

PLAIN LANGUAGE SUMMARY

Chinese herbal medicines for osteoporosis

Review question

We conducted a review of the effects of Chinese herbal medicines for people with primary osteoporosis. We found 108 studies with 10,655 people.

Background: what is primary osteoporosis and what are Chinese herbal medicines?

Bone is a living, growing part of your body. Throughout your lifetime, new bone cells grow and old bone cells break down to make room for the new, stronger bone. When you have osteoporosis, the old bone breaks down faster than the new bone can replace it. As this happens, the bones lose minerals (such as calcium). This makes bones weaker and more likely to break even after a minor injury, like a little bump or fall.

Chinese herbal medicines are products made from any part of medicinal plants (leaves, stems, buds, flowers or roots). Sometimes nonplant based components (for example insects, deer horn, snake, various shells and powdered fossil) are included. These can be used in the form of raw plant materials, or water or alcohol extracts of raw plant materials. Herbs can also be taken by mouth as capsules, tablets or liquids, or as injections.

Chinese herbal medicines are widely used in China for primary osteoporosis but their benefits and harms have not been appraised in order to inform clinical practice.

Study characteristics

After searching for all relevant studies up to January 2013, we found 108 studies with 10,655 people with osteoporosis. Ninety-nine different Chinese herbal medicines were tested and compared with placebo (three trials), no intervention (five trials) or conventional medicine (61 trials), or Chinese herbal medicines plus conventional medicine were compared with conventional medicine (47 trials). The average length of treatment was 5.7 months (ranging from 3 to 12 months).

Key results: what happens to people with osteoporosis who take Chinese herbal medicines?

New fractures

We are uncertain whether Chinese herbal medicines reduce the chance of having a new bone fracture. Seven trials evaluated the incidence of fractures. However, these trials were small and had flaws in their methods.

Quality of life

People who took Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol rated their quality of life to be 5.30 points better on a scale of 0 to 100 after three months compared to people who did not take the herbal medicine.

People who took Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol rated their quality of life to be 56.05 on a scale of 0 to 100.

People who took calcium carbonate tablets and alfacalcidol rated their quality of life to be 50.75 on a scale of 0 to 100.



Serious side effects or deaths

No serious side effects or deaths occurred in the trials.

We often do not have precise information about side effects and complications. This is particularly true for rare but serious side effects. Possible side effects may include a mild stomach ache or diarrhoea.

Bone mineral density (the amount and type of minerals in the bone)

We found studies that compared Chinese herbal medicines with placebo (fake treatment), with no treatment and with conventional medicine. We also found studies that compared Chinese herbal medicines plus conventional medication with just conventional medication.

Compared to placebo (fake treatment), three studies showed that bone mineral density increased slightly with Chinese herbal medicines.

Compared to no treatment or conventional medicine, some studies showed an increase in bone mineral density with Chinese herbal medicines while others did not.

When Chinese herbal medicines plus conventional medication was compared with just conventional medicine, some studies showed an increase in bone mineral density while others did not.

Quality of the evidence

In people with osteoporosis:

- Chinese herbal medicines may improve bone mineral density and quality of life slightly. Further research is likely to change this estimate of how Chinese herbal medicines affect bone mineral density and quality of life.

- We are uncertain whether Chinese herbal medicines reduce the chance of having a new bone fracture.

- No trial reported death or serious side effects.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. Chinese herbal medicines versus placebo for osteoporosis

Chinese herbal medicines versus placebo for osteoporosis

Patient or population: patients with osteoporosis

Settings: inpatients

Intervention: Chinese herbal medicine versus placebo

Outcomes	Illustrative compa	arative risks* (95% CI)	Relative effect (95% CI)	No of partici- pants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk		(studies)	(GRADE)	(95% CI)
	Control (place- bo)	Chinese herbal medi- cine				
New fractures (Kanggusong capsule ver- sus placebo)	185 per 1000	0 per 1000 (0 to 157)	RR 0.05 (0 to 0.85)	104 (1 study)	⊕000 very low ^{1,2,3}	We are uncertain about the esti- mate ³
Follow-up: 12 months						
Quality of life	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Death	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Serious adverse events	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
BMD of lumbar spine	The mean BMD in the control	The mean BMD in the		140 (1. studu)		MD 0.06 g/cm ³ (0.02 to 0.10)
(Kanggusong capsule ver- sus placebo)	groups was 0.82 g/cm ³	intervention groups was 0.06 higher (0.02 to 0.1 higher)		(1 study)	low ^{1,4}	Absolute risk difference 2% (1% to 3%)
Follow-up: 12 months Scale from: 0 to 4						Relative per cent change 7% (2% to 12%)
						NNT 5 (3 to 13)
BMD of ulna	The mean BMD in the control	The mean BMD in the intervention groups		59 (1 study)	⊕⊕⊝⊙ low ^{1,4}	MD 0.06 g/cm ³ (0.02 to 0.10)

Chinese herbal medicin	(Bushen Yigu soft extract versus placebo) Follow-up: 3 months Scale from: 0 to 4	groups was 0.59 g/cm ³	was 0.06 higher (0.02 to 0.1 higher)				Absolute risk difference 2% (1% to 3%) Relative per cent change 10% (3% to 17%) NNT 3 (2 to 8)
Chinese herbal medicines for treating osteoporosis (Review)	BMD of radius (Bushen Yigu soft extract versus placebo) Follow-up: 3 months Scale from: 0 to 4	The mean BMD in the control groups was 0.58 g/cm ³	The mean BMD in the intervention groups was 0.06 higher (0.03 to 0.09 higher)		59 (1 study)	⊕⊕©© low ^{1,4}	MD 0.06 g/cm ³ (0.03 to 0.09) Absolute risk difference 2% (1% to 2%) Relative per cent change 10% (5% to 16%) NNT 3 (2 to 6)
	based on the assumed risk in BMD: bone mineral density; GRADE Working Group grade High quality: Further resear Moderate quality: Further re Low quality: Further resear Very low quality: We are ve ¹ No information on adequate ² The total population size is le ³ Seven trials reported on the	CI: confidence intervates of evidence rch is very unlikely to have the search is likely to have the search is likely to have the sequence generation the sequence generation as than 300 (a threshold	al; MD: mean difference; N change our confidence in t ve an important impact or e an important impact on e estimate. and not all the outcomes old rule-of-thumb value).	NT: number needed the estimate of effect n our confidence in t our confidence in th that were of interest	to treat; RR: risk ra t. he estimate of effec e estimate of effec in this review were	ct and may change t t and is likely to cha reported.	
	A seven trials reported on the and the results were not consi ⁴ The total population size is le Summary of findings 2. (Chinese herbal medicines v Patient or population: pati Settings: inpatients and out Intervention: Chinese herbal	istent. ess than 400 (a thresh Chinese herbal mea versus no interventio ents with osteoporosi tpatients	old rule-of-thumb value). dicines versus no inter on for osteoporosis				
σ	Outcomes	Illustrative compara	tive risks* (95% CI)	Relative effect (95% CI)	No of partici- pants (studies)	Quality of the evidence (GRADE)	Comments



	Assumed risk	Corresponding risk				
	Control (no in- tervention)	Chinese herbal medi- cine				
New fractures	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Quality of life	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Death	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Serious adverse events	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
BMD of lumbar spine	The mean BMD	The mean BMD in the in-		61		MD 0.07 g/cm ³ (-0.06 to 0.20)
(Bushen Shengsui prin- ciple versus no interven- tion)	in the control groups was 0.82 g/cm ³	tervention groups was 0.07 higher (0.06 lower to 0.2 high-		(1 study)	low ^{1,2}	Absolute risk difference 2% (-2% to 5%)
Follow-up: 6 months Scale from: 0 to 4		er)				Relative per cent change 9% (-7% to 24%)
						Not statistically significant
BMD of femoral neck	The mean BMD	The mean BMD in the in-		80	⊕⊕ ⊝⊝	MD 0.08 g/cm ³ (0.03 to 0.13)
(Shigu yin versus no in- tervention)	in the control groups was 0.60 g/cm ³	tervention groups was 0.08 higher (0.03 to 0.13 higher)		(1 study)	low ^{1,2}	Absolute risk difference 2% (1% to 3%)
Follow-up: 6 months Scale from: 0 to 4		(0.05 to 0.15 higher)				Relative per cent change 13% (5% to 22%)
						NNT 4 (3 to 8)
BMD of femoral neck	The mean BMD	The mean in the inter-		34 (1. studu)	$\oplus \oplus \odot \odot$	MD 0.02 g/cm ³ (-0.06 to 0.09)
(Shengu capsule versus no intervention) Follow-up: 6 months	in the control groups was 0.62 g/cm ³	vention groups was 0.02 higher (0.06 lower to 0.09 high-		(1 study)	low ^{1,2}	Absolute risk difference 1% (-2% to 2%)
Scale from: 0 to 4		er)				Relative per cent change 3% (-10% to 15%)
						Not statistically significant

6

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **BMD:** bone mineral density; **CI:** confidence interval; **MD:** mean difference; **NNT:** number needed to treat; **RR:** risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹No information on adequate sequence generation and not all the outcomes that were of interest in this review were reported. ²The total population size is less than 400 (a threshold rule-of-thumb value).

Summary of findings 3. Chinese herbal medicines versus western medicine for osteoporosis

Chinese herbal medicines versus western medicine for osteoporosis

Patient or population: patients with osteoporosis Settings: outpatients and inpatients

Intervention: Chinese herbal medicine versus western medicine

Outcomes	Illustrative compa	arative risks* (95% CI)	Relative effect (95% CI)	No of partici- pants	Quality of the evidence	Comments
	Assumed risk	Corresponding risk		(studies)	(GRADE)	
	Control (west- ern medicine)	Chinese herbal medi- cine				
New fractures (Kanggusong granule versus calcium and vitamin D) Follow-up: 9 months	0 per 40	0 per 31	Not estimable	71 (1 study)	⊕⊕⊙⊙ very low ^{1,2}	We are uncertain about the esti- mate ³
Quality of life	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Death	See comment See comment N		Not estimable	0 (0)	See comment	No trial reported this outcome
Serious adverse events	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome

7

ochrane ibrary

Trusted evide Informed deci Better health.

BMD of lumbar spine (Bushenjianpi Zhuangguyin	The mean BMD in the control	The mean BMD in the intervention groups	100 (1 study)	⊕⊕⊝⊝ low ^{1,2}	MD 0.16 g/cm ³ (0.10 to 0.22)
versus Caltrate and calci- tonin)	groups was 0.79 g/cm ³	was 0.16 higher			Absolute risk difference 4% (3% to 6%)
Follow-up: 12 weeks Scale from: 0 to 4		(0.1 to 0.22 higher)			Relative per cent change 20% (13% to 18%)
					NNT 3 (2 to 4)
BMD of lumbar spine	The mean BMD	The mean BMD in the	71		MD 0.05 g/cm ³ (0.03 to 0.07)
(Liuwei Dihuang pills versus calcium and vitamin D) Follow-up: 6 months	in the control groups was 0.89 g/cm ³	intervention groups was 0.05 higher	(1 study)	low ^{1,2}	Absolute risk difference 1% (1% to 2%)
Follow-up: 6 months Scale from: 0 to 4		(0.03 to 0.07 higher)			Relative per cent change 6% (3% to 8%)
					NNT 3 (2 to 5)
BMD of femoral neck	The mean BMD in the control	The mean BMD in the	71 (1 atual)		MD 0.01 g/cm ³ (-0.03 to 0.05)
(Kanggusong granule versus calcium and vitamin D)	groups was 0.71 w	intervention groups was 0.01 higher	(1 study)	low ^{1,2}	Absolute risk difference 0.25% (-1% to 1%)
Follow-up: 9 months Scale from: 0 to 4		(0.03 lower to 0.05 higher)			Relative per cent change 1% (-4% to 7%)
					Not statistically significant
based on the assumed risk in th	ne comparison group confidence interval;	and the relative effect of	ies) is provided in footnotes. The co the intervention (and its 95% CI). number needed to treat; RR: risk ra		(and its 95% confidence interval) is
High quality: Further research Moderate quality: Further rese	is very unlikely to cha earch is likely to have is very likely to have a	an important impact on ou an important impact on ou	estimate of effect. Ir confidence in the estimate of effe confidence in the estimate of effec		
lo information on adequate ser		Id not all the outcomes tha I rule-of-thumb value).	t were of interest in this review were	e reported.	

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cochrane Database of Systematic Reviews

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Summary of findings 4. Chinese herbal medicines plus western medicine versus western medicine for osteoporosis

Chinese herbal medicines plus western medicine versus western medicine for osteoporosis

Patient or population: patients with osteoporosis

Settings: inpatients

Intervention: Chinese herbal medicine plus western medicine versus western medicine

Outcomes	Illustrative com CI)	parative risks* (95%	Relative effect (95% CI)	No of partici- pants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk		(otudios)	(010.02)	
	Control (west- Chinese herbal ern medicine) medicine plus western medicine					
New fractures	114 per 1000	0 per 1000	RR 0.06	140 (1. studu)	⊕⊕⊝⊝ 	We are uncertain
(Yigu capsule plus calcium versus placebo plus calcium)		(0 to 114)	(0 to 1)	(1 study)	very low ^{1,2}	about the estimate ³
Follow-up: 6 months						
New fractures	17 per 1000	0 per 1000	RR 0.33	120	⊕⊕⊝© 	We are uncertain
(Xianlinggubao capsule (low-dose) plus calci- um and vitamin D versus placebo plus calci- um and vitamin D)		(0 to 134)	(0.01 to 8.02)	(1 study)	very low ^{1,2}	about the estimate ³
Follow-up: 12 months						
New fractures	104 per 1000	46 per 1000	RR 0.44	155	000	We are uncertain
(Bushen Zhuanggu granules plus calcium and vitamin D versus placebo granules plus calci- um and vitamin D)		(14 to 149)	(0.13 to 1.43)	(1 study)	very low ^{1,2}	about the estimate ³
Follow-up: 5 years						
New fractures	33 per 1000	0 per 1000	RR 0.22	75 (1. study)	⊕⊕⊝⊝ 	We are uncertain
(Kanggusong soup plus calcium and vitamin D versus calcium and vitamin D)		(0 to 178)	(0.01 to 5.34)	(1 study)	very low ^{1,2}	about the estimate ³
Follow-up: 3 months						

•<u>,1</u>],1].

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Quality of life (Bushenhuoxue therapy plus calcium carbon- ate tablets and alfacalcidol versus calcium carbonate tablets and alfacalcidol) Follow-up: 3 months Scale from: 0 to 100	The mean qual- ity of life in the control groups was 50.75	The mean quality of life in the inter- vention groups was 5.3 higher (3.67 to 6.93 high- er)		80 (1 study)	⊕⊕⊙© low ^{1,4}	MD 5.30 g/cm ³ (3.67 to 6.93) Absolute risk differ- ence 5% (4% to 7%) Relative per cent change 10% (7% to 14%) NNT 2 (2 to 3)
Death	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome
Serious adverse events	See comment	See comment	Not estimable	0 (0)	See comment	No trial reported this outcome

*The basis for the **assumed risk** (e.g. the median control group risk across studies) is provided in footnotes. The **corresponding risk** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI). **CI:** confidence interval; **MD:** mean difference; **NNT:** number needed to treat; **RR:** risk ratio

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. **Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹No information on adequate sequence generation and not all the outcomes that were of interest in this review were reported.

²The total population size is less than 300 (a threshold rule-of-thumb value).

³Five trials reported on the outcome of fracture incidence, but these trials were small in sample size, suffered from various biases, tested different Chinese herbal medicines and the results were not consistent.

⁴The total population size is less than 400 (a threshold rule-of-thumb value).

ochrane ibrary

Trusted evide Informed deci Better health.



BACKGROUND

Description of the condition

Osteoporosis is a worldwide common public health problem with high prevalence (Cole 2008; Woolf 2003). It is defined as a progressive, systemic disease characterised by low bone mass and structural deterioration of bone tissue, leading to bone fragility and an increased susceptibility to fractures (Diez 2002; NOF 2014; Wylie 2010). While osteoporosis is often thought of as an older person's disease, it can strike at any age (Cole 2008; NOF 2014). It is estimated that worldwide osteoporosis is currently a problem for 200 million middle-aged and elderly persons, and there are 75 million people with osteoporosis in America, Western Europe and Japan. In terms of its incidence rate osteoporosis has been ranked as seventh among common diseases worldwide (Nguyen 2000; Xue 2000). In China, there are already 50 million people with osteoporosis and a large-scale epidemiological study found that the prevalence in people over 50 years is 50% (Qiu 2001). As life expectancy increases, this number is expected to continue to grow (Bengner 1988; Cumming 1997; Kushner 1998).

Osteoporosis is a highly prevalent disorder associated with sequelae that often have devastating effects on the quality of life of those affected, and may be a high risk factor for death. Morbidity and mortality rates from osteoporosis-related injuries are high (Diez 2002; Holroyd 2008). Osteoporosis-related sequelae therefore have a major impact on healthcare costs, both direct and indirect, especially those related to hip fracture (Diez 2002; Holroyd 2008). Three kinds of major fractures are associated with osteoporosis: hip, vertebrae and the distal forearm (such as wrist) (Diez 2002; NOF 2014). Epidemiologic studies from several countries have reported the incidence and impact of hip fractures, and their absolute number is expected to double in the next 25 years, with a projected total of more than six million occurrences per year throughout the world by the year 2050 (Genant 1999). Some studies have found that the mortality rate associated with hip fracture is 15% to 25%, caused by complications such as pneumonia, other infections and cardiac insufficiency. The expense of therapy and hospitalisation is USD 25 billion each year (Xue 2000). It is difficult to calculate the incidence of spinal fractures because many are asymptomatic or may not be diagnosed, however they are also an important fracture in many elderly people (Diez 2002). Therefore, osteoporosis has become an important social and medical care problem.

Osteoporosis is often called the 'silent disease' because bone loss occurs gradually and without symptoms or warning signs until the disease is advanced (Cole 2008; NOF 2014; Wylie 2010). Some people may suffer from chronic or acute pain, muscle fatigue and limited mobility, but they may not know that they have osteoporosis until their bones become so weak that a sudden strain, bump or fall causes a fracture or a vertebra to collapse. Collapsed vertebrae may initially be felt or seen in the form of severe back pain, loss of height or spinal deformities such as kyphosis (stooped posture) (IOF 2014; Xia 2001).

At present, the pathogenesis of osteoporosis is still not clear, but may be associated with heredity, poor nutrition, malabsorption, gonadal insufficiency, inadequate physical activity, lack of sunlight irradiation and smoking (Diez 2002; Raisz 2005; Winsloe 2009; Zhou 2001b).

Description of the intervention

Currently, there are a range of therapeutic approaches for osteoporosis. Conventional medicines include oestrogen, raloxifene, bisphosphonates (such as alendronate, etidronate, risedronate), calcitriol, calcitonin, Caltrate (Confavreux 2012; Diez 2002; Guo 2003a; Guo 2003b; Horst-Sikorska 2011; Leong 2002; Rizzoli 2012; Sambrook 2000; Silverman 2012; Wells 2008a; Wells 2008b; Wells 2008c; Zhang 2012). Although fluoride has the ability to increase bone mineral density (BMD) at the lumbar spine (Haguenauer 2005), it has been found ineffective for reducing vertebral fractures in postmenopausal women with osteoporosis. Oestrogen therapy has limited effectiveness and long-term use increases the risks of breast cancer, endometrial haemorrhage and endometrial cancer (Leong 2002). A Cochrane systematic review shows that exercise has the potential to be a safe and effective way to avert bone loss in postmenopausal women (Howe 2011). Although concerted research efforts have been made to identify safe and effective therapies, treatment options are still needed.

In China and other countries, people are looking for alternative modalities to treat osteoporosis and Chinese herbal medicines are one of the popular therapies used. Chinese herbal medicines are defined in this review as products derived from any part of medicinal plants (e.g. leaves, stems, buds, flowers, roots or tubers) used for the treatment of osteoporosis (Rates 2001) and some non-plant based component (e.g. insects, deer horn, snake, various shells and powdered fossil, etc.) are sometimes included. Chinese herbal medicines can be in the form of raw plant materials, or water or alcohol extracts of raw plant materials, or herbal formulations in capsules, tablets, decoctions or injections.

How the intervention might work

In China, many herbs have been tested in clinical trials and claims made as to their effectiveness in treating osteoporosis (Cao GY 2010; Dong Y 2010; Jian QQ 2010; Wang JM 2008; Zhang XG 2011). For example, Zhang et al found that Zhuangguyin (a formula containing different herbs, such as common yam rhizome, red and white peony root, Chinese angelica, Radix codonopsis pilosulae, liquorice root, etc. plus dry powder of Placenta hominis) improved primary osteoporosis, and proposed that the therapy improved the BMD of the lumbar spine and femoral neck (Zhang XG 2011). One clinical trial found that Gujian capsule (studied and produced by Xiyuan Hospital under the Institute of Traditional Chinese Medicine) improved BMD, increased levels of calcitonin, oestradiol, testosterone, follicle-stimulating hormone and luteinising hormone, and decreased levels of parathyroid hormone (Meng 2003).

Why it is important to do this review

Cochrane reviews have assessed the efficacy of Chinese herbal medicines in the treatment of many conditions such as atopic eczema (Gu 2013), cholelithiasis (Gan 2013), colorectal cancer (Guo 2012), gastric cancer (Yang 2013), endometriosis (Flower 2012), heart failure (Chen 2012), osteoarthritis (Cameron 2013) and nephrotic syndrome (Chen 2013; Feng 2013), but not osteoporosis. Chinese herbal medicines are widely used in China for the treatment of osteoporosis and many herbal drugs have been approved by the China State Food and Drug Administration (SFDA) for the market. Each year, many clinical trials are published in China, however, there is no critical appraisal of the evidence on

Chinese herbal medicines for treating osteoporosis (Review)

Copyright $\ensuremath{\mathbb S}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cochrane Library

Trusted evidence. Informed decisions. Better health.

the potential benefits and harms of Chinese herbal medicines for treating osteoporosis. The purpose of this review is to systematically identify available randomised clinical trials of Chinese herbal medicines for primary osteoporosis to appraise their benefit and harm in order to inform clinical practice.

OBJECTIVES

To assess the beneficial and harmful effects of Chinese herbal medicines as a general experimental intervention for treating primary osteoporosis by comparing herbal treatments with placebo, no intervention and conventional medicine.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised clinical trials were included irrespective of blinding, publication status or language. For adverse effects associated with medicinal herbs in osteoporosis treatment, we planned to include data from cohort studies for the evaluation of safety.

Types of participants

Study participants with primary osteoporosis or osteopenia regardless of age, gender or ethnic origin were included. Those with secondary osteoporosis including corticosteroid-induced osteoporosis due to diseases affecting metabolism of bone and the liver, kidney and haematopoietic system, and disability of the heart and cerebral vessels, were excluded.

Osteoporosis could be diagnosed on the basis of one of the following criteria for bone mineral density (BMD) levels. BMD was detected by one of the following methods of examination: single photon absorptiometry (SPA), dual photon absorptiometry (DPA), quantitative computed tomography (QCT), dual energy X-ray absorptiometry (DXA) or peripheral dual energy X-ray absorptiometry (pDXA).

The World Health Organization (WHO) have recommended criteria for primary osteoporosis based on BMD levels (WHO 1994):

- Normal: BMD is within +1 or -1 standard deviations (SD) of the young adult mean.
- Osteopenia (low bone mass): BMD is between -1 and -2.5 SD below the young adult mean.
- Osteoporosis: BMD is -2.5 SD or more than the young adult mean.
- Severe (established) osteoporosis: BMD is more than -2.5 SD and one or more osteoporotic fractures have occurred.

The Chinese diagnostic criteria for primary osteoporosis based on BMD levels (Osteoporosis 1999):

- Normal: BMD is within +1 or -1 SD of peak bone mass of the same race, gender and region.
- Osteopenia (low bone mass): BMD is between -1 and -2 standard deviations below peak bone mass of the same race, gender and region.
- Osteoporosis: BMD is -2 SD or more than the peak bone mass of the same race, gender and region.

• Severe (established) osteoporosis: BMD is more than -2 SD and one or more osteoporotic fractures have occurred.

Types of interventions

experimental interventions included single herbs, The combinations of herbs or Chinese proprietary medicines. There was no standard for the classification of Chinese herbal medicines. Therefore, to make it easier, we classified Chinese herbal medicines into two major types: a) Chinese proprietary medicine which was approved by the China State Food and Drug Administration (SFDA) and produced by pharmaceutical companies with good manufacture practices; b) herbal formulae prescribed by Chinese medicine practitioners based on a Chinese medicine diagnosis (i.e. pattern differentiation of symptoms). This type of medicine was usually cooked as decoction by the patients themselves or prepared by a hospital pharmacy. As we predicted great variation in the type, timing, dosage and administration of herbs and their combination with other interventions, we did not limit any of these aspects.

The control intervention could be no treatment, placebo or conventional pharmaceutical medicine (such as hormone replacement therapy, bisphosphonate, calcitonin, calcium and vitamin D), as well as non-pharmaceutical interventions such as exercise. Co-intervention was allowed as long as all groups from the randomised allocation received the same co-intervention.

We excluded studies in which the duration of herbal treatment was less than three months.

Types of outcome measures

Major outcomes

Major outcome measures sought at the end of treatment or at maximal follow-up:

- 1. Number of individuals with fractures and type of fractures (lumbar spine, radius, femoral neck).
- 2. Quality of life or symptoms including pain, muscle fatigue and limited mobility.
- 3. Death directly or indirectly attributed to osteoporosis.
- 4. Adverse effects including serious adverse events and withdrawals: serious adverse events are defined as any untoward medical occurrence that resulted in death or fracture, was life-threatening, resulted in persistent or significant disability, or any important medical event which may have jeopardised the patient or required intervention to prevent it (ICH GCP 1997). All other adverse effects were considered nonserious. We recorded reports of adverse effects associated with the herbs used in the treatment of osteoporosis from any type of study in order to evaluate harms.

Minor outcomes

Minor outcomes at the end of treatment or at maximal follow-up:

- 1. Bone mineral density (BMD).
- 2. Biochemical indicators: serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), oestradiol (E2), parathyroid hormone (PTH), calcitonin (CT), bone Gla protein (BGP), interleukin-6 (IL-6).

Search methods for identification of studies

Electronic searches

We searched the following electronic databases irrespective of language or publication status: the Cochrane Central Register of Controlled Trials (CENTRAL) in *The Cochrane Library* (2012, Issue 12), MEDLINE, EMBASE, LILACS, JICST-E (Japan Information Center for Science and Technology), AMED, the database of the Cochrane Complementary Medicine Field, Chinese Biomedical Database (CBM), CINAHL (Cumulative Index to Nursing and Allied Health Literature) and the Chinese Academic Conference Papers Database.

We used the following MeSH and free-text terms: osteoporosis, medicine-Chinese-traditional, plants-medicinal, drugs-Chineseherbal, plants extracts and herbs. The full search strategies were in Appendix 1 (MEDLINE), Appendix 2 (EMBASE), Appendix 3 (CENTRAL) and Appendix 4 (CBM). All electronic searches were from inception to 9 January 2013.

Searching other resources

We handsearched the following journals published in Chinese: Chinese Journal of Integrated Traditional and Western Medicine (1981 to 2012), Chinese Journal of Osteoporosis (1995 to 2012), Chinese Journal of Geriatrics (1982 to 2012) and Journal of Clinical Orthopaedics (1998 to 2012).

We screened reference lists of all retrieved articles and reviews for possible eligible trials.

Data collection and analysis

Selection of studies

Two authors (Y Liu, Y Xia) independently selected the trials to be included in the review according to the prespecified selection criteria. Any disagreement was resolved by discussion.

Data extraction and management

Two authors (Y Liu, Y Xia) extracted data independently using a self developed data extraction form which was piloted for formal use. Disagreement was resolved by discussion.

We extracted the following characteristics and data from each included trial: primary author, study setting, methodology, mean age, gender and ethnicity of patients, number of randomised patients, reasons and number of patients who dropped out or were lost during the follow-up, patient inclusion and exclusion criteria, symptoms of the patients, diagnostic criteria, type of herb or herbs, route of administration, dosage and duration of the herb, details of comparison regime, outcome measures (end of treatment and follow-up), and number and type of adverse effects.

If the above data were not available in the trial reports, we sought further information by correspondence with the principal author. If the information was still lacking after the author was contacted, we recorded the last reported observed response.

Assessment of risk of bias in included studies

Based on the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* (Chapter 8: Assessing risk of bias in included studies), we made separate critical assessments for seven specific domains: sequence generation, allocation concealment, blinding of participants and personnel, blinding

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

of outcome assessment, incomplete outcome data, selective outcome reporting and 'other' issues (the baseline comparability between groups) (Higgins 2011). Two authors (Y Liu, Y Xia) assessed the risk of bias independently and assigned a judgement of 'low' risk of bias, 'high' risk of bias or 'unclear' risk of bias. Any disagreement was resolved by discussion.

Measures of treatment effect

We presented dichotomous data as risk ratio (RR) and continuous outcomes as mean difference (MD), both with 95% confidence intervals (Cl).

Unit of analysis issues

For a trial with multiple treatment groups, in order to overcome a unit of analysis error, we selected the following approaches accordingly.

- Combining groups of the same Chinese herbal medicine with different dosages to create a single pair-wise comparison.
- Selecting one pair of interventions and excluding the others.
- Splitting the 'shared' group into two or more groups with smaller sample size, and including two or more (reasonably independent) comparisons.

Dealing with missing data

Based on the recommendations in the *Cochrane Handbook for Systematic Reviews of Interventions* (Chapter 16.1: Missing data), we used two options for dealing with missing data (Higgins 2011).

- Analysing only the available data when data were assumed to be missing at random (i.e. ignoring the missing data).
- Imputing the missing data with replacement values (such as a poor outcome) when data were not assumed to be missing at random.

Assessment of heterogeneity

We assessed heterogeneity using the l^2 statistic, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error (chance) (Higgins 2011). A rough guide to interpretation of l^2 is as follows:

- 0% to 40%: might not be important;
- 30% to 60%: may represent moderate heterogeneity;
- 50% to 90%: may represent substantial heterogeneity;
- 75% to 100%: considerable heterogeneity.

Assessment of reporting biases

We planned to detect reporting biases with funnel plots, which is a simple scatter plot of the intervention effect estimates from individual studies against some measure of each study's size or precision (Higgins 2011).

Data synthesis

We compared types of Chinese herbal medicines with each control (such as placebo) regardless of the treatment regimen. We performed meta-analysis within comparisons of the same herb versus the similar control intervention. Whenever there was significant heterogeneity ($I^2 > 50\%$), we used the random-effects model; otherwise we reported fixed-effect models (Altman 2003).



We carried out the statistical analyses using Review Manager 5.2 (Cochrane software) (RevMan 2012).

We tabulated the following comparisons when data were available:

- Chinese herbal medicines versus no intervention or placebo;
- Chinese herbal medicines versus conventional medicine (such as hormone replacement therapy, bisphosphonate);
- Chinese herbal medicines versus non-pharmaceutical intervention.

We presented trials of herbs plus active intervention versus active intervention alone as a separate comparison.

Subgroup analysis and investigation of heterogeneity

We performed subgroup analyses on different Chinese herbal medicines and on body parts of participants for BMD measurement. However, due to the limited number of randomised trials for individual Chinese herbal medicines, the following subgroup analyses were not performed: duration of the herbal treatment, types of osteoporosis (for example, senile or postmenopausal osteoporosis) and severity of osteoporosis.

Sensitivity analysis

Similarly, due to the heterogeneity of the interventions, we were unable to pool results into a meta-analysis and therefore could not undertake a sensitivity analysis to explore the influence of trial methodological quality on effect estimates.

'Summary of findings' tables

We created 'Summary of findings' tables for different comparisons and included the following patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD). We assessed the overall quality of the evidence by outcome using the GRADE approach and incorporated this in the tables.

RESULTS

Description of studies

Results of the search


Our initial searches identified 4427 references: 4378 from electronic searches and 49 from handsearches. After reading titles and abstracts, 4176 of these articles were excluded because they were duplicates, non-clinical studies, without a control group, traditional reviews, animal studies, case reports or had study objectives different from this review. We retrieved a total of 251 references published in Chinese or English for further assessment. Of these, 143 references were excluded because they did not meet our inclusion criteria. Reasons for exclusion were shown in the Characteristics of excluded studies table.

In this review, 108 randomised clinical trials met the inclusion criteria. All trials were conducted in China between 1996 and 2012. We did not find any cohort studies for the evaluation of the safety of Chinese herbal medicines for osteoporosis. The included studies reported random allocation of patients with osteoporosis to Chinese herbal medicines versus control (placebo in three trials, no treatment in five trials, conventional pharmaceutical medicine (such as calcium and vitamin D, calcium gluconate, tibolone tablets, nilestriol, calcitonin, alendronate, calcium, vitamin D, etc.) in 61 trials, Chinese herbal medicines plus co-intervention versus the same co-intervention in 47 trials). No trial compared Chinese herbal medicines with non-pharmaceutical interventions. Eighteen trials (An SJ 2000; Chen ZX 2002; Dai Y 2007; Gong L 2001; Liao L 2004; Miu JQ 2008; Peng T 2002; Ruan XY 2006; Song XW 2000; Wang XY 2000; Wu MS 2007; Xiong YH 2008; Xu H 2010; Xu M 2009; Zhan HS 2009; Zhang YS 2003; Zhang YP 2007; Zhu HM 2012) had more than two arms. Attributes of the 108 included studies are shown in the Characteristics of included studies table. Four trials were published in English (Deng WM 2012; Qiu RB 2004; Xie J 2004; Zhu HM 2012) and 104 studies were published in Chinese.

The study flow diagram is shown in Figure 1.



Figure 1. The study screening flow diagram.



Included studies

Participants

A total of 10,655 patients with osteoporosis were randomised in the 108 trials, among which 65 trials included postmenopausal osteoporosis patients, eight trials included senile osteoporosis patients and 35 trials included primary osteoporosis patients unspecified as to life-stage or co-morbidity. The race/ethnicity of all patients studied was Chinese in all 108 trials. One hundred and five randomised clinical trials included adults with a mean age of 61.3 years. Three trials did not report data on gender or age or both (Lin W 2000; Xiong YH 2008; Zhao LN 2003). The average number of participants in the trials was 98, ranging from 20 to 600 patients per trial.

Diagnosis

Among the 108 included trials, the diagnostic criteria for osteoporosis in 18 trials were based on WHO criteria (An SJ 2000; Cao W 2010; Chen NQ 2006; Chen ZX 2002; Cui TH 1999; Dai Y 2007; Gang PH 2001; Hu J 2012; Li HW 2004; Li YH 2008; Miu JQ 2008; Wang SW 2003; Ye AN 1998; Zhang RH 2004; Zhang YL 1996; Zhao G 2002; Zheng WK 2007; Zhou LZ 2001), and in the others the Chinese diagnostic criteria for osteoporosis were used. BMD was detected by dual energy X-ray absorptiometry (DXA), single photon absorptiometry (SPA) or CUBA ultrasound bone densitometer in all of the studies.

Interventions

Ninety-nine different Chinese herbal medicines were tested in 108 randomised trials. Only eight Chinese herbal medicines were tested twice or more, including Kanggusong granule in two trials (An SJ 2000; Wu MS 2001), Bushen Qiangshen pill in two trials (Mu G 2001; Mu G 2001a), Migu tablets in two trials (Dai Y 2007; Xie J 2004), Gukang oral liquid in three trials (Chen JP 1999; Shao M 2003; Wang JM 2008), Gushukang granule in three trials (Chen ZX 2002; Wu MS 2007; Zhang YS 2003), Qianggu capsule in three trials (Ruan XY 2006; Wang J 2007; Xu H 2010), Liuwei Dihuang pills in two trials (Ma C 2011; Zhang J 2003) and Xianlinggubao capsule in seven trials (Dai Y 2007; Dong Y 2010; Qiu ZX 2010; Wu W 2005; Xu M 2009; Zhang XZ 2004; Zhu HM 2012). However, even when the same Chinese herbal medicines were tested, the control interventions were different for



each trial. Therefore, there was no trial which tested exactly the same Chinese herbal medicine and the same control in this review. Seven trials tested two or more different Chinese herbal medicines respectively (Dai Y 2007; Gong L 2001; Wu MS 2007; Xiong YH 2008; Zhan HS 2009; Zhang YS 2003; Zhang ZF 2011). According to the categories of medicinal herbs, two trials tested single herbs (Yang B 2007; Zhao LN 2003) and the remaining trials tested compounds of multiple herbs. Based on our standard classification for Chinese herbal medicines, 45 trials tested Chinese proprietary medicine and the others tested prescribed herbal formulae. The composition and treatment regimens of the Chinese herbal medicines varied (see Table 1: 'The preparation and composition of the Chinese herbal medicines in the included trials'). The median duration of treatment was 5.7 months (ranging from 3 to 12 months).

The control interventions included placebo in three trials and no treatment in five trials. In the other trials the control interventions were conventional pharmaceutical medicine or Chinese herbal medicines plus co-intervention versus the same co-intervention.

The interventions in the included trials are described in the Characteristics of included studies table.

Outcomes

Seven trials reported fracture incidence (An SJ 2000; Deng WM 2012; Li ZP 2011; Zhang RH 2004; Zhang ZF 2011; Zhao HX 2001; Zhu HM 2012). None of the 108 trials reported death directly or indirectly caused by osteoporosis. The outcomes reported were mainly surrogate outcomes, including BMD, biochemical indicators (serum calcium, phosphorus, alkaline phosphatase, oestradiol, parathyroid hormone, calcitonin, bone Gla protein, interleukin-6, etc.), the improvement of lumbago and backache, and adverse effects. Only two trials reported quality of life and medical expenses (Liang DB 2012; Zhang ZF 2011). Adverse effects were reported in 44 trials and included nausea, diarrhoea, dry mouth, constipation, tiredness, dental ulcer, epigastric discomfort, breast pain, dizziness, stomach discomfort, etc. All the reported outcomes were measured at the end of treatment.

Risk of bias in included studies

In this review, all 108 trials were reported as parallel-group randomised trials and three trials were multicentre randomised trials (Deng WM 2012; Xiong YH 2008; Zhu HM 2012). Of the 108, only 27 reported the methods used for the generation of the allocation sequence. Among them, four used random numbers generated by a computer or calculator (Xu YL 2007; Zhang RH 2004; Zhao HX 2001; Zhu HM 2012), 20 used a random numbers table (Chen XL 2010; Chen ZX 2002; Dai Y 2007; He N 2006; Hu J 2012; Li BL 2007; Li HW 2004; Li YH 2008; Ma C 2011; Qiu RB 2008; Wang CC 2005; Wu MS 2007; Wu W 2005; Xiong YH 2008; Xu H 2010; Xu M 2009; Zhang DS 2011; Zhang XZ 2004; Zhao G 2002; Zhu HJ 2011) and one used random drawings (Wang ZK 2004).

Only one trial (Zhu HM 2012) provided information about allocation concealment.

Double-blinding was reported in 10 trials (An SJ 2000; Lin W 2000; Wang SW 2003; Wang XD 2011; Xiong YH 2008; Zhan HS 2009; Zhao HX 2001; Zhao LN 2003; Zheng WK 2007; Zhu HM 2012). Eight trials reported use of single-blinding (Chen JP 1999; Chen NQ 2006; Mao YF 2011; Wang XY 2000; Xie YM 1997; Yuan YN 2000; Zhou ZK 2006; Zou JJ 2005).

Two trials (Deng WM 2012; Zhu HM 2012) reported a pre-trial estimation of sample size and reported performing intention-to-treat analysis. Nineteen trials reported withdrawals (Deng WM 2012; He MT 2007; Li SL 2004; Li YH 2010; Ma C 2011; Meng XD 2003; Peng T 2002; Ruan XY 2006; Wang CC 2005; Wang JM 2008; Xiong YH 2008; Xu YL 2007; Zhan HS 2009; Zhang XJ 2008; Zhang RH 2004; Zhang ZF 2011; Zhao HX 2001; Zheng WK 2007; Zhu HM 2012).

None of the 108 trials reported all outcomes of interest in this review.

Seventy trials appeared to be free of other sources of bias, while the 38 other trials did not report the baseline comparability between groups in detail.

The risk of bias in the included studies is shown in detail in Figure 2 and Figure 3.

Figure 2. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.






Figure 3. 'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.



Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Figure 3. (Continued)

	-	_	-	-	-	
Huang JW 2008	?	?	?	+	?	•
Huang ZJ 2008		•	?	•	?	•
Hu J 2012	•	?	?	•	?	•
Jian QQ 2010	?	?	?	•	?	?
Lan ZX 2006	?	?	?	•	?	•
Liang DB 2012	•	?	?	÷	?	•
Liao L 2004	?	?	?	•	?	•
Li BL 2007	?	?	?	+	?	?
Li HW 2004	÷	?	?	÷	?	•
Ling JY 2008	?	?	?	•	?	•
Lin W 2000	?	?	•	÷	?	?
Li SL 2004	?	?	?	•	?	•
Liu JM 2012	?	?	?	•	?	•
Li YH 2008	•	?	?	•	?	•
Li YH 2010	?	?	?	•	?	•
Li ZP 2011	?	?	?	•	?	•
Li ZY 2006	?	?	?	÷	?	•
Lv ZH 2002	?	?	?	•	?	•
Ma C 2011	•	?	?	•	?	•
Ma CZ 2011	?	?	?	•	?	•
Mao YF 2011	?	?	?	?	?	•
Ma YJ 2011	?	?	?	•	?	•
Meng XD 2003	?	?	?	•	?	•
Miu JQ 2008	?	?	?	•	?	•
Mu G 2001	?	?	?	•	?	•
Mu G 2001a	?	?	?	•	?	?
Ou L 2011	?	?	?	•	?	•
Peng T 2002	•	?	?	•	?	•
Qiu RB 2004	?	?	?	•	?	•
Qiu RB 2008	•	?	?	•	?	•
Qiu ZX 2010	?	?	?	•	?	?



Figure 3. (Continued)

	-	_	_	-	_	
Qiu ZX 2010	?	?	?	÷	?	?
Qi ZX 1998	?	?	?	÷	?	•
Ruan XY 2006	?	?	?	÷	?	?
Shao M 2003	?	?	?	•	?	?
Shi CD 2012	?	?	?	÷	?	•
Song XW 2000	?	?	?	•	?	?
Tang ZA 2012	?	?	?	•	?	•
Wang CC 2005	?	?	?	•	?	•
Wang H 2007	•	?	?	•	?	•
Wang J 2007	?	?	?	+	?	•
Wang JM 2008	?	?	?	•	?	?
Wang SW 2003	?	?	•	•	?	?
Wang XD 2011	?	?	•	•	?	?
Wang XY 2000	?	?	•	•	?	•
Wang YZ 2008	?	?	?	•	?	?
Wang ZK 2004	•	?	?	•	?	?
Wei RY 2011	?	?	?	•	?	•
Wu JZ 2010	?	?	?	•	?	•
Wu MS 2001	?	?	?	•	?	?
Wu MS 2007	•	?	?	•	?	•
Wu W 2005	•	?	?	•	?	•
Xiao W 2008	?	?	?	•	?	?
Xie J 2004	?	?	?	•	?	?
Xie YM 1997	?	?	•	•	?	?
Xiong YH 2008	?	?	?	•	?	•
Xu H 2010	?	?	?	•	?	•
Xu M 2009	?	?	?	•	?	•
Xu W 2005	?	?	?	•	?	•
Xu YL 2007	•	?	?	•	?	•
Yang B 2007	?	?	?	•	?	•
Ye AN 1998	?	?	?	•	?	?



Figure 3. (Continued)

	_	_	-	-	-	- 1
Ye AN 1998	?	?	?	÷	?	?
Yuan YN 2000	?	?	•	•	?	?
Zhang DS 2011	?	?	?	•	?	?
Zhang J 2003	?	?	?	•	?	?
Zhang RH 2004	•	?	•	•	?	•
Zhang XG 2011	?	?	?	•	?	?
Zhang XJ 2008	?	?	?	•	?	?
Zhang XZ 2004	?	?	?	•	?	?
Zhang YL 1996	?	?	?	÷	?	?
Zhang YP 2007	?	?	?	÷	?	•
Zhang YS 2003	?	?	?	•	?	•
Zhang ZF 2011	?	?	?	•	?	•
Zhan HS 2009	?	?	•	?	?	•
Zhan ML 2007	?	?	?	÷	?	•
Zhao G 2002	÷	?	?	÷	?	•
Zhao HX 2001	•	?	•	?	?	•
Zhao LN 2003	?	?	•	•	?	?
Zheng WK 2007	?	?	•	÷	?	•
Zhong RQ 2007	?	?	?	•	?	•
Zhou LZ 2001	?	?	?	•	?	•
Zhou XT 2001	?	?	?	•	?	•
Zhou ZK 2006	?	?	•	+	?	•
Zhu HJ 2011	•	?	?	+	?	•
Zhu HM 2012	•	?	•	?	?	•
Zou JJ 2005	?	?	•	•	?	?

The poor availability of information about study design meant that we rated most items as having unclear risk of bias. Based on The Cochrane Collaboration's recommended summary assessments for risk of bias (Higgins 2011), the 'Risk of bias' assessment should be for the important outcomes, therefore for the outcome of fracture we evaluated the risk of bias as 'unclear' for sequence generation, allocation concealment, blinding and selective outcome reporting in those seven studies that reported it (Figure 3).

Assessment of reporting biases

Due to the small number of trials testing the same intervention and same outcome, a meaningful funnel plot analysis could not be conducted.

Effects of interventions

See: Summary of findings for the main comparison Chinese herbal medicines versus placebo for osteoporosis; Summary of findings 2 Chinese herbal medicines versus no intervention for osteoporosis; Summary of findings 3 Chinese herbal medicines



versus western medicine for osteoporosis; **Summary of findings 4** Chinese herbal medicines plus western medicine versus western medicine for osteoporosis

Chinese herbal medicines versus placebo (Comparison 01)

Three trials (involving 219 patients) compared the effects of Chinese herbal medicines with placebo (Lin W 2000; Wang XY 2000; Zhao HX 2001). Based on our standard classification for Chinese herbal medicines, the tested Chinese herbal medicines included two prescribed herbal formulae (Migu decoction and Bushen Yigu soft extract), and one Chinese proprietary medicine (Kanggusong capsules). The reported outcomes included BMD of the lumbar spine, radius and ulna, and the levels of oestradiol (E2). We were not able to pool the data due to the heterogeneity of the Chinese herbal medicines that were studied.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD) (see Summary of findings for the main comparison).

Fractures

In three trials of Chinese herbal medicines versus placebo, one trial reported new compression fractures of the backbone in the placebo group (0/50 versus 10/54) (RR 0.05; 95% CI 0.00 to 0.85) (Analysis 1.1) (Zhao HX 2001).

Quality of life or symptoms including pain, muscle fatigue and limited mobility

No trials reported quality of life.

One trial reported improvement in bone pain in the group treated with Chinese herbal medicines compared to placebo (49/50 versus 44/54) (RR 1.20; 95% CI 1.05 to 1.37) (Analysis 1.4) (Zhao HX 2001).

Death

No trials reported this outcome.

Adverse effects

In three trials of Chinese herbal medicines versus placebo, one trial reported some mild adverse effects in the Chinese herbal medicines group, including stomach/intestinal upset, headache and dizziness (Zhao HX 2001). Two trials did not report on adverse effects (Lin W 2000; Wang XY 2000).

Bone mineral density (BMD)

BMD of the lumbar spine

Compared with placebo, the group treated with Migu decoction showed a statistically significant increase in BMD of the lumbar spine after four months treatment (MD 0.16 g/cm³; 95% CI 0.06 to 0.26) (Analysis 1.2) (Lin W 2000). The group treated with Kanggusong capsules had a statistically significant increase in BMD when compared to the placebo group after 12 months treatment (MD 0.06 g/cm³; 95% CI 0.02 to 0.10) (Analysis 1.2) (Zhao HX 2001).

BMD of the radius

The group treated with Bushen Yigu soft extract showed a statistically significant increase in BMD of the radius compared to a

group treated with placebo after three months treatment (MD 0.06 g/cm³; 95% CI 0.03 to 0.09) (Analysis 1.2) (Wang XY 2000).

BMD of the ulna

Those treated with Bushen Yigu soft extract showed a statistically significant increase in BMD of the ulna when compared to a placebo group after three months treatment (MD 0.06 g/cm³; 95% CI 0.02 to 0.10) (Analysis 1.2) (Wang XY 2000).

Biochemical indicators

The effects of the interventions on biochemical indicators are shown in Appendix 5.

Summary: Comparison 01

In summary, compared with placebo, Migu decoction and Kanggusong capsule seemed to improve the BMD of the lumbar spine; Bushen Yigu soft extract improved the BMD of the radius and the ulna.

Chinese herbal medicines versus no intervention (Comparison 02)

Five trials (involving 628 patients) compared seven different Chinese herbal medicines with no intervention (Gong L 2001; Liao L 2004; Peng T 2002; Zhang YP 2007; Zhang YS 2003). Two trials with two arms compared different herbs with no intervention (Gong L 2001; Zhang YS 2003). The tested herbs included Yishen Zhuanggu mixture, Shengu capsule, Bushen Shengsui principle, Qianggu soft extract, Huoluo Gukang pills, Shigu yin and Gushukang granule. Based on our standard classification for Chinese herbal medicines, five herbs were Chinese proprietary medicine, and two were prescribed herbal formulae. The reported outcomes included BMD of the lumbar spine and femoral neck, and the levels of oestradiol (E2) and osteocalcin, also known as bone Gla protein (BGP), but we were not able to pool the data due to the heterogeneity of the Chinese herbal medicines that were studied.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD) (see Summary of findings 2).

Fractures

None of the five trials reported the outcome fractures.

Quality of life or symptoms including pain, muscle fatigue and limited mobility

None of the five trials reported these outcomes.

Death

None of the five trials reported this outcome.

Adverse effects

Four trials reported some mild adverse effects, such as mild stomach discomfort, intestinal upset or constipation, but this did not affect the continuation of treatment (Gong L 2001; Peng T 2002; Zhang YS 2003; Zhang YP 2007). One trial reported no adverse effects (Liao L 2004).

Chinese herbal medicines for treating osteoporosis (Review)

Copyright ${\ensuremath{\mathbb C}}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Bone mineral density (BMD)

BMD of lumbar spine

Compared with no intervention, treatment with Bushen Shengsui principle showed no evidence of effect after six months treatment (MD 0.07 g/cm³; 95% CI -0.06 to 0.20) (Analysis 2.1) (Liao L 2004).

BMD of femoral neck

Compared with no intervention, treatment with Bushen Shengsui principle did not increase the BMD of the femoral neck after six months (MD 0.10 g/cm³; 95% CI 0.00 to 0.20) (Analysis 2.1) (Liao L 2004), and nor did treatment with Yishen Zhuanggu mixture after six months (MD 0.05 g/cm³; 95% CI -0.01 to 0.11) (Analysis 2.1) (Gong L 2001) or Shengu capsule (MD 0.02 g/cm³; 95% CI -0.06 to 0.09) (Analysis 2.1) (Gong L 2001). Treatment with Qianggu soft extract resulted in a statistically significant increase in the BMD of the femoral neck after six months treatment (MD 0.09 g/cm³; 95% CI 0.03 to 0.15) (Analysis 2.1) (Peng T 2002), as did Shigu yin after six months treatment (MD 0.08 g/cm³; 95% CI 0.03 to 0.13) (Analysis 2.1) (Zhang YP 2007).

Biochemical indicators

The effects of the interventions on biochemical indicators are shown in Appendix 5.

Summary: Comparison 02

In summary, compared with no intervention, Qianggu soft extract appeared to improve the BMD of the femoral neck significantly. Shigu yin also seemed to improve the BMD of the femoral neck. However, some groups treated with Chinese herbal medicines showed no significant difference from those receiving no intervention, including Bushen Shengsui principle (BMD of the lumbar spine and femoral neck), Yishen Zhuanggu mixture (BMD of the femoral neck) and Shengu capsule (BMD of the femoral neck) after six months of treatment.

Chinese herbal medicines versus western medicine (Comparison 03)

Sixty-one trials (involving 4805 patients) compared 56 different Chinese herbal medicines with western medicine (An SJ 2000; Chen JP 1999; Chen NQ 2006; Chen X 2008; Chen ZX 2002; Cui TH 1999; Dong YF 2004; Gang PH 2001; He MT 2007; He N 2006; Huang ZJ 2008; Lan ZX 2006; Li BL 2007; Li YH 2008; Li YH 2010; Li ZY 2006; Liao L 2004; Ling JY 2008; Lv ZH 2002; Ma C 2011; Mao YF 2011; Meng XD 2003; Mu G 2001a; Ou L 2011; Peng T 2002; Qi ZX 1998; Qiu RB 2004; Qiu RB 2008; Ruan XY 2006; Shao M 2003; Shi CD 2012; Song XW 2000; Wang CC 2005; Wang H 2007; Wang J 2007; Wang JM 2008; Wang XY 2000; Wang YZ 2008; Wang ZK 2004; Wei RY 2011; Wu JZ 2010; Wu MS 2001; Wu MS 2007; Xie YM 1997; Xu H 2010; Xu M 2009; Xu W 2005; Xu YL 2007; Yang B 2007; Yuan YN 2000; Zhan ML 2007; Zhang XG 2011; Zhang YP 2007; Zhang J 2003; Zhang XJ 2008; Zhang YL 1996; Zhao LN 2003; Zhong RQ 2007; Zhou LZ 2001; Zhou ZK 2006; Zhu HJ 2011). Among them, two trials compared herbs with two different Western pharmaceutical medicines (An SJ 2000; Song XW 2000). One trial (Wu MS 2007) compared two herbs with western medicine.

The tested herbal preparations included Acupoint sticking of Migudan, Bugu Shengsui capsule, Bushen Huoxue capsules, Bushen Jianpi Huoxue recipe, Bushen Jianpi Jingu decoction,

Bushen Jianpi Migu prescription, Bushen Qianggutang, Bushen Qiangshen pill, Bushen Tianjing Huoxue therapy, Bushen Shengsui principle, Bushen Yangxue tang, Bushen Yigu soft extract, Bushen Zhuanggu tang, Bushenjianpi Zhuangguyin, Erxian soup, Gujian capsule, Gukang decoction, Gukang oral liquid, Guli powder, Gumikang capsule, Gumiling granule, Gushen Yijing tang, Gushukang granule, Huangqi, Huangqi Sanxian tang, Jiangu capsule, Jiangu recipe, Jianshenfang granule, Jiawei Bushen Zhuangjintang, Jiawei Zhuangyao Jianshen tang, Jingujian granule, Jingujian granule (1,2,3), Kanggusong capsule, Kanggusong granule, Kangshu Jiangu granule, kidney-tonifying herbs, Liuwei Dihuang pills, prescription for tonifying kidney, Qianggu capsule, Qianggu paste, Qianggu soft extract, Radix rehmanniae preparata and Radix astragali, Shangke Jiegu tablet, Shenyao capsules, Shigu yin, Strong Bone capsule, TPF capsule, Tongbu Qianggutang, urinary bladder (Kidney) meridian sticking, Xianling Gusong capsules, Xianlinggubao capsule, Yanghuo Sanzi tang, Yinyanghuo, Herba epimedii prescription (including Herba epimedii, Fructus psoraleae, Cortex eucommiae, Concha ostreae, Radix aconiti preparata, Radix aconiti kusnezoffii, Radix angelicae sinensis and Rhizome chuanxiong), Yishen Yanggan mixture and Zishen Gukang pill. All these herbal preparations except Yinyanghuo and Huangqi (Radix Astragali) are mixtures of herbs. Based on our standard classification for Chinese herbal medicines, 22 herbs were Chinese proprietary medicine, and 34 were prescribed herbal formulae.

The reported outcomes included BMD of the lumbar spine, radius, ulna, femoral neck, Ward's triangle, trochanter, hipbone, distal radius and calcaneus. Levels of oestradiol (E2), serum calcium (Ca), phosphorus (P), alkaline phosphatase (ALP), bone Gla protein (BGP), interleukin-6 (IL-6), parathyroid hormone (PTH) and calcitonin (CT) were also measured, as was the improvement of lumbago and backache.

We were not able to pool the data due to the variations in the herbal preparations and control interventions that were used in the studies.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, serious adverse events, BMD) (see Summary of findings 3).

Fractures

Of the 61 trials, one trial reported that no new fracture occurred (An SJ 2000).

Quality of life or symptoms including pain, muscle fatigue and limited mobility

No trials reported the outcome of quality of life.

Twenty trials out of 61 reported the improvement of lumbago and backache. Among these 20 trials, eight reported that Chinese herbal medicines were better than western medicines without reporting the number of cases with ache improvement in each group (Chen NQ 2006; Dong YF 2004; Ou L 2011; Qi ZX 1998; Wang ZK 2004; Xie YM 1997; Xu H 2010; Zhang XJ 2008). The other 12 trials reported as follows:

46/48 versus 24/42: RR 1.68; 95% CI 1.28 to 2.19 (Analysis 3.4) (Lv ZH 2002);

- 76/78 versus 11/21: RR 1.86; 95% CI 1.24 to 2.80 (Analysis 3.4) (Peng T 2002);
- 24/30 versus 15/30: RR 1.60; 95% CI 1.07 to 2.39 (Analysis 3.4) (Wu MS 2001);
- 53/60 versus 26/50: RR 1.70; 95% Cl 1.28 to 2.25 (Analysis 3.4) (Xu W 2005);
- 13/15 versus 9/10: RR 0.96; 95% CI 0.72 to 1.28 (Analysis 3.4) (Zhao LN 2003);
- 15/15 versus 2/10: RR 4.26; 95% CI 1.43 to 12.72 (Analysis 3.4) (Gang PH 2001);
- 25/29 versus 20/29: RR 1.25; 95% CI 0.94 to 1.66 (Analysis 3.4) (He N 2006);
- 28/30 versus 22/30: RR 1.27; 95% CI 1.01 to 1.61 (Analysis 3.4) (Huang ZJ 2008);
- 52/60 versus 11/40: RR 3.15; 95% CI 1.89 to 5.26 (Analysis 3.4) (Li YH 2008);
- 18/21 versus 12/22: RR 1.57; 95% CI 1.03 to 2.39 (Analysis 3.4) (Li ZY 2006);
- 43/48 versus 19/32: RR 1.51; 95% CI 1.12 to 2.04 (Analysis 3.4) (Wei RY 2011);
- 56/60 versus 34/60: RR 1.65; 95% CI 1.31 to 2.08 (Analysis 3.4) (Qiu RB 2008).

Death

No trials reported this outcome.

Adverse effects

Twenty-three trials out of 61 reported adverse effects. These included:

- two patients with midsection discomfort in the herbal group (Cui TH 1999);
- a few patients with dizziness, rash, nausea, vomiting and cardiopalmus at the beginning of therapy, but no significant difference in comparison groups (Dong Y 2010);
- 11 patients with dry mouth symptoms, five with stomach discomfort, two with constipation and one with cardiopalmus in the herbal group, and nine patients with stomach discomfort and one with constipation in the western medicine group (Li YH 2010);
- three patients with spotting vaginal bleeding at the beginning of treatment, which did not affect observation, and five cases with breast pain who withdrew from the western medicine group (Liao L 2004);
- six patients with constipation and five with dry mouth symptoms in the herbal group, which did not affect observation (Meng XD 2003);
- two patients with abdominal distention and sour regurgitation in the herbal group, and three with gastrointestinal symptoms in the western medicine group (Ma C 2011);
- three patients in the herbal group and one in the western medicine group with stomach discomfort (Peng T 2002);
- one patient with stomach discomfort in the western medicine group (Wang CC 2005);
- five patients with stomach discomfort in the herbal group and two in the western medicine group (Wang H 2007);
- two patients with mild constipation and one with dry mouth symptoms in the herbal group (Wang J 2007);

• a few patients with nausea, stomach ache and dizziness in the western medicine group (Wu MS 2001);

- two patients with dry and hard stools during treatment in the herbal group (Xie YM 1997);
- five patients with nausea in the herbal group and three in the western medicine group (Xu H 2010);
- two patients with nausea in the herbal group and three in the western medicine group (Xu M 2009);
- three patients with gastrointestinal reactions in the western medicine group (Chen X 2008);
- one patient with palpitations, two patients with constipation and four patients with stomach discomfort in the Jingujian granule group, and five patients with constipation and two patients with abdominal distention in the western medicine group (Li YH 2008); and
- one trial (Zhang YP 2007) which reported patients with constipation in the control group without reporting data.

Six trials reported no adverse effects (Chen NQ 2006; Gang PH 2001; Xu YL 2007; Yuan YN 2000; Zhang XJ 2008; Zhou LZ 2001).

Most of the adverse effects did not affect continuation of treatment. Thirty-eight trials did not report adverse effects.

Bone mineral density (BMD)

BMD of the lumbar spine

No significant difference between groups in the BMD of the lumbar spine was reported for any of the following comparisons of treatment groups:

- Kanggusong granule versus ipriflavone plus Caltrate (MD 0.00 g/ cm³; 95% CI -0.05 to 0.05), Kanggusong granule versus Caltrate after nine months treatment (MD 0.04 g/cm³; 95% CI -0.02 to 0.10) (Analysis 3.2) (An SJ 2000);
- Strong Bone capsule versus Caltrate after three months treatment (MD -0.01 g/cm³; 95% CI -0.08 to 0.06) (Analysis 3.2) (Cui TH 1999);
- Herba epimedii prescription versus vitamin D plus Caltrate after six months treatment (MD 0.03 g/cm³; 95% CI 0.00 to 0.06) (Analysis 3.2) (Dong YF 2004);
- Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone after six months treatment (MD 0.00 g/ cm³; 95% CI -0.12 to 0.12) (Analysis 3.2) (Liao L 2004);
- Bushen Jianpi Jingu decoction versus calcitonin after three months treatment (MD 0.02 g/cm³; 95% CI -0.09 to 0.13) (Analysis 3.2) (Mao YF 2011);
- Gukang oral liquid versus alendronate after six months treatment (MD 0.01 g/cm³; 95% CI -0.03 to 0.05) (Analysis 3.2) (Shao M 2003);
- kidney-tonifying herbs versus nilestriol (MD -0.02 g/cm³; 95% CI -0.09 to 0.05), kidney-tonifying herbs versus calcium (MD 0.02 g/cm³; 95% CI -0.04 to 0.08) after six months treatment (Analysis 3.2) (Song XW 2000);
- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (MD 0.02 g/cm³; 95% CI -0.01 to 0.05) after six months treatment (Analysis 3.2) (He MT 2007);



- Huangqi Sanxian tang versus nilestriol after three months treatment (MD 0.00 g/cm³; 95% CI -0.03 to 0.04) (Analysis 3.2) (Zhou ZK 2006);
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.04 g/cm³; 95% CI -0.01 to 0.09) (Analysis 3.2) (Wang J 2007);
- Jianshenfang granule versus alendronate sodium after six months treatment (MD 0.09 g/cm³; 95% CI -0.03 to 0.21) (Analysis 3.2) (Li BL 2007);
- Jiangu recipe versus alendronate sodium after 12 months treatment (MD 0.02 g/cm³; 95% CI 0.00 to 0.04) (Analysis 3.2) (Qiu RB 2008);
- Gukang fang versus alendronate sodium tablets after four months treatment (MD 0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 3.2) (Chen X 2008);
- Qianggu capsule versus alendronate (MD 0.01 g/cm³; 95% CI -0.04 to 0.05) after six months treatment (Analysis 3.2) (Xu H 2010);
- Bushen Huoxue capsules versus Caltrate and calcitonin (MD 0.02 g/cm³; 95% CI -0.05 to 0.09) after 12 months treatment (Analysis 3.2) (Zhang XJ 2008);
- Yinyanghuo versus conjugated oestrogens (MD 0.03 g/cm³; 95% CI -0.04 to 0.10) after six months treatment (Analysis 3.2) (Zhao LN 2003);
- Shenyao capsules versus Caltrate (MD 0.00 g/cm³; 95% CI -0.05 to 0.05) after six months treatment (Analysis 3.2) (Chen NQ 2006);
- Guli powder versus Caltrate after three months treatment (male: MD 0.02 g/cm³; 95% CI -0.01 to 0.05; female: MD 0.04 g/cm³; 95% CI -0.07 to 0.15) (Analysis 3.2) (Lan ZX 2006);
- Gushen Yijing tang versus Caltrate after six months treatment (MD 0.06 g/cm³; 95% CI -0.02 to 0.14) (Analysis 3.2) (Zhong RQ 2007);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.12 g/cm³; 95% CI -0.01 to 0.26) (Analysis 3.2) (Xie YM 1997);
- Xianling Gusong capsules versus Caltrate after six months treatment (MD -0.03 g/cm³; 95% CI -0.08 to 0.02) (Analysis 3.2) (Li ZY 2006);
- Zishen Gukang pill versus Caltrate plus vitamin D after three months treatment (MD -0.00 g/cm³; 95% CI -0.05 to 0.04) (Analysis 3.2) (Huang ZJ 2008);
- Gukang decoction versus alendronate sodium tablets after four months treatment (MD -0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 3.2) (Chen X 2008);
- Gumiling granule versus chewable bicarbonate calcium after six months treatment (MD 0.04 g/cm³; 95% CI -0.02 to 0.09) (Analysis 3.2) (Gang PH 2001);
- Gujian capsule versus alfacalcidol after three months treatment (MD 0.08 g/cm³; 95% CI -0.02 to 0.18) (Analysis 3.2) (Meng XD 2003);
- Xianlinggubao capsule versus alendronate after six months treatment (MD 0.00 g/cm³; 95% CI -0.02 to 0.02) (Analysis 3.2) (Xu M 2009);
- Bushen Tianjing Huoxue therapy versus Caltrate and calcitriol soft capsule after six months treatment (MD 0.04 g/cm³; 95% CI 0.00 to 0.07) (Analysis 3.2) (Zhu HJ 2011).

In 13 trials Chinese herbal medicines were reported to have statistically significant better effects on the BMD of the lumbar spine when compared with western medicine (calcium supplementation, vitamin D, hormones or different combinations):

- Jiawei Bushen Zhuangjintang versus calcium granules after three months treatment (MD 0.10 g/cm³; 95% CI 0.05 to 0.15) (Analysis 3.2) (Lv ZH 2002);
- Yishen Yanggan mixture versus calcium gluconate after three months treatment (MD 0.04 g/cm³; 95% CI 0.01 to 0.07) (Analysis 3.2) (Xu W 2005);
- Kanggusong granule versus Caltrate after six months treatment (MD 0.06 g/cm³; 95% CI 0.02 to 0.11) (Analysis 3.2) (Wei RY 2011);
- Bushen Qianggutang versus Caltrate after three months treatment (MD 0.09 g/cm³; 95% CI 0.01 to 0.17) (Analysis 3.2) (Qi ZX 1998);
- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.06 g/cm³; 95% CI 0.03 to 0.09) (Analysis 3.2) (Wang ZK 2004);
- Bushen Zhuanggu tang versus alendronate sodium tablets after three months treatment (MD 0.04 g/cm³; 95% CI 0.01 to 0.07) (Analysis 3.2) (Ling JY 2008);
- Bushenjianpi Zhuangguyin versus Caltrate and calcitonin after 12 weeks treatment (MD 0.16 g/cm³; 95% CI 0.10 to 0.22) (Analysis 3.2) (Zhang XG 2011);
- Liuwei Dihuang pills versus Caltrate after six months (MD 0.05 g/ cm³; 95% CI 0.03 to 0.07) (Analysis 3.2) (Ma C 2011);
- Gujian capsule versus alfacalcidol after six months treatment (MD 0.14 g/cm³; 95% CI 0.03 to 0.26) (Analysis 3.2) (Meng XD 2003);
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.05 g/cm³; 95% Cl 0.03 to 0.07) (Analysis 3.2) (Ou L 2011);
- Kangshu Jiangu granule versus Caltrate after six months treatment (MD 0.11 g/cm³; 95% CI 0.01 to 0.21) (Analysis 3.2) (Shi CD 2012);
- Erxian soup versus Caltrate after six months treatment (MD 0.06 g/cm³; 95% CI 0.02 to 0.11) (Analysis 3.2) (Wu JZ 2010);
- Shangke Jiegu tablet versus vitamin D2 plus calcium tablet after six months treatment (MD 0.25 g/cm³; 95% CI 0.11 to 0.39) (Analysis 3.2) (Yuan YN 2000).

BMD of the radius

Treatment with Liuwei Dihuang pills statistically significantly increased the BMD of the radius as compared to a group supplemented with calcium. The difference at 12 months between before and after treatment was MD 0.04 g/cm³ (95% CI 0.03 to 0.05) (Analysis 3.2) (Zhang J 2003). Another trial of treatment with Gukang oral liquid as compared to treatment with calcium gluconate reported a significant increase in the BMD of the radius after six months treatment (MD 0.02 g/cm³; 95% CI 0.01 to 0.04) (Analysis 3.2) (Chen JP 1999). A third trial showed positive effects of herbal treatments when compared to vitamin D and Caltrate: compared with vitamin D plus Caltrate, Herba epimedii prescription statistically significantly increased the BMD of the radius after six months treatment (MD 0.07 g/cm³; 95% CI 0.04 to 0.11) (Analysis 3.2) (Dong YF 2004).

Chinese herbal medicines for treating osteoporosis (Review)

Copyright ${\ensuremath{\mathbb C}}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Other trials comparing herbal treatments to vitamin D and calcium showed no significant difference in the BMD of the radius, including:

- Bushen Yigu soft extract versus Alfacalcidol after three months treatment (MD 0.01 g/cm³; 95% CI -0.02 to 0.04) (Analysis 3.2) (Wang XY 2000);
- Bugu Shengsui capsule versus vitamin D2 and calcium tablets after six months treatment (MD 0.08 g/cm³; 95% CI -0.12 to 0.28) (Analysis 3.2) (Xie YM 1997);
- Shangke Jiegu tablet versus vitamin D2 and calcium tablets after six months treatment (MD 0.04 g/cm³; 95% CI 0.02 to 0.11) (Analysis 3.2) (Yuan YN 2000).

BMD of the ulna

Four trials showed no significant effects on the BMD of the ulna:

- Gukang oral liquid versus calcium gluconate (MD 0.00 g/cm³; 95% CI -0.02 to 0.02) (Analysis 3.2) (Chen JP 1999);
- Bushen Yigu soft extract versus Alfacalcidol after three months treatment (MD 0.02 g/cm³; 95% CI -0.01 to 0.05) (Analysis 3.2) (Wang XY 2000);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablets after six months treatment (MD 0.06 g/cm³; 95% CI -0.01 to 0.13) (Analysis 3.2) (Xie YM 1997);
- Shangke Jiegu tablet versus vitamin D2 plus calcium tablets after six months treatment (MD 0.05 g/cm³; 95% Cl 0.00 to 0.11) (Analysis 3.2) (Yuan YN 2000).

After 12 months treatment with Liuwei Dihuang pills, the BMD of the ulna was statistically significantly increased when compared with calcium supplementation (MD 0.02 g/cm^3 ; 95% CI 0.01 to 0.03) (Analysis 3.2) (Zhang J 2003).

BMD of the femoral neck

Eight trials of Chinese herbal medicines compared with supplementation with calcium or calcium plus other western medicine showed a significant increase in the BMD of the femoral neck:

- Qianggu soft extract versus calcium gluconate after six months treatment (MD 0.07 g/cm³; 95% CI 0.02 to 0.12) (Analysis 3.2) (Peng T 2002);
- Herba epimedii prescription versus vitamin D plus Caltrate after six months treatment (MD 0.06 g/cm³; 95% CI 0.02 to 0.10) (Analysis 3.2) (Dong YF 2004);
- Kangshu Jiangu granule versus Caltrate after six months treatment (MD 0.08 g/cm³; 95% CI 0.01 to 0.15) (Analysis 3.2) (Shi CD 2012);
- kidney-tonifying herbs versus calcium after six months treatment (MD 0.05 g/cm³; 95% CI 0.01 to 0.09) (Analysis 3.2) (Song XW 2000);
- Qianggu paste versus calcium gluconate after six months treatment (MD 0.07 g/cm³; 95% CI 0.03 to 0.11) (Analysis 3.2) (Wang H 2007);
- Yanghuo Sanzi Tang versus Caltrate after six months treatment (MD 0.05 g/cm³; 95% CI 0.02 to 0.08) (Analysis 3.2) (Qiu RB 2004);
- Jiangu capsule versus Caltrate after 12 months treatment (MD 0.04 g/cm³; 95% CI 0.03 to 0.06) (Analysis 3.2) (Wang YZ 2008);

 Gujian capsule versus alfacalcidol after six months treatment (MD 0.08 g/cm³; 95% CI 0.03 to 0.14) (Analysis 3.2) (Meng XD 2003).

Ten other trials showed no significant difference in the BMD of the femoral neck for those treated with Chinese herbal medicines when compared to control groups:

- Kanggusong granule versus Caltrate after nine months treatment (MD 0.01 g/cm³; 95% CI -0.03 to 0.05), Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD -0.01 g/cm³; 95% CI -0.04 to 0.02) (Analysis 3.2) (An SJ 2000);
- Bushen Jianpi decoction versus calcitonin (MD 0.05 g/cm³; 95% CI -0.02 to 0.12) (Analysis 3.2) (Mao YF 2011);
- Gumikang capsule versus calcium gluconate after six months treatment (MD 0.02 g/cm³; 95% CI -0.04 to 0.08) (Analysis 3.2) (Wang CC 2005);
- Yanghuo Sanzi Tang versus Caltrate after three months treatment (MD 0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 3.2) (Qiu RB 2004);
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.03 g/cm³; 95% CI -0.01 to 0.07) (Analysis 3.2) (Wang J 2007);
- Shigu yin versus Caltrate after six months treatment (MD 0.03 g/ cm³; 95% CI -0.01 to 0.07) (Analysis 3.2) (Zhang YP 2007);
- Bushen Huoxue capsule versus Caltrate plus calcitriol after 12 months treatment (MD 0.02 g/cm³; 95% CI -0.06 to 0.10) (Analysis 3.2) (Zhang XJ 2008);
- Bushenjianpi Zhuangguyin versus Caltrate and calcitonin after 12 weeks (MD 0.06 g/cm³; 95% CI 0.00 to 0.12) (Analysis 3.2) (Zhang XG 2011);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.09 g/cm³; 95% CI -0.05 to 0.23) (Analysis 3.2) (Xie YM 1997);
- Shangke Jiegu tablet versus vitamin D2 plus calcium tablet after six months treatment (MD 0.07 g/cm³; 95% CI -0.06 to 0.20) (Analysis 3.2) (Yuan YN 2000).

Three trials compared Chinese herbal medicines with western medicine and found no significant differences between groups on measurement of BMD of the femoral neck:

- Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone after six months treatment (MD -0.01 g/ cm³; 95% CI -0.11 to 0.09) (Analysis 3.2) (Liao L 2004);
- kidney-tonifying herbs versus nilestriol after six months treatment (MD 0.02 g/cm³; 95% CI -0.02 to 0.06) (Analysis 3.2) (Song XW 2000);
- Qianggu capsules versus oestradiol valerate after six months treatment (MD 0.02 g/cm³; 95% CI -0.02 to 0.06) (Analysis 3.2) (Ruan XY 2006).

BMD of Ward's triangle

Two trials showed no evidence of an effect on the BMD of Ward's triangle of Chinese herbal medicines when compared with alendronate after six months treatment:

- Qianggu capsule (MD 0.01 g/cm³; 95% CI -0.02 to 0.03) (Analysis 3.2) (Xu H 2010);
- Xianlinggubao capsule (MD 0.00 g/cm³; 95% Cl -0.02 to 0.02) (Analysis 3.2) (Xu M 2009).

Two other trials showed no evidence of an effect of Chinese herbal medicines when compared with vitamin D2 plus calcium tablet after six months treatment:

- Bugu Shengsui capsule (MD 0.07 g/cm³; 95% CI -0.05 to 0.19) (Analysis 3.2) (Xie YM 1997);
- Shangke Jiegu capsule (MD 0.10 g/cm³; 95% CI -0.01 to 0.22) (Analysis 3.2) (Yuan YN 2000).

There was no significant difference between Chinese herbal medicine (Kanggusong granule) and ipriflavone plus Caltrate (MD -0.03 g/cm³; 95% CI -0.07 to 0.01), or Caltrate alone (MD 0.00 g/cm³; 95% CI -0.04 to 0.04) after nine months treatment (Analysis 3.2) (An SJ 2000). Gujian capsule appeared statistically significantly better than alfacalcidol after six months treatment (MD 0.08 g/cm³; 95% CI 0.01 to 0.15) (Analysis 3.2) (Meng XD 2003).

The trial comparing kidney-tonifying herbs with treatment with nilestriol (MD 0.06 g/cm³; 95% CI 0.02 to 0.10) or supplementation with calcium (MD 0.10 g/cm³; 95% CI 0.06 to 0.14) (Analysis 3.2) (Song XW 2000) found a significant improvement in the BMD of Ward's triangle.

BMD of the trochanter

One trial showed better treatment effects of Chinese herbal medicines on the BMD of the trochanter when compared with calcium supplementation:

 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet after six months treatment (MD 0.19 g/cm³; 95% CI 0.04 to 0.33) (Analysis 3.2) (Yuan YN 2000).

However, two other trials showed no evidence of an effect of Chinese herbal medicines:

- Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD -0.01 g/cm³; 95% CI -0.05 to 0.03) (Analysis 3.2) (An SJ 2000), or versus Caltrate alone (MD 0.03 g/ cm³; 95% CI 0.00 to 0.06) (Analysis 3.2) (An SJ 2000);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.11 g/cm³; 95% CI -0.04 to 0.27) (Analysis 3.2) (Xie YM 1997).

There was a significant difference between Gujian capsule and alfacalcidol after six months treatment (MD 0.14 g/cm³; 95% CI 0.07 to 0.20) (Analysis 3.2) (Meng XD 2003).

BMD of the hip bone

There was no significant difference between the Chinese herbal medicine Gushukang granule and Calcium carbonate with vitamin D chewable tablets in the BMD of the hip bone after six months treatment: the MD was 0.02 g/cm³ (95% CI -0.02 to 0.06) (Analysis 3.2) (Chen ZX 2002). There was also no significant difference between the Chinese herbal medicine Guli powder when compared with Caltrate after six months treatment (MD 0.03 g/cm³; 95% CI -0.05 to 0.11) (Analysis 3.2) (Lan ZX 2006).

BMD of the distal radius

TPF capsule compared to calcium granules statistically significantly increased the BMD of the distal radius (MD 0.20 g/cm³; 95% CI 0.17 to 0.23) (Analysis 3.2) (Zhang YL 1996).

BMD of the calcaneus

Jiawei Zhuangyao Jianshen tang compared to compound calcium amino acid chelate capsules statistically significantly increased the BMD of the calcaneus (MD 0.06 g/cm³; 95% CI 0.01 to 0.11) (Analysis 3.2) (He N 2006).

T score in BMD measurement

Two trials reported T score in bone mineral density measurement:

- Jingujian granule versus Caltrate after three months treatment (MD 0.05; 95% CI -0.57 to 0.67) (Analysis 3.3) (Li YH 2008);
- Jingujian granule versus Caltrate after three months treatment (MD 0.03; 95% CI -0.04 to 0.10) (Analysis 3.3) (Li YH 2010).

Biochemical indicators

The effects of the interventions on biochemical indicators are shown in Appendix 5.

Summary: Comparison 03

In summary, 61 trials out of the 108 included trials evaluated Chinese herbal medicines compared with conventional western medicines.

The following Chinese herbal medicines increased the BMD of the lumbar spine: Jiawei Bushen Zhuangjintang Yishen Yanggan mixture, Kanggusong granule, Bushen Qianggutang, Bushen Jianpi Migu prescription, Bushen Zhuanggu tang, Bushenjianpi Zhuangguyin, Gujian capsule, Erxian soup, Shangke Jiegu tablet, Liuwei Dihuang pills, Kangshu Jiangu granule, Radix rehmanniae preparata and Radix astragali. However, the following did not increase the BMD of the lumbar spine: Kanggusong granule, Strong Bone capsule, Herba epimedii prescription, Bushen Shengsui principle, Bushen Jianpi Jingu decoction, Gukang oral liquid, kidney-tonifying herbs, Bushen Jianpi Huoxue recipe, Huangqi Sanxian tang, Qianggu capsule, Jianshenfang granule, Jiangu recipe, Gukang fang, Qianggu capsule, Bushen Huoxue capsules, Yinyanghuo, Shenyao capsules, Guli powder, Gushen Yijing tang, Bugu Shengsui capsule, Xianling Gusong capsules, Zishen Gukang pill, Gukang decoction, Gumiling granule, Gujian capsule, Xianlinggubao capsule and Bushen Tianjing Huoxue therapy.

Gukang oral liquid, Herba epimedii prescription and Liuwei Dihuang pills increased the BMD of the radius, while Bushen Yigu soft extract, Bugu Shengsui capsule and Shangke Jiegu tablet did not.

Liuwei Dihuang pills appeared to increase the BMD of the ulna, while Gukang oral liquid, Bushen Yigu soft extract, Bugu Shengsui capsule and Shangke Jiegu tablet did not.

The following Chinese herbal medicines appeared to improve the BMD of the femoral neck: Qianggu soft extract, Herba epimedii prescription, kidney-tonifying herbs, Qianggu paste, Yanghuo Sanzi tang, Jiangu capsule, Kangshu Jiangu granule and Gujian capsule. However, the following did not: Kanggusong granule, Bushen Jianpi decoction, Gumikang capsule, Yanghuo Sanzi Tang,



Qianggu capsule, Shigu yin, Bushen Huoxue capsule, Bushenjianpi Zhuangguyin, Bugu Shengsui capsule, Shangke Jiegu tablet and Bushen Shengsui principle.

Gujian capsule and kidney-tonifying herbs seemed to increase the BMD of Ward's triangle, while Qianggu capsule, Xianlinggubao capsule, Bugu Shengsui capsule, Shangke Jiegu capsule and Kanggusong granule did not.

Shangke Jiegu tablet and Gujian capsule appeared to increase the BMD of the trochanter, while Kanggusong granule and Bugu Shengsui capsule did not.

Gushukang granule and Guli powder did not show statistically significant increases in the BMD of the hip bone.

TPF capsule appeared to increase the BMD of the distal radius.

Jiawei Zhuangyao Jianshen tang statistically significantly increased the BMD of the calcaneus.

Jingujian granule did not show a statistically significant increase in the T score of BMD.

Chinese herbal medicines plus western medicine versus western medicine (Comparison 04)

Fourty-seven trials (involving 5529 patients) compared 42 different Chinese herbal medicines plus western medicine with western medicine (Cao GY 2010; Cao W 2010; Chen FS 2001; Chen XL 2010; Chen YQ 2001; Chen ZX 2002; Dai Y 2007; Deng WM 2012; Dong Y 2010; Fan HX 2004; Guo JH 2008; Han XL 2007; He XQ 2006; Hu J 2012; Huang JW 2008; Jian QQ 2010; Liang DB 2012; Li HW 2004; Li SL 2004; Liu JM 2012; Ma C 2011; Ma CZ 2011; Ma YJ 2011; Miu JQ 2008; Mu G 2001; Qiu ZX 2010; Ruan XY 2006; Tang ZA 2012; Wang SW 2003; Wang XD 2011; Wu W 2005; Xie J 2004; Xiong YH 2008; Xu H 2010; Xu M 2009; Yang B 2007; Ye AN 1998; Zhan HS 2009; Zhang DS 2011; Zhang RH 2004; Zhang XZ 2004; Zhang ZF 2011; Zhao G 2002; Zheng WK 2007; Zhou XT 2001; Zhu HM 2012; Zou JJ 2005).

The tested herbs included Antai capsule, Bushenhuoxue therapy, Bushen Qianggu Huoxue therapy, Bushen Qiangshen pill, Bushen Yangxue tang, Bushen Zhuanggutang, Bushen Zhuanggu granules, Bushen Kangsong pill, Bushenyiqihuoxue soup, Chinese medicine (combination of 10 herbs), Chinese medicine Bushenhuoxue recipe, Erxian Yanggu decoction, Gengnian Anyi tablet, Guben Zhuanggu capsules, Guilu Erxiantang, Gukang tablet, Gushen decoction, Gushukang granule, Gusongbao granule, Heche Dazao pill, Huangqi, Hugu capsule, Jiangu granule, Jiarong tablet, Jinwugutong capsules, Kanggusong soup, Liuwei Dihuang pills, Migu tablet, Qianggu capsule, Shangke Yishen Zhuanggu pill, Shengsuiyin recipe, Shugan zishen huoxue tang, traditional Chinese capsule, Xianlinggubao capsule, Xuduanzhuanggu capsule, Yigu capsule, Yishen Zhuanggu decoction, Yiyuanjiangu decoction, Zhuanggu capsule, Zhuangguqiangjin tablet, Zishen prescription and Ziyin Bushen Zhuanggu prescription. All these Chinese herbal medicines, except Huangqi, were mixtures of herbs. Based on our standard classification for Chinese herbal medicines, 17 herbs were Chinese proprietary medicine, and 25 were prescribed herbal formulae.

The reported outcomes included BMD of the lumbar spine, femoral neck, Ward's triangle, trochanter, hip bone and distal radius. Levels of oestradiol (E2), serum calcium (Ca), phosphorus (P), alkaline

phosphatase (ALP), bone Gla protein (BGP) and interleukin-6 (IL-6) were also measured, as was the improvement of lumbago and backache. We were not able to pool the data due to the variability of the tested Chinese herbal medicines and control interventions.

Based on the included trials, we created a 'Summary of findings' table for patient-important outcomes (fractures, quality of life, death, adverse effects) (see Summary of findings 4).

Fractures

Five trials reported the outcome fractures. One trial reported that eight new fractures occurred in the control group treated with placebo and calcium (0/70 versus 8/70; RR 0.06; 95% CI 0.00 to 1.00) (Analysis 4.1) (Zhang RH 2004). One trial reported one new fracture in the control group treated with placebo plus calcium and vitamin D (low-dose group: 0/60 versus 1/60; RR 0.33; 95% CI 0.01 to 8.02; high-dose group: 0/56 versus 1/60; RR 0.36; 95% CI 0.01 to 8.58) (Analysis 4.1) (Zhu HM 2012). One trial reported four new fractures in the herbal group (Bushen Zhuanggu granules plus calcium and vitamin D) and seven new fractures in the control group (placebo granules plus calcium and vitamin D) (4/88 versus 7/67; RR 0.44; 95% CI 0.13 to 1.43) (Analysis 4.1) (Deng WM 2012). One trial reported one new fracture in the control group (calcium and vitamin D) (0/45 versus 1/30; RR 0.22; 95% CI 0.01 to 5.34) (Analysis 4.1) (Li ZP 2011). One trial reported that no new fracture occurred in any group (Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule group, and calcitonin ampoule group) (Analysis 4.1) (Zhang ZF 2011).

Quality of life or symptoms including pain, muscle fatigue and limited mobility

Eight of 48 trials reported the improvement of lumbago and backache. Among them, four trials reported that Chinese herbal medicines were better than western medicines without reporting the number of cases with ache improvement in each group (Liang DB 2012; Wang XD 2011; Xu H 2010; Zhan HS 2009). The other three trials reported as follows:

- 55/57 versus 48/57: RR 1.15; 95% CI 1.01 to 1.30 (Analysis 4.5) (Chen XL 2010);
- 53/54 versus 51/53: RR 1.33; 95% CI 1.09 to 1.61 (Analysis 4.5) (Dong Y 2010);
- 40/45 versus 18/30: RR 1.48; 95% CI 1.09 to 2.02 (Analysis 4.5) (Li ZP 2011).

In another trial, no significant difference was found between comparable groups (43/45 versus 35/37: RR 1.01; 95% CI 0.91 to 1.12) (Analysis 4.5) (Zhang ZF 2011).

Only one trial reported the outcome quality of life: the mean difference in quality of life score was 5.30 (95% CI 3.67 to 6.93) (Analysis 4.4) (Liang DB 2012).

Death

No trials reported this outcome.

Adverse effects

Eight trials out of 48 reported no remarkable adverse effects occurring in any groups (Chen FS 2001; Liang DB 2012; Liu JM 2012; Ruan XY 2006; Tang ZA 2012; Xie J 2004; Zheng WK 2007; Zou JJ 2005). Fourteen trials reported some adverse symptoms:



- a few patients with nausea, vomiting, etc. after one month of treatment (Cao W 2010);
- three patients with constipation and canker sore symptoms (Chen YQ 2001);
- 21 (23.86%) and 21 (31.34%) adverse effects in the herbal group and control group, respectively, with the predominant effects being liver enzyme abnormality and gastrointestinal complaints (Deng WM 2012);
- a few patients with dizziness, rash, nausea, vomiting and cardiopalmus at the beginning of therapy, but no significant difference in comparison groups (Dong Y 2010);
- one patient with irregular vaginal bleeding and two with breast tenderness in the western medicine group (Fan HX 2004);
- two cases of abdominal distention, acid reflux, etc. in the Liuwei Dihuang pills group, three cases with similar gastrointestinal symptoms in the Liuwei Dihuang pills plus calcium and vitamin D group, and three with similar gastrointestinal symptoms in the calcium and vitamin D group (Ma C 2011);
- three patients with mild constipation in the herbal group (Wang XD 2011);
- four patients with adverse effects (gastrointestinal reaction, nervous system response, anaphylactic reaction, etc.) in the Jiangu granule group, five in the Gusongbao granule group and five in the western medicine group (Xiong YH 2008);
- six patients with nausea in the herbal group and three in the western medicine group (Xu H 2010);
- three patients with nausea in the herbal group and three in the western medicine group (Xu M 2009);
- three patients with constipation, one with dysthesia, one with elevated ALT, six with abdominal discomfort and one with gum swelling in the Xuduanzhuanggu capsule group; one with dizziness, one with skin petechiae, one with abdominal discomfort and one with gum swelling in the Gusongbao granule group; one with constipation, one with abdominal discomfort, one with sore throat, one with gum swelling and one with electrocardiogram abnormality in the control group (Zhan HS 2009);
- five patients with dry mouth symptoms, dreaminess, drynessheat in the experimental group, a few with a transient heightened blood calcium in the control group (Zhang RH 2004);
- five with flushed face, one with nausea and one with vomiting in 90 patients after using calcitonin (Zhang ZF 2011);
- 11 (18%), 12 (21%) and 11 (18%) adverse effects in the low-dose Xianlinggubao capsule group, high-dose Xianlinggubao capsule group and the control group, respectively, with the predominant effects being liver enzyme abnormality and gastrointestinal complaints (Zhu HM 2012).

The other 26 trials did not report adverse effects.

Bone mineral density (BMD)

BMD of the lumbar spine

Twenty-one trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of the lumbar spine:

 Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol after six months treatment (MD 0.06 g/cm³; 95% CI 0.01 to 0.11) (Analysis 4.2) (Chen FS 2001);

- Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate and alendronate sodium tablets after six months treatment (MD 0.12 g/cm³; 95% CI 0.08 to 0.16) (Analysis 4.2) (Han XL 2007);
- Shangke Yishen Zhuanggu pill, plus Caltrate and calcitonin, versus Caltrate and calcitonin after three months treatment (MD 0.04 g/cm³; 95% CI 0.03 to 0.05) (Analysis 4.2) (Hu J 2012);
- Gukang tablet plus oyster shell calcium chewable tablets and vitamin A and D capsules versus oyster shell calcium chewable tablets and vitamin A and D capsules after three months treatment (MD 0.24 g/cm³; 95% CI 0.14 to 0.34) (Analysis 4.2) (Liu JM 2012);
- Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after eight months treatment (MD 0.14 g/cm³; 95% CI 0.08 to 0.20) (Analysis 4.2) (Li HW 2004);
- Liuwei Dihuang pills plus Caltrate versus Caltrate after six months treatment (MD 0.05 g/cm³; 95% CI 0.02 to 0.08) (Analysis 4.2) (Ma C 2011);
- Xianlinggubao capsule plus Caltrate versus Caltrate after 12 months treatment (MD 0.30 g/cm³; 95% CI 0.25 to 0.35) (Analysis 4.2) (Wu W 2005);
- Migu tablet plus Caltrate versus Caltrate after 12 months treatment (MD 0.08 g/cm³; 95% CI 0.07 to 0.09) (Analysis 4.2) (Xie J 2004);
- Bushen Zhuanggutang plus Caltrate versus Caltrate after six months treatment (MD 0.14 g/cm³; 95% CI 0.06 to 0.22) (Analysis 4.2) (Ye AN 1998);
- Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after eight months treatment (MD 0.14 g/cm³; 95% CI 0.08 to 0.20) (Analysis 4.2) (Zhao G 2002);
- Guben Zhuanggu capsules plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm³; 95% CI 0.01 to 0.05) (Analysis 4.2) (Zou JJ 2005);
- Qianggu capsule plus alendronate versus alendronate after six months treatment (MD 0.08 g/cm³; 95% CI 0.03 to 0.12) (Analysis 4.2) (Xu H 2010);
- Xianlinggubao capsule plus alendronate versus alendronate after six months treatment (MD 0.06 g/cm³; 95% CI 0.03 to 0.09) (Analysis 4.2) (Xu M 2009);
- Xianlinggubao capsule plus Caltrate versus Caltrate after 12 months treatment (MD 0.31 g/cm³; 95% CI 0.28 to 0.34) (Analysis 4.2) (Qiu ZX 2010);
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.18 g/cm³; 95% CI 0.14 to 0.22), and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.17 g/cm³; 95% CI 0.14 to 0.20) (Analysis 4.2) (Dai Y 2007);
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.11 g/cm³; 95% CI 0.07 to 0.15) (Analysis 4.2) (Zheng WK 2007);
- Chinese medicine Bushenhuoxue recipe plus conventional western medicine (alfacalcidol soft capsules, bisphosphonate and salmon calcitonin, etc.) versus conventional western medicine after three months treatment (MD 0.16 g/cm³; 95% CI 0.09 to 0.22) (Analysis 4.2) (Cao GY 2010);

 Shengsuiyin recipe plus Caltrate versus Caltrate after 12 months treatment (MD 0.31 g/cm³; 95% CI 0.28 to 0.34) (Analysis 4.2) (Jian QQ 2010);

Cochrane

Librar\

- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.08 g/cm³; 95% CI 0.04 to 0.12) (Analysis 4.2) (Zhang RH 2004);
- Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 0.10 g/cm³; 95% CI 0.06 to 0.14) (Analysis 4.2) (Cao W 2010);
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after six months treatment (MD 0.06 g/cm³; 95% CI 0.01 to 0.11) (Analysis 4.2) (Yang B 2007).

No significant difference in the BMD of the lumbar spine was reported for any of the following comparisons of treatment groups:

- Jiarong tablet plus Caltrate versus Caltrate (MD 0.04 g/cm³; 95% CI -0.06 to 0.14) (Analysis 4.2) (Chen YQ 2001);
- Bushen Kangsong pill plus calcium carbonate tablets versus calcium carbonate tablets (MD 0.01 g/cm³; 95% CI -0.03 to 0.04) (Analysis 4.2) (Guo JH 2008);
- Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate and alendronate sodium tablets after three months treatment (MD 0.04 g/cm³; 95% CI -0.01 to 0.09) (Analysis 4.2) (Han XL 2007);
- Bushen Yangxue tang plus Caltrate versus Caltrate (MD 0.02 g/ cm³; 95% CI -0.02 to 0.06) (Analysis 4.2) (He XQ 2006);
- Bushenhuoxue therapy plus calcium carbonate tablets and alfacalcidol versus calcium carbonate tablets and alfacalcidol (MD -0.01 g/cm³; 95% CI -0.04 to 0.02) (Analysis 4.2) (Liang DB 2012);
- Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after four months treatment (MD 0.05 g/cm³; 95% CI 0.00 to 0.10) (Analysis 4.2) (Li HW 2004);
- Zhuanggu capsule plus Caltrate versus Caltrate (MD 0.01 g/cm³; 95% CI 0.00 to 0.02) (Analysis 4.2) (Li SL 2004);
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet (MD 0.02 g/cm³; 95% CI -0.01 to 0.05) (Analysis 4.2) (Ma CZ 2011);
- Yishen Zhuanggu decoction plus calcitriol soft capsule versus calcitriol soft capsule (MD 0.02 g/cm³; 95% CI 0.00 to 0.05) (Analysis 4.2) (Ma YJ 2011);
- Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil (MD 0.05 g/cm³; 95% CI -0.01 to 0.11) (Analysis 4.2) (Tang ZA 2012);
- Antai capsule plus Caltrate versus Caltrate (MD 0.04 g/cm³; 95% CI 0.00 to 0.08) (Analysis 4.2) (Wang SW 2003);
- Hugu capsule plus Caltrate versus placebo capsule plus Caltrate (MD 0.03 g/cm³; 95% CI 0.00 to 0.06) (Analysis 4.2) (Wang XD 2011);
- Xianlinggubao capsule plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm³; 95% CI -0.02 to 0.08) (Analysis 4.2) (Wu W 2005);
- Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after four months treatment (MD 0.05 g/cm³; 95% CI 0.00 to 0.10) (Analysis 4.2) (Zhao G 2002);

Guilu Erxiantang plus calcium carbonate tablet versus calcium carbonate tablet (MD 0.03 g/cm³; 95% CI -0.03 to 0.09) (Analysis 4.2) (Zhou XT 2001);

- Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (MD 0.00 g/cm³; 95% CI -0.04 to 0.04) and Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (MD 0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 4.2) (Zhu HM 2012);
- Bushen Kangsong pill plus calcium carbonate tablets versus calcium carbonate tablets after six months treatment (MD 0.01 g/cm³; 95% CI -0.03 to 0.04) (Analysis 4.2) (Guo JH 2008);
- Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.01 g/cm³; 95% CI -0.07 to 0.05) (Analysis 4.2) (Xiong YH 2008);
- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.03 g/cm³; 95% CI -0.03 to 0.09) (Analysis 4.2) (Dong Y 2010);
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD 0.01 g/cm³; 95% CI -0.03 to 0.06) (Analysis 4.2) (Zhang XZ 2004);
- Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD 0.04 g/cm³; 95% CI -0.02 to 0.10) (Analysis 4.2) (Xiong YH 2008);
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.02 g/cm³; 95% CI -0.01 to 0.05) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD -0.01 g/cm³; 95% CI -0.05 to 0.03) (Analysis 4.2) (Zhan HS 2009);
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD 0.01 g/cm³; 95% CI -0.04 to 0.06) (Analysis 4.2) (Zhang ZF 2011);
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after three months treatment (MD 0.03 g/cm³; 95% CI -0.01 to 0.07) (Analysis 4.2) (Yang B 2007).
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD 0.01 g/cm³; 95% CI -0.04 to 0.06) (Analysis 4.2) (Zhang ZF 2011);
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after three months treatment (MD 0.03 g/cm³; 95% CI -0.01 to 0.07) (Analysis 4.2) (Yang B 2007).

BMD of the femoral neck

Seven trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of the femoral neck:

 Jiarong tablet plus Caltrate versus Caltrate after six months treatment (MD 0.09 g/cm³; 95% CI 0.02 to 0.15) (Analysis 4.2) (Chen YQ 2001);



- Xianlinggubao capsule plus Caltrate versus Caltrate after 12 months treatment (MD 0.30 g/cm³; 95% CI 0.25 to 0.35) (Analysis 4.2) (Wu W 2005);
- Migu tablet plus Caltrate versus Caltrate (MD 0.09 g/cm³; 95% CI 0.08 to 0.10) (Analysis 4.2) (Xie J 2004);
- Chinese medicine Bushenhuoxue recipe plus conventional western medicine (alfacalcidol soft capsules, bisphosphonate and salmon calcitonin, etc.) versus conventional western medicine after three months treatment (MD 0.17 g/cm³; 95% CI 0.12 to 0.23) (Analysis 4.2) (Cao GY 2010);
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.26 g/cm³; 95% CI 0.22 to 0.30) and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.24 g/cm³; 95% CI 0.21 to 0.27) (Analysis 4.2) (Dai Y 2007);
- Huangqi plus calcium and vitamin D versus calcium and vitamin D after six months treatment (MD 0.07 g/cm³; 95% CI 0.03 to 0.11) (Analysis 4.2) (Yang B 2007);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.04 g/cm³; 95% CI 0.01 to 0.07) (Analysis 4.2) (Zhang RH 2004).

No significant difference in the BMD of the femoral neck was reported for any of the following comparisons of treatment groups:

- Qianggu capsules plus oestradiol valerate versus oestradiol valerate after six months treatment (MD 0.03 g/cm³; 95% CI -0.01 to 0.07) (Analysis 4.2) (Ruan XY 2006);
- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 0.01 g/cm³; 95% CI -0.02 to 0.04) (Analysis 4.2) (Wang SW 2003);
- Xianlinggubao capsule plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm³; 95% CI -0.02 to 0.08) (Analysis 4.2) (Wu W 2005);
- Guben Zhuanggu capsules plus Caltrate versus Caltrate after six months treatment (MD 0.01 g/cm³; 95% CI -0.01 to 0.02) (Analysis 4.2) (Zou JJ 2005);
- Heche Dazao pill plus oyster shell calcium chewable tablets versus oyster shell calcium chewable tablets after three months treatment (MD 0.04 g/cm³; 95% CI 0.00 to 0.07) (Analysis 4.2) (Chen XL 2010);
- Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD 0.01 g/ cm³; 95% CI -0.03 to 0.05) and Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.02 g/cm³; 95% CI -0.07 to 0.03) (Analysis 4.2) (Xiong YH 2008);
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.01 g/cm³; 95% CI -0.01 to 0.03) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 4.2) (Zhan HS 2009);

- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD 0.01 g/cm³; 95% CI -0.01 to 0.03) (Analysis 4.2) (Ma CZ 2011);
- Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil after three months treatment (MD 0.02 g/cm³; 95% CI -0.02 to 0.05) (Analysis 4.2) (Tang ZA 2012);
- Xianlinggubao capsule (low-dose or high-dose) plus calcium and vitamin D versus placebo plus calcium and vitamin D (MD -0.01 g/cm³; 95% CI -0.05 to 0.03) (Analysis 4.2) (Zhu HM 2012).

BMD of Ward's triangle

Six trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of Ward's triangle:

- Migu tablet plus Caltrate versus Caltrate (MD 0.09 g/cm³; 95% CI 0.08 to 0.10) (Analysis 4.2) (Xie J 2004);
- Qianggu capsule plus alendronate versus alendronate after six months treatment (MD 0.05 g/cm³; 95% CI 0.02 to 0.07) (Analysis 4.2) (Xu H 2010);
- Xianlinggubao capsule plus alendronate versus alendronate after six months treatment (MD 0.04 g/cm³; 95% CI 0.02 to 0.06) (Analysis 4.2) (Xu M 2009);
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.23 g/cm³; 95% Cl 0.19 to 0.27) and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.28 g/cm³; 95% Cl 0.24 to 0.32) (Analysis 4.2) (Dai Y 2007);
- Bushen Qianggu Huoxue therapy plus calcium and cod liver oil versus calcium and cod liver oil after three months treatment (MD 0.04 g/cm³; 95% CI 0.02 to 0.07) (Analysis 4.2) (Tang ZA 2012);
- Hugu capsule plus Caltrate versus placebo capsule plus Caltrate after six months treatment (MD 0.05 g/cm³; 95% CI 0.02 to 0.08) (Analysis 4.2) (Wang XD 2011).

No significant difference in the BMD of Ward's triangle was reported for any of the following comparisons of treatment groups:

- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 4.2) (Wang SW 2003);
- Gusongbao granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.01 g/ cm³; 95% CI -0.06 to 0.04) and Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule after six months treatment (MD -0.01 g/cm³; 95% CI -0.06 to 0.04) (Analysis 4.2) (Xiong YH 2008);
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.02 g/cm³; 95% Cl 0.00 to 0.04) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment

Copyright ${\ensuremath{\mathbb C}}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Chinese herbal medicines for treating osteoporosis (Review)

(MD 0.01 g/cm³; 95% CI -0.02 to 0.04) (Analysis 4.2) (Zhan HS 2009);

 Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.04 g/cm³; 95% CI 0.00 to 0.08) (Analysis 4.2) (Zhang RH 2004).

BMD of the trochanter

Cochrane

Three trials showed positive effects of Chinese herbal medicines plus western medicine treatments when compared to the same western medicine on the BMD of the trochanter:

- Migu tablet plus Caltrate versus Caltrate after six months treatment (MD 0.15 g/cm³; 95% CI 0.14 to 0.16) (Analysis 4.2) (Xie J 2004);
- Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.13 g/cm³; 95% CI 0.08 to 0.18) and Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule after six months treatment (MD 0.12 g/cm³; 95% CI 0.07 to 0.17) (Analysis 4.2) (Dai Y 2007);
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after six months treatment (MD 0.02 g/cm³; 95% Cl 0.01 to 0.04) (Analysis 4.2) (Ma CZ 2011).

No significant difference in the BMD of the trochanter was reported for any of the following comparisons of treatment groups:

- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 0.03 g/cm³; 95% CI 0.00 to 0.06) (Analysis 4.2) (Wang SW 2003);
- Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.00 g/cm³; 95% CI -0.02 to 0.02) and Gusongbao granule plus calcium tablet versus placebo plus calcium tablet after six months treatment (MD 0.00 g/cm³; 95% CI -0.03 to 0.03) (Analysis 4.2) (Zhan HS 2009);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 0.02 g/cm³; 95% CI -0.02 to 0.06) (Analysis 4.2) (Zhang RH 2004).

BMD of the hip bone

Compared with Calcium carbonate with vitamin D chewable tablets, Gushukang granule plus Calcium carbonate with vitamin D chewable tablets showed a statistically significantly better effect on the BMD of the hip bone after six months treatment (MD 0.15 g/ cm³; 95% CI 0.11 to 0.19) (Analysis 4.2) (Chen ZX 2002). There was no significant difference in the comparison of Jinwugutong capsules plus calcium and placebo plus calcium regarding the BMD of the hip bone (MD 0.01 g/cm³; 95% CI -0.02 to 0.04) (Analysis 4.2) (Zheng WK 2007).

BMD of the distal radius

There was no significant difference in the comparison of Gengnian Anyi tablet plus Caltrate and Caltrate regarding the BMD of the distal radius (MD 0.01 g/cm³; 95% CI -0.06 to 0.08) (Analysis 4.2) (Fan HX 2004). However, Bushen Zhuanggu granules plus calcium and vitamin D showed positive effects on the BMD of the distal radius when compared with placebo granules plus calcium and vitamin

D after five-year follow-up (MD 0.10 g/cm³; 95% CI 0.09 to 0.10) (Analysis 4.2) (Deng WM 2012).

T score in BMD measurement

One trial reported the T score in bone mineral density measurement: Erxian Yanggu decoction plus alendronate sodium tablets versus alendronate sodium tablets (MD of T score 0.91; 95% CI 0.57 to 1.25) (Analysis 4.3) (Huang JW 2008).

Biochemical indicators

The effects of the interventions on biochemical indicators are shown in Appendix 5.

Summary: Comparison 04

In summary, 37 trials out of 93 included trials evaluated Chinese herbal medicines plus conventional medicine compared with the same conventional medicine.

The results showed that the following Chinese herbal medicines appeared to increase the BMD of the lumbar spine: Gushen decoction, Shugan zishen huoxue tang, Erxian Yanggu decoction, Ziyin Bushen Zhuanggu prescription, Xianlinggubao capsules, Migu tablet, Bushen Zhuanggutang, Zishen prescription, Guben Zhuanggu capsules, Qianggu capsule, Jinwugutong capsule, Shengsuiyin recipe, Yigu capsule and Huangqi. However, the following did not: Jiarong tablet, Bushen Kangsong pill, Shugan zishen huoxue tang, Bushen Yangxue tang, Bushenhuoxue therapy, Ziyin Bushen Zhuanggu prescription, Zhuanggu capsule, Yiyuanjiangu decoction, Yishen Zhuanggu decoction, Bushen Qianggu Huoxue therapy, Antai capsule, Hugu capsule, Xianlinggubao capsule, Zishen prescription, Guilu Erxiantang, Bushen Kangsong pill, Gusongbao granule, Jiangu granule, Zhuangguqiangjin tablet and Shujinbogu tablet, Xuduanzhuanggu capsule and Huangqi.

The following Chinese herbal medicines appeared to increase the BMD of the femoral neck: Jiarong tablet, Xianlinggubao capsule, Migu tablet, Bushenhuoxue recipe, Huangqi and Yigu capsule. However, the following did not: Qianggu capsules, Antai capsule, Xianlinggubao capsule, Guben Zhuanggu capsules, Heche Dazao pill, Gusongbao granule, Jiangu granule, Xuduanzhuanggu capsule, Yiyuanjiangu decoction and Bushen Qianggu Huoxue therapy.

The following Chinese herbal medicines appeared to increase the BMD of Ward's triangle: Migu tablet, Qianggu capsule, Xianling Gubao capsule, Bushen Qianggu Huoxue therapy and Hugu capsule. However, the following did not: Antai capsule, Gusongbao granule, Xuduanzhuanggu capsule and Yigu capsule.

The following Chinese herbal medicines appeared to increase the BMD of the trochanter: Migu tablet, Yiyuanjiangu decoction and Xianlinggubao capsule. However, the following did not: Antai capsule, Xuduanzhuanggu capsule and Yigu capsule.

Gushukang granule seemed to increase the BMD of the hip bone, while Jinwugutong capsules did not.

Bushen Zhuanggu granules appeared to increase the BMD of the distal radius, while Gengnian Anyi tablet dd not.

Erxian Yanggu decoction appeared to increase the T score of BMD.



DISCUSSION

Due to poor study quality and limited data on the individual herbal interventions, no definitive conclusions can be drawn from this review on the effectiveness of any Chinese herbal medicine intervention tested to date.

Summary of main results

One hundred and eight randomised trials were included in this review. Ninety-nine different Chinese herbal medicines were compared with placebo, no intervention, conventional pharmaceutical medicine or with the same co-intervention received by the Chinese herbal medicines group. In this review, many of the trials showed a symptomatic benefit of Chinese herbal medicines in patients with osteoporosis either when compared with placebo, no intervention or conventional western medicine. However, there was a lack of replicable evidence because no more than one trial ever compared the same Chinese herbal medicine and control treatment. Thus, the finding of a benefit of Chinese herbal medicine treatment may not be conclusive. Furthermore, the findings of this review should be interpreted with caution due to the small sample sizes and generally low methodological quality of the included studies.

Compared with placebo in three trials, Chinese herbal medicines had a statistically significant effect in increasing bone mineral density (BMD) in each trial. One reported some mild adverse effects (such as stomach/intestinal upset, headache and dizziness) from Chinese herbal medicines, but there were no significant differences between the Chinese herbal medicines and placebo groups.

Five randomised trials compared seven different Chinese herbal medicines with no intervention. Two trials showed Chinese herbal medicines to be significantly effective in increasing BMD, while three others showed no better effect. Four trials reported mild adverse effects (e.g. mild stomach discomfort, intestinal upset, etc.) of Chinese herbal medicines, but this did not affect the continuation of the treatment.

Sixty-one trials compared 58 different Chinese herbal medicines with western medicine. Twenty-three trials showed that Chinese herbal medicines were significantly effective in increasing BMD, while 38 showed no better effect. Twenty-three reported some adverse effects (e.g. dizziness, rash, nausea, vomiting, etc.) from Chinese herbal medicines, but most of them did not affect the continuation of the treatment. Six reported no occurrence of adverse effects and 38 did not report adverse effects.

Forty-eight trials compared 42 different Chinese herbal medicines plus western medicine with western medicine. Twenty-six showed better effects in increasing BMD, while 22 did not. Fourteen reported some adverse symptoms (e.g. nausea, vomiting, etc.) from Chinese herbal medicines, but there was no significant difference between comparison groups. Eight reported no remarkable adverse effects and the other 26 did not report adverse effects.

Overall completeness and applicability of evidence

We performed this review to evaluate the benefit and harm of Chinese herbal medicines in patients with osteoporosis. Most of the Chinese herbal medicines evaluated were mixtures of different herbs and most of them were prescribed by the investigators without reporting of the quality standards for the preparations. Interpretation of these findings should therefore be cautious considering that along with the other methodological limitations in the study designs, these studies cannot be replicated. There is a risk that statistically significant findings from a handful of studies at questionable risk of bias are given more prominence than the lack of data for relevant endpoints available from the vast majority of included studies in the review.

The Chinese herbal medicines evaluated generally appeared to be safe. However, we cannot conclude that using Chinese herbal medicines in osteoporosis patients is safe, because adverse effects were not sufficiently and adequately reported in all the included trials. In clinical trials beneficial and harmful effects should receive equal attention, and the recording and reporting of adverse effects must improve if we are to draw any conclusions about safety.

Quality of the evidence

Due to the variations in the Chinese herbal medicines tested and the methodological limitations of the included trials, the evidence for Chinese herbal medicines for the treatment of osteoporosis is not conclusive. In general, Chinese herbal medicines might be a promising treatment. However, it is premature to recommend Chinese herbal medicines for routine use in osteoporosis considering the generally low quality of the evidence.

Most of the included trials suffered from insufficient reporting or inadequate methods of randomisation. The majority of the trials did not report how the random allocation was generated and concealed. Some trials had a significantly skewed distribution of participants among the groups compared which could not be explained if randomisation had been carried out properly. These trials were highly prone to selection bias.

Very few trials used a double-blinding method. The majority of treatment approaches in the included trials aimed to improve pain symptoms, which is a subjective indicator. If the outcome assessment is not blinded, then performance and detection bias may be a problem.

Most of the included trials were small. Although some data analyses did not demonstrate a statistically significant difference between the groups compared, the results were likely to have been underpowered to demonstrate equivalence. Therefore, the analyses from the small sample trials may not be able to establish with confidence that the two interventions had equivalent effects.

Overall the evidence is limited: potential bias may have occurred in the selection of participants, the administration of treatment and the assessment of outcomes in the included trials, which may obscure or exaggerate treatment effects. Methodologically less rigorous trials have been shown to have significantly larger intervention effects than trials conducted with more rigour (Egger 2003; Moher 1998; Schulz 1995). Therefore, the implications of our findings for clinical practice are very limited.

The trials identified in this review were mostly Chinese and all were conducted in Chinese participants: publication bias might therefore be an issue. An empirical study has shown that Chinese trials are significantly affected by publication bias (Vickers 1998). Furthermore, it is certainly an issue that so few of the included studies actually reported the right outcomes and we downgraded studies for selective reporting. Accordingly, publication bias should be taken into consideration when interpreting the present findings.

Moreover, most of the trials were of short duration and were not followed up long-term, thus they were unable to detect endpoint outcomes such as fracture or long-term adverse effects of the herbal treatments in patients with osteoporosis. Primary outcomes such as the occurrence of new fractures were reported in only a few trials, so we could not draw any conclusions about efficacy and safety.

Potential biases in the review process

In this review, we comprehensively searched for studies from appropriate databases, and selected trials and extracted data in duplicate. However, we did not find any unpublished studies or studies published in languages other than Chinese or English. Secondly, due to our limited resources, including time, we were not able to contact the original authors to verify unclear information, such as the methods used for random allocation generation and concealment. Furthermore, almost all Chinese herbal medicines in the included trials were tested only once and on small samples. This made it impossible for us to pool data to draw a robust conclusion.

Agreements and disagreements with other studies or reviews

We could not find any other reviews evaluating the benefits and harms of Chinese herbal medicines in patients with osteoporosis. Therefore, this review is the first time this has been reported. Many trials are not included in this review and are listed as excluded studies. Due to the variation among the Chinese herbal medicine interventions, it is not meaningful to compare the results from these excluded trials with those included in this review.

AUTHORS' CONCLUSIONS

Implications for practice

Based on this systematic review, some Chinese herbal medicines may have beneficial effects on the bone mineral density at anatomical sites in people with osteoporosis. However, a large number of the included studies have an uncertain risk of bias, there is a lack of relevant clinical endpoints in the available literature and the evidence is of low quality. Further rigorous studies are needed to demonstrate whether these effects are clinically meaningful and to detect other effects.

Implications for research

The potential benefit of Chinese herbal medicines as a treatment for osteoporosis needs to be further investigated by conducting high-quality trials to produce convincing evidence. Trials comparing Chinese herbal medicines with conventional pharmaceutical medicine should be designed rigorously. It would also be interesting to verify the additional benefits of Chinese herbal medicines when combined with conventional medicine versus the same medicine by itself. There are a wide range of therapeutic strategies in Traditional Chinese Medicine that address osteoporosis and the related Chinese medicine diagnosis of kidney deficiency. It would be useful for those with expertise in Chinese herbal medicine to group the herbal formulae by therapeutic strategy, so that the Chinese herbal medicines can be tested with reference to the therapeutic framework from which they were derived.

Outcome measures should include both clinical and surrogate outcomes. Standardised monitoring and reporting should be used for assessment of adverse effects. The methodological quality of randomised trials of Chinese herbal medicines for osteoporosis needs to be improved. The following aspects should be addressed: (i) detailed reporting of the methods used to generate the allocation sequence and conceal allocation; (ii) sufficient application of double-blinding with the use of an adequate placebo; (iii) clear descriptions of withdrawals/drop-outs during the trial and use of intention-to-treat analysis; (iv) reporting of clinically important outcome measures from long-term follow-up; and (v) reporting of the trial according to the CONSORT Statement guidelines (www.consort-statement.org).

ACKNOWLEDGEMENTS

The authors wish to acknowledge the helpful comments from Elizabeth Ghogomu, Lara Maxwell and the editorial group and their long-term support to make this review possible, and Christine Wade's contributions to the protocol and review.

This work is partially supported by the grant number 2011ZX09302-006(5) from the Ministry of Science and Technology of China. Jian Ping Liu was partially supported by grant number R24 AT001293 from the National Center for Complementary and Alternative Medicine of the US National Institutes of Health.



REFERENCES

References to studies included in this review

An SJ 2000 {published data only}

An SJ, Li T, Li E. Effect of kidney-tonifying herbs on ovary function and bone mass in postmenopausal women. *Chinese Journal of Osteoporosis* 2000;**6**(2):55-9.

Cao GY 2010 {published data only}

Cao GY, Zhang XM. Clinical observation of integrated traditional Chinese and western medicine in the treatment of osteoporosis. *Nei Mongol Journal of Traditional Chinese Medicine* 2010;**29**(2):18-9.

Cao W 2010 {published data only}

Cao W, Li JW. Clinical research of the treatment of postmenopausal osteoporosis with integration of traditional and western medicine. *Journal of New Chinese Medicine* 2010;**42**(4):44-5.

Chen FS 2001 {published data only}

Chen FS, Wei AS, Lang JM. Clinical observation on effect of 32 cases of postmenopausal osteoporosis treated with integrated traditional with western medicine. *New Journal of Traditional Chinese Medicine* 2001;**33**(11):42-3.

Chen JP 1999 {published data only}

Chen JP, Shao M, Du Y, Huang HX, Zhu BH, Lin YF. Clinical observation of the therapeutic effect of 36 cases with postmenopausal osteoporosis treated with Gukang oral solution. *New Journal of Traditional Chinese Medicine* 1999;**31**(7):22-3.

Chen NQ 2006 {published data only}

Chen NQ, An MH, Wu CL. Clinical study of Shenyao capsules on the treatment of 50 cases with primary osteoporosis. *Clinical Journal of Traditional Chinese Medicine* 2006;**18**(2):161-2.

Chen X 2008 {published data only}

Chen X. Curative effect observation of Gukangfang on treatment of primary osteoporosis. *Zhejiang Journal of Integrative Traditional and Western Medicine* 2008;**18**(7):402-4.

Chen XL 2010 {published data only}

Chen XL, Liang XH. Clinical observation of Heche Dazao pill on the treatment of 57 cases with primary osteoporosis. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2010;**16**(8):40-1.

Chen YQ 2001 {published data only}

Chen YQ, Huang YH. Clinical study of a Chinese medicine of replenishing kidney in treating postmenopausal osteoporosis. *China Contemporary Medicine* 2001;**7**(4):57-8.

Chen ZX 2002 {published data only}

Chen ZX, Xu XJ, Huang G, Hu JM. Clinical study of the treatment of postmenopausal osteoporosis with Gushukang granule combined with calcium. *Chinese Journal of Clinical Rehabilitation* 2002;**6**(23):3541-2.

Cui TH 1999 {published data only}

Cui TH, Yu JH, Ding S, Wang RP, Liu H, Shi QY, et al. A clinical study in 74 cases of type primary osteoporosis treated with Chinese medicine Strong bone capsule. *Suzhou University Journal of Medical Science* 1999;**19**(12):1291-4.

Dai Y 2007 {published data only}

Dai Y, Shen L, Yang YP, Xie J, Zhou PQ. Effects of Migu tablet on bone mineral density, serum levels of osteoprotegerin and its ligand and bone metabolic markers in patients with postmenopausal osteoporosis. *Chinese Journal of Integrative Traditional and Western Medicine* 2007;**27**(8):696-9.

Deng WM 2012 {published data only}

Deng WM, Zhang P, Huang H, Shen YG, Yang QH, Cui WL, et al. Five-year follow-up study of a kidney-tonifying herbal Fufang for prevention of postmenopausal osteoporosis and fragility fractures. *Journal of Bone and Mineral Metabolism* 2012;**30**:517-24.

Dong Y 2010 {published data only}

Dong Y, Lu Y, Hua LX. Efficacy of salmon calcitonin plus Xianlinggubao for osteoporosis and ostealgia in postmenopausal women: a clinical observation. *China Pharmacy* 2010;**21**(2):154-6.

Dong YF 2004 {published data only}

Dong YF. Clinical observation of Herba epimedii prescription in treating osteoporosis. *Journal of Chinese Medicinal Materials* 2004;**27**(8):620-2.

Fan HX 2004 {published data only}

Fan HX, Fan HY, Wang ZH. Clinical observation on the therapeutic effect of Gengnian Anyi tablet on postmenopausal osteoporosis. *Tianjin Journal of Traditional Chinese Medicine* 2004;**21**(1):20-1.

Gang PH 2001 {published data only}

Gang PH, Jiang SY. Clinical observation of Gumiling on osteoporosis. The national academic seminar of osteoporosis and osteoarthritis in 2001. 2001:327-30.

Gong L 2001 {published data only}

Gong L, Wang MY, Xia P, Cao JQ, Zhou JQ, Hu J. Clinical study of Yishen Zhuanggu mixture in treating 80 cases with primary osteoporosis. *Chinese Journal of Osteoporosis* 2001;**7**(2):149-51.

Guo JH 2008 {published data only}

Guo JH, Zhang YW, Zhao ZM, Yao RB, Shang W, Zang XL, et al. Effects of Bushen Kangsong pellet on bone mineral density in postmenopausal osteoporosis. *Journal of Anhui Traditional Chinese Medicine College* 2008;**27**(5):14-5.

Han XL 2007 {published data only}

Han XL, Lou ZJ, Shang FM, Lin HW. Clinical observation of Shugan zishen huoxue tang on 25 cases with postmenopausal osteoporosis. *Liaoning Journal of Traditional Chinese Medicine* 2007;**34**(9):1279-80.

Chinese herbal medicines for treating osteoporosis (Review)

Copyright $\ensuremath{\mathbb{C}}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



He MT 2007 {published data only}

He MT, Liang XM, Liang ZJ, Zhang BD. Clinical study of Bushen Huoxue recipe on the treatment of postmenopausal osteoporosis. *Shandong Journal of Traditional Chinese Medicine* 2007;**26**(7):447-9.

He N 2006 {published data only}

He N. Treatment of postmenopausal osteoporosis by modified 'Zhaungyao Jianshen Tang': a therapeutic effect observation. *Journal of Traditional Chinese Orthopedics and Traumatology* 2006;**18**(11):10-1.

He XQ 2006 {published data only}

He XQ. Clinical study of Bushen Yangxue tang on the treatment of postmenopausal osteoporosis and effect on BMD. *Journal of New Chinese Medicine* 2006;**38**(4):42-3.

Huang JW 2008 {published data only}

Huang JW, Chen JC, Huang JH, Lin AJ, Lin XZ. The influence of bone mineral density and cell factors of Erxianyanggu decoction and alendronate sodium tablets for patients with osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2008;**20**(3):12-3.

Huang ZJ 2008 {published data only}

Huang ZJ, Chen JX, Bai YB. Clinical research of Zishengukang pill for osteoporosis. *Letters in Biotechnology* 2008;**19**(2):263-4.

Hu J 2012 {published data only}

Hu J, Li C. Clinical observation of Bushenjianpi treatment of primary osteoporosis. *Hubei Journal of TCM* 2012;**34**(4):11-2.

Jian QQ 2010 {published data only}

Jian QQ, Xu Y. Clinical observation on effect of integration of traditional and western medicine in treating postmenopausal osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2010;**28**(9):82-3.

Lan ZX 2006 {published data only}

Lan ZX, Li LZ, Zhang JT, Wang ZQ, Chen C, Liu JY. Clinical study of Guli on treating primary osteoporosis of deficiency in spleen and kidney. *Journal of Sichuan Traditional Chinese Medicine* 2006;**24**(6):75-7.

Liang DB 2012 {published data only}

Liang DB, Zhuang H. Clinical observation of Bushenhuoxue therapy of osteoporosis. *Journal of New Chinese Medicine* 2012;**44**(5):53-5.

Liao L 2004 {published data only}

Liao L, Li XS, Cai QH, Liang YS, Lai RB, Xiao WC, et al. Clinical research of the Bushen Shengsui principle treating postmenopausal osteoporosis. *Chinese Journal of Information on traditional Chinese medicine* 2004;**11**(4):287-90.

Li BL 2007 {published data only}

Li BL, Huang CB, Tan JW, Li YF, Yang B. The Influence of bone metabolism using traditional Chinese medicine Jianshenfang granule in treating of postmenopausal osteoporosis patients. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(11):15-7.

Li HW 2004 {published data only}

Li HW, Liu F. Clinical observation on effect of Ziyin Bushen Zhuanggu prescription in treating postmenopausal osteoporosis. *The Chinese Medicine Magazine of China* 2004;**2**(3):114-6.

Ling JY 2008 {published data only}

Ling JY, Liu Q. Clinical study on treatment of postmenopausal osteoporosis by Bushenzhuanggu prescription. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):22-3.

Lin W 2000 {published data only}

Lin W, Wu HF, Deng LP, Wei XY, Ye GC, Liu QS, et al. Clinical use of traditional Chinese medicine Migu decoction in treating postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2000;**6**(3):71-2.

Li SL 2004 {published data only}

Li SL, Fan GJ, Tang AH, Liu CH, Luo GB, Tang XY. Clinical study of the treatment of postmenopausal osteoporosis with Strong bone capsule. *Chinese Journal of Osteoporosis* 2004;**10**(3):330-2.

Liu JM 2012 {published data only}

Liu JM, Xue L, Tian DX. Clinical research of primary osteoporosis treated with Gukang tablets. *World Journal of Integrated Traditional and Western Medicine* 2012;**7**(4):323-5, 354.

Li YH 2008 {published data only}

Li YH, Liu HH, Yang HJ, Li Y, Zhang LF, Liu F, et al. Clinical research of Jingujian granule for old people with osteoporosis. *Beijing Journal of Traditional Chinese Medicine* 2008;**27**(10):758-61.

Li YH 2010 {published data only}

Li YH, Xue L, Zhao FF, Zhu QQ, Li Y, Yang HJ. Effect of Jingujian granule on 129 primary osteoporosis cases. *Journal of Traditional Chinese Medicine* 2010;**51**(6):520-3.

Li ZP 2011 {published data only}

Li ZP, Tong HT, Sun GH, Lao RP, Liu ZJ. The effects of Kanggusong soup plus Caltrate on ALP and IL-6 of postmenopausal osteoporosis. *Journal of Yunnan University of Traditional Chinese Medicine* 2011;**34**(4):37-8, 46.

Li ZY 2006 {published data only}

Li ZY, Liu BG, Liu YM, Zhang JX. Clinical observation of Xianling Gubao capsules on postmenopausal osteoporosis. *Journal of Sichuan Traditional Chinese Medicine* 2006;**24**(1):83-4.

Lv ZH 2002 {published data only}

Lv ZH, Wen ZJ, Wu SP, Qiu JM, Qiu JX. Clinical observation of Jianwei Bushen Zhuangjintang on the treatment of primary osteoporosis. *China Journal of Orthopaedics and Traumatology* 2002;**15**(5):263-4.

Ma C 2011 {published data only}

Ma C. Clinical analysis on Liuwei Dihuang pills plus calcium in treating postmenopausal osteoporosis. *China Medicine and Pharmacy* 2011;**1**(18):74-5.

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Ma CZ 2011 {published data only}

Ma CZ. Clinical observation on combined treatment of traditional Chinese medicine and western medicine in treating osteoporosis. *Journal of New Chinese Medicine* 2011;**43**(9):56-7.

Mao YF 2011 {published data only}

Mao YF. Effect of Bushen Jianpi Jingu decoction on 75 postmenopausal osteoporosis. *Beijing Journal of Traditional Chinese Medicine* 2011;**30**(4):292-3.

Ma YJ 2011 {published data only}

Ma YJ, Ma YJ, Ma YL. A clinical observation on treating senile osteoporosis with Yishen Zhuanggu decoction. *Chinese Journal of the Practical Chinese with Modern Medicine* 2011;**24**(5):18-9.

Meng XD 2003 {published data only}

Meng XD, Xie YM, Huang YZ, Cui TH, Gao R, Tu RS, et al. Clinical study of Gujian capsule in treating primary osteoporosis with kidney-yang deficiency syndrome. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(3):445-7, 457.

Miu JQ 2008 {published data only}

Miu JQ. Clinical biochemical parameters observation of integrative Chinese and Western medicine for postmenopausal osteoporosis. *Chinese Journal of Applied Physiology* 2008;**24**(1):54-5.

Mu G 2001 {published data only}

Mu G, Mu JJ, Wang P, Zhang K. Clinical observation of Bushen Qiangshen pill plus Caltrate on postmenopausal osteoporosis. *Chinese Journal of Integrated Traditional with Western Medicine* 2001;**21**(5):382-3.

Mu G 2001a {published data only}

Mu G, Wang P, Mu JJ. Clinical study of Bushen Qiangshen pill on postmenopausal osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2001;**9**(1):20-2.

Ou L 2011 {published data only}

Ou L, Zeng XH, Zhao P. Clinical observation on Radix rehmanniae preparata and Radix astragali in treating postmenopausal osteoporosis. *Beijing Journal of Traditional Chinese Medicine* 2011;**30**(8):605-6.

Peng T 2002 {published data only}

Peng T, Huang ML, Xiong W, Wang L, Yang YP, Qi K, et al. Clinical and experimental study of Qianggu soft extract in treatment of type postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2002;**8**(4):337-41, 364.

Qiu RB 2004 {*published data only*}

Qiu RB, Shen RZ, Zhang PQ. Treatment of postmenopausal osteoporosis with Yanghuo Sanzi tang---A report of 30 cases. *Journal of Traditional Chinese Medicine* 2004;**24**(2):102-4.

Qiu RB 2008 {published data only}

Qiu RB, Shen RZ, Zhang PQ, Chen YL, Ye HP, Zhang Y. Clinical study about treatment of postmenopausal osteoporosis with Jiangu recipe. *Chinese Archives of Traditional Chinese Medicine* 2008;**26**(7):1529-30.

Qiu ZX 2010 {published data only}

Qiu ZX. Observation of the effect of Xianlinggubao capsule on 67 senile osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2010;**18**(8):52.

Qi ZX 1998 {published data only}

Qi ZX, Lin HY. Clinical observation on Bushen Qianggutang in treating primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 1998;**6**(6):41-2.

Ruan XY 2006 {published data only}

Ruan XY, Qi JM, Liu YL, Ji Y, Chen BY. Effects of traditional Chinese medicine on bone mineral density and femoral neck strength in postmenopausal women. *Chinese Journal of Osteoporosis* 2006;**12**(2):181-4.

Shao M 2003 {published data only}

Shao M, Huang HX, Zhao J. Clinical observation on effect of Gukang oral preparation in treating postmenopausal osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2003;**15**(3):11-2.

Shi CD 2012 {published data only}

Shi CD, Yuan PW, Yang XH. Observation of Kangshu Jiangu granule on postmenopausal osteoporosis, a report of 40 cases. *Shanxi Journal of Traditional Chinese Medicine* 2012;**28**(1):16-7.

Song XW 2000 {published data only}

Song XW, Chen BX, Shen PZ. Clinical study on postmenopausal osteoporosis treated by kidney-nourishing herbs. *Shanghai Journal of Traditional Chinese Medicine* 2000;**34**(7):28-9.

Tang ZA 2012 {published data only}

Tang ZA. Clinical observation on Bushen Qianggu Huoxue therapy in treating 42 primary osteoporosis. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2012;**18**(4):50-1.

Wang CC 2005 {published data only}

Wang CC, Shang LL, Liang JY. Clinical observation on the therapeutic effect of Gumikang capsule plus nuclear honey beans on postmenopausal osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2005;**17**(8):15-6.

Wang H 2007 {published data only}

Wang H. Clinical observation of Qianggu paste II for old people with osteoporosis. *Hubei Journal of Traditional Chinese Medicine* 2007;**29**(10):54-5.

Wang J 2007 {published data only}

Wang J, Zhang WK, Wang ZH. Qianggu capsule for postmenopausal osteoporosis in 28 cases. *Herald of Medicine* 2007;**26**(11):1325-7.

Wang JM 2008 {published data only}

Wang JM, Liu T. Clinical observation of Gukang on bone quality in postmenopausal osteoporosis patients. *Chinese Journal of Medical Traumatology & Orthopedics* 2008;**16**(11):8-9.

Chinese herbal medicines for treating osteoporosis (Review)



Wang SW 2003 {published data only}

Wang SW, Zheng BR, Sun JY, Xie YH. Effects of Antai capsule on women with postmenopausal osteoporosis. *Journal of the Fourth Military Medical University* 2003;**24**(14):1324-7.

Wang XD 2011 {published data only}

Wang XD, Deng WM, Hong MJ, Liu F, Wang Q, Sun P. Clinical study on Hugu capsule in treating postmenopausal osteoporosis. *Journal of Practical Medicine* 2011;**27**(9):1662-4.

Wang XY 2000 {published data only}

Wang XY, Zhang CL, Mo LL, Qu YQ, Han LL. The effect of Bushen Jianpi herbs on bone metabolism and estrogen in perimenopausal woman. *Journal of Guangzhou University of Traditional Chinese Medicine* 2000;**17**(3):230-2.

Wang YZ 2008 {published data only}

Wang YZ, Wang HC. Clinical research of Jiangu capsule for osteoporosis. *Chinese Journal of Guang Ming Chinese Medicine* 2008;**23**(8):1125-6.

Wang ZK 2004 {published data only}

Wang ZK. The effects of Bushen Jianpi Migu prescription on pain and relevant biochemical indexes in patients with senile osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(27):5930, 5949.

Wei RY 2011 {published data only}

Wei RY, Lao RP, Liu ZJ, Xu GR, Li ZP. Effect of anti-osteoporosis capsule on ostealgia and bone metabolism of postmenopausal osteoporosis patients. *Journal of New Chinese Medicine* 2011;**43**(1):61-3.

Wu JZ 2010 {published data only}

Wu JZ, Zhou XM, Zheng CX. Clinical observation of Erxian soup for primary osteoporosis. *Journal of New Chinese Medicine* 2010;**42**(2):25-6.

Wu MS 2001 {published data only}

Wu MS, Zhao SZ, Li E. Clinical study of Kanggusong granule in preventing and treating primary osteoporosis. *Traditional Chinese Medicine Research* 2001;**14**(1):26-8.

Wu MS 2007 {published data only}

Wu MS, Li E, Zhao SZ, Bai X, Li AY. Channel tropism of the prescription for kidney tonifying by target-oriented administration for osteoporosis. *Journal of Clinical Rehabilitative Tissue Engineering Research* 2007;**11**(27):5336-40.

Wu W 2005 {published data only}

Wu W, Li DF, Zhi XM, Han MQ. Preventive and therapeutic effects of Xianling Gubao capsule for postmenopausal osteoporosis. *Journal of Guangzhou University of Traditional Chinese Medicine* 2005;**22**(3):191-3.

Xiao W 2008 {published data only}

Xiao W, Huang MQ. Therapeutic effect observation of selfmade Gusong recipe for postmenopausal osteoporosis. *Medicine Innovation Research* 2008;**5**(14):67-8.

Xie J 2004 {published data only}

Xie J, Shen L, Yang YP, Zhou PQ, Gao L. Prevention action of Chinese herbs for tonifying kidney on bone loss in senile males: 1 year follow-up. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(24):5180-1.

Xie YM 1997 {published data only}

Xie YM, Zhang FZ, Zhou WQ, Gao P, Fu RJ, Zhao TY, et al. Clinical study of Bugu Shengsui capsule in treating primary osteoporosis with kidney-yang deficiency syndrome. *Chinese Journal of Integrated Traditional and Western Medicine* 1997;**17**(9):526-30.

Xiong YH 2008 {published data only}

Xiong YH, Teng WR, Liu T, Fu SC, Gu PF, Fu WY, et al. Jiangu granules in treatment of postmenopausal osteoporosis: a randomized, double-blind, double dummy, multicenter clinical trial. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):17-21.

Xu H 2010 {published data only}

Xu H, Ren DH, Liang Z, Wang J. Clinical observation of Qianggu capsule plus alendronate on postmenopausal osteoporosis. *Journal of Zhejiang University of Traditional Chinese Medicine* 2010;**34**(4):503-4.

Xu M 2009 {published data only}

Xu M, Liu BX, Huang CJ, Tang FY, Lou YM, Liang Z, et al. Clinical observation of Xianlinggubao plus alendronate on postmenopausal osteoporosis. *Journal of Liaoning University of Traditional Chinese Medicine* 2009;**11**(1):94-5.

Xu W 2005 {published data only}

Xu W, Chen YC, Zhang JF. Clinical observation on effect of Yishen Yanggan mixture in treating liver-kidney deficiency postmenopausal osteoporosis. *Chinese Traditional and Herbal Drugs* 2005;**36**(6):898-9.

Xu YL 2007 {published data only}

Xu YL, Jin JJ, Xu DY, Zheng Y. Effects of acupoint sticking of Migudan on bone Gla protein and hydroxyproline in the patients of primary osteoporosis. *Chinese Journal of Information on Traditional Chinese Medicine* 2007;**14**(6):17-9.

Yang B 2007 {published data only}

Yang B, Yang J. Clinical research of Huangqi for patients with postmenopausal osteoporosis. *Sichuan Medical Journal* 2007;**28**(3):291-3.

Ye AN 1998 {published data only}

Ye AN. Clinical observation of Bushen Zhuanggutang in treating 60 cases with senile osteoporosis. *New Journal of Traditional Chinese Medicine* 1998;**30**(7):52-3.

Yuan YN 2000 {published data only}

Yuan YN, Liu Y, Han P. Treatment of 30 cases of primary osteoporosis with Shanke Jiegu tables. *Hunan Guiding Journal of Traditional Chinese Medicine and Pharmacology* 2000;**6**(9):31-2.



Zhang DS 2011 {published data only}

Zhang DS, Cao W, Chen H, Zhang FK. Treatment of integration of traditional and western medicine on 60 cases with postmenopausal osteoporosis. *Traditional Chinese Medicinal Research* 2011;**24**(3):34-6.

Zhang J 2003 {published data only}

Zhang J, Yin SL, Yin HQ, Ling HW, Li W, Li XQ. Clinical observation on effect of Liuwei Dihuang pills in treating postmenopausal osteoporosis. *Journal of Clinical Internal Medicine* 2003;**20**(10):558.

Zhang RH 2004 {published data only}

Zhang RH, Chen KJ, Lu DX, Zhu XF, Ma XC. Clinical study on treatment of postmenopausal osteoporosis by Yiigu capsule. *Chinese Journal of Integrated Traditional with Western Medicine* 2004;**24**(8):680-4.

Zhang XG 2011 {published data only}

Zhang XG. Effect of Zhuangguyin on 100 cases with primary osteoporosis. *Acta Chinese Medicine and Pharmacology* 2011;**39**(1):109-11.

Zhang XJ 2008 {published data only}

Zhang XJ, He BR, Nie J. Clinical study on effect of Bushenhuoxue capsules for treatment of osteoporosis in aged males. *Chinese Archives of Traditional Chinese Medicine* 2008;**26**(2):307-11.

Zhang XZ 2004 {published data only}

Zhang XZ, Han JF, Qian GF, He M, Li Y, Gu L. Effects of Xianlinggubao capsule on bone mineral density and cytokines in postmenopausal osteoporotic patients. *Chinese Journal of Osteoporosis* 2004;**10**(1):90-3.

Zhang YL 1996 {published data only}

Zhang YL, Wu SL. Clinical observation of herbal medicine in treating 120 senile male cases with primary osteoporosis. *New Journal of Traditional Chinese Medicine* 1996;**28**(2):58-60.

Zhang YP 2007 {published data only}

Zhang YP, Cui YH, Kang HY, Zhang B. Therapeutic effect observation and influence of bone formation and damage indexes of Shigu yin for patients with postmenopausal osteoporosis. *Journal of New Chinese Medicine* 2007;**39**(1):30-1.

Zhang YS 2003 {published data only}

Zhang YS, Zhai MY, Guo L, Liu N, Han MX, Bai XM. Clinical and experimental study of the treatment of primary osteoporosis with Huoluo Gukang pills. *Journal of Traditional Chinese Orthopedics and Traumatology* 2003;**15**(7):9-11.

Zhang ZF 2011 {published data only}

Zhang ZF, Ye WH. Effect of Zhuangguqiangjin tablet on cases with liver and kidney deficiency osteoporosis. *Journal of New Chinese Medicine* 2011;**43**(5):70-2.

Zhan HS 2009 {published data only}

Zhan HS, Shi YY, Zhao YF, Hu XY, He ZY, Lou XF, et al. Phase clinical investigation of Xuduanzhuanggu capsules to the primary osteoporotic patient. *Chinese Journal of Osteoporosis* 2009;**15**(3):197-200.

Zhan ML 2007 {published data only}

Zhan ML, Yang YF, Zhang J, Li JP. Therapeutic effect observation of Bushenyangxue decoction for postmenopausal osteoporosis. *Gansu Journal of Traditional Chinese Medicine* 2007;**20**(2):37-8.

Zhao G 2002 {published data only}

Zhao G, Cai DF, Dong SF, Fan Y. Clinical study in 25 cases of postmenopausal osteoporosis treated with Zishen prescription. *Journal of Traditional Chinese Medicine* 2002;**43**(6):444-5.

Zhao HX 2001 {published data only}

Zhao HX. Clinical efficacy of Kanggusong capsule in treating postmenopausal osteoporosis. *Chinese Journal of Traditional Chinese Medicine and Pharmacy* 2001;**16**(2):31-3.

Zhao LN 2003 {published data only}

Zhao LN. Preventive and therapeutic effects of Yinyanghuo for osteoporosis. *Modern Journal of Integrated Traditional Chinese and Western Medicine* 2003;**12**(9):922-3.

Zheng WK 2007 {published data only}

Zheng WK, Liu CY, Han CY, Zhou YJ. Clinical study on treatment of postmenopausal osteoporosis by Jinwugutong capsule. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(3):30-2.

Zhong RQ 2007 {published data only}

Zhong RQ, Pan GM, Deng WM, Zhang GC. Clinical study of Gushenyijingtang on the treatment of primary osteoporosis of deficiency in kidney yang. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(9):16-8.

Zhou LZ 2001 {published data only}

Zhou LZ, Ma Y. Clinical observation of traditional Chinese medicine on primary osteoporosis. The National Academic Seminar of Osteoporosis and Osteoarthritis in 2001. 2001:134-9.

Zhou XT 2001 {published data only}

Zhou XT. Clinical research of 45 cases with osteoporosis treated by Guilu Erxiantang. *Jiangsu Journal of Traditional Chinese Medicine* 2001;**22**(6):28.

Zhou ZK 2006 {published data only}

Zhou ZK, Zeng HB, Qin JJ, Chen C. Clinical observation of Huangqi Sanxian tang on 30 cases with postmenopausal osteoporosis. *Journal of New Chinese Medicine* 2006;**38**(6):40-1.

Zhu HJ 2011 {published data only}

Zhu HJ, Duan ZZ, Liao KH, Tan N, Huang SG. Clinical observation on Bushen Tianjing Huoxue therapy in treating primary osteoporosis. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2011;**17**(12):30-2.

Zhu HM 2012 {published data only}

Zhu HM, Qin L, Garnero P, Genant HK, Zhang G, Dai K, et al. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis. *Osteoporosis International* 2012;**23**:1317-27.

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Zou JJ 2005 {*published data only*}

Zou JJ, Liu ZM, Zheng JY, Zhao WM, Liu Y, Shi YQ. Clinical investigation of Gu Ben Jian Gu capsules to the primary osteoporotic patient. *Journal of Practical Training of Medicine* 2005;**33**(2):96-8.

References to studies excluded from this review

Ai SC 2003 {published data only}

Ai SC, Yang L, Liao FZ, Chen XL. Influence of herbal application at Shenque (CV 8) on BGP in primary osteoporosis. *Shanghai Journal of Acupuncture and Moxibustion* 2003;**22**(3):39-40.

Ai SC 2003a {published data only}

Ai SC, Wong M, Liao FZ, Chen XL. Influence of herbal application at Shenque on interleukin-6 in primary osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2003;**21**(2):13-5.

Bo LY 2003 {published data only}

Bo LY, Wu CS, Wang XX. Clinical observation on the use of Gushukang in treating of osteoporotic compression fracture of the spine. *Chinese Journal of Bone Tumor and Bone Disease* 2003;**2**(5):298-300.

Chen AP 2005 {published data only}

Chen AP, Chen YZ. Clinical observation on effect of Liuwei Dihuang pills in treating senile osteoporosis. *Journal of Chinese Modern Medicine* 2005;**2**(5):456-7.

Chen JJ 2010 {published data only}

Chen JJ, Lou Q, Ning JC. Analysis of CT bone mineral density of senile osteoporosis cases treated by integration of traditional Chinese and western medicine. *International Medicine & Health Guidance News* 2010;**16**(12):1488-90.

Chen XF 2003 {published data only}

Chen XF, Jiang YX. Effect of Xianling Gubao plus vitamin D3 and calcium amino acid chelate on bone mineral density and pain in osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(27):3769.

Chen XF 2007 {published data only}

Chen XF, Lan TF. Therapeutic effect observation of Bushen Jianpi Huoxue method for patients with senile osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2007;**25**(10):60-1.

Dai Y 2007a {published data only}

Dai Y, Shen L. Effects of Migu tablet on bone mineral density, serum matrix metalloproteinase-2 level and bone metabolic markers in postmenopausal osteoporosis. *China Journal of Chinese Materia Medica* 2007;**32**(22):2409-12.

Deng WM 1997 {published data only}

Deng WM, He YS, Feng YJ. Clinical study on postmenopausal osteoporosis syndrome treated with tonifying kidney to strength bone decoction. *Chinese Journal of Traditional Medical Science and Technology* 1997;**4**(2):70-2.

Deng WM 1997a {published data only}

Deng WM, He YS, Feng YJ. Clinical effect of kidney-tonifying herbs on postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 1997;**3**(1):64-6.

Deng WM 2001 {published data only}

Deng WM, Shen YG, He YS, Wei S. Influences of Bushen Zhuanggu granule on contents of sexual hormones and metabolism of calcium and phosphorous in early menopausal woman. *Journal of Guangzhou University of Traditional Chinese Medicine* 2001;**18**(4):301-3.

Deng WM 2002 {published data only}

Deng WM, Cui WL, Shen YG, Yang QH, He YS, Wei S. Effects of a 2-year treatment with Bushen Zhuanggu granule for postmenopausal osteoporosis. *Journal of Guangzhou University of Traditional Chinese Medicine* 2002;**19**(4):275-8.

Ding GZ 1995 {published data only}

Ding GZ, Zhang ZL, Zhou Y, Li R. Clinical study on effect of Bushen Jiangu capsule on postmenopausal osteoporosis. *Chinese Journal of Integrated Traditional and Western Medicine* 1995;**15**(7):392-4.

Dong YL 2004 {published data only}

Dong YL. Clinical observation of Liuwei Dihuang pills combined with west medicine in treating 60 senile patients with deficiency of kidney-YIN osteoporosis. *Clinical Journal of Traditional Chinese Medicine* 2004;**16**(2):135-6.

Fan GF 2008 {published data only}

Fan GF, Qi ZJ, Chen RX, Dong SL, Wang FG, Zhou CJ. Therapeutic effect observation of Qiangjin Zhuanggu pill for patients with primary osteoporotic lumbago and backache. *Journal of Traditional Chinese Orthopedics and Traumatology* 2008;**20**(2):13-4.

Fan ZY 1995 {published data only}

Fan ZY. Clinical observation on effect of Yugu pill in treating osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 1995;**13**(1):43-4.

Ge L 2005 {published data only}

Ge L, Dai FF, Cai X. Clinical observation of treating primary osteoporosis of female patients with Jiangu pills. *Jiangsu Journal of Traditional Chinese Medicine* 2005;**26**(3):24-5.

Gong L 2000 {published data only}

Gong L, Wang MY, Cao JQ, Xu F, Zhou PQ, Hu J. Clinical study of Yishen Zhuanggu mixture in treating 17 cases with osteoporosis. *Journal of Traditional Chinese Medicine* 2000;**41**(10):606-7.

Gong ZF 2011 {published data only}

Gong ZF. Effect of Bushenshujing soup and Celecoxib on primary osteoporosis with low back pain. *Chinese Journal of Clinical Research* 2011;**24**(2):155-6.

Gu M 2004 {published data only}

Gu M, Guo JN. Clinical study of the treatment of primary osteoporosis with Fortune's drynaria rhizome. *Chinese Journal of Rehabilitation* 2004;**19**(5):297.

Chinese herbal medicines for treating osteoporosis (Review)

Guo F 2003 {published data only}

Guo F. Clinical observation on Yishen Yanggan decoction treating 30 cases of osteoporosis. *Modern Diagnosis & Treatment* 2003;**14**(5):268-9.

Guo HN 1998 {published data only}

Guo HN, Wang WZ, Tian WM. Clinical observation of herbal medicine in treating 120 primary osteoporosis. *Journal of Hebei Traditional Chinese Medicine and Pharmacology* 1998;**13**(3):4-6.

Gu T 2011 {published data only}

Gu T, Jin W. Integration of traditional and western medicine on 26 primary osteoporosis. *Yunnan Journal of Traditional Chinese Medicine and Materia Medica* 2011;**32**(4):32.

He YC 2008 {published data only}

He YC, Liao KX, Huang YR, Jiang TB. Curative effect of Xianlinggubao capsule on thoracolumbar burst fracture in senile patients with osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**163**(312-13):12-3.

Hu XD 2011 {published data only}

Hu XD. Clinical discussion on treating 164 cases of patients with senile osteoporosis in TCM. *Clinical Journal of Chinese Medicine* 2011;**3**(3):94-5.

Jia JH 2010 {published data only}

Jia JH, Chen XF, Zhang Z, Wang XP. Shugukang decoction in the treatment of primary osteoporosis: a clinical observation of 60 cases. *Journal of Anhui Traditional Chinese Medical College* 2010;**29**(1):28-31.

Jiang SY 1995 {published data only}

Jiang SY, Shang YP, Wu LS, Liu BY, Zhang L, Guo RY, et al. Clinical observation of Gushukang granule on osteoporosis. *Chinese Journal of Osteoporosis* 1995;**1**(2):158, 167-9.

Ke Q 2005 {published data only}

Ke Q, Liu HQ, Niu W. Effect of kidney-tonifying herbs on bone mineral density, serum calcium and serum alkaline phosphatase in postmenopausal osteoporosis patients. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(31):186, 189.

Ke Q 2005a {published data only}

Ke Q, Liu HQ, Chen XC, Wu DF. Clinical observation of kidneytonifying herbs in treating 95 senile male cases with renal deficiency primary osteoporosis. *Information on Traditional Chinese Medicine* 2005;**22**(6):26-7.

Li BL 2007a {published data only}

Li BL, Li YF, Tan JW, Geng WZ, Zhan Q. Effect of bone metabolism index of Jianshen prescription for patients with postmenopausal osteoporotic vertebral fracture. *Journal of Traditional Chinese Orthopedics and Traumatology* 2007;**19**(9):4-5.

Li CX 2005 {published data only}

Li CX. Effect of movement therapy plus herbal medicine on bone mineral density in senile osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2005;**9**(7):95, 97.

Li JF 2008 {published data only}

Li JF, Xiao YH. Therapeutic effect observation of Bushen Qianggu tang for primary osteoporosis. *Practical Clinical Medicine* 2008;**9**(5):66-7.

Lin HY 1998 {published data only}

Lin HY, Qi ZX. Clinical observation of Yishen Jiangu tang in treating osteoporosis. *Fujian Journal of Traditional Chinese Medicine* 1998;**29**(2):9-10.

Liu HB 2005 {published data only}

Liu HB, Ai SC, Wu LD. Clinical observation of medicineseparated sticking on Shenque on sex hormone in primary osteoporosis. *Journal of Sichuan of Traditional Chinese Medicine* 2005;**23**(9):74-5.

Liu HQ 2010 {published data only}

Liu HQ, Qin JJ. Effect of Gukang granule in treating postmenopausal osteoporosis with kidney yang deficiency. *Journal of Shandong University of TCM* 2010;**34**(1):48-9.

Liu TS 2008 {published data only}

Liu TS. Therapeutic effect of integrative Chinese and Western medicine for patients with osteoporosis in 62 cases. *Journal of Shanxi College of Traditional Chinese Medicine* 2008;**9**(6):34-5.

Liu YS 2011 {published data only}

Liu YS. Treatment of 49 cases of postmenopausal osteoporosis with Jiaweierxian soup. *Guangming Journal of Chinese Medicine* 2011;**26**(4):698-9.

Liu YX 1998 {published data only}

Liu YX. Clinical study of Fuguning granule on postmenopausal osteoporosis. *Liaoning Journal of Traditional Chinese Medicine* 1998;**25**(6):284-5.

Li YM 2005 {published data only}

Li YM. Treatment of 60 cases of postmenopausal osteoporosis with Bushen Huoxue preparation. *Journal of Nanjing University of Traditional Chinese Medicine* 2005;**21**(1):56-7.

Luo QY 2011 {published data only}

Luo QY, Wen DH. Treatment of 24 cases of senile osteoporosis with Huoluoxiaoling pill. *Journal of Practical Traditional Chinese Medicine* 2011;**27**(4):245.

Lu W 2004 {published data only}

Lu W, Chu XG, Peng TP. Clinical study of the treatment of primary osteoporosis with Bushen Jiangu tang. *Jiangxi Journal of Traditional Chinese Medicine* 2004;**35**(259):27.

Lu ZD 2004 {published data only}

Lu ZD, Wang YS. Clinical observation of Gushukang in treating 80 primary osteoporosis patients. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(18):3652.

Pan X 2004 {published data only}

Pan X, Wang DY. Treatment of 34 cases of primary osteoporosis with Huangqi injection to acupoint. *Shanxi Journal of Traditional Chinese Medicine* 2004;**25**(12):1133-4.

Chinese herbal medicines for treating osteoporosis (Review)



Peng T 2003 {published data only}

Peng T, Chu ZR, Lu Y, Qi K, Liu JQ, Huang JH. Clinical observation of Qianggu extracts in treating postmenopausal osteoporosis. *Acta Universitatis Traditionis Medicalis Sinensis Pharmacologiaeque Shanghai* 2003;**17**(3):25-7.

Qi ZX 2000 {published data only}

Qi ZX, Lin HY. The clinical research of Shengsuiyin on the primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2000;**8**(5):21-2.

Ren JH 2011 {published data only}

Ren JH. Effect of Jinwugutong and alendronate sodium on postmenopausal osteoporosis patients with pain. *Guiding Journal of Traditional Chinese Medicine and Pharmacy* 2011;**17**(1):60-1.

Shang YM 2007 {published data only}

Shang YM, Liu YY, Li HP. Clinical observation of Xianlinggubao capsule on postmenopausal osteoporosis. *Chinese Journal of Integrated Traditional and Western Medicine in Intensive and Critical Care* 2007;**14**(1):55.

Shi B 2010 {published data only}

Shi B. Clinical observation of traditional Chinese Medicine for senile osteoporosis. *Chinese Journal of Ethnomedicine and Ethnopharmacy* 2010;**19**(12):39-40.

Shou ZX 2008 {published data only}

Shou ZX, Shen L, Fan H, Xie J, Yang YP, Zhou PQ, et al. Clinical observation on Qianggu Huoli pills in the treatment of primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(10):1-2.

Shuai B 2008 {published data only}

Shuai B, Shen L, Yang YP, Xie J, Zhou PQ, Gao L, et al. Clinical study (phase III) on the effects of Jiangu granula in primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(3):27-30.

Shu J 2005 {published data only}

Shu J. Clinical observation of Bushen Yijing prescription in treating 50 osteoporosis patients. *Journal of Occupational Health and Damage* 2005;**20**(2):143-4.

Song HX 2003 {published data only}

Song HX. Treatment of 84 cases of osteoporosis with Bushen Yijing method. *Shanxi Journal of Traditional Chinese Medicine* 2003;**24**(12):1075-7.

Song XW 1997 {published data only}

Song XW, Song ZJ, Shen PZ. Clinical observation of Bushen herbal medicine in treating postmenopausal osteoporosis. *The Practical Journal of Integrating Chinese with Modern Medicine* 1997;**10**(9):892.

Song XW 2001 {published data only}

Song XW, Shen PZ, Chen BX. Clinical study of Bushenhuoxue recipe on postmenopausal osteoporosis. *China Journal of Orthopaedics and Traumatology* 2001;**14**(8):476.

Su CH 2004 {published data only}

Su CH, Cui TH, Sang SB, Wu YW, Ding S, Jiang YM, et al. Comparison of strong bone capsule and calcium carbonate combined with vitamin D in the treatment of senile osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(29):6429-31.

Su CH 2005 {published data only}

Su CH, Cui TH, Sang SB, Wu YW, Wang DL, Jiang JW, et al. Clinical study of 105 patients with postmenopausal osteoporosis treated by TCM strong bone capsule and Caltrate. *Liaoning Journal of Traditional Chinese Medicine* 2005;**32**(7):701-3.

Sun JM 2002 {published data only}

Sun JM, Fu GM, Zhang HL. Analysis of the therapeutic effect of Yiqi Tiansui mixture on osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2002;**6**(9):1309.

Sun X 2002 {published data only}

Sun X. Clinical observation of the therapeutic effect of Jiawei Zuogui pill on osteoporosis with back pain. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2002;**10**(5):36-7.

Sun YM 2008 {published data only}

Sun YM, Wang PM, Zha W, Zhao HQ, Xia JL, Liu XQ, et al. Research on the influence of the manifestations in the primary osteoporosis patients by Ge Gen (Radix Puerariae). *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):14-6.

Su YB 2008 {published data only}

Su YB, Li MX, Lin YF, Zheng YM, Wu ZB, Rao HC, et al. Clinical observation of Qianggu Huoxue tang for primary osteoporosis combined with distal radius fracture. *Journal of Traditional Chinese Orthopedics and Traumatology* 2008;**20**(7):17-8.

Su ZW 2010 {published data only}

Su ZW, Zheng ZY, Jin J. Clinical observation of Bushenzhuanggu soup for primary osteoporosis. *Journal of Hebei Traditional Chinese Medicine and Pharmacology* 2010;**25**(1):17-8.

Tang JM 1999 {published data only}

Tang JM, Liu KJ, Wang GX. Effect of Jiangu powder on bone mineral density in three type of renal deficiency of osteoporosis. *Chinese Journal of Information on Traditional Chinese Medicine* 1999;**6**(10):51.

Tan X 2010 {published data only}

Tan X, Huang H, Liu Z, Liu HY, Shao Y, Ceng D, et al. Clinical study of the effect of Bushen Zhuanggu powder on bone transformation in aged males with osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2010;**18**(7):17-20.

Tu PS 2008 {published data only}

Tu PS, Deng WQ, Li MJ, Wu XY, Lv ZY, Zhou HJ. Clinical observation of Shuanggu decoction for patients with postmenopausal osteoporosis in 30 cases. *Chinese Journal of Traditional Medical Science and Technology* 2008;**15**(6):471-2.

Chinese herbal medicines for treating osteoporosis (Review)



Wang CH 2003 {published data only}

Wang CH, Tian LM, Jiang YP, Li JC, Chen XF, Li F, et al. Clinical effects of Gusongkang capsule on senile osteoporosis. *Journal of the Fourth Military Medical University* 2003;**24**(11):1029-31.

Wang GH 2011 {published data only}

Wang GH, Wei XX. Clinical observation on primary osteoporosis treated by Zhuanggutongluobao. *China Journal of Chinese Medicine* 2011;**26**(8):999-1000.

Wang HM 1998 {published data only}

Wang HM, Ge JR, Li N. Clinical observation of treating osteoporosis of old people with Bugu capsule. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 1998;**6**(4):13-4.

Wang J 2008 {published data only}

Wang J, Li WJ, Wang HY, Yang JY, Lin XS, Li A. Therapeutic effect observation of Ganshen Tongzhi method in treating postmenopausal osteoporosis in 38 cases. *Journal of New Chinese Medicine* 2008;**40**(6):54-5.

Wang JH 2001 {published data only}

Wang JH, Li ZG. The investigation on the treatment effect with osteoporosis by Qianggu pill. *Hunan Guiding Journal of Traditional Chinese Medicine and Pharmacology* 2001;**7**(5):243-4.

Wang LM 2004 {published data only}

Wang LM, Guo HS, Guo MX. Clinical observation on effect of Jiangu tang in treating 69 cases with senile osteoporosis. *Chinese Journal of Clinical Practical Medicine* 2004;**5**(11):103-4.

Weng M 2003 {published data only}

Weng M, Ai SC. Influence of medicine-separated sticking on Shenque (RN8) on calcitonin in primary osteoporosis. *Tianjin Journal of Traditional Chinese Medicine* 2003;**20**(5):48-9.

Wu CM 2004 {published data only}

Wu CM, Zhang SQ, Zhang ZM. Clinical observation on effect of Bushen Zhuanggu capsule in treating osteoporosis. *Journal of Sichuan Traditional Chinese Medicine* 2004;**22**(2):76-7.

Wu D 2008 {published data only}

Wu D, Chen RH, Fang JL. Bushen Tiaogan method for patients with senile osteoporosis in 31 cases. *Journal of Shandong University of Traditional Chinese Medicine* 2008;**32**(2):126-7.

Wu XG 2008 {published data only}

Wu XG, Wu DH. Effects of Xianlinggubao, compound calcium amino acid chelate capsules and salcalcitonin in treating osteoporosis fracture. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2008;**16**(4):20-1.

Xia WF 2006 {published data only}

Xia WF, Chen LL. Comparison of traditional Chinese medicine (Qianggu capsule) and risedronate sodium in management of postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2006;**12**(4):393-6.

Xie J 2001 {published data only}

Xie J, Shen L, Yang YP, Zhou PQ, Gao L. The effect of Chinese traditional medicine of kidney invigoration on bone mass after Colles' fracture. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2001;**9**(2):1-3.

Xie J 2003 {published data only}

Xie J, Shen L, Yang YP, Zhou PQ, Gao L. Clinical study on bone loss preventive effect of Chinese drugs for kidney-tonifying in aged males. *Chinese Journal of Integrated Traditional and Western Medicine* 2003;**23**(1):4-6.

Xu CY 2004 {published data only}

Xu CY, Li BS, Xin BZ. Effect of the self-made Bushen Jianpi Tongluo decoction on pain and bone mineral density of patients with osteoporosis. *Chinese Journal of Clinical Rehabilitation* 2004;**8**(30):6698-9.

Xu LZ 2001 {published data only}

Xu LZ, Hou BX, Shi Q, Xie KY. Analysis of the therapeutic effect of Yishen Zhuanggu granules on osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 2001;**13**(9):9-10.

Xu PH 2001 {published data only}

Xu PH, Huang ZJ, Xiong FL, Zhang HM, Yu DK. Clinical study of Bushen Jiangu capsule in treating liver-kidney deficiency osteoporosis. *Traditional Chinese Drug Research & Clinical Pharmacology* 2001;**12**(4):245-7, 307.

Yang JP 2007 {published data only}

Yang JP, Wang JB, Ding CG, Huo ST. Effect of Gushibao capsule on bone density and bone metabolism of osteoporosis. *Hebei Journal of Traditional Chinese Medicine* 2007;**29**(5):399-400.

Yang WH 2010 {published data only}

Yang WH, Shi X. Clinical study on Bushen Tongluo decoction plus western medicine in treating primary osteoporosis of kidney deficiency and blood-stasis. *Shanghai Journal of Traditional Chinese Medicine* 2010;**44**(7):36-7, 46.

Yan XP 2007 {published data only}

Yan XP, Zhu JL, Yan Y, Kong WP, Lu P, Tao QW. Clinical study of Bushen Qiangdu recipe on 102 cases with ankylosing spondylitis, osteoporosis or osteopenia. *China Journal of Traditional Chinese Medicine and Pharmacy* 2007;**22**(8):571-3.

Yu YH 2011 {published data only}

Yu YH, Chen JY, Wang J. Effect of Erzhi pill on postmenopausal osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2011;**19**(4):42-3.

Zhang GM 2001 {published data only}

Zhang GM, Guan SY, Wang WZ. Clinical study in postmenopausal osteoporosis treated with Xianguning powder. *Acta Chinese Medicine and Pharmacology* 2001;**29**(2):31-2.

Zhang H 1999 {published data only}

Zhang H, Wei ZY, Dong JW, Cui DZ, Cheng YC. Clinical observation on effect of Gubao capsule in treating primary

Chinese herbal medicines for treating osteoporosis (Review)



osteoporosis. *Journal of Traditional Chinese Orthopedics and Traumatology* 1999;**11**(11):3-4, 63.

Zhang WY 2005 {published data only}

Zhang WY. Report of treating 45 cases of senile osteoporosis with Bupi Yishen Huoxue prescription. *Gansu Journal of Traditional Chinese Medicine* 2005;**18**(12):22-3.

Zhao G 2004 {published data only}

Zhao G, Xu ZL, Shao QX, Feng JL, Xue JP, Wang XG, et al. Comparison of tibolone tablets and kidney-invigorating traditional Chinese medicine in prevention and treatment of postmenopausal osteoporosis. *Chinese Journal of Osteoporosis* 2004;**10**(3):337-9.

Zhao Z 2010 {published data only}

Zhao Z, Xiang K, Sun L. Clinical observation of 30 cases of primary osteoporosis in elderly people treated with Yanghe capsule. *World Journal of Integrated Traditional and Western Medicine* 2010;**5**(8):698-700.

Zheng NX 2011 {published data only}

Zheng NX, Zhang XH, Guo HM, Wang PC, Du HF, Guo HY, et al. Clinical observation of Duhuojishengtang on osteoporosis. *Hebei Medicine* 2011;**17**(2):225-7.

Zheng XH 2004 {published data only}

Zheng XH, Huang L. The clinical research of Gukangye on the primary osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2004;**12**(3):20-1.

Zheng ZW 2010 {published data only}

Zheng ZW, Wang Z. Clinical observation of Bushenzhuanggu soup on primary osteoporosis. *Family Medicine* (*Medical Tribune*) 2010;**2**(7):516-8. [DOI: 10.3969/ j.issn.1671-4954.2010.07.030]

Zhong J 2010 {published data only}

Zhong J, Tan SS, Xie LS. Zhuanggubushen decoction and acupuncture treat osteoporosis. *Journal of Zhejiang University of Traditional Chinese Medicine* 2010;**34**(3):408, 410.

Zhong RQ 2007a {published data only}

Zhong RQ, Pan GM, Deng WM, Zhang GC. Clinical observation on effects of Gushenyijingtang in treating hip osteoporotic fractures. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 2007;**15**(7):50-2.

Zhong RQ 2007b {published data only}

Zhong RQ, Pan GM, Deng WM, Zhang GC. Clinical observation of Gushenyijing tang on treatment of thoracic vertebral compression osteoporotic fracture. *Journal of South Medical University* 2007;**27**(11):1724-5.

Zhou PQ 1997 {published data only}

Zhou PQ, Shen L, Yang YP, Xie J. Clinical study on effect of Migu tablet on postmenopausal osteoporosis. *Chinese Journal of Traditional Medical Traumatology & Orthopedics* 1997;**15**(1):20-2.

Zhu LP 2008 {published data only}

Zhu LP. Effect of Bushen Jianpi decoction on osteoporosis during climacteric. *Zhejiang Journal of Integrated Traditional Chinese and Western Medicine* 2008;**18**(3):139-41.

Additional references

Altman 2003

Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ* 2003;**326**(7382):219.

Bengner 1988

Bengner U, Johnell O, Redlund-Johnell I. Changes in incidence and prevalence of vertebral fractures during 30 years. *Calcified Tissue International* 1988;**42**(5):293-6.

Cameron 2013

Cameron M, Chrubasik S. Topical herbal therapies for treating osteoarthritis. *Cochrane Database of Systematic Reviews* 2013, Issue 5. [DOI: 10.1002/14651858.CD010538]

Chen 2012

Chen J, Yao Y, Chen H, Kwong JSW, Chen J. Shengmai (a traditional Chinese herbal medicine) for heart failure. *Cochrane Database of Systematic Reviews* 2012, Issue 11. [DOI: 10.1002/14651858.CD005052.pub4]

Chen 2013

Chen Y, Gong Z, Chen X, Tang L, Zhao X, Yuan Q, et al. Tripterygium wilfordii Hook F (a traditional Chinese medicine) for primary nephrotic syndrome. *Cochrane Database of Systematic Reviews* 2013, Issue 8. [DOI: 10.1002/14651858.CD008568.pub2]

Cole 2008

Cole ZA, Dennison EM, Cooper C. Osteoporosis epidemiology update. *Current Rheumatology Reports* 2008;**10**(2):92-6.

Confavreux 2012

Confavreux CB, Canoui-Poitrine F, Schott AM, Ambrosi V, Tainturier V, Chapurlat R. Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database. *European Journal of Endocrinology* 2012;**166**(4):735-41.

Cumming 1997

Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. *Epidemiologic Reviews* 1997;**19**(2):244-57.

Diez 2002

Diez F. Guidelines for the diagnosis of osteoporosis by densitometric methods. *Journal of Manipulative and Physiological Therapeutics* 2002;**25**(6):403-15.

Egger 2003

Egger M, Juni P, Bartlett C, Holenstein F, Sterne J. How important are comprehensive literature searches and the assessment of trial quality in systematic reviews? Empirical study. *Health Technology Assessment* 2003;**7**(1):1-76.

Chinese herbal medicines for treating osteoporosis (Review)



Feng 2013

Feng M, Yuan W, Zhang R, Fu P, Wu T. Chinese herbal medicine Huangqi type formulations for nephrotic syndrome. *Cochrane Database of Systematic Reviews* 2013, Issue 6. [DOI: 10.1002/14651858.CD006335.pub3]

Flower 2012

Flower A, Liu JP, Lewith G, Little P, Li Q. Chinese herbal medicine for endometriosis. *Cochrane Database of Systematic Reviews* 2012, Issue 5. [DOI: 10.1002/14651858.CD006568.pub3]

Gan 2013

Gan T, Chen J, Jin SJ, Wang Y. Chinese medicinal herbs for cholelithiasis. *Cochrane Database of Systematic Reviews* 2013, Issue 6. [DOI: 10.1002/14651858.CD004547.pub2]

Genant 1999

Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. *Osteoporosis International* 1999;**10**(4):259-64.

Gu 2013

Gu S, Yang AWH, Xue CCL, Li CG, Pang C, Zhang W, et al. Chinese herbal medicine for atopic eczema. *Cochrane Database of Systematic Reviews* 2013, Issue 9. [DOI: 10.1002/14651858.CD008642.pub2]

Guo 2003a

Guo SHF. Advances in treatment of osteoporosis (I). *Modern Diagnosis & Treatment* 2003;**14**(5):257-62.

Guo 2003b

Guo SHF. Advances in treatment of osteoporosis (II). *Modern Diagnosis & Treatment* 2003;**14**(6):321-6.

Guo 2012

Guo Z, Jia X, Liu JP, Liao J, Yang Y. Herbal medicines for advanced colorectal cancer. *Cochrane Database of Systematic Reviews* 2012, Issue 9. [DOI: 10.1002/14651858.CD004653.pub3]

Haguenauer 2005

Haguenauer D, Welch V, Shea B, Tugwell P, Wells G. Fluoride for treating postmenopausal osteoporosis. *Cochrane Database of Systematic Reviews* 2005, Issue 1. [DOI: 10.1002/14651858.CD002825]

Higgins 2011

Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. The Cochrane Collaboration.

Holroyd 2008

Holroyd C, Cooper C, Dennison E. Epidemiology of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 2008;**22**(5):671-85.

Horst-Sikorska 2011

Horst-Sikorska W, Wawrzyniak A. The role of hormonal therapy in osteoporosis. *Endokrynologia Polska* 2011;**62**(1):61-4.

Chinese herbal medicines for treating osteoporosis (Review)

Copyright ${\small ©}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Howe 2011

Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmenopausal women. *Cochrane Database of Systematic Reviews* 2011, Issue 7. [DOI: 10.1002/14651858.CD000333]

ICH GCP 1997

International Conference on Harmonisation Expert Working Group. Code of Federal Regulations & International Conference on Harmonisation Guidelines. 1. Vol. **1**, Pennsylvania: Parexel/ Barnett, 1997.

IOF 2014

International Osteoporosis Foundation. What is Osteoporosis?. http://www.iofbonehealth.org/what-is-osteoporosis.

Kushner 1998

Kushner P. Osteoporosis: unmasking the silent epidemic. *Hospital Medicine* 1998;**34**:25-39.

Leong 2002

Leong KH. Medical treatment of osteoporosis--increasing options. *Annals of the Academy of Medicine, Singapore* 2002;**31**(1):43-7.

Meng 2003

Meng XD, Xie YM, Huang YZH, Cui TH, Gao R, Tu RSH, et al. Clinical study of Gu-Jian capsule in treating primary osteoporosis with kidney-yang deficiency syndrome. *Chinese Journal of Clinical Rehabilitation* 2003;**7**(3):445-7, 457.

Moher 1998

Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses. *Lancet* 1998;**352**(9128):609-13.

Nguyen 2000

Nguyen TV, Center JR, Eisman JA. Association between breast cancer and bone mineral density: the Dubbo Osteoporosis Epidemiology Study. *Maturitas* 2000;**36**(1):27-34.

NOF 2014

National Osteoporosis Foundation. What is Osteoporosis?. http://nof.org/articles/7.

Osteoporosis 1999

Osteoporosis diagnostic criteria subject group in China. The Chinese diagnostic criteria of primary osteoporosis. *Chinese Journal of Osteoporosis* 1999;**5**(1):1-3.

Qiu 2001

Qiu GX. Osteoporosis and fracture. The First Countrywide Osteoporosis Academic Conference of China Medical Association. 2001:12-9.

Raisz 2005

Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. *Journal of Clinical Investigation* 2005;**115**(12):3318-25.



Rates 2001

Rates SMK. Plants as source of drugs. *Toxicon* 2001;**39**(5):603-13.

RevMan 2012 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2012.

Rizzoli 2012

Rizzoli R. Bisphosphonates treatment in patients with osteoporosis. *Therapeutische Umschau. Revue Thérapeutique* 2012;**69**(3):173-81.

Sambrook 2000

Sambrook P, O'Neill S, Diamond T, Flicker L, MacLennan A. Postmenopausal osteoporosis treatment guidelines. *Australian Family Physician* 2000;**29**(8):756-8.

Schulz 1995

Schulz KF, Chalmers I, Hayes R, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. *JAMA* 1995;**273**(5):408-12.

Silverman 2012

Silverman S, Christiansen C. Individualizing osteoporosis therapy. *Osteoporosis International* 2012;**23**(3):797-809.

Vickers 1998

Vickers A, Goyal N, Harland R, Rees R. Do certain countries produce only positive results? A systematic review of controlled trials. *Controlled Clinical Trials* 1998;**19**(2):159-66.

Wells 2008a

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD001155.pub2]

Wells 2008b

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD003376.pub3]

Wells 2008c

Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. *Cochrane Database of Systematic Reviews* 2008, Issue 1. [DOI: 10.1002/14651858.CD004523.pub3]

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

An SJ 2000

Methods Country: China

Chinese herbal medicines for treating osteoporosis (Review)

Copyright ${\small ©}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WHO 1994

World Health Organization. Assessment of fracture risk and its application to screening postmenopausal osteoporosis. Report of a WHO Study Group. WHO Technical Report Series 843, 1994:1-129.

Winsloe 2009

Winsloe C, Earl S, Dennison EM, Cooper C, Harvey NC. Early life factors in the pathogenesis of osteoporosis. *Current Osteoporosis Reports* 2009;**7**(4):140-4.

Woolf 2003

Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. *Bulletin of the World Health Organization* 2003;**81**(9):646-56.

Wylie 2010

Wylie CD. Setting a standard for a "silent" disease: defining osteoporosis in the 1980s and 1990s. *Studies in History and Philosophy of Biological and Biomedical Sciences* 2010;**41**(4):376-85.

Xia 2001

Xia YX. Medicated diets therapy for osteoporosis. The First Countrywide Osteoporosis Academic Conference of China Medical Association. 2001:171-2.

Xue 2000

Xue Y. The retrospect and prospect of osteoporosis. New Century Seminar of Osteoporosis and Arthrosis Prospect and Constructing Convention of Osteoporosis and Osteoarthrosis of China Health Care Scientific and Technological College. 2000:1.

Yang 2013

Yang J, Zhu L, Wu Z, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. *Cochrane Database of Systematic Reviews* 2013, Issue 4. [DOI: 10.1002/14651858.CD005096.pub4]

Zhang 2012

Zhang H, Huang QR, Gu JM, Hu WW, Liu YJ, Hu YQ, et al. Comparison of the effects of cholecalciferol and calcitriol on calcium metabolism and bone turnover in Chinese postmenopausal women with vitamin D insufficiency. *Acta Pharmacologica Sinica* 2012;**33**:490-5.

Zhou 2001b

Zhou LZH, Ma Y. Clinical examining of purgation-tonifying therapy of Chinese traditional medicine on primary osteoporosis. Academic Seminar of Countrywide Osteoporosis and Osteoarthrosis. 2001:134-9. An SJ 2000 (Continued)

All 55 2000 (Continued)	Setting: hospital based		
	Aim: to observe the therapeutic effect and mechanism of kidney-tonifying herbs on postmenopausal osteoporosis		
	Study design: double-blind, randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	111 postmenopausal o group, 40 in Caltrate gr	steoporosis patients enrolled: 31 in Kanggusong granule group, 40 in ipriflavone roup	
	Inclusion criteria: diagr WHO; BMD detected by	nostic criteria for osteoporosis based on bone density levels recommended by v DXA	
	Exclusion criteria: secondary osteoporosis		
Interventions	Experimental: Kanggusong granule, 12 g, twice daily, for 9 months		
	Control 1: ipriflavone (200 mg, 3 times a day) and Caltrate (1 tablet per day), for 9 months		
	Control 2: Caltrate (1 tablet per day), for 9 months		
Outcomes	BMD, E2, Ca, P, ALP, fractures		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Low risk	It was described as double-blind but did not describe who was blinded	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Cao GY 2010

Cuo 01 2010	
Methods	Country: China
	Setting: hospital based
	Aim: to observe the therapeutic effect of integrated traditional Chinese and western medicine on pri- mary osteoporosis

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Cao GY 2010 (Continued)			
	Study design: randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese 57 primary osteoporosis patients enrolled: 30 in trial group, 27 in control group		
	Inclusion criteria: WHO) diagnostic criteria for osteoporosis based on bone density levels	
	Exclusion criteria: seco	ondary osteoporosis	
Interventions	Experimental: Chinese medicine Bushenhuoxue recipe (1 dose per day, water fried) and conventional western medicine (alfacalcidol soft capsules, bisphosphonate and salmon calcitonin, etc.) based on the patient's condition, for 3 months		
	Control: conventional western medicine based on the patient's condition, for 3 months		
Outcomes	BMD		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	No detailed description and P value for the baseline comparison not stated	

Cao W 2010	
Methods	Country: China
	Setting: hospital based
	Aim: to observe the therapeutic effect of integrated traditional Chinese and western medicine on post- menopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese

Chinese herbal medicines for treating osteoporosis (Review)



Unclear risk

Cao W 2010 (Continued)	120 postmenopausal osteoporosis patients enrolled: 60 in trial group, 60 in control group Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels Exclusion criteria: serious women's illnesses, malignant tumour, diabetes, etc.		
Interventions	Experimental: Chinese medicine (combinations of herbs) (1 dose per day, water fried 300 ml, twice a day), tamoxifen (20 mg per day) and Caltrate (600 mg, 1 to 2 tablets per day), for 3 months Control: tamoxifen (20 mg per day) and Caltrate (600 mg, 1 to 2 tablets per day), for 3 months		
Outcomes	BMD, Ca, ALP, adverse events		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated	

Unclear risk Insufficient information to permit judgement of 'low	risk' or 'high risk'.
---	-----------------------

Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'.
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

No information provided

Chen FS 2001

Allocation concealment

Methods	Country: China	
	Setting: outpatients and inpatients	
	Aim: to observe the therapeutic effect of integrated traditional Chinese and western medicine on post- menopausal osteoporosis	
	Study design: randomised controlled trial	
	Analysis: T-test	
	Loss to follow-up: not reported	
Participants	Ethnicity: Chinese	
	64 postmenopausal osteoporosis patients enrolled: 32 in trial group, 32 in control group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA	
	Exclusion criteria: not mentioned	

Chinese herbal medicines for treating osteoporosis (Review)



Chen FS 2001 (Continued)

Interventions	Experimental: Gushen decoction (1 dose per day), Caltrate (600 mg per day) and Alfacalcidol (0.25 μg per day), for 24 weeks		
	Control: Caltrate (600 mg per day) and Alfacalcidol (0.25 μg per day), for 24 weeks		
Outcomes	BMD, E2, Ca, P, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Chen JP 1999			
Methods	Country: China		
	Setting: outpatients		
	Aim: to observe the therapeutic effect of Gukang oral liquid on postmenopausal osteoporosis		
	Study design: single-blind, randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese 61 postmenopausal osteoporosis patients enrolled: 36 in trial group, 25 in control group		
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by single photon absorptiometry (SPA)		
	Exclusion criteria: secondary osteoporosis, etc.		
Interventions	Experimental: Gukang oral liquid (a basic herbal compound), 10 ml, 3 times a day, for 6 months		
	Control: Tridin, 1 tablet, 3 times a day, for 6 months		
Outcomes	BMD		

Chinese herbal medicines for treating osteoporosis (Review)



Chen JP 1999 (Continued)

Notes

No funding sources or declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Chen NQ 2006

Bias	Authors' judgement Support for judgement
Risk of bias	
Notes	No funding sources or declarations of interest for the primary researchers reported
Outcomes	BMD, Ca, P, ALP, adverse effects
	Control: Caltrate (600 mg, once a day), for 6 months
Interventions	Experimental: Shenyao capsules (2 capsules, 3 times a day) for 6 months
	Exclusion criteria: secondary osteoporosis, endocrine disease
	Inclusion criteria: WHO diagnostic criteria for osteoporosis, BMD detected by DXA
	100 primary osteoporosis patients enrolled: 50 in trial group, 50 in control group
Participants	Ethnicity: Chinese
	Loss to follow-up: not reported
	Analysis: T-test
	Study design: single-blind, randomised controlled trial
	Aim: to observe the therapeutic effect of Shenyao capsules on primary osteoporosis
	Setting: outpatients
Methods	Country: China

Chinese herbal medicines for treating osteoporosis (Review)

Chen NQ 2006 (Continued)

Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description and P value for baseline comparison not stated

Chen X 2008

Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the the	rapeutic effect of Gukang decoction on primary osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test, Chi ² tes	st	
	Loss to follow-up: not r	reported	
Participants	Ethnicity: China		
	83 primary osteoporos	is patients enrolled: 42 in trial group, 41 in control group	
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis, BMD detected by DXA	
	Exclusion criteria: not r	nentioned	
Interventions	Experimental: Gukang	decoction, 1 dose per day, for 4 months	
	Control: alendronate se	odium tablets, 10 mg, once a day, for 4 months	
Outcomes	BMD, E2, adverse effect	ts	
Notes	No funding sources or o	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	High risk	Sequence generated by some rule based on clinic time	
Allocation concealment	High risk	Allocation based on clinic time	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Chinese herbal medicines for treating osteoporosis (Review)

Chen X 2008 (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Chen XL 2010

Methods	Country: China Setting: outpatients Aim: to observe the therapeutic effect of Heche Dazao pill on primary osteoporosis			
	Study design: randomi	ised controlled trial		
	Analysis: T-test			
	Loss to follow-up: not i	reported		
Participants	Ethnicity: Chinese			
	114 primary osteoporo	osis patients enrolled: 57 in trial group, 57 in control group		
	Inclusion criteria: Chin	ese diagnostic criteria for osteoporosis		
	Exclusion criteria: liver	r or kidney disease, endocrine diseases, etc.		
Interventions	Experimental: Heche Dazao pill (1 dose per day, water fried twice, twice a day) and Gaitianli (300 mg, 3 times a day), for 3 months			
	Control: Gaitianli (300 mg, 3 times a day), for 3 months			
Outcomes	BMD			
Notes	No funding sources or	declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk	Random numbers		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		

Chinese herbal medicines for treating osteoporosis (Review)



Chen XL 2010 (Continued)

Free of other bias

Low risk

Methods	Country: China			
	Setting: outpatients			
	Aim: to observe the the	erapeutic effect of Jiarong tablet on postmenopausal osteoporosis		
	Study design: randomi			
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
	61 postmenopausal os group	teoporosis patients enrolled: 20 in trial group, 20 in Livial group, 21 in Caltrate		
	Inclusion criteria: Chine tected by DXA	ese diagnostic criteria for osteoporosis based on bone density levels, BMD de-		
	Exclusion criteria: not mentioned			
Interventions	Experimental: Jiarong tablet (5 g, 3 times a day) and Caltrate (1 tablet per day), for 6 months Control: Livial (2.5 mg, every other day) and Caltrate (1 tablet per day), or Caltrate (1 tablet per day), for 6 months			
Outcomes	BMD, adverse effects			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Unclear risk	No information on baseline comparison		

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Methods	Country: China			
	Setting: hospital based			
	Aim: to observe the the	rapeutic effect of Gushukang granule on postmenopausal osteoporosis		
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese 62 postmenopausal osteoporosis patients enrolled: 23 in Gushukang granule and Calcium carbonate with vitamin D chewable tablets group, 20 in Gushukang granule group, 19 in Calcium carbonate with vitamin D chewable tablets group			
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels recommended by WHO, BMD detected by DXA			
	Exclusion criteria: secondary osteoporosis			
Interventions	Experimental: Gushukang granule (10 g, twice a day) and Calcium carbonate with vitamin D chewable tablets (1 tablet, twice a day), or Gushukang granule (10 g, twice a day), for 6 months			
	Control: Calcium carbonate with vitamin D chewable tablets, 1 tablet, twice a day, for 6 months			
Outcomes	BMD, Ca, P, ALP			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk	Random numbers table		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Cui TH 1999

 Methods
 Country: China

 Setting: hospital based
 Setting: hospital based

 Aim: to observe the therapeutic effect of Strong Bone capsule on postmenopausal osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)



Cui TH 1999 (Continued)		
	Study design: randomi	sed controlled trial
	Analysis: T-test	
	Loss to follow-up: not r	reported
Participants	Ethnicity: Chinese	
	105 postmenopausal o	steoporosis patients enrolled: 74 in trial group, 31 in control group
	Inclusion criteria: diag WHO; BMD detected by	nostic criteria for osteoporosis based on bone density levels recommended by y DXA
	Exclusion criteria: not i	mentioned
Interventions	Experimental: Strong E	Bone capsule (a basic herbal compound), 5 capsules, 3 times a day, for 3 months
	Control: Caltrate, 1 tab	let per day, for 3 months
Outcomes	BMD, E2, Ca, P, ALP, BG	P, CT, adverse effects
Notes		ed by administration of traditional Chinese medicine scientific research funds in no declarations of interest for the primary researchers reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed	Low risk	No missing outcome data

All outcomes		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

Dai Y 2007	
Methods	Country: China
	Setting: hospital based
	Aim: to observe the therapeutic effect of Migu tablet on BMD, OPG, etc. in patients with post- menopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: analysis of variance (F-test)
	Loss to follow-up: not reported

Chinese herbal medicines for treating osteoporosis (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Dai Y 2007 (Continued)		
Participants	Ethnicity: Chinese	
		steoporosis patients enrolled: 54 in Migu tablet trial group, 53 in Xianlinggubao d calcium amino acid chelate capsules group
	Inclusion criteria: diag	nostic criteria for osteoporosis, BMD detected by DXA
	Exclusion criteria: dise	ase-affected bone metabolism, endocrine diseases, etc
Interventions	Experimental: Migu tab chelate capsule, 1 g, or	blet group: Migu tablet, 1 tablet, 3 times a day and compound calcium amino acid nce a day; for 24 weeks
	Xianlinggubao group: › chelate capsule, 1 g, or	Kianlinggubao capsule, 0.5, g 3 times a day and compound calcium amino acid nce a day, for 24 weeks
	Control: compound ca	lcium amino acid chelate capsule, 1 g, once a day, for 24 weeks
Outcomes	BMD	
Notes	The study was supported by a health department funded project in Hubei Province, but no declarations of interest for the primary researchers was reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

Deng WM 2012

Ξ

Methods	Country: China
	Setting: hospital based
	Aim: to observe the kidney-tonifying herbal Fufangs with phytoestrogenic Epimedium for prevention of postmenopausal osteoporosis with both BMD and fracture as study endpoints
	Study design: a multicentre, double-blind, randomised controlled trial
	Analysis: F-test, Chi ² test based on the intention-to-treat (ITT) principle
	Loss to follow-up: 5-year follow-up. At the end of 5 years, 155 participants had completed the study (13 drop-outs in the treatment group, 26 drop-outs in the control group); the difference in drop-out rate was statistically significant between the 2 groups (P < 0.05)

Chinese herbal medicines for treating osteoporosis (Review)

Deng WM 2012 (Continued)			
Participants	Ethnicity: Chinese		
	194 postmenopausal o	steoporosis patients enrolled: 101 in experimental group, 93 in placebo group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis		
	the past year; current r eases, including Paget mineral metabolism, a disorders, gastrointest	e who used any kind of anti-osteoporosis drugs or had been under HRT during nedical disease(s) associated with potential development of metabolic bone dis- disease, osteomalacia, bone marrow disease, hereditary disorders of calcium or drenal disorders, poorly controlled diabetes mellitus, severe connective tissue inal diseases and current or past history of clinically significant haematological, iovascular, renal, hepatic, gastrointestinal, psychiatric or neurological diseases	
Interventions	Experimental: Bushen Zhuanggu granules (10 g per day, twice per day), plus calcium (600 mg) and vita- min D (400 IU)		
	Control: placebo granu	lles (10 g per day, twice per day), plus calcium (600 mg) and vitamin D (400 IU)	
Outcomes	BMD, fracture, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	No information on baseline comparison	

Dong Y 2010	
Methods	Country: China
	Setting: outpatients
	Aim: to evaluate the efficacy and safety of salmon calcitonin plus Xianlinggubao for osteoporosis and ostealgia in postmenopausal women
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese

Chinese herbal medicines for treating osteoporosis (Review)

Dong Y 2010 (Continued)	160 postmenopausal osteoporosis patients enrolled: 54 in Xianlinggubao plus salmon calcitonin group, 53 in Xianlinggubao group, 53 in salmon calcitonin control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism, endocrine diseases, secondary osteoporosis, liv- or or kidnow disease, atc		
Interventions	calcitonin (500 IU, once Xianlinggubao group: >	gubao plus salmon calcitonin group: Xianlinggubao (1.5g, twice a day), salmon e a day) and Caltrate (1 tablet per day), for 3 months Kianlinggubao (1.5g, twice a day) and Caltrate (1 tablet per day), for 3 months onin (500 IU, once a day) and Caltrate (1 tablet per day), for 3 months	
Outcomes	BMD, ALP, BGP, Ca, P, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Dong YF 2004

Methods	Country: China			
	Setting: outpatients			
	Aim: to observe the therapeutic effect of traditional Chinese herbs on primary osteoporosis			
	Study design: randomised controlled trial			
	Analysis: T-test, Chi ² test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	80 senile osteoporosis patients enrolled: 40 in trial group, 40 in control group			
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA			

Chinese herbal medicines for treating osteoporosis (Review)



Dong YF 2004 (Continued)	Exclusion criteria: endocrine diseases, secondary osteoporosis, etc.		
Interventions	Experimental: traditional Chinese herbs (Longspur Epimedium, etc.), 1 dose per day, fo		
	Control: vitamin D (10000 U, once a day), Caltrate (600 mg, once a day), for 6 months		
Outcomes	BMD		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	P value for the baseline comparison not stated	

an HX 2004			
Methods	Country: China		
	Setting: outpatients		
	Aim: to observe the therapeutic effect of Gengnian Anyi tablet on postmenopausal osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	60 postmenopausal osteoporosis patients enrolled: 22 in herb trial group, 18 in nilestriol control group 20 in Caltrate group		
	Inclusion criteria: international diagnostic criteria for osteoporosis, BMD detected by SPA		
	Exclusion criteria: endocrine diseases, etc.		
Interventions	Experimental: Gengnian Anyi tablet (6 tablets, 3 times a day) and Caltrate (1 tablet per day), for 6 months		
	Control: nilestriol (2 mg, once a half month) and Caltrate (1 tablet per day), or Caltrate (1 tablet per day), for 6 months		

Chinese herbal medicines for treating osteoporosis (Review)



Fan HX 2004 (Continued)

Outcomes

BMD, adverse effects

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

Gang PH 2001 Methods Country: China Setting: outpatients Aim: to observe the therapeutic effect of Gumiling granule on primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported Participants Ethnicity: Chinese 25 primary osteoporosis patients enrolled: 15 in herb trial group, 10 in control group Inclusion criteria: BMD, detected by DXA Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc. Interventions Experimental: Gumiling granule (10 g, 3 times a day), for 6 months Control: bicarbonate calcium chewable(1 g, twice a day), for 6 months Outcomes BMD, adverse effects No funding sources or declarations of interest for the primary researchers reported Notes **Risk of bias** Bias Authors' judgement Support for judgement

Chinese herbal medicines for treating osteoporosis (Review)

Gang PH 2001 (Continued)

Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline comparison

Gong L 2001 Methods Country: China Setting: outpatients Aim: to observe the therapeutic effect of Yishen Zhuanggu mixture on primary osteoporosis Study design: randomised controlled trial Analysis: T-test, F-test Loss to follow-up: not reported Participants **Ethnicity: Chinese** 80 primary osteoporosis patients enrolled: 46 in herb trial group, 17 in herb control group, 17 in blank control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine diseases, etc. Interventions Experimental: Yishen Zhuanggu mixture (25 ml, twice a day) in herb trial group, Shengu capsule (2 capsules, 3 times a day) in herb control group, for 6 months Control: blank BMD, BGP, adverse effects Outcomes The study was supported by a Science and Technology Commission funded project in Beijing, but no Notes declarations of interest of the primary researchers reported **Risk of bias** Bias **Authors' judgement** Support for judgement Adequate sequence gener-Unclear risk No information provided ation

Chinese herbal medicines for treating osteoporosis (Review)

Gong L 2001 (Continued)

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Guo JH 2008

Methods	Country: China		
	Setting: outpatients		
	Aim: to explore the effe	ect of Bushen Kangsong pill on BMD in postmenopausal osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	84 postmenopausal os	teoporosis patients enrolled: 42 in trial group, 42 in control group	
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA		
	Exclusion criteria: disease-affected bone metabolism, liver or kidney disease, etc.		
Interventions	Experimental: Bushen Kangsong pill, 3 g, 3 times a day, calcium carbonate, 4 tablets, 3 times a day, fo 6 months		
	Control: calcium carbonate, 4 tablets, 3 times a day, for 6 months		
Outcomes	BMD		
Notes	The study was supported by the Science Foundation for Post-doctoral Scientists of Jiangsu Province, but no declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Chinese herbal medicines for treating osteoporosis (Review)

Guo JH 2008 (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Han XL 2007

Adequate sequence gener-	Unclear risk	No information provided	
Risk of bias Bias	Authors' judgement	Support for judgement	
Notes	No funding sources or	declarations of interest for the primary researchers reported	
Outcomes	BMD, E2		
	Control: Caltrate (1.2 g, twice a day) and alendronate sodium tablets (10 mg, once a day), for 6 months		
Interventions	Experimental: Shugan Zishen Huoxue tang (100 ml, twice a day), Caltrate (1.2 g, twice a day) and alen- dronate sodium (10 mg, once a day), for 6 months		
	Exclusion criteria: endo	ocrine diseases, etc.	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	42 postmenopausal osteoporosis patients enrolled: 25 in herb trial group, 17 in control group		
Participants	Ethnicity: Chinese		
	Loss to follow-up: not reported		
	Analysis: T-test, Chi ² te	st	
	Setting: outpatients and inpatients Aim: to explore the effect of Shugan Zishen Huoxue tang on postmenopausal osteoporosis Study design: randomised controlled trial		
Methods	Country: China		

Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

Chinese herbal medicines for treating osteoporosis (Review)



Han XL 2007 (Continued)

Free of other bias

Low risk

Methods	Country: China		
	Setting: outpatients		
	Aim: to explore the effe	ect of Bushen Jianpi Huoxue recipe on postmenopausal osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	160 postmenoporosis p	patients enrolled: 80 in herb trial group, 80 in control group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	Exclusion criteria: endocrine diseases, fractures, metabolic disease, etc.		
Interventions	Experimental: Bushen Jianpi Huoxue recipe (1 dose per day), for 6 months		
	Control: alendronate sodium tablets (70 mg per week), for 6 months		
Outcomes	BMD, IL-6, BGP, ALP, E2		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

He N 2006

Methods Country: China

Chinese herbal medicines for treating osteoporosis (Review)

He N 2006 (Continued)				
	Setting: hospital based			
	Aim: to explore the effect of Jiawei Zhuangyao Jianshen tang on postmenopausal osteoporosis Study design: randomised controlled trial			
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
	58 postmenopausal os	teoporosis patients enrolled: 29 in trial group, 29 in control group		
	Inclusion criteria: diag DXA	nostic criteria for osteoporosis based on bone density levels, BMD detected by		
	Exclusion criteria: not i	mentioned		
Interventions	Experimental: Jiawei Zhuangyao Jianshen tang (1 dose per day) for 3 months			
	Control: compound calcium amino acid chelate capsules (1 g, once a day), for 3 months			
Outcomes	BMD			
Notes	No funding sources or	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk	Random numbers		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

He XQ 2006

Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to explore the effect of Bushen Yangxue tang on postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



He XQ 2006 (Continued)

	Loss to follow-up: not r	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese 60 postmenopausal osteoporosis patients enrolled: 32 in trial group, 28 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA			
	Exclusion criteria: endocrine disease, liver or kidney disease			
Interventions	Experimental: Bushen Yangxue tang (1 dose per day) and Caltrate (once a day), for 6 months			
	Control: Caltrate (once a day), for 6 months			
Outcomes	BMD			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Hu J 2012 Methods Country: China Setting: inpatients Setting: inpatients Aim: to explore the effect of Shangke Yishen Zhuanggu pill on primary osteoporosis Study design: randomised controlled trial Analysis: T-test, F-test, Chi² test Loss to follow-up: not reported Participants Ethnicity: Chinese 300 primary osteoporosis patients enrolled: 155 in trial group, 145 in control group Inclusion criteria: WHO diagnostic criteria for osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)

Copyright $\ensuremath{\textcircled{O}}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Hu J 2012 (Continued)	Exclusion criteria: not r	mentioned
Interventions		e Yishen Zhuanggu pill (6 g, 3 times a day), Caltrate (1.2 g, twice a day), and mia- 8 times a day, intramuscular injection), for 3 months
	Control: Caltrate (1.2 g, twice a day), and miacalcic ampoule (50 U, 3 times a day, intra tion), for 3 months	
Outcomes	BMD	
Notes	No funding sources or	declarations of interest for the primary researchers reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Huang JW 2008	
Methods	Country: China
	Setting: hospital based
	Aim: to explore the effect of Erxian Yanggu decoction on postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese
	67 postmenopausal osteoporosis patients enrolled: 34 in trial group, 33 in control group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA
	Exclusion criteria: endocrine diseases, secondary osteoporosis, patients with uterine/breast disease
Interventions	Experimental: Erxian Yanggu decoction, 1 dose per day, alendronate sodium tablets, 70 mg per week, for 6 months

Chinese herbal medicines for treating osteoporosis (Review)



Huang JW 2008 (Continued)

Control: alendronate sodium tablets, 70 mg per week, for 6 months

Outcomes	IL-6	
Notes	The study was supported by administration of traditional Chinese medicine scientific research funds in Zhejiang Province, but no declarations of interest for the primary researchers reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Huang ZJ 2008

Country: China		
Setting: hospital based		
Aim: to study the effects of Zishen Gukang pill in the treatment of postmenopausal osteoporosis		
Study design: randomised controlled trial		
Analysis: T-test		
Loss to follow-up: not reported		
Ethnicity: Chinese		
60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group		
Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA, DPA, SPA, etc.		
Exclusion criteria: disease-affected bone metabolism, etc.		
Experimental: Zishen Gukang pill (6 g, 3 times a day)		
Control: Caltrate (2 pills, once a day), for 3 months		
BMD		
No funding sources or declarations of interest for the primary researchers reported		

Chinese herbal medicines for treating osteoporosis (Review)



Huang ZJ 2008 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	sequence gener- High risk Sequence generated by some rule based on clinic time		
Allocation concealment	High risk	Allocation based on clinic time	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Jian QQ 2010

Bias	Authors' judgement Support for judgement		
Risk of bias			
Notes	No funding sources or declarations of interest for the primary researchers reported		
Outcomes	BMD		
	Control: Caltrate, 750 mg, once a day, for 12 months		
Interventions	Experimental: Shengsuiyin recipe (1 dose per day, water fried) and Caltrate (750 mg, once a day), for 12 months		
	Exclusion criteria: not mentioned		
	Inclusion criteria: diagnostic criteria for osteoporosis on Obstetrics and Gynecology in Chinese Medi- cine		
	144 postmenopausal osteoporosis patients enrolled: 73 in trial group, 71 in control group		
Participants	Ethnicity: Chinese		
	Loss to follow-up: not reported		
	Analysis: T-test		
	Study design: randomised controlled trial		
	Aim: to study the effects of Shengsuiyin recipe in the treatment of postmenopausal osteoporosis		
	Setting: inpatients		
Methods	Country: China		

Chinese herbal medicines for treating osteoporosis (Review)

Jian QQ 2010 (Continued)

Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Lan ZX 2006 Methods Country: China Setting: hospital based Aim: to study the effects of Guli powder in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported Participants **Ethnicity: Chinese** 60 primary osteoporosis patients enrolled: 30 in trial group, 30 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism Interventions Experimental: Guli powder (10 g, 3 times a day), for 3 months Control: Caltrate (once a day), for 3 months Outcomes BMD, Ca, P, ALP Notes The study was supported by administration of traditional Chinese medicine scientific research funds in Sichuan Province, but no declarations of interest for the primary researchers reported **Risk of bias** Bias Authors' judgement Support for judgement Unclear risk Adequate sequence gener-No information provided ation Allocation concealment Unclear risk No information provided Unclear risk Blinding Insufficient information to permit judgement of 'low risk' or 'high risk'

Chinese herbal medicines for treating osteoporosis (Review)

Copyright $\ensuremath{\mathbb S}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Lan ZX 2006 (Continued) All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Li BL 2007

Methods	Country: China			
	Setting: hospital based			
	Aim: to observe the mechanism of Jianshen decoction in treating patients with postmenopausal osteo- porosis			
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	60 postmenopausal os	teoporosis patients enrolled: 30 in trial group, 30 in control group		
	Inclusion criteria: diag	nostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: endocrine diseases, disease-affected bone metabolism			
Interventions	Experimental: Jianshen decoction, 1 dose per day, for 6 months			
	Control: alendronate s	odium tablets, 10 mg, once a day, for 6 months		
Outcomes	BMD, ALP, BGP, E2, IL-6			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	nclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		

Free of selective reporting Unclear risk

Not all the outcomes that were of interest in this review were reported

Chinese herbal medicines for treating osteoporosis (Review)



Li BL 2007 (Continued)

Free of other bias

Unclear risk

Li HW 2004

Methods	Country: China			
	Setting: hospital based			
	Aim: to study the effects of Ziyin Bushen Zhuanggu prescription in the treatment of postmenopausal osteoporosis			
	Study design: randomi	sed controlled trial		
	Analysis: T-test, Chi ² te	st		
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
	45 postmenopausal os	teoporosis patients enrolled: 25 in trial group, 20 in control group		
	Inclusion criteria: inter	national diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: endocrine diseases, etc			
Interventions	Experimental: Ziyin Bushen Zhuanggu prescription (1 dose per day), Caltrate (1.2 g, twice a day) and miacalcin (50 IU, injection, twice per week), for 8 months			
	Control: Caltrate (1.2 g, twice a day) and miacalcin (50 IU, injection, twice a week), for 8 months			
Outcomes	BMD, E2			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk Random numbers			
Allocation concealment	Unclear risk No information provided			
Blinding All outcomes	Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'			
Incomplete outcome data addressed All outcomes	Low risk	Low risk No missing outcome data		
Free of selective reporting	Unclear risk Not all the outcomes that were of interest in this review were reported			
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Methods	Country: China			
	Setting: hospital based			
	Aim: to study the effects of Zhuanggu capsule in the treatment of postmenopausal osteoporosis			
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
	60 postmenopausal os	teoporosis patients enrolled: 30 in trial group, 30 in control group		
	Inclusion criteria: diagı DXA	nostic criteria for osteoporosis based on bone density levels, BMD detected by		
	Exclusion criteria: endocrine diseases, etc			
Interventions	Experimental: Zhuanggu capsule (4 capsules, 3 times a day) and Caltrate (600 mg, once a day), for 6 months			
	Control: Caltrate (600 mg, once a day), for 6 months			
Outcomes	BMD, E2, Ca, P, ALP, BGP			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'			
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Li YH 2008

Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to study the effects of Jingujian granule in the treatment of senile osteoporosis
	Study design: randomised controlled trial

Chinese herbal medicines for treating osteoporosis (Review)



Li YH 2008 (Continued)				
	Analysis: T-test, Chi ² te	est		
	Loss to follow-up: not	reported		
Participants	Ethnicity: Chinese			
	120 senile osteoporosi	s patients enrolled: 80 in trial group, 40 in control group		
	Inclusion criteria: diag WHO	nostic criteria for osteoporosis based on bone density levels recommended by		
	Exclusion criteria: secc	ondary osteoporosis, liver or kidney disease		
Interventions	Experimental: Jingujian granule, 8 g, twice a day, for 3 months			
	Control: Caltrate, 600 mg, once a day, for 3 months			
Outcomes	BMD, ALP, BGP, adverse	BMD, ALP, BGP, adverse effects		
Notes	The study was supported by a China academy of traditional Chinese medicine advantage diseases re- search project, but no declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk	Random numbers		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		

 111	20	10
 Y 8	- 20	

Free of other bias

Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to study the effects of Jingujian granule 1, 2 or 3 in the treatment of primary osteoporosis based on epigastralgia traditional Chinese medicine
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test
	Loss to follow-up: 30 drop-outs (11 in trial group, 19 in control group) were not included in the analysis
Participants	Ethnicity: Chinese

The study appears to be free of other sources of bias

Chinese herbal medicines for treating osteoporosis (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Low risk



Li YH 2010 (Continued)	210 primary osteoporosis patients enrolled: 140 in trial group (11 drop-outs), 70 in control group (19 drop-outs)		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis and guiding principles for clinical re- search on new drugs in traditional Chinese medicine, BMD detected by DXA		
	Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.		
Interventions	Experimental: Jingujian granule 1, 2 or 3 based on epigastralgia traditional Chinese medicine (kidney deficiency; spleen and kidney deficiency; spleen and kidney deficiency, and blood stasis), 8 g, twice a day, for 3 months		
	Control: Caltrate, 600 mg, once a day, for 3 months		
Outcomes	BMD, ALP, E2, CT, BGP, adverse events		
Notes	The study was supported by a China academy of traditional Chinese medicine advantage diseases re- search project, but no declarations of interest for the primary researchers reported		
Diele of him			

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Li ZP 2011

LI 2F 2011			
Methods	Country: China		
	Setting: hospital based		
	Aim: to study the effects of Kanggusong soup in the treatment of postmenopausal osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	75 postmenopausal osteoporosis patients enrolled: 45 in trial group, 30 in control group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis		

Chinese herbal medicines for treating osteoporosis (Review)

Li ZP 2011 (Continued)	Exclusion criteria: secondary osteoporosis, endocrine disease, liver or kidney disease, etc.		
Interventions	Experimental: Kanggusong soup (1 dose per day, twice a day) and Caltrate (1 tablet per night), for 3 months		
	Control: Caltrate (1 tab	let per night), for 3 months	
Outcomes	ALP, IL-6, fractures		
Notes	No funding sources or o	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

i ZY 2006			
Methods	Country: China		
	Setting: hospital based		
	Aim: to study the effects of Xianling Gusong capsules in the treatment of postmenopausal osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test, Ridit test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	43 postmenopausal osteoporosis patients enrolled: 21 in trial group, 22 in control group		
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA		
	Exclusion criteria: secondary osteoporosis, liver or kidney disease		
Interventions	Experimental: Xianling Gusong capsules (4 capsules, 3 times a day), for 6 months		
	Control: Caltrate (1 pill, twice a day), for 6 months		

Chinese herbal medicines for treating osteoporosis (Review)



Li ZY 2006 (Continued)

Outcomes	BMD	

Notes

No funding sources or declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Liang DB 2012

	Country China
Methods	Country: China
	Setting: hospital based
	Aim: to study the effects of Bushenhuoxue therapy in the treatment of primary osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test, Ridit test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese
	80 primary osteoporosis patients enrolled: 40 in trial group, 40 in control group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis
	Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.
Interventions	Experimental: Bushenhuoxue therapy (1 dose, per day), calcium carbonate tablets (1 tablet (0.5 g), twice a day), and alfacalcidol (1 tablet (0.5 μg) per day), for 3 months
	Control: calcium carbonate tablets (1 tablet (0.5 g), twice a day), and alfacalcidol (1 tablet (0.5 μg) per day), for 3 months
Outcomes	BMD, quality of life, adverse events
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias	

Chinese herbal medicines for treating osteoporosis (Review)



Liang DB 2012 (Continued)

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	No information provided
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Country: China		
Setting: hospital based		
Aim: to study the effects of Bushen Shengsui principle in the treatment of postmenopausal osteoporo- sis		
Study design: randomised controlled trial		
Analysis: T-test		
Loss to follow-up: not reported		
Ethnicity: Chinese		
100 postmenopausal osteoporosis patients enrolled: 32 in herb trial group, 39 in control group, 29 in blank group		
Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA		
Exclusion criteria: endocrine diseases, etc.		
Experimental: Bushen Shengsui principle, 1 dose per day, for 6 months		
Control: Premarin (1 tablet per day) and medroxyprogesterone (2.5 mg per day), or blank, for 6 months		
BMD, E2, adverse effects		
The study was supported by a science and technology planning project Zhongshan, Guangdong Province, but no declarations of interest for the primary researchers reported		
Authors' judgement Support for judgement		
Unclear risk No information provided		

Chinese herbal medicines for treating osteoporosis (Review)



Liao L 2004 (Continued)

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Lin W 2000

Methods	Country: China	
	Setting: hospital based	i de la constanción d
	Aim: to study the effect	ts of Migu decoction in the treatment of postmenopausal osteoporosis
	Study design: double-b	blind, randomised controlled trial
	Analysis: T-test	
	Loss to follow-up: not i	reported
Participants	Ethnicity: Chinese	
	20 postmenopausal os	teoporosis patients enrolled: 13 in trial group, 7 in control group
	Inclusion criteria: diag DXA	nostic criteria for osteoporosis based on bone density levels, BMD detected by
	Exclusion criteria: ende	ocrine diseases
Interventions	Experimental: Migu decoction, for 4 months	
	Control: placebo, for 4 months	
Outcomes	BMD	
Notes	No funding sources or declarations of interest for the primary researchers reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed	Low risk	No missing outcome data

Chinese herbal medicines for treating osteoporosis (Review)



Lin W 2000 (Continued) All outcomes

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

Methods	Country: China		
	Setting: outpatients		
	Aim: to study the effect	s of Bushen Zhuanggu decoction in the treatment of primary osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test, Ridit test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	60 primary osteoporos	is patients enrolled: 30 in trial group, 30 in control group	
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis, BMD detected by DXA	
	Exclusion criteria: endo	ocrine diseases, liver or kidney disease, etc	
Interventions	Experimental: Bushen Zhuanggu decoction, 1 dose per day, for 3 months		
	Control: alendronate se	odium tablets, 10 mg, once a day, for 3 months	
Outcomes	BMD, E2, ALP, P		
Notes	No funding sources or o	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Liu JM 2012

Bias	Authors' judgement Support for judgement		
Risk of bias			
Notes	No funding sources or declarations of interest for the primary researchers reported		
Outcomes	BMD, adverse effects		
	Control: Gaitianli tablets (50 mg per tablet, 2 tablets, 3 times a day), and vitamin A and D capsules (1 pill, twice a day), for 3 months		
Interventions	Experimental: Gukang tablet (0.5 g per tablet, 6, 3 times a day), Gaitianli tablets (50 mg per tablet, 2 tablets, 3 times a day) and vitamin A and D capsules (1 pill, twice a day), for 3 months		
	Exclusion criteria: endocrine diseases, liver or kidney disease, etc.		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis		
	80 primary osteoporosis patients enrolled: 40 in trial group, 40 in control group		
Participants	Ethnicity: Chinese		
	Loss to follow-up: not reported		
	Analysis: T-test, Chi ² test, Ridit test		
	Study design: randomised controlled trial		
	Aim: to study the effects of Gukang tablet in the treatment of primary osteoporosis		
	Setting: outpatients		
Methods	Country: China		

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Lv ZH 2002

Methods

Country: China Setting: hospital based

Aim: to study the effects of Jiawei Bushen Zhuangjintang in the treatment of primary osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)



Trusted evidence. Informed decisions. Better health.

Lv ZH 2002 (Continued)			
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² te	st	
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	90 primary osteoporos	is patients enrolled: 48 in trial group, 42 in control group	
	Inclusion criteria: Chin tected by DXA	ese diagnostic criteria for osteoporosis based on bone density levels, BMD de-	
	Exclusion criteria: not i	mentioned	
Interventions	Experimental: Jiawei Bushen Zhuangjintang, 1 dose per day, for 3 months		
	Control: calcium granu	ile, 5 g, 3 times a day, for 3 months	
Outcomes	BMD		
Notes		ed by administration of traditional Chinese medicine scientific research funds in out no declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Ma C 2011	
Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to study the effects of Liuwei Dihuang pills in the treatment of postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: F-test, Chi ² test
	Loss to follow-up: 1 drop-out in Liuwei Dihuang pills group was not included in the analysis
Participants	Ethnicity: Chinese

Chinese herbal medicines for treating osteoporosis (Review)



MaC2011 (Continued)	108 postmenopausal o	steoporosis patients enrolled: 36 in Liuwei Dihuang pills group, 36 in Caltrate		
		uang pills plus Caltrate group		
	Inclusion criteria: diag	Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: endo	ocrine diseases, etc.		
Interventions	Liuwei Dihuang pills gr	oup: Liuwei Dihuang pills, 8 pills, 3 times a day, for 6 months		
	Caltrate group: Caltrate	e, 1 tablet, 3 times a day, for 6 months		
	Liuwei Dihuang pills pl tablet, 3 times a day), f	us Caltrate group: Liuwei Dihuang pills (8 pills, 3 times a day) and Caltrate (1 or 6 months		
Outcomes	BMD, adverse effects			
Notes	No funding sources or o	declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk	Random numbers		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Ma CZ 2011

Methods	Country: China		
	Setting: outpatients and inpatients		
	Aim: to study the effects of Yiyuanjiangu decoction in the treatment of primary osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	120 primary osteoporosis patients enrolled: 60 in trial group, 60 in control group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis		
	Exclusion criteria: endocrine diseases, liver or kidney disease, etc.		

Chinese herbal medicines for treating osteoporosis (Review)



Ma CZ 2011 (Continued)

Interventions	Experimental: Yiyuanjiangu decoction (1 dose per day), Miacalcin ampoule (50 U, once a day, intramus- cular), and calcium carbonate tablet (1 tablet (0.75 g), twice a day), for 3 months		
	Control: Miacalcin amp (0.75 g), twice a day), f	boule (50 U, once a day, intramuscular) and calcium carbonate tablet (1 tablet or 3 months	
Outcomes	BMD, ALP, Ca, P		
Notes	No funding sources or	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Ma YJ 2011

Methods	Country: China
	Setting: outpatients
	Aim: to study the effects of Yishen Zhuanggu decoction in the treatment of senile osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test, Ridit test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese
	100 senile osteoporosis enrolled: 50 in trial group, 50 in control group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis
	Exclusion criteria: secondary osteoporosis, endocrine diseases, liver or kidney disease, etc.
Interventions	Experimental: Yishen Zhuanggu decoction (1 dose per day) and calcitriol soft capsule (0.25 mg, twice a day), for 3 months
	Control: calcitriol soft capsule (0.25 mg, twice a day), for 3 months
Outcomes	BMD

Chinese herbal medicines for treating osteoporosis (Review)



Ma YJ 2011 (Continued)

Notes

No funding sources or declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Mao YF 2011

Bias	Authors' judgement Support for judgement
Risk of bias	
Notes	No funding sources or declarations of interest for the primary researchers reported
Outcomes	BGP
	Control: Miacalcin ampoule (50 U), for 3 months
Interventions	Experimental: Bushen Jianpi Jingu decoction, 1 dose per day, for 3 months
	Exclusion criteria: liver or kidney disease, disease-affected bone metabolism, etc.
	Inclusion criteria: diagnostic criteria for osteoporosis recommend by WHO, BMD detected by DXA
	75 postmenopausal osteoporosis patients enrolled: 39 in trial group, 36 in control group
Participants	Ethnicity: Chinese
	Loss to follow-up: not reported
	Analysis: T-test, Chi ² test
	Study design: single-blind, randomised controlled trial
	Aim: to study the effects of Bushen Jianpi Jingu decoction in the treatment of postmenopausal osteo- porosis
	Setting: outpatients
Methods	Country: China

Chinese herbal medicines for treating osteoporosis (Review)

Mao YF 2011 (Continued)

Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Single-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Unclear risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Meng XD 2003 Methods Country: China Setting: hospital based Aim: to study the effects of Gujian capsule in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi² test Loss to follow-up: not reported Ethnicity: Chinese Participants 68 primary osteoporosis patients enrolled: 35 in trial group (1 drop-out), 33 in control group (2 dropout) Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc. Interventions Experimental: Gujian capsule (2 capsules, 3 times a day), for 6 months Control: alfacalcidol (0.5 µg, twice a day), for 6 months Outcomes BMD, PTH, CT, E2, adverse effects Notes No funding sources or declarations of interest for the primary researchers reported **Risk of bias** Bias **Authors' judgement** Support for judgement Adequate sequence gener-Unclear risk No information provided ation Unclear risk Allocation concealment No information provided Blinding Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'

Chinese herbal medicines for treating osteoporosis (Review)



Meng XD 2003 (Continued) All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Miu JQ 2008

Methods	Country: China			
Methods				
	Setting: outpatients and inpatients Aim: to study the effects of a traditional Chinese medicine capsule in the treatment of postmenopausal osteoporosis			
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	90 postmenopausal osteoporosis patients enrolled: 60 in trial group, 30 in control group			
	Inclusion criteria: diag	nostic criteria for osteoporosis recommend by WHO, BMD detected by DXA		
	Exclusion criteria: secondary osteoporosis, liver or kidney disease			
Interventions	Experimental: traditional Chinese medicine capsule (300 mg per pill, 5 pills per day), calcium glu- conate, 2 g, 3 times a day, for 9 months Control: calcium gluconate, 2 g, 3 times a day, for 9 months			
Outcomes	BGP, ALP			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		

Chinese herbal medicines for treating osteoporosis (Review)



Miu JQ 2008 (Continued)

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Methods	Country: China		
	Setting: outpatients		
	Aim: to study the effects of Bushen Qiangshen pill in the treatment of postmenopausal osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test, Ridit test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	40 postmenopausal os	teoporosis patients enrolled: 20 in trial group, 20 in control group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by CUBA ultrasound absorptiometry		
	Exclusion criteria: endocrine diseases, secondary osteoporosis		
Interventions	Experimental: Bushen Qiangshen pill (1 pill, twice a day) and Caltrate (1 tablet, twice a weeks		
	Control: Caltrate, 1 tablet, twice a day, for 12 weeks		
Outcomes	E2, ALP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Chinese herbal medicines for treating osteoporosis (Review)



Methods	Country: China		
	Setting: outpatients		
	Aim: to study the effects of Bushen Qiangshen pill in the treatment of postmenopausal osteoporosis		
	Study design: randomi	sed controlled trial	
	Analysis: T-test, Chi ² test, Ridit test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	30 postmenopausal os	teoporosis patients enrolled: 15 in trial group, 15 in control group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by CUBA ultrasound absorptiometry		
	Exclusion criteria: endocrine diseases, secondary osteoporosis		
Interventions	Experimental: Bushen Qiangshen pill, 1 pill, twice a day, for 12 weeks		
	Control: Caltrate, 1 tablet, twice a day, for 12 weeks		
Outcomes	E2, ALP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	No information on baseline	

Ou L 2011

Methods

Country: China

Setting: hospital based

Aim: to study the effects of Radix rehmanniae preparata, Radix astragali, etc. in the treatment of postmenopausal osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)



Ou L 2011 (Continued)		
	Study design: randomi	sed controlled trial
	Analysis: T-test	
	Loss to follow-up: not reported	
Participants	Ethnicity: Chinese	
	64 postmenopausal os	teoporosis patients enrolled: 32 in trial group, 32 in control group
	Inclusion criteria: Chin	ese and WHO diagnostic criteria for osteoporosis
	Exclusion criteria: not i	mentioned
Interventions	Experimental: Radix rehmanniae preparata, Radix astragali, etc. (1 dose per day), for 6 months	
	Control:calcium carbo	nate tablets (600 mg per day, once a day), for 6 months
Outcomes	BMD, E2, ALP, Ca, P, PTH, CT	
Notes	The study was supported by Shanxi Provincial Department of Education project, but no declarations of interest for the primary researchers reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Peng T 2002	
Methods	Country: China
	Setting: hospital based
	Aim: to study the effects of Qianggu soft extract in the treatment of postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese

Chinese herbal medicines for treating osteoporosis (Review)



Peng T 2002 (Continued)	
	118 postmenopausal osteoporosis patients enrolled: 78 in trial group, 21 in calcium gluconate oral group, 19 in blank control group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA
	Exclusion criteria: endocrine diseases
Interventions	Experimental: Qianggu soft extract, 20 ml, 3 times a day, for 6 months
	Control: calcium gluconate (500 mg, 3 times a day), or blank, for 6 months
Outcomes	BMD, E2, Ca, ALP, adverse effects

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Qi ZX 1998

Methods	Country: China			
	Setting: hospital based			
	Aim: to study the effects of Bushen Qianggutang in the treatment of primary osteoporosis			
	Study design: randomised controlled trial			
	Analysis: T-test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	40 primary osteoporosis patients enrolled: 20 in trial group, 20 in control group			
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA			
	Exclusion criteria: secondary osteoporosis			

Chinese herbal medicines for treating osteoporosis (Review)



Qi ZX 1998 (Continued)

Interventions	Experimental: Bushen Qianggutang, 1 dose per day, fried, for 3 months		
	Control: Caltrate, 600 r	ng, twice a day, for 3 months	
Outcomes	BMD		
Notes	No funding sources or	No funding sources or declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

iu RB 2004	
Methods	Country: China
	Setting: hospital based
	Aim: to study the effects of Yanghuo Sanzi tang in the treatment of postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese
	60 postmenopausal osteoporosis patients enrolled: 30 in trial group, 30 in control group
	Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA
	Exclusion criteria: not mentioned
Interventions	Experimental: Yanghuo Sanzi tang, 150 ml, twice a day, for 6 months
	Control: Caltrate, 2 tablets per day, for 6 months
Outcomes	BMD, E2, BGP, IL-6
Notes	No funding sources or declarations of interest for the primary researchers reported

Chinese herbal medicines for treating osteoporosis (Review)



Qiu RB 2004 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Qiu RB 2008

Bias	Authors' judgement Support for judgement			
Risk of bias				
Notes	The study was supported by a Shenzhen science and technology planning project, but no declarations of interest for the primary researchers reported			
Outcomes	BMD, BGP, E2, IL-6			
	Control: alendronate sodium tablets, 10 mg, once a day, for 6 months			
Interventions	Experimental: Jiangu prescription, 1 dose per day, for 6 months			
	Exclusion criteria: endocrine disease, liver or kidney disease, disease-affected bone metabolism, etc.			
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA			
	120 postmenopausal osteoporosis enrolled: 60 in trial group, 60 in control group			
Participants	Ethnicity: Chinese			
	Loss to follow-up: not reported			
	Analysis: T-test, Chi ² test			
	Study design: randomised controlled trial			
	Aim: to study the effects of Jiangu prescription in the treatment of postmenopausal osteoporosis			
	Setting: outpatients			
Methods	Country: China			

Chinese herbal medicines for treating osteoporosis (Review)

Qiu RB 2008 (Continued)

Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Qiu ZX 2010 Methods Country: China Setting: inpatients Aim: to study the effects of Xianlinggubao capsule in the treatment of senile osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported Participants **Ethnicity: Chinese** 136 senile osteoporosis patients enrolled: 67 in trial group, 69 in control group Inclusion criteria: BMD Exclusion criteria: other diseases Interventions Experimental: Xianlinggubao capsule (1 g, 3 times a day) and Caltrate (1 tablet, twice a day), for 12 months Control: Caltrate, 1 tablet, twice a day, for 12 months BMD Outcomes Notes No funding sources or declarations of interest for the primary researchers reported **Risk of bias** Bias Authors' judgement Support for judgement Adequate sequence gener-Unclear risk Patients were randomly allocated ation Allocation concealment Unclear risk No information provided Blinding Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk'

Chinese herbal medicines for treating osteoporosis (Review)



Qiu ZX 2010 (Continued) All outcomes

Alloutcomes		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description of diagnostic standard and P value for the baseline comparison not stated

Ruan XY 2006

Methods	Country: China			
	Setting: outpatients			
	Aim: to study the effect	s of Qianggu capsules in the treatment of postmenopausal osteoporosis		
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
		steoporosis or osteopenia patients enrolled: 50 in herbal trial and hormone up, 50 in hormone group		
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA			
	Exclusion criteria: endocrine disease, digestion disease, mental disorder, etc.			
Interventions		capsules (1 capsule, 3 times a day) and oestradiol valerate (0.5 to 1.5 mg, once a nggu capsules (1 capsule, 3 times a day), for 24 weeks		
	Control: oestradiol vale	erate (0.5 to 1.5 mg, once a day), for 24 weeks		
Outcomes	BMD, adverse effects			
Notes	The study was supported by Beijing administration of traditional Chinese medicine scientific research funds and Capital Foundation of Medical Developments Project, but no declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		

Chinese herbal medicines for treating osteoporosis (Review)

Ruan XY 2006 (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Shao M 2003

Methods	Country: China			
	Setting: hospital based	1		
	Aim: to study the effect	ts of Gukang oral liquid in the treatment of postmenopausal osteoporosis		
	Study design: randomi	ised controlled trial		
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
	60 postmenopausal os	teoporosis patients enrolled: 30 in trial group, 30 in control group		
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA			
	Exclusion criteria: seco	ondary osteoporosis, etc.		
Interventions	Experimental: Gukang oral liquid, 10 ml, 3 times a day, for 6 months			
	Control: alendronate, 1	1 tablet per day, for 6 months		
Outcomes	BMD, E2, ALP, BGP, IL-6			
Notes	No funding sources or	declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		

Chinese herbal medicines for treating osteoporosis (Review)



Shao M 2003 (Continued)

Free of other bias

Unclear risk

Shi CD 2012

Methods	Country: China	
	Setting: outpatients	
	Aim: to study the effect	ts of Kangshu Jiangu granule in the treatment of postmenopausal osteoporosis
	Study design: randomi	sed controlled trial
	Analysis: T-test, Chi ² te	st
	Loss to follow-up: not r	reported
Participants	Ethnicity: Chinese	
	76 postmenopausal os	teoporosis patients enrolled: 40 in trial group, 36 in control group
	Inclusion criteria: Chin	ese diagnostic criteria for osteoporosis
	Exclusion criteria: liver	or kidney disease, endocrine disease, etc.
Interventions	Experimental: Kangshu	Jiangu granule, 4 g, 3 times a day, for 6 months
	Control: Caltrate, 1 tab	let, once a day, for 6 months
Outcomes	BMD	
Notes		ed by Shanxi Provincial Department of traditional Chinese medicine (TCM) mod- in, but no declarations of interest for the primary researchers reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Methods	Country: China				
	Setting: hospital based				
	Aim: to study the effect	ts of kidney-tonifying herbs in the treatment of postmenopausal osteoporosis			
	Study design: randomi	sed controlled trial			
	Analysis: T-test				
	Loss to follow-up: not r	reported			
Participants	Ethnicity: Chinese				
	68 postmenopausal os trol group	teoporosis patients enrolled: 23 in herb group, 23 in nilestriol group, 22 in con			
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA				
	Exclusion criteria: secondary osteoporosis				
Interventions	Experimental: kidney-tonifying herbs, twice a day, for 6 months				
	Control: nilestriol, 0.2 mg, twice per month; or calcium, 400 mg/d, for 6 months				
Outcomes	BMD				
Notes	No funding sources or o	declarations of interest for the primary researchers reported			
Risk of bias					
Bias	Authors' judgement	Support for judgement			
Adequate sequence gener- ation	Unclear risk	No information provided			
Allocation concealment	Unclear risk	No information provided			
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'			
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data			
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported			
Free of other bias	Unclear risk	No information on baseline			

Tang ZA 2012

 Methods
 Country: China

 Setting: outpatients and inpatients
 Setting: outpatients of Bushen Qianggu Huoxue therapy in the treatment of postmenopausal osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)



Tang ZA 2012 (Continued)	Study design: randomi	sed controlled trial
	Analysis: T-test	
	Loss to follow-up: not r	reported
Participants	Ethnicity: Chinese	
	82 postmenopausal os	teoporosis patients enrolled: 42 in trial group, 40 in control group
	Inclusion criteria: WHO) diagnostic criteria for osteoporosis
	Exclusion criteria: liver	or kidney disease, endocrine disease, metabolic disease, etc.
Interventions	Experimental: Bushen liver oil (1 pill per day),	Qianggu Huoxue therapy (1 dose per day), calcium (1000 mg per day) and cod for 3 months
	Control: calcium (1000	mg per day) and cod liver oil (1 pill per day), for 3 months
Outcomes	BMD, adverse effects	
Notes	No funding sources or	declarations of interest for the primary researchers reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wang CC 2005	
Methods	Country: China
	Setting: hospital based
	Aim: to study the effects of Gumikang capsule in the treatment of postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test, Chi ² test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese

Chinese herbal medicines for treating osteoporosis (Review)



Wang CC 2005 (Continued)	
	60 postmenopausal osteoporosis patients enrolled: 32 in trial group, 28 in control group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA
	Exclusion criteria: metabolic disease, endocrine disease
Interventions	Experimental: Gumikang capsule, 5 capsules, twice a day, for 6 months
	Control: calcium gluconate, 500 mg, 3 times a day, for 6 months
Outcomes	BMD, E2, Ca, ALP
Notes	No funding sources or declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wang H 2007

Methods	Country: China				
	Setting: hospital based				
	Aim: to study the effects of Qianggu paste II in the treatment of senile osteoporosis				
	Study design: randomised controlled trial				
	Analysis: T-test				
	Loss to follow-up: not reported				
Participants	Ethnicity: Chinese				
	123 senile osteoporosis patients enrolled: 75 in trial group, 48 in control group				
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA				
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: disease-affected bone metabolism				

Chinese herbal medicines for treating osteoporosis (Review)



Wang H 2007 (Continued)

Control: calcium gluconate (500 mg, 3 times a day, for 6 months)

Outcomes	BMD, E2, ALP, Ca, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Low risk	Random numbers	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk The study appears to be free of other sources of bias		

lang J 2007			
Methods	Country: China		
	Setting: hospital based		
	Aim: to study the effects of Qianggu capsule in the treatment of senile osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Ridit test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	54 postmenopausal osteoporosis patients enrolled: 28 in trial group, 26 in control group		
	Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: disease-affected bone metabolism		
Interventions	Experimental: Qianggu capsule, 0.25 g, 3 times a day, for 6 months		
	Control: alfa calcidiol capsule, 0.5 μg , twice a day, for 6 months		
Outcomes	BMD, Ca, P, ALP, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			

Chinese herbal medicines for treating osteoporosis (Review)



Wang J 2007 (Continued)

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wang JM 2008			
Methods	Country: China		
	Setting: outpatients and inpatients		
	Aim: to study the effect	ts of Gukang oral liquid in the treatment of postmenopausal osteoporosis	
	Study design: randomised controlled trial		
	Analysis: T-test, Ridit te	est	
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	70 postmenopausal osteoporosis patients enrolled: 32 in trial group, 34 in control group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: dise	ase-affected bone metabolism, secondary osteoporosis	
Interventions	Experimental: Gukang oral liquid,10 ml, 3 times a day, for 6 months		
	Control: alendronate s	odium tablets, 10 mg, once a day, for 6 months	
Outcomes	ALP, Ca, E2		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Chinese herbal medicines for treating osteoporosis (Review)



Wang JM 2008 (Continued) All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Wang SW 2003

Methods	Country: China		
	Setting: hospital based		
	Aim: to study the effect	ts of Antai capsule in the treatment of postmenopausal osteoporosis	
	Study design: double-b	olind, randomised controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese 168 postmenopausal osteoporosis patients enrolled: 65 in herbal group, 60 in ipriflavone group, 63 Caltrate group Inclusion criteria: WHO diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: endo	ocrine disease	
Interventions	Experimental: Antai capsule (3 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months		
	Control: ipriflavone (20 for 6 months	00 mg, 3 times a day) and Caltrate (1 tablet per day), or Caltrate (1 tablet per day),	
Outcomes	BMD, E2, Ca, P, ALP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Low risk Double-blind but did not describe who was blind		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	

Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported

Chinese herbal medicines for treating osteoporosis (Review)



Wang SW 2003 (Continued)

Free of other bias

Unclear risk

Wang XD 2011			
Methods	Country: China		
	Setting: hospital based		
	Aim: to study the effect	ts of Hugu capsule in the treatment of postmenopausal osteoporosis	
	Study design: double-blind, placebo-controlled, randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
		steoporosis patients enrolled: 61 in trial group, 61 in control group ese diagnostic criteria for osteoporosis	
	Exclusion criteria: bone metabolic disease, endocrine disease, etc.		
Interventions	Experimental: Hugu capsule (4 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months		
	Control: placebo capsule (4 capsules, 3 times a day) and Caltrate (1 tablet per day), for 6 months		
Outcomes	BMD, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	Patients were randomly allocated	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Low risk	Double-blind	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	No information on baseline	

Wang XY 2000

Methods	Country: China	
	Setting: hospital based	
Chinese herbal medio	cines for treating osteoporosis (Review)	105



Wang XY 2000 (Continued)	Aim: to study the effect	ts of Bushen Yigu soft extract in the treatment of osteoporosis
	-	ind, placebo-controlled, randomised controlled trial
	Analysis: F-test, T-test	
	Loss to follow-up: not r	reported
Participants	Ethnicity: Chinese	
	96 osteoporosis patien	ts enrolled: 37 in herbal group, 37 in Alfacalcidol group, 22 in placebo group
	Inclusion criteria: Chin	ese diagnostic criteria for osteoporosis, BMD detected by SPA
	Exclusion criteria: endo	ocrine disease
Interventions	Experimental: Bushen	Yigu soft extract, 20 ml, twice a day, for 3 months
	Control: Alfacalcidol, 0	.25 mg per day, or placebo, for 3 months
Outcomes	BMD, E2	
Notes	The study was supported by a national department of traditional Chinese medicine (TCM) modernisa- tion research project, but no declarations of interest for the primary researchers reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Single-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wang	YΖ	20	08
------	----	----	----

Methods	Country: China
	Setting: outpatients
	Aim: to study the effects of Jiangu capsule in the treatment of primary osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test
	Loss to follow-up: not reported

Chinese herbal medicines for treating osteoporosis (Review)



Dies	Antheorem independent Comment for independent		
Risk of bias			
Notes	No funding sources or declarations of interest for the primary researchers reported		
Outcomes	BMD		
	Control: Caltrate, 1 tablet per day, for 12 months		
Interventions	Experimental: Jiangu capsule, 9 g, 3 times a day, for 12 months		
	Exclusion criteria: secondary osteoporosis, metabolic disease, etc.		
	Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA		
	125 primary osteoporosis patients enrolled: 63 in trial group, 62 in control group		
Participants	Ethnicity: Chinese		
Wang YZ 2008 (Continued)			

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Wang ZK 2004 Methods Country: China Setting: hospital based Setting: hospital based Aim: to study the effects of Bushen Jianpi Migu prescription in the treatment of senile osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi² test Loss to follow-up: not reported Participants Ethnicity: Chinese 150 senile osteoporosis patients enrolled: 83 in trial group, 67 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine disease, secondary osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)



Wang ZK 2004 (Continued)

Interventions	Experimental: Bushen	Jianpi Migu prescription, 1 dose per day, for 3 months	
	Control: Caltrate, 1 tab	let, twice a day, for 3 months	
Outcomes	BMD, Ca, P, ALP, BMC	BMD, Ca, P, ALP, BMC	
Notes	No funding sources or	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Low risk	Drawing of lots	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	No information on baseline	

Wei RY 2011 Methods Country: China Setting: hospital based Aim: to study the effects of Kanggusong capsule in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T-test, Chi² test Loss to follow-up: not reported Participants **Ethnicity: Chinese** 80 postmenopausal osteoporosis patients enrolled: 48 in trial group, 32 in control group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, the Chinese diagnostic criteria for primary osteoporosis Exclusion criteria: secondary osteoporosis Interventions Experimental: Kanggusong capsule, 3, 3 times a day, for 6 months Control: Caltrate, 1 tablet each night, for 6 months BMD Outcomes

Chinese herbal medicines for treating osteoporosis (Review)



Wei RY 2011 (Continued)

Notes

No funding sources or declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wu JZ 2010

Bias	Authors' judgement Support for judgement
Risk of bias	
Notes	No funding sources or declarations of interest for the primary researchers reported
Outcomes	BMD, ALP, Ca, P
	Control: Caltrate, 1 tablet per day, for 6 months
Interventions	Experimental: Erxian soup, 1 pack per day, for 6 months
	Exclusion criteria: bone metabolic disease, endocrine disease, etc.
	Inclusion criteria: the Chinese diagnostic criteria for primary osteoporosis and guiding principles for clinical research on new drugs in traditional Chinese medicine
	58 primary osteoporosis patients with deficiency of liver and kidney enrolled: 30 in trial group, 28 in control group
Participants	Ethnicity: Chinese
	Loss to follow-up: not reported
	Analysis: F-test, Chi ² test
	Study design: randomised controlled trial
	Aim: to study the effects of Erxian soup in the treatment of primary osteoporosis
	Setting: outpatients and inpatients
Methods	Country: China

Chinese herbal medicines for treating osteoporosis (Review)

Wu JZ 2010 (Continued)

Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wu MS 2001 Methods Country: China Setting: outpatients and inpatients Aim: to study the effects of Kanggusong granule in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: F-test, T-test Loss to follow-up: not reported Participants **Ethnicity: Chinese** 90 postmenopausal osteoporosis patients enrolled: 30 in Kanggusong granule Tieji group, 30 in Kanggusong granule group, 30 in ipriflavone group Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: endocrine diseases, etc. Interventions Experimental: Kanggusong granule, 12 g, twice a day, for 3 months Control: ipriflavone, 1 tablet, 3 times a day, for 3 months Outcomes E2, Ca, P, ALP, PTH Notes The study was supported by the National Natural Science Foundation, but no declarations of interest for the primary researchers reported **Risk of bias** Bias **Authors' judgement** Support for judgement Unclear risk No information provided Adequate sequence generation Allocation concealment Unclear risk No information provided

Chinese herbal medicines for treating osteoporosis (Review)

Wu MS 2001 (Continued)

Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

Wu MS 2007

Methods	Country: China		
	Setting: outpatients and inpatients		
	Aim: to study the effect	ts of prescription for tonifying kidney in the treatment of osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test, Ridit te	est	
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	180 osteoporosis patients enrolled: 30 in prescription for tonifying kidney group, 30 in kidney meridian sticking group, 30 in urinary bladder meridian sticking group, 30 in ipriflavone group, 30 in Gushukang group, 30 in non-meridian or acupoint sticking group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	Exclusion criteria: secondary osteoporosis, patients with fractures, etc.		
Interventions	Experimental: prescription for tonifying kidney, 10 pills, 3 times a day; Kanggusong Tieji (kidney meridi- an sticking or urinary bladder meridian sticking), once per 2 days; for 6 months		
	Control: ipriflavone, 20	0 mg, 3 times a day, for 6 months	
Outcomes	BMD, Ca, P, E2, PTH, CT, adverse effects		
Notes	The study was supported by the National Natural Science Foundation, but no declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Low risk	Random numbers	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Chinese herbal medicines for treating osteoporosis (Review)

Wu MS 2007 (Continued)

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Wu W 2005

Methods	Country: China			
	Setting: outpatients and inpatients			
	Aim: to study the effect	s of Xianling Gubao capsules in the treatment of postmenopausal osteoporosis		
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not r	reported		
Participants	Ethnicity: Chinese			
	68 postmenopausal os	teoporosis patients enrolled: 34 in trial group, 34 in control group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA			
	Exclusion criteria: seco	ndary osteoporosis		
Interventions	Experimental: Xianling Gubao capsules (1 g, 3 times a day) and Caltrate (1 tablet per day), for months Control: Caltrate, 1 tablet per day, for 12 months			
Outcomes	BMD			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Low risk	Random numbers		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		

Chinese herbal medicines for treating osteoporosis (Review)



Wu W 2005 (Continued)

Free of other bias

Low risk

Methods	Country: China		
	Setting: hospital based		
	-	s of Gusong decoction in the treatment of osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	40 osteoporosis patien	ts enrolled: 20 in trial group, 20 in control group	
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis based on bone density levels	
	Exclusion criteria: secondary osteoporosis		
Interventions	Experimental: Gusong day), for 5 months	decoction (15 ml, 3 times a day) and alendronate sodium tablet (1 tablet per	
	Control: alendronate sodium tablet, 1 tablet per day, for 5 months		
Outcomes	BMD, E2, ALP, IL-6, BGP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	P value for the baseline comparison not stated	

Xie J 2004

 Methods
 Country: China

 Chinese herbal medicines for treating osteoporosis (Review)
 1



Alim: to study the effects of Migu tablet in the treatment of senile osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: 21 drop-outs were not included in the analysis Participants Ethnicity: Chinese 65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc. Interventions Experimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Outcomes BMD, adverse effects Notes No funding sources or declarations of interest for the primary researchers reported Risk of bios Unclear risk No information provided Allocation concealment Unclear risk No information provided Alloutcomes High risk No information provided Incomplete outcome data High risk No missing outcome data addressed High risk No missing outcome data Alloutcomes Unclear risk Not all the outcomes that were of interest in this review were reported Free of other bias Unclear risk P value for the baseline comparison not stated	Xie J 2004 (Continued)	Setting: hospital based	
Study design: randomised controlled trial Analysis: T-test Loss to follow-up: 21 drop-outs were not included in the analysisParticipantsEthnicity: Chinese 65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc.InterventionsExperimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 yearOutcomesBMD, adverse effectsNotesNo funding sources or declarations of interest for the primary researchers reported Risk of biasAuthors' judgement Adequate sequence gener ationUnclear riskNo information providedNo information providedAllocation concealmentUnclear riskMiloutcomesHigh riskNo missing outcome data addressedHigh riskNo missing outcome data addiressedHigh riskNo missing outcome data addressedNo all the outcomes that were of interest in this review were reported		_	
Analysis: T-test Loss to follow-up: 21 drop-outs were not included in the analysisParticipantsEthnicity: Chinese 65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc.InterventionsExperimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 yearOutcomesBMD, adverse effectsNotesNo funding sources or declarations of interest for the primary researchers reported Risk of biasAuthors' judgement BiasAuthors' judgementAdequate sequence gener- ationUnclear riskNo information providedAllocation concealmentUnclear riskMo information providedBinding All outcomesHigh riskNo missing outcome data addressedHigh riskNo missing outcome data addressedUnclear riskNo tall the outcomes that were of interest in this review were reported			
Loss to follow-up: 21 drop-outs were not included in the analysis Participants Ethnicity: Chinese 65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc. Interventions Experimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 year Outcomes BMD, adverse effects Notes No funding sources or declarations of interest for the primary researchers reported Risk of bias Support for judgement Adequate sequence gener ation Unclear risk No information provided Allocation concealment Unclear risk No information provided Blinding All outcomes High risk No missing outcome data addressed All outcomes Free of selective reporting Unclear risk No tall the outcomes that were of interest in this review were reported		Study design: randomi	sed controlled trial
Participants Ethnicity: Chinese 65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc. Interventions Experimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 year Outcomes BMD, adverse effects Notes No funding sources or declarations of interest for the primary researchers reported <i>Risk of bias</i> Unclear risk Bias Authors' judgement Allocation concealment Unclear risk No information provided Insufficient information to permit judgement of 'low risk' or 'high risk' All outcomes Blinding Allocationes High risk No missing outcome data addressed All outcomes Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported		Analysis: T-test	
65 senile osteoporosis males enrolled (21 drop-out): 24 in trial group, 20 in control group Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc.InterventionsExperimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 yearOutcomesBMD, adverse effectsNotesNo funding sources or declarations of interest for the primary researchers reportedBiasAuthors' judgementSupport for judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesHigh riskNo missing outcome data aldressedFree of selective reportingUnclear riskNo missing outcome stat were of interest in this review were reported		Loss to follow-up: 21 d	rop-outs were not included in the analysis
Inclusion criteria: diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: metabolic disease, etc.InterventionsExperimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 yearOutcomesBMD, adverse effectsNotesNo funding sources or declarations of interest for the primary researchers reportedRisk of biasExperimental: Migu tabletBiasAuthors' judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskUnclear riskNo information to permit judgement of 'low risk' or 'high risk' All outcomesIncomplete outcome data All outcomesHigh riskNo missing outcome data All outcomesHigh riskNo tall the outcomes that were of interest in this review were reported	Participants	Ethnicity: Chinese	
Exclusion criteria: metabolic disease, etc. Interventions Experimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Control: Caltrate, 600 mg per day, for 1 year Outcomes BMD, adverse effects Notes No funding sources or declarations of interest for the primary researchers reported Risk of bias Authors' judgement Bas Authors' judgement Adequate sequence generation Unclear risk Allocation concealment Unclear risk Blinding All outcomes Unclear risk Incomplete outcome data All outcomes High risk No missing outcome data All outcomes Free of selective reporting Unclear risk		65 senile osteoporosis	males enrolled (21 drop-out): 24 in trial group, 20 in control group
Interventions Experimental: Migu tablet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year Outcomes BMD, adverse effects Notes No funding sources or declarations of interest for the primary researchers reported Risk of bias Support for judgement Adequate sequence generation Unclear risk Allocation concealment Unclear risk No information provided Insufficient information to permit judgement of 'low risk' or 'high risk' Allouctomes High risk No missing outcome data addressed All outcomes No information provided to permit judgement of 'low risk' or 'high risk' No missing outcome data addressed All outcomes No missing outcome data addressed All outcomes Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported		Inclusion criteria: diag	nostic criteria for osteoporosis, BMD detected by DXA
Control: Caltrate, 600 mg per day, for 1 yearOutcomesBMD, adverse effectsNotesNo funding sources or declarations of interest for the primary researchers reportedRisk of biasSupport for judgementBiasAuthors' judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskHigh riskNo missing outcome data addressed All outcomesFree of selective reportingUnclear riskNot all the outcomes that were of interest in this review were reported		Exclusion criteria: meta	abolic disease, etc.
OutcomesBMD, adverse effectsNotesNo funding sources or declarations of interest for the primary researchers reportedRisk of biasAuthors' judgementSupport for judgementBiasAuthors' judgementSupport for judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskNo information to permit judgement of 'low risk' or 'high risk'Incomplete outcome data addressed All outcomesHigh riskNo missing outcome dataFree of selective reportingUnclear riskNot all the outcomes that were of interest in this review were reported	Interventions	Experimental: Migu tab	olet (3 tablets, 3 times a day) and Caltrate (600 mg per day), for 1 year
NotesNo funding sources or declarations of interest for the primary researchers reportedRisk of biasBiasAuthors' judgementSupport for judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'Incomplete outcome data addressed All outcomesHigh riskNo missing outcome dataFree of selective reportingUnclear riskNot all the outcomes that were of interest in this review were reported		Control: Caltrate, 600 r	ng per day, for 1 year
Risk of biasBiasAuthors' judgementSupport for judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskInsufficient information to permit judgement of 'low risk' or 'high risk' All outcomesIncomplete outcome data addressed 	Outcomes	BMD, adverse effects	
BiasAuthors' judgementSupport for judgementAdequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'Incomplete outcome data addressed All outcomesHigh riskNo missing outcome dataFree of selective reportingUnclear riskNot all the outcomes that were of interest in this review were reported	Notes	No funding sources or	declarations of interest for the primary researchers reported
Adequate sequence generationUnclear riskNo information providedAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskInsufficient information to permit judgement of 'low risk' or 'high risk'Incomplete outcome data addressed All outcomesHigh riskNo missing outcome dataFree of selective reportingUnclear riskNot all the outcomes that were of interest in this review were reported	Risk of bias		
ationAllocation concealmentUnclear riskNo information providedBlinding All outcomesUnclear riskInsufficient information to permit judgement of 'low risk' or 'high risk' All outcomesIncomplete outcome data addressed All outcomesHigh riskNo missing outcome data All outcomes that were of interest in this review were reportedFree of selective reportingUnclear riskNot all the outcomes that were of interest in this review were reported	Bias	Authors' judgement	Support for judgement
Blinding All outcomes Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk' Incomplete outcome data addressed All outcomes High risk No missing outcome data Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported	-	Unclear risk	No information provided
All outcomes Incomplete outcome data High risk No missing outcome data addressed All outcomes Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported	Allocation concealment	Unclear risk	No information provided
addressed All outcomes Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported	-	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
	addressed	High risk	No missing outcome data
Free of other bias Unclear risk P value for the baseline comparison not stated	Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
	Free of other bias	Unclear risk	P value for the baseline comparison not stated

Xie YM 1997

Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to study the effects of Bugu Shengsui capsule in the treatment of primary osteoporosis
	Study design: single-blind, randomised controlled trial
	Analysis: T-test, Chi ² test, Ridit test
	Loss to follow-up: not reported

Chinese herbal medicines for treating osteoporosis (Review)



Participants	Ethnicity: Chinese
	80 primary osteoporosis patients with kidney-yang deficiency enrolled: 50 in trial group, 30 in contro group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by SPA and DXA
	Exclusion criteria: secondary osteoporosis, endocrine disease, etc.
Interventions	Experimental: Bugu Shengsui capsule, 3 capsules, 3 times a day, for 6 months
	Control: vitamin D2 (10,000 U per day) and calcium tablet (500 mg, 3 times a day), for 6 months
Outcomes	BMD, Ca, ALP, PTH, CT, adverse effects
Notes	The study was supported by the state administration of traditional Chinese medicine youth fund, but no declarations of interest for the primary researchers reported

Risk	of	bias	

	Support for judgement
Unclear risk	No information provided
Unclear risk	No information provided
Low risk	Single-blind but did not describe who was blind
Low risk	No missing outcome data
Unclear risk	Not all the outcomes that were of interest in this review were reported
Unclear risk	P value for the baseline comparison not stated
	Unclear risk Low risk Low risk Unclear risk

Xiong YH 2008

Methods	Country: China		
	Setting: hospital based		
	Aim: to study the effects of Gusongbao granule in the treatment of postmenopausal osteoporosis		
	Study design: double-blind, placebo-controlled, randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: 36 drop-outs (12 in Gusongbao granule group, 13 in placebo group, 11 in Jiangu granule group) were not included in the analysis		
Participants	Ethnicity: Chinese		
	144 postmenopausal osteoporosis patients enrolled: 48 (12 drop-outs) in Gusongbao granule group, 48 (13 drop-outs) in placebo group, 48 (11 drop-outs) in Jiangu granule group		

Chinese herbal medicines for treating osteoporosis (Review)

Xiong YH 2008 (Continued)	Inclusion criteria: diag DXA	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA		
	Exclusion criteria: seco	ondary osteoporosis, liver or kidney disease, etc.		
Interventions	0 0 0	Gusongbao granule group: Gusongbao granule, 1 dose, twice a day, Osteoform calcium amino acid chelate compound capsule, 1 pill, twice a day, for 6 months		
	Jiangu granule group: pill, twice a day, for 6 n	1 dose, twice a day, Osteoform calcium amino acid chelate compound capsule, 1 nonths		
	Placebo group: 1 dose, twice a day, Osteoform calcium amino acid chelate compound capsule, 1 pill twice a day			
Outcomes	BMD, adverse effects			
Notes	No funding sources or	declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Xu H 2010

u H 2010	
Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to study the effects of Qianggu capsule in the treatment of postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese
	120 postmenopausal osteoporosis patients enrolled: 40 in trial group, 40 in control A group, 40 in con- trol B group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)



u H 2010 (Continued)				
	Exclusion criteria: not mentioned			
Interventions	Experimental: Qianggu	capsule (1 capsule, 3 times a day) and alendronate sodium (70 mg per week)		
	Control A: alendronate	sodium (70 mg per week)		
	Control B: Qianggu cap	Control B: Qianggu capsule (1 capsule, 3 times a day)		
Outcomes	BMD, adverse events	BMD, adverse events		
Notes	No funding sources or o	declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	Random numbers table		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		

(u M 2009	
Methods	Country: China
	Setting: outpatients and inpatients
	Aim: to study the effects of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis
	Study design: randomised controlled trial
	Analysis: T-test
	Loss to follow-up: not reported
Participants	Ethnicity: Chinese
	156 postmenopausal osteoporosis patients enrolled: 52 in trial group, 52 in control A group, 52 in con- trol B group
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA
	Exclusion criteria: secondary osteoporosis, disease-affected bone metabolism, endocrine disease, etc.
Interventions	Experimental: Xianlinggubao capsule (3 capsules, 3 times a day) and alendronate sodium (70 mg per week)

Chinese herbal medicines for treating osteoporosis (Review)



Xu M 2009 (Continued)

Control A: alendronate sodium (70 mg per week)

Control B: Xianlinggubao capsule (3 capsules, 3 times a day)

Outcomes	BMD, adverse events	
Notes	No funding sources or	declarations of interest for the primary researchers reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	Random numbers table
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Country: China		
Setting: outpatients		
Aim: to study the effects of Yishen Yanggan mixture in the treatment of postmenopausal osteoporosis		
Study design: randomised controlled trial		
Analysis: T-test, Chi ² test		
Loss to follow-up: not reported		
Ethnicity: Chinese		
110 postmenopausal osteoporosis patients with liver-kidney deficiency enrolled: 60 in trial group, 50 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA		
Exclusion criteria: not mentioned		
Experimental: Yishen Yanggan mixture, 50 ml, twice a day, for 6 months		
Control: calcium gluconate, 4 tablets, 3 times a day, for 6 months		
BMD		
No funding sources or declarations of interest for the primary researchers reported		

Chinese herbal medicines for treating osteoporosis (Review)



Xu W 2005 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Xu YL 2007

Methods	Country: China		
	Setting: outpatients		
	Aim: to study the effect	ts of acupoint sticking of Migudan in the treatment of primary osteoporosis	
	Study design: randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	96 primary osteoporos	is patients enrolled: 48 in trial group, 48 in control group	
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis, BMD detected by DXA	
	Exclusion criteria: seco	ndary osteoporosis, endocrine disease	
Interventions	Experimental: acupoint	t sticking of Migudan (3 times a week), for 3 months	
	Control: Gaitianli (3 tab	plets, 3 times a day), for 3 months	
Outcomes	BGP, Hyp, adverse effec	cts	
Notes	No funding sources or o	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Low risk	Random numbers	

Chinese herbal medicines for treating osteoporosis (Review)

Xu YL 2007 (Continued)

Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Yang B 2007

Methods	Country: China		
	Setting: inpatients		
	Aim: to study the effec	ts of Huangqi in the treatment of osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: F-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
		nts enrolled: 20 in trial group of Huangqi, 20 in control group of Liweiai, 18 in con- Iusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA	
	Exclusion criteria: end	ocrine disease, liver or kidney disease, etc.	
Interventions	Experimental: Huangqi, 1 dose per day, for 6 months		
	Control: Liweiai, 2.5 m	g, once a day, for 6 months	
	Blank group: no drug		
Outcomes	BMD, ALP, P, Ca		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed	Low risk	No missing outcome data	

Chinese herbal medicines for treating osteoporosis (Review)



Yang B 2007 (Continued) All outcomes

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Methods	Country: China		
	Setting: outpatients and inpatients		
	Aim: to observe the effe	ects of Bushen Zhuanggutang in the treatment of senile osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	eported	
Participants	Ethnicity: Chinese		
	60 senile osteoporosis	patients enrolled: 31 in trial group, 29 in control group	
	Inclusion criteria: WHO by DXA	diagnostic criteria for osteoporosis based on bone density levels, BMD detected	
	Exclusion criteria: seco	ndary osteoporosis	
Interventions	Experimental: Bushen Zhuanggutang (1 dose per day, fried) and Caltrate (1 tablet per day), for 6 months		
	Control: Caltrate (1 tablet per day), for 6 months		
Outcomes	BMD		
Notes	No funding sources or o	declarations of interest for the primary researchers reported	
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	No information on baseline	

Chinese herbal medicines for treating osteoporosis (Review)



Yuan YN 2000

uan YN 2000				
Methods	Country: China			
	Setting: hospital based			
	Aim: to observe the effe	ects of Shangke Jiegu tablet in the treatment of primary osteoporosis		
	Study design: single-bl	inded, randomised controlled trial		
	Analysis: T-test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	60 primary osteoporos	is patients enrolled: 30 in trial group, 30 in control group		
	Inclusion criteria: Chine tected by SPA	ese diagnostic criteria for osteoporosis based on bone density levels, BMD de-		
	Exclusion criteria: endocrine disease, etc.			
Interventions	Experimental: Shangke Jiegu tablet, 4 tablets, 3 times a day, for 6 months			
	Control: vitamin D2 (10,000 U per day) and calcium tablet (500 mg, 3 times a day), for 6 months			
Outcomes	BMD			
Notes	No funding sources or o	declarations of interest for the primary researchers reported		
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Low risk	Single-blind but did not describe who was blind		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Unclear risk	P value for the baseline comparison not stated		

Zhan HS 2009

Methods

Country: China Setting: hospital based Aim: to observe the effects of Xuduanzhu

Aim: to observe the effects of Xuduanzhuanggu capsule in the treatment of primary osteoporosis

Chinese herbal medicines for treating osteoporosis (Review)

Zhan HS 2009 (Continued)	
	Study design: double-blinded, placebo and positive-controlled, randomised controlled trial
	Analysis: T-test
	Loss to follow-up: 67 drop-outs (37 in herb trial group, 18 in positive control group, 21 in placebo group) were not included in the analysis
Participants	Ethnicity: Chinese
	600 primary osteoporosis patients enrolled: 360 in herb trial group (37 drop-outs), 120 in positive con- trol group (18 drop-outs), 120 in placebo group (21 drop-outs)
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis
	Exclusion criteria: secondary osteoporosis, disease-affected bone metabolism, metabolic disease, liver or kidney disease, etc.
Interventions	Experimental: Xuduanzhuanggu capsule (2 capsules, 3 times a day), Gusongbao granule placebo (1 packet, 3 times a day) and calcium tablet (1 tablet, once a day), for 6 months
	Control: Xuduanzhuanggu capsule placebo (2 capsules, 3 times a day), Gusongbao granule (1 packet, 3 times a day) and calcium tablet (1 tablet, once a day), for 6 months
	Placebo: Xuduanzhuanggu capsule placebo (2 capsules, 3 times a day), Gusongbao granule placebo (1 packet, 3 times a day) and calcium tablet (1 tablet, once a day), for 6 months
Outcomes	BMD, adverse events
Notes	The study was supported by a National High Technology Research and Development Program, but no declarations of interest for the primary researchers reported
Risk of bias	

Authors' judgement Unclear risk Unclear risk	Support for judgement Insufficient information about the sequence generation process Insufficient information to permit judgement of 'low risk' or 'high risk'
Unclear risk	
	Insufficient information to permit judgement of 'low risk' or 'high risk'
Lauradal.	
Low risk	Double-blind but did not describe who was blind
Unclear risk	Insufficient information about drop-outs
Unclear risk	Not all the outcomes that were of interest in this review were reported
Low risk	The study appears to be free of other sources of bias
	Unclear risk Unclear risk

Zhan ML 2007

Methods	Country: China
	Setting: hospital based
	Aim: to observe the effects of Bushen Yangxue decoction in the treatment of postmenopausal osteo- porosis

Chinese herbal medicines for treating osteoporosis (Review)



Zhan ML 2007 (Continued)			
	Study design: randomi	sed controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	40 postmenopausal os	teoporosis patients enrolled: 20 in trial group, 20 in control group	
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis, BMD detected by DXA	
	Exclusion criteria: not r	nentioned	
Interventions	Experimental: Bushen	Yangxue decoction, 1 dose per day, for 6 months	
	Control: calcium gluconate, 4 tablets, 3 times a day, for 6 months		
Outcomes	Ca, P		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Zhang DS 2011			
Methods	Country: China		
	Setting: outpatients		
	Aim: to observe the effects of Bushenyiqihuoxue soup in the treatment of postmenopausal osteoporo- sis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		

Chinese herbal medicines for treating osteoporosis (Review)

Bias	Authors' judgement Support for judgement		
Risk of bias			
Notes	No funding sources or declarations of interest for the primary researchers reported		
Outcomes	ALP, Ca		
	Control: tamoxifen (20 mg, once a day) and Caltrate (1 tablet, twice a day), for 3 months		
Interventions	Experimental: Bushenyiqihuoxue soup (1 dose per day, water fried 600 ml, twice a day), tamoxifen (20 mg, once a day) and Caltrate (1 tablet, twice a day), for 3 months		
	Exclusion criteria: metabolic disease, etc.		
	Inclusion criteria: guiding principles for clinical research on new drugs in traditional Chinese medicine		
Zhang DS 2011 (Continued)	120 postmenopausal osteoporosis patients enrolled: 60 in trial group, 60 in control group		

Blas	Authors' Judgement	Support for Judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No detailed description of the detection of BMD and biochemical indicators

Zhang J 2003

Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the effects of Liuwei Dihuang pills in the treatment of postmenopausal osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	42 postmenopausal osteoporosis patients enrolled: 24 in trial group, 18 in control group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: not mentioned		
Interventions	Experimental: Liuwei Dihuang pills, 8 pills, 3 times a day, for 12 months		

Chinese herbal medicines for treating osteoporosis (Review)



Zhang J 2003 (Continued)

Control: calcium, 500 mg per day, for 12 months

Outcomes	BMD, ALP	
Notes	No funding sources or declarations of interest for the primary researchers reported	
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the effects of Yigu capsule in the treatment of postmenopausal osteoporosis		
	Study design: double-blinded, randomised controlled trial		
	Analysis: F-test, Chi ² test		
	Loss to follow-up: 10 drop-outs were not included in the analysis		
Participants	Ethnicity: Chinese		
	210 postmenopausal osteoporosis patients enrolled: 70 (3 drop-outs) in herbal trial group, 70 (4 drop- outs) in control group, 70 (3 drop-outs) in placebo group		
	Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA		
	Exclusion criteria: metabolic disease, etc.		
Interventions	Experimental: Yigu capsule (4 capsules, 3 times a day) and calcium (510 mg), for 6 months		
	Control: Alfacalcidol (1 capsule per day) and calcium (510 mg), or placebo and calcium (510 mg), for 6 months		
Outcomes	BMD, E2, Ca, P, ALP, BGP, fractures		

Chinese herbal medicines for treating osteoporosis (Review)



Zhang RH 2004 (Continued)

Notes

The study was supported by the National Science Foundation and China Postdoctoral Science Foundation, but no declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers generated by computer
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blinded
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Zhang XG 2011

Bias	Authors' judgement Support for judgement		
Risk of bias			
Notes	No funding sources or declarations of interest for the primary researchers reported		
Outcomes	BMD, Ca, P, ALP		
	Control: Caltrate, 600 mg, twice a day, and Miacalcin ampoule 50 IU, once a day, for 12 weeks		
Interventions	Experimental: Bushenjianpi Zhuangguyin, 1 dose per day, water fried, twice a day, for 12 weeks		
	Exclusion criteria: secondary osteoporosis, disease-affected bone metabolism, etc.		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	100 primary osteoporosis patients enrolled: 50 in trial group, 50 in control group		
Participants	Ethnicity: Chinese		
	Loss to follow-up: not reported		
	Analysis: T-test		
	Study design: randomised controlled trial		
	Aim: to observe the effects of Bushenjianpi Zhuangguyin in the treatment of primary osteoporosis		
	Setting: outpatients		
Methods	Country: China		

Chinese herbal medicines for treating osteoporosis (Review)

Zhang XG 2011 (Continued)

Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	P value for the baseline comparison not stated

Zhang XJ 2008

Methods	Country: China		
	Setting: outpatients an	nd inpatients	
	Aim: to observe the effects of Bushenhuoxue capsule in the treatment of senile osteoporosis		
	Study design: randomi	sed controlled trial	
	Analysis: T-test, F-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	60 senile osteoporosis	patients enrolled: 30 in trial group, 30 in control group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	Exclusion criteria: seco	ndary osteoporosis, liver or kidney disease, disease-affected bone metabolism	
Interventions	Experimental: Bushenhuoxue capsule, 4 pills, 3 times a day, for 12 months		
	Control: Caltrate, 600 n	ng, once a day and Rocaltrol, 0.5 mg, once a day, for 12 months	
Outcomes	BMD, E2, IL-6, BGP		
Notes	The study was supported by the Zhejiang Provincial Department of traditional Chinese medicine (TCM) modernisation research project, but no declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Chinese herbal medicines for treating osteoporosis (Review)



Zhang XJ 2008 (Continued) All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

Zhang XZ 2004

Methods	Country: China			
	Setting: outpatients and inpatients Aim: to observe the effects of Xianlinggubao capsule in the treatment of postmenopausal osteoporosis			
	Study design: randomi	sed controlled trial		
	Analysis: T-test			
	Loss to follow-up: not i	reported		
Participants	Ethnicity: Chinese			
		steoporosis patients enrolled: 62 in trial group (Xianlinggubao capsule), 66 in ne), 50 in control group 2 (Osteoform)		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA			
	Exclusion criteria: liver or kidney disease, disease-affected bone metabolism, etc.			
Interventions	Experimental: Xianlinggubao capsule and Osteoform, 1.0 g, 3 times a day, for 48 weeks			
	Control 1:tibolone tablets and Osteoform, 1.25 mg, once a day			
	control 2: Osteoform, 1 g, once a day			
Outcomes	BMD, E2, ALP, BGP, IL-6			
Notes	The study was supported by National Natural Science Foundation, but no declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	Random numbers table		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed	Low risk	No missing outcome data		

Chinese herbal medicines for treating osteoporosis (Review)



Zhang XZ 2004 (Continued) All outcomes

Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

Methods	Country: China		
	Setting: outpatients and inpatients		
	Aim: to observe the effe	ects of TPF capsule in the treatment of senile osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	120 senile osteoporosis	s patients enrolled: 60 in trial group, 60 in control group	
	Inclusion criteria: WHO diagnostic criteria for osteoporosis based on bone density levels, BMD detected by SPA		
	Exclusion criteria: not mentioned		
Interventions	Experimental: TPF capsule, 3 to 4 capsules, 3 times a day, for 6 months		
	Control: calcium granule, 10 g, twice a day, for 6 months		
Outcomes	BMD, ALP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Unclear risk	P value for the baseline comparison not stated	

Chinese herbal medicines for treating osteoporosis (Review)



Zhang YP 2007

Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the effe	ects of Shigu yin in the treatment of postmenopausal osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test, F-test,	Chi ² test	
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	120 postmenopausal o blank group	steoporosis patients enrolled: 40 in Shigu yin group, 40 in Caltrate group, 40 in	
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis, BMD detected by DXA	
	Exclusion criteria: disease-affected bone metabolism, metabolic disease, etc.		
Interventions	Experimental: Shigu yin, 200 ml, twice a day, for 6 months		
	Control: Caltrate, 600 mg, twice a day, for 6 months		
	blank: no treatment		
Outcomes	BMD, BGP, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Zhang YS 2003

Methods Country: China Setting: outpatients

Chinese herbal medicines for treating osteoporosis (Review)



Zhang YS 2003 (Continued)			
	Aim: to observe the effe	ects of Huoluo Gukang pills in the treatment of primary osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test, Chi ² test		
	Loss to follow-up: not r	reported	
Participants	Ethnicity: Chinese		
	210 primary osteoporo blank group	osis patients enrolled: 81 in herbal trial group, 74 in herbal control group, 55 in	
	Inclusion criteria: Chin tected by DXA	ese diagnostic criteria for osteoporosis based on bone density levels, BMD de-	
	Exclusion criteria: seco	ondary osteoporosis, etc.	
Interventions	Experimental: Huoluo Gukang pills, 6.0 g, 3 times a day, for 6 months; Gushukang granule, 10.0 g, twice a day, for 6 months		
	Control: blank (no drug	g)	
Outcomes	E2, BGP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data	
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported	
Free of other bias	Low risk	The study appears to be free of other sources of bias	

Zhang ZF 2011

MethodsCountry: ChinaSetting: hospital basedAim: to observe the effects of Zhuangguqiangjin tablet in the treatment of primary osteoporosisStudy design: randomised controlled trialAnalysis: T-test, Chi² test

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Zhang ZF 2011 (Continued)

Zhang ZF 2011 (Continued)	Loss to follow-up: 8 drop-outs (3 in trial group, 5 in control group) were not included in the analysis			
Participants	Ethnicity: Chinese			
	90 primary osteoporosis patients with deficiency of kidney and liver enrolled: 48 in trial group (3 drop- outs), 42 in control group (5 drop-outs)			
	Inclusion criteria: Chin	ese diagnostic criteria for primary osteoporosis, BMD detected by DXA		
	Exclusion criteria: dise	ases which can affect bone conversion biochemical index, etc.		
Interventions	Experimental: Zhuangguqiangjin tablet (5, 3 times a day for 3 months, then twice a day for 1 year), Shu- jinbogu tablet (5 tablets, 3 times a day, for 2 to 4 weeks), Miacalcin ampoule (50 IU, injection, once every other day for 10 days; once every 2 days for 10 days; once every 5 days for 10 days. In the 3rd, 6th, 9th and 12th month repeated again)			
	Control: Miacalcin ampoule (50 IU, injection, once every other day for 10 days; once every 2 days for 10 days; once every 5 days for 10 days. In the 3rd, 6th, 9th and 12th month repeated again)			
Outcomes	BMD, Ca, P, ALP, adverse effects, fracture			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Zhao G 2002			
Methods	Country: China		
	Setting: outpatients		
	Aim: to observe the effects of Zishen prescription in the treatment of postmenopausal osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		

Chinese herbal medicines for treating osteoporosis (Review)

Zhao G 2002 (Continued)		
	45 postmenopausal osteoporosis patients enrolled: 25 in trial group, 20 in control group	
Inclusion criteria: international diagnostic criteria for osteoporosis based on bone der detected by DXA		
	Exclusion criteria: diseases which can affect therapeutic effect	
Interventions	Experimental: Zishen prescription (25 ml, twice a day), Caltrate (1.2 g, twice a day) and Miacalcin (50 IU, injection, twice weekly), for 8 months	
	Control: Caltrate (1.2 g, twice a day) and Miacalcin (50 IU, injection, twice weekly), for 8 months	
Outcomes	BMD, E2	
Notes	No funding sources or declarations of interest for the primary researchers reported	

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Zhao HX 2001

Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the effects of Kanggusong capsule in the treatment of postmenopausal osteoporosis		
	Study design: double-blinded, placebo-controlled, randomised controlled trial		
	Analysis: T-test, Chi ² test		
	Loss to follow-up: 35 drop-outs (11 in trial group, 16 in control group, 8 in opening experimental group) were not included in the analysis		
Participants	Ethnicity: Chinese		
	198 postmenopausal osteoporosis patients enrolled: 70 (11 drop-outs) in trial group, 70 (16 drop-outs) in control group, 58 (8 drop-outs) in opening experimental group		
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA		

Chinese herbal medicines for treating osteoporosis (Review)



Zhao HX 2001 (Continued)

	Exclusion criteria: diseases which can affect biochemical markers of bone turnover		
Interventions	Experimental: Kanggusong capsule, 3 capsules, 3 times a day, for 1 year		
	Control: placebo, 3 capsules, 3 times a day, for 1 year		
Outcomes	BMD, fractures		
Notes	No funding sources or declarations of interest for the primary researchers reported		

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Computer QBASIC procedure
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Unclear risk	No reasons for missing data provided
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Zhao LN 2003

2003			
Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the effects of Yinyanghuo in the treatment of postmenopausal osteoporosis		
	Study design: double-blinded, randomised controlled trial		
	Analysis: T-test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	25 postmenopausal osteoporosis patients enrolled: 15 in trial group, 10 in control group		
	Inclusion criteria: diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA		
	Exclusion criteria: not mentioned		
Interventions	Experimental: Yinyanghuo, fried, 200 g per day, 3 times a day, for 3 to 6 months		
	Control: Premarin, 0.625 mg per day, for 3 to 6 months		
Outcomes	BMD, Ca, P, ALP		

Chinese herbal medicines for treating osteoporosis (Review)



Zhao LN 2003 (Continued)

Notes

No funding sources or declarations of interest for the primary researchers reported

Risk of bias

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Unclear risk	No information on baseline

Zheng WK 2007

Bias	Authors' judgement Support for judgement		
Risk of bias			
Notes	No funding sources or declarations of interest for the primary researchers reported		
Outcomes	BMD, BGP, ALP, Ca, P, adverse effect		
	Control: placebo capsules (3 capsules, 3 times a day) plus calcium (510 mg per day), for 6 months		
Interventions	Experimental: Jinwugutong capsules (3 capsules, 3 times a day) plus calcium (510 mg per day), for 6 months		
	Exclusion criteria: disease-affected bone metabolism, used medicines that affected bone metabolism		
	Inclusion criteria: WHO diagnostic criteria for osteoporosis, BMD detected by DXA		
	120 postmenopausal osteoporosis patients enrolled: 60 in trial group, 60 in control group		
Participants	Ethnicity: Chinese		
	Loss to follow-up: 11 drop-outs (5 in trial group, 6 in control group) were not included in the analysis		
	Analysis: T-test, F-test, Chi ² test		
	Study design: double-blinded, placebo-controlled, randomised controlled trial		
	Aim: to observe the effects of Jinwugutong capsules in the treatment of postmenopausal osteoporosis		
	Setting: hospital based		
Methods	Country: China		

Chinese herbal medicines for treating osteoporosis (Review)

Zheng WK 2007 (Continued)

Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Low risk	Double-blind but did not describe who was blind
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Methods	Country: China		
	Setting: outpatients		
	Aim: to observe the effe	ects of Gushen Yijing tang in the treatment of primary osteoporosis	
	Study design: randomi	sed controlled trial	
	Analysis: T-test, Chi ² te	st	
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	80 primary osteoporos	is patients enrolled: 39 in trial group, 41 in control group	
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	Exclusion criteria: endocrine disease, liver or kidney disease		
Interventions	Experimental: Gushen Yijing tang (1 dose and 2 times a day), for 6 months		
	Control: Caltrate (600 mg, twice a day) for 6 months		
Outcomes	BMD, Ca, P, ALP		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			
Bias	Authors' judgement	Support for judgement	
Adequate sequence gener- ation	Unclear risk	No information provided	
Allocation concealment	Unclear risk	No information provided	
Blinding	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'	

Chinese herbal medicines for treating osteoporosis (Review)



Zhong RQ 2007 (Continued) All outcomes

Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Zhou LZ 2001

Methods	Country: China		
	Setting: hospital based		
	Aim: to observe the effects of Tongbu Qianggutang in the treatment of primary osteoporosis		
	Study design: randomised controlled trial		
	Analysis: T-test, Chi ² test		
	Loss to follow-up: not reported		
Participants	Ethnicity: Chinese		
	40 primary osteoporosis patients enrolled: 30 in trial group, 10 in control group		
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD de- tected by DXA		
	Exclusion criteria: secondary osteoporosis, liver or kidney disease, etc.		
Interventions	Experimental: Tongbu Qianggutang (400 ml per day), for 3 months		
	Control: calcium (1.5 g, 3 times a day) plus vitamin D3 (0.25 μg per day), for 3 months		
Outcomes	ALP, CT, BGP, Ca, P, E2, adverse effects		
Notes	No funding sources or declarations of interest for the primary researchers reported		
Risk of bias			

Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Unclear risk	No information provided
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported

Chinese herbal medicines for treating osteoporosis (Review)

=



Zhou LZ 2001 (Continued)

Free of other bias

Low risk

Zhou XT 2001 Methods Country: China Setting: outpatients Aim: to observe the effects of Guilu Erxiantang in the treatment of primary osteoporosis Study design: randomised controlled trial Analysis: T-test Loss to follow-up: not reported Participants **Ethnicity: Chinese** 85 primary osteoporosis patients enrolled: 45 in trial group, 40 in control group Inclusion criteria: Chinese diagnostic criteria for osteoporosis based on bone density levels, BMD detected by DXA Exclusion criteria: secondary osteoporosis Interventions Experimental: Guilu Erxiantang (1 dose per day) and calcium carbonate tablet (300 mg per day), for 6 months Control: calcium carbonate tablet (300 mg per day), for 6 months Outcomes BMD Notes No funding sources or declarations of interest for the primary researchers reported **Risk of bias** Bias Authors' judgement Support for judgement Adequate sequence gener-Unclear risk No information provided ation Allocation concealment Unclear risk No information provided Unclear risk Insufficient information to permit judgement of 'low risk' or 'high risk' Blinding All outcomes Incomplete outcome data Low risk No missing outcome data addressed All outcomes Free of selective reporting Unclear risk Not all the outcomes that were of interest in this review were reported Free of other bias Low risk The study appears to be free of other sources of bias

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Methods	Country: China Setting: outpatients and inpatients			
				Aim: to observe the effe
		Study design: randomi	sed controlled trial	
	Analysis: T-test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	50 postmenopausal os	teoporosis patients enrolled: 30 in trial group, 20 in control group		
	Inclusion criteria: Chine	ese diagnostic criteria for osteoporosis, BMD detected by DXA		
	Exclusion criteria: bone metabolic disease induced by diabetes mellitus, liver or kidney disease			
Interventions	Experimental: Huangqi Sanxian tang (1 dose per day), for 3 months			
	Control: nilestriol (2 mg, twice per month), for 3 months			
Outcomes	BMD, E2, ALP			
Notes	No funding sources or declarations of interest for the primary researchers reported			
Risk of bias				
Bias	Authors' judgement	Support for judgement		
Adequate sequence gener- ation	Unclear risk	No information provided		
Allocation concealment	Unclear risk	No information provided		
Blinding All outcomes	Low risk	Single-blind		
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data		
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported		
Free of other bias	Low risk	The study appears to be free of other sources of bias		

Zhu HJ 2011

MethodsCountry: ChinaSetting: inpatientsAim: to observe the effects of Bushen Tianjing Huoxue therapy in the treatment of primary osteoporo-
sisStudy design: randomised controlled trial

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Zhu HJ 2011 (Continued)		
	Analysis: T-test	
	Loss to follow-up: not r	reported
Participants	Ethnicity: Chinese	
	61 primary osteoporos	is patients enrolled: 31 in trial group, 30 in control group
	Inclusion criteria: Chin	ese diagnostic criteria for osteoporosis
	Exclusion criteria: seco	ondary osteoporosis, endocrine disease, liver or kidney disease, etc.
Interventions	Experimental: Bushen	Tianjing Huoxue therapy (1 dose per day, twice a day), for 6 months
	Control: Caltrate (600 r	ng, once a day) and calcitriol soft capsule (0.25 μg , once a day), for 6 months
Outcomes	BMD	
Notes	No funding sources or	declarations of interest for the primary researchers reported
Risk of bias		
Bias	Authors' judgement	Support for judgement
Adequate sequence gener- ation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias

Zhu HM 2012

Methods	Country: China
	Setting: hospital based
	Aim: to observe the effects of Bushen Tianjing Huoxue therapy in the treatment of primary osteoporo- sis
	Study design: a multicentre, double-blinded, placebo-controlled, randomised controlled trial
	Analysis: F-test, based on the intention-to-treat (ITT) principle
	Loss to follow-up: 42 drop-outs (15 in low-dose Xianlinggubao group, 14 in high-dose Xianlinggubao group, 13 in placebo group)
Participants	Ethnicity: Chinese

Chinese herbal medicines for treating osteoporosis (Review)



Zhu HM 2012 (Continued)	180 postmenopausal osteoporosis patients enrolled: 61 in low-dose Xianlinggubao group, 58 in high- dose Xianlinggubao group, 61 in placebo group Inclusion criteria: BMD criteria for osteoporosis				
	Exclusion criteria: previous exposure to toremifene, tamoxifen, droloxifene, lasofoxifene or other inves- tigational selective oestrogen receptor modulators; use of bisphosphonates during the past 24 months; history of advanced scoliosis, osteoarthritis or other clinical spinal deformity which would interfere with BMD measurement etc.				
Interventions	Experimental: Xianlinggubao capsule, 3 g (6 capsules) per day in low-dose group, or 6 g (12 capsules) per day in high-dose group, plus calcium (500 mg) and vitamin D (200 IU), for 12 months				
	Control: placebo capsu months	lle (12 capsules per day), plus calcium (500 mg) and vitamin D (200 IU), for 12			
Outcomes	BMD, fracture, adverse	effects			
Notes	No funding sources or declarations of interest for the primary researchers reported				
Risk of bias					
Bias	Authors' judgement	Support for judgement			
Bias Adequate sequence gener- ation	Authors' judgement	Support for judgement Random numbers			
Adequate sequence gener-					
Adequate sequence gener- ation	Low risk	Random numbers			
Adequate sequence gener- ation Allocation concealment Blinding	Low risk Unclear risk	Random numbers No information provided			
Adequate sequence gener- ation Allocation concealment Blinding All outcomes Incomplete outcome data addressed	Low risk Unclear risk Low risk	Random numbers No information provided Double-blind			

Zou JJ 2005

200 JJ 2005				
Methods	Country: China			
	Setting: outpatients			
	Aim: to observe the effects of Guben Zhuanggu capsules in the treatment of primary osteoporosis			
	Study design: single-blinded, randomised controlled trial			
	Analysis: T-test, Chi ² test			
	Loss to follow-up: not reported			
Participants	Ethnicity: Chinese			
	60 primary osteoporosis patients enrolled: 30 in trial group, 30 in control group			
	Inclusion criteria: Chinese diagnostic criteria for osteoporosis, BMD detected by DXA			

Chinese herbal medicines for treating osteoporosis (Review)



Zou JJ 2005 (Continued)	Exclusion criteria: secondary osteoporosis, endocrine disease					
Interventions	Experimental: Guben Zhuanggu capsules (2 capsules, 3 times a day) and Caltrate (600 mg, once a for 6 months					
	Control: Guben Zhuanggu capsules simulated (2 capsule, 3 times a day) and Caltrate (600 mg, once a day), for 6 months					
Outcomes	BMD, adverse effects					
Notes	No funding sources or	declarations of interest for the primary researchers reported				
Risk of bias						
Bias	Authors' judgement	Support for judgement				
Adequate sequence gener- ation	Unclear risk	No information provided				
Allocation concealment	Unclear risk	No information provided				
Blinding All outcomes	Low risk	Single-blind				
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data				
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported				
Free of other bias	Unclear risk	P value for the baseline comparison not stated				
ALP: alkaline phosphatase BGP: bone Gla protein BMC: bone mineral content BMD: bone mineral density Ca: serum calcium CT: computed tomography DPA: dual photon absorptiom DXA: dual energy X-ray absorp E2: oestradiol HRT: hormone replacement fl	otiometry					

E2: oestradiol HRT: hormone replacement therapy Hyp: hydroxyproline IL-6: interleukin-6 OPG: osteoprotegerin P: phosphorus PTH: parathyroid hormone SPA: single photon absorptiometry WHO: World Health Organization

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Ai SC 2003	Randomised controlled trial comparing herbal application Shenque (CV 8) with sodium etidronate in 70 primary osteoporosis patients. However, the herbal intervention was acupoint patch and did not meet the inclusion criteria

Chinese herbal medicines for treating osteoporosis (Review)

Study	Reason for exclusion				
Ai SC 2003a	Non-randomised study comparing herbal application Shenque with sodium etidronate in 70 pa- tients with osteoporosis				
Bo LY 2003	Randomised controlled trial comparing Gushukang particles with calcium carbonate plus vitamin D in 94 cases with osteoporotic compression fracture of the spine. However, the outcome measure was general therapeutic effect based on different evaluated standards and did not meet the inclu- sion criteria				
Chen AP 2005	Randomised controlled trial comparing Liuwei Dihuang pills with Caltrate in 40 senile osteoporosis patients. However, the diagnosis of osteoporosis was not based on a BMD test				
Chen JJ 2010	Randomised controlled trial comparing Zini Bushenjiangu soup and routine western medicine treatment with routine western medicine treatment in 43 senile osteoporosis patients. However, the treatment duration was less than 3 months				
Chen XF 2003	Randomised controlled trial comparing Xianlinggubao plus vitamin D3 and calcium amino acid chelate with calcium gluconate in 150 osteoporosis patients. The trial intervention did not meet the inclusion criteria				
Chen XF 2007	Randomised controlled trial comparing Bushen Jianpi mixture with Caltrate in 64 senile primary osteoporosis patients. However, it did not report the part of BMD measured				
Dai Y 2007a	Randomised controlled trial comparing Migupian (68) and Xianlinggubao (50) with Caltrate (42) in 160 postmenopausal osteoporosis patients. However, the trial was published repeatedly				
Deng WM 1997	Randomised controlled trial comparing tonifying kidney to strength bone decoction with calcitonin in 135 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Deng WM 1997a	Randomised controlled trial comparing kidney-tonifying herbs with calcitonin in 77 post- menopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Deng WM 2001	The participants were not osteoporosis patients				
Deng WM 2002	Randomised controlled trial comparing Bushen Zhuanggu granule with calcitonin in 175 post- menopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Ding GZ 1995	Randomised controlled trial comparing Bushen Jiangu capsule with calcium in 34 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Dong YL 2004	Randomised controlled trial comparing Liuwei Dihuang pills plus calcium tablet and vitamin C with calcium tablet plus vitamin C in 60 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and did not meet the inclusion criteria				
Fan GF 2008	Randomised controlled trial comparing Qiangjin Zhuanggu pill with oyster shell calcium chewable tablets in 248 primary osteoporosis patients. However, the outcome measure was general thera- peutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Fan ZY 1995	Randomised controlled trial comparing Yugu pill with nilestriol in 90 primary osteoporosis pa- tients. However, the diagnostic method was not based on a BMD test				
Ge L 2005	Randomised controlled trial comparing Jiangu pills with Caltrate in 40 primary osteoporosis pa- tients. However, the diagnostic method was not based on a BMD test				

Study	Reason for exclusion				
Gong L 2000	Randomised controlled trial comparing traditional medicine (Yishen Zhuanggu mixture or Shengu capsule) with no treatment in 80 primary osteoporosis patients. However, it was a duplicate publi- cation				
Gong ZF 2011	Randomised controlled trial comparing Bushenshujin soup and celecoxib capsules with celecoxib capsules in 90 primary osteoporosis patients. However, the treatment duration was 4 to 12 weeks				
Gu M 2004	Randomised controlled trial comparing Fortune's drynariae rhizome with calcium gluconate in 82 primary osteoporosis patients. However, it did not report the part of BMD measured				
Gu T 2011	Randomised controlled trial comparing Gushu recipes, calcium carbonate D3 and elcatonin injec- tion with calcium carbonate D3 and elcatonin injection in 43 primary osteoporosis patients. How- ever, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Guo F 2003	Randomised controlled trial comparing Yishen Yanggan decoction with calcium gluconate in 60 os- teoporosis patients. However, it did not report the part of BMD measured				
Guo HN 1998	Randomised controlled trial comparing Tiankui tang with gonadal hormone in 120 primary osteo- porosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
He YC 2008	Randomised controlled trial comparing Xianlinggubao capsule with salmon calcitonin in 88 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on dif- ferent evaluated standards and it did not meet the inclusion criteria				
Hu XD 2011	Randomised controlled trial comparing Chinese Traditional Medicine recipe with high calcium tablets and Caltrate in 164 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Jia JH 2010	The type of interventions did not meet the inclusion criteria				
Jiang SY 1995	Randomised controlled trial comparing Gushukang granule with calcium tablet and vitamin D in 400 primary osteoporosis patients. However, it did not report the BMD of the ulna and radius re- spectively				
Ke Q 2005	Randomised controlled trial comparing Jiangu recipe preparation with alendronate sodium tablet in 70 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Ke Q 2005a	Randomised controlled trial comparing Jiangu recipe preparation with alendronate sodium tablet in 95 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Li BL 2007a	Randomised controlled trial comparing Jianshen prescription with alendronate sodium in 60 post- menopausal osteoporosis patients. However, it was a duplicate publication				
Li CX 2005	Randomised controlled trial comparing movement therapy plus Bushen Tongluo tang with Caltrate in 87 senile osteoporosis patients. The therapy intervention did not meet the inclusion criteria				
Li JF 2008	Randomised controlled trial comparing Bushen Qianggu tang plus calcium with calcium in 120 pri- mary osteoporosis patients. However, the treatment duration was less than 3 months				
Li YM 2005	Non-randomised study comparing Bushen Huoxue preparation with Caltrate in 60 patients with postmenopausal osteoporosis				

Chinese herbal medicines for treating osteoporosis (Review)

Study	Reason for exclusion			
Lin HY 1998	Randomised controlled trial comparing Yishen Jiangu tang with Caltrate in 40 primary osteoporo- sis patients. However, it was published repeatedly			
Liu HB 2005	Non-randomised study comparing medicine-separated sticking on Shenqu with sodium etidronate in 130 patients with primary osteoporosis			
Liu HQ 2010	The type of interventions did not meet the inclusion criteria			
Liu TS 2008	Randomised controlled trial comparing Traditional Chinese Medicine plus alfacalcidol soft capsule with alfacalcidol soft capsule in 124 primary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria			
Liu YS 2011	Without control group			
Liu YX 1998	Randomised controlled trial comparing Fuguning granule with calcium tablet in 100 post- menopausal osteoporosis patients. However, it did not report the BMD of the ulna and radius re- spectively			
Lu W 2004	Randomised controlled trial comparing Bushen Jiangu tang with tibolone tablets in 80 primary os- teoporosis patients. However, the diagnostic method was not based on a BMD test			
Lu ZD 2004	Randomised controlled trial comparing Gushukang with nilestriol in 40 postmenopausal osteo- porosis patients. However, it did not report the part of BMD measured			
Luo QY 2011	Without control group			
Pan X 2004	Non-randomised study comparing Huangqi injection to acupoint plus Caltrate with Caltrate in 64 patients with primary osteoporosis			
Peng T 2003	Non-randomised study comparing Qianggu extracts with calcium gluconate in 102 patients with postmenopausal osteoporosis			
Qi ZX 2000	Randomised controlled trial comparing Shengsuiyin with Caltrate in 40 primary osteoporosis pa- tients. However, it was published repeatedly			
Ren JH 2011	Randomised controlled trial comparing Jinwugutong capsule and alendronate with alendronate in 90 postmenopausal osteoporosis patients. However, the outcome measure was general therapeu- tic effect about pain degree based on visual analogue scale (VAS) and it did not meet the inclusion criteria			
Shang YM 2007	Randomised controlled trial comparing Xianlinggubao capsule with conjugated oestrogens or cal- cium, or both, in 90 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test			
Shi B 2010	Randomised controlled trial comparing Traditional Chinese Medicine differentiation with calcium and vitamin D in 110 senile osteoporosis patients. However, it did not report the part of BMD mea- sured			
Shou ZX 2008	Randomised controlled trial comparing Qianggu Huoli tablet plus Caltrate with Caltrate in 227 pri- mary osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria			
Shu J 2005	Randomised controlled trial comparing Bushen Yijing prescription with calcium tablet in 50 cases of osteoporosis. The interventions in both arms were used for 7 weeks (less than 3 months)			

Chinese herbal medicines for treating osteoporosis (Review)

Study	Reason for exclusion
Shuai B 2008	Randomised controlled trial comparing Jiangu granule with Gusongbao granule in 96 primary os- teoporosis patients. However, the control treatment did not meet the inclusion criteria
Song HX 2003	Randomised controlled trial comparing Bushen Zhuanggu pill with calcium in 84 osteoporosis pa- tients. However, it did not report the part of BMD measured
Song XW 1997	Randomised controlled trial comparing Bushen herbal medicine with calcium in 55 post- menopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Song XW 2001	Randomised controlled trial comparing Bushenhuoxue recipe with nilestriol or calcium in 68 post- menopausal osteoporosis patients. However, it was published repeatedly
Su CH 2004	Randomised controlled trial comparing strong bone capsule with calcium carbonate plus vitamin D in 250 senile osteoporosis patients. However, the diagnostic method was not based on a BMD test
Su CH 2005	Randomised controlled trial comparing strong bone capsule with Caltrate in 105 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test
Su YB 2008	Randomised controlled trial comparing Qianggu Huoxue pill with Caltrate in 61 primary osteoporo- sis patients. However, the treatment duration was less than 3 months
Su ZW 2010	Randomised controlled trial comparing Bushenzhuanggu soup, calcitriol capsule, calcium supple- ment with vitamin D chewable tablets, salcatonin injection and bone peptide injection with cal- citriol capsule, calcium supplement with vitamin D chewable tablets, salcatonin injection and bone peptide injection in 110 primary osteoporosis patients. However, the treatment duration was less than 3 months
Sun JM 2002	Randomised controlled trial comparing Yiqi Tiansui mixture plus Caltrate with Caltrate in 40 pa- tients. However, this trial had the same data as the trial conducted by Mu G 2001
Sun X 2002	Randomised controlled trial comparing Jiawei Zuogui pill with calcium in 90 patients. However, this trial had the same data as the trial conducted by Lv ZH
Sun YM 2008	Randomised controlled trial comparing Gegen with alfacalcidol in 44 primary osteoporosis pa- tients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria
Tan X 2010	The type of interventions did not meet the inclusion criteria
Tang JM 1999	Randomised controlled trial comparing Jiangu powder with activated calcium powder in 98 prima- ry osteoporosis patients. However, the diagnostic method was not based on a BMD test
Tu PS 2008	Randomised controlled trial comparing Bushen prescription with no treatment in 60 osteoporosis patients. However, the treatment duration was less than 3 months
Wang CH 2003	Non-randomised study comparing Gusongkang capsule with calcium lactate in 100 patients with senile osteoporosis
Wang GH 2011	Randomised controlled trial comparing Zhuanggutongluobao with vitamin D2 plus calcium tablet in 65 patients with primary osteoporosis. However, the comparability between groups was bad
Wang HM 1998	Non-randomised study comparing Bugu capsule with activated calcium powder in 60 patients with senile osteoporosis
Wang J 2008	Randomised controlled trial comparing Bugan Yishen tang with alfacalcidol in 65 postmenopausal osteoporosis patients. However, the treatment duration was less than 3 months

Chinese herbal medicines for treating osteoporosis (Review)

Study	Reason for exclusion				
Wang JH 2001	Randomised controlled trial comparing Qianggu pill with calcium lactate plus vitamin D in 120 os- teoporosis patients. However, it was not clear that all were primary osteoporosis patients				
Wang LM 2004	Randomised controlled trial comparing Jiangu tang with Suplical in 99 senile osteoporosis pa- tients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Weng M 2003	Randomised controlled trial comparing medicine-separated sticking on Shenque (RN8) with sodi- um etidronate in 70 primary osteoporosis patients. However, the herbal intervention was an acu- point patch and it did not meet the inclusion criteria				
Wu CM 2004	Randomised controlled trial comparing Bushen Zhuanggu capsule with diethylstilbestrol in 71 os- teoporosis patients. However, the outcome measure was general therapeutic effect based on dif- ferent evaluated standards and it did not meet the inclusion criteria				
Wu D 2008	Randomised controlled trial comparing Xiaoyao san plus Caltrate with Caltrate in 60 senile osteo- porosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Wu XG 2008	Randomised controlled trial comparing Xianlinggubao capsule with no treatment in 87 osteoporo- sis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Xia WF 2006	Unavailable data				
Xie J 2001	The participants were not patients with osteoporosis				
Xie J 2003	The participants were not patients with osteoporosis				
Xu CY 2004	Randomised controlled trial comparing Bushen Jianpi Tongluo decoction plus Yishen Jiangu tablet and Caltrate with Yishen Jiangu tablet and Caltrate in 125 primary osteoporosis patients. The inter- ventions in both arms were used for 60 days (less than 3 months)				
Xu LZ 2001	Randomised controlled trial comparing Bupi Yishen Huoxue prescription with calcium or analgesic discontinuously in 130 osteoporosis patients. However, it was not clear that all were primary osteoporosis patients				
Xu PH 2001	Non-randomised study comparing Bushen Jiangu capsule with Gusongbao particles in 330 pa- tients with osteoporosis				
Yan XP 2007	Without control group				
Yang JP 2007	Randomised controlled trial comparing Gushibao capsule with calcium tablet plus vitamin D in 105 osteoporosis patients. However, it was not clear that all were primary osteoporosis patients				
Yang WH 2010	The type of interventions did not meet the inclusion criteria				
Yu YH 2011	Randomised controlled trial comparing Erzhi pill with alendronate sodium tablets, Erzhi pill and alendronate sodium tablets with alendronate sodium tablets, in 60 postmenopausal osteoporosis patients. However, it did not report the part of BMD measured				
Zhang GM 2001	Randomised controlled trial comparing Xianguning powder with nilestriol in 80 postmenopausal osteoporosis patients. However, the diagnostic method was not based on a BMD test				

Study	Reason for exclusion				
Zhang H 1999	Randomised controlled trial comparing Gubao capsule with Vita-D3 or Longmu Zhuanggu powder in 140 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Zhang WY 2005	Randomised controlled trial comparing Bupi Yishen Huoxue prescription with oestradiol or testos- terone in 45 senile osteoporosis patients. However, the outcome measure was general therapeutic effect based on different evaluated standards and it did not meet the inclusion criteria				
Zhao G 2004	Randomised controlled trial comparing Qianggu capsule with tibolone tablets in 69 post- menopausal osteoporosis patients. However, the diagnostic method was not reported definitively				
Zhao Z 2010	Randomised controlled trial comparing Yanghe capsule with Caltrate in 60 primary osteoporosis patients. However, it did not report the part of BMD measured				
Zheng NX 2011	The type of interventions did not meet the inclusion criteria				
Zheng XH 2004	Randomised controlled trial comparing Gukangye with calcium tablet in 150 primary osteoporosis patients. However, the diagnostic method was not based on a BMD test				
Zheng ZW 2010	Randomised controlled trial comparing Bushenzhuanggu soup plus western medicines (ossifica- tion alcohol capsule, calcium supplement with vitamin D chewable tablets, calcitonin and salmon calcitonin injection) with the same western medicines in 110 primary osteoporosis patients. How- ever, the treatment duration was less than 3 months				
Zhong J 2010	Randomised controlled trial comparing Zhuanggubushen decoction plus carp calcitonin injection J with carp calcitonin injection in 50 osteoporosis patients. However, the treatment duration was less than 3 months and the participants did not meet the inclusion criteria				
Zhong RQ 2007a	Randomised controlled trial comparing Gushen Yijing tang with Caltrate in 79 osteoporotic fracture patients. However, the participants did not meet the inclusion criteria				
Zhong RQ 2007b	Randomised controlled trial comparing Gushen Yijing tang with Caltrate in 124 osteoporotic frac- ture patients. However, the participants did not meet the inclusion criteria				
Zhou PQ 1997	Non-randomised study comparing Migu tablet with nilestriol in 50 patients with postmenopausal osteoporosis				
Zhu LP 2008	Randomised controlled trial comparing Bushen Jianpi tang plus oyster shell calcium chewable tablets with oyster shell calcium chewable tablets in 80 postmenopausal osteoporosis patients. However, the treatment duration was less than 3 months				

BMD: bone mineral density

DATA AND ANALYSES

Comparison 1. Chinese herbal medicines versus placebo

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 New fractures	1	104	Risk Ratio (M-H, Fixed, 95% CI)	0.05 [0.00, 0.85]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1.1 Kanggusong capsule versus placebo (12 months)	1	104	Risk Ratio (M-H, Fixed, 95% CI)	0.05 [0.00, 0.85]
2 Bone mineral density (BMD)	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Migu decoction versus placebo (BMD of lumbar spine, 4 months)	1	20	Mean Difference (IV, Fixed, 95% CI)	0.16 [0.06, 0.26]
2.2 Kanggusong capsule versus placebo (BMD of lumbar spine, 12 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	0.06 [0.02, 0.10]
2.3 Bushen Yigu soft extract versus placebo (BMD of radius, 3 months)	1	59	Mean Difference (IV, Fixed, 95% CI)	0.06 [0.03, 0.09]
2.4 Bushen Yigu soft extract versus placebo (BMD of ulna, 3 months)	1	59	Mean Difference (IV, Fixed, 95% CI)	0.06 [0.02, 0.10]
3 Oestradiol (E2)	1		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
3.1 Bushen Yigu soft extract versus placebo (3 months)	1	59	Mean Difference (IV, Ran- dom, 95% CI)	122.89 [92.97, 152.81]
4 Symptoms including pain, muscle fa- tigue and limited mobility	1	104	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [1.05, 1.37]
4.1 Kanggusong capsule versus placebo (Bone pain at lumbar spine, 12 months)	1	104	Risk Ratio (M-H, Fixed, 95% CI)	1.20 [1.05, 1.37]

Analysis 1.1. Comparison 1 Chinese herbal medicines versus placebo, Outcome 1 New fractures.

Study or subgroup	Herbal drugs	Placebo	Ris	k Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fi	xed, 95% CI		M-H, Fixed, 95% CI
1.1.1 Kanggusong capsule versus p	lacebo (12 months)					
Zhao HX 2001	0/50	10/54		_	100%	0.05[0,0.85]
Subtotal (95% CI)	50	54		-	100%	0.05[0,0.85]
Total events: 0 (Herbal drugs), 10 (Pla	acebo)					
Heterogeneity: Not applicable						
Test for overall effect: Z=2.07(P=0.04)						
Total (95% CI)	50	54		-	100%	0.05[0,0.85]
Total events: 0 (Herbal drugs), 10 (Pla	acebo)					
Heterogeneity: Not applicable						
Test for overall effect: Z=2.07(P=0.04)						
	Fa	avours treatment	0.002 0.1	1 10 5	⁶⁰⁰ Favours control	

Study or subgroup	Her	bal drugs	Р	lacebo	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
1.2.1 Migu decoction versus place	bo (BMD	of lumbar spine	, 4 mont	hs)			
Lin W 2000	13	0.9 (0.1)	7	0.7 (0.1)		100%	0.16[0.06,0.26]
Subtotal ***	13		7			100%	0.16[0.06,0.26]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.18(P=0)							
1.2.2 Kanggusong capsule versus	placebo ((BMD of lumbar	spine, 12	months)			
Zhao HX 2001	70	0.9 (0.1)	70	0.8 (0.1)	-+-	100%	0.06[0.02,0.1]
Subtotal ***	70		70		•	100%	0.06[0.02,0.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.08(P=0)							
1.2.3 Bushen Yigu soft extract vers	sus place	bo (BMD of radi	us, 3 moi	nths)			
Wang XY 2000	37	0.6 (0.1)	22	0.6 (0)	+	100%	0.06[0.03,0.09]
Subtotal ***	37		22		•	100%	0.06[0.03,0.09]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.19(P<0.00	001)						
1.2.4 Bushen Yigu soft extract vers	sus place	bo (BMD of ulna	, 3 mont	hs)			
Wang XY 2000	37	0.7 (0.1)	22	0.6 (0.1)		100%	0.06[0.02,0.1]
Subtotal ***	37		22		•	100%	0.06[0.02,0.1]
Heterogeneity: Tau ² =0; Chi ² =0, df=0	(P<0.0001	L); I ² =100%					
Test for overall effect: Z=3.18(P=0)							
<u>.</u>			Fa	vours control -0.5	-0.25 0 0.25	0.5 Favours trea	atment

Analysis 1.2. Comparison 1 Chinese herbal medicines versus placebo, Outcome 2 Bone mineral density (BMD).

Analysis 1.3. Comparison 1 Chinese herbal medicines versus placebo, Outcome 3 Oestradiol (E2).

Study or subgroup	Tr	eatment	P	lacebo	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
1.3.1 Bushen Yigu soft extract	versus place	ebo (3 months)					
Wang XY 2000	37	169.5 (68.9)	22	46.6 (48)		100%	122.89[92.97,152.81]
Subtotal ***	37		22		▲	100%	122.89[92.97,152.81]
Heterogeneity: Not applicable							
Test for overall effect: Z=8.05(P	<0.0001)						
			Fa	vours control	-200 -100 0 100 200	Favours tre	atment

Analysis 1.4. Comparison 1 Chinese herbal medicines versus placebo, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility.

Study or subgroup	Herbal drugs	West medicine			Risk Ratio			Weight	Risk Ratio	
	n/N	n/N		M-H	, Fixed, 95	% CI			M-H, Fixed, 95% CI	
1.4.1 Kanggusong capsule v 12 months)	versus placebo (Bone pain	n at lumbar spine,								
Zhao HX 2001	49/50	44/54			+			100%	1.2[1.05,1.37]	
Subtotal (95% CI)	50	54			•			100%	1.2[1.05,1.37]	
	Fa	vours experimental	0.01	0.1	1	10	100	Favours control		

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herbal drugs	West medicine			Risk Ratio			Weight	Risk Ratio
	n/N	n/N		M-H	l, Fixed, 95%	6 CI			M-H, Fixed, 95% Cl
Total events: 49 (Herbal drugs), 44 (\	West medicine)								
Heterogeneity: Not applicable									
Test for overall effect: Z=2.72(P=0.01	.)								
Total (95% CI)	50	54			•			100%	1.2[1.05,1.37]
Total events: 49 (Herbal drugs), 44 (\	West medicine)								
Heterogeneity: Not applicable									
Test for overall effect: Z=2.72(P=0.01	.)								
	Fav	ours experimental	0.01	0.1	1	10	100	Favours control	

Comparison 2. Chinese herbal medicines versus no intervention

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 Bone mineral density (BMD)	4		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
1.1 Bushen Shengsui principle versus no intervention (BMD of lumbar spine, 6 months)	1	61	Mean Difference (IV, Fixed, 95% CI)	0.07 [-0.06, 0.20]
1.2 Bushen Shengsui principle versus no intervention (BMD of femoral neck, 6 months)	1	61	Mean Difference (IV, Fixed, 95% CI)	0.10 [-0.00, 0.20]
1.3 Qianggu soft extract versus no in- tervention (BMD of femoral neck, 6 months)	1	97	Mean Difference (IV, Fixed, 95% CI)	0.09 [0.03, 0.15]
1.4 Shigu yin versus no treatment (BMD of Femoral neck, 6 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	0.08 [0.03, 0.13]
1.5 Yishen Zhuanggu mixture versus no intervention (BMD of femoral neck, 6months)	1	63	Mean Difference (IV, Fixed, 95% CI)	0.05 [-0.01, 0.11]
1.6 Shengu capsule versus no interven- tion (BMD of femoral neck, 6 months)	1	34	Mean Difference (IV, Fixed, 95% CI)	0.02 [-0.06, 0.09]
2 Oestradiol (E2)	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
2.1 Bushen Shengsui principle versus no intervention (6 months)	1	61	Mean Difference (IV, Fixed, 95% CI)	4.40 [-4.61, 13.41]
2.2 Yishen Zhuanggu mixture versus no treatment (6 months)	1	22	Mean Difference (IV, Fixed, 95% CI)	2.10 [-6.22, 10.42]
2.3 Huoluo Gukang pills versus no inter- vention (6 months)	1	136	Mean Difference (IV, Fixed, 95% CI)	2.40 [-1.22, 6.02]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.4 Gushukang granule versus no inter- vention (6 months)	1	129	Mean Difference (IV, Fixed, 95% CI)	2.10 [-1.69, 5.89]
3 Bone Gla protein (BGP)	3		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
3.1 Yishen Zhuanggu mixture versus no treatment (6 months)	1	63	Mean Difference (IV, Ran- dom, 95% CI)	-1.0 [-6.15, 4.15]
3.2 Shengu capsule versus no treatment (6 months)	1	34	Mean Difference (IV, Ran- dom, 95% CI)	-5.10 [-10.63, 0.43]
3.3 Huoluo Gukang pills versus no treat- ment (6 months)	1	136	Mean Difference (IV, Ran- dom, 95% CI)	2.70 [1.23, 4.17]
3.4 Gushukang granule versus no treat- ment (6 months)	1	129	Mean Difference (IV, Ran- dom, 95% CI)	3.5 [1.92, 5.08]
3.5 Shigu yin versus no treatment (6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	1.2 [0.17, 2.23]

Analysis 2.1. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 1 Bone mineral density (BMD).

Study or subgroup	Her	bal drugs	No in	tervention	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
2.1.1 Bushen Shengsui principle ve 6 months)	ersus no	intervention (B	MD of lur	nbar spine,			
Liao L 2004	32	0.9 (0.3)	29	0.8 (0.3)		100%	0.07[-0.06,0.2]
Subtotal ***	32		29			100%	0.07[-0.06,0.2]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.05(P=0.29)						
2.1.2 Bushen Shengsui principle ve 6 months)	ersus no	intervention (B	MD of fer	noral neck,			
Liao L 2004	32	0.9 (0.2)	29	0.8 (0.2)		100%	0.1[-0,0.2]
Subtotal ***	32		29			100%	0.1[-0,0.2]
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P<0.0001	1); I ² =100%					
Test for overall effect: Z=1.95(P=0.05)						
2.1.3 Qianggu soft extract versus n months)	o interv	rention (BMD of	femoral	neck, 6			
Peng T 2002	78	0.6 (0.1)	19	0.5 (0.1)	- <mark></mark> -	100%	0.09[0.03,0.15]
Subtotal ***	78		19			100%	0.09[0.03,0.15]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.98(P=0)							
2.1.4 Shigu yin versus no treatmer	t (BMD o	of Femoral neck	, 6 montl	ns)			
Zhang YP 2007	40	0.7 (0.1)	40	0.6 (0.1)	- -	100%	0.08[0.03,0.13]
Subtotal ***	40		40		●	100%	0.08[0.03,0.13]
Heterogeneity: Not applicable							
	-		Fa	vours control	-0.4 -0.2 0 0.2	0.4 Favours tre	atment

Chinese herbal medicines for treating osteoporosis (Review)

_



Trusted evidence. Informed decisions. Better health.

Study or subgroup	Her	bal drugs	No in	tervention		Mea	an Differenc	e		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Fi	xed, 95% CI				Fixed, 95% CI
Test for overall effect: Z=3.37(P=0)											
2.1.5 Yishen Zhuanggu mixture ve 6months)	ersus no i	ntervention (BM	ID of fem	ioral neck,							
Gong L 2001	46	0.7 (0.1)	17	0.6 (0.1)			+-+			100%	0.05[-0.01,0.11]
Subtotal ***	46		17				•			100%	0.05[-0.01,0.11]
Heterogeneity: Not applicable											
Test for overall effect: Z=1.61(P=0.12	1)										
2.1.6 Shengu capsule versus no in	terventio	on (BMD of femo	ral neck	, 6 months)							
Gong L 2001	17	0.6 (0.1)	17	0.6 (0.1)						100%	0.02[-0.06,0.09]
Subtotal ***	17		17				•			100%	0.02[-0.06,0.09]
Heterogeneity: Not applicable											
Test for overall effect: Z=0.4(P=0.69)											
Test for subgroup differences: Chi ² =	3.42, df=1	(P=0.64), I ² =0%									
			Fa	wours control	-0.4	-0.2	0	0.2	0.4	Favours trea	atment

Analysis 2.2. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 2 Oestradiol (E2).

Study or subgroup	Her	bal drugs	No in	tervention	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
2.2.1 Bushen Shengsui principle ve	rsus no	intervention (6	months)				
Liao L 2004	32	25.2 (19.3)	29	20.8 (16.6)		100%	4.4[-4.61,13.41]
Subtotal ***	32		29			100%	4.4[-4.61,13.41]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.96(P=0.34)							
2.2.2 Yishen Zhuanggu mixture ver	sus no t	reatment (6 mo	nths)				
Gong L 2001	18	25.6 (10.2)	4	23.5 (7)		100%	2.1[-6.22,10.42]
Subtotal ***	18		4			100%	2.1[-6.22,10.42]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.49(P=0.62))						
2.2.3 Huoluo Gukang pills versus n	o interv	ention (6 month	s)				
Zhang YS 2003	81	25.9 (10.5)	55	23.5 (10.6)		100%	2.4[-1.22,6.02]
Subtotal ***	81		55		•	100%	2.4[-1.22,6.02]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.3(P=0.19)							
2.2.4 Gushukang granule versus no	interve	ntion (6 month	5)				
Zhang YS 2003	74	25.6 (11.2)	55	23.5 (10.6)		100%	2.1[-1.69,5.89]
Subtotal ***	74		55		•	100%	2.1[-1.69,5.89]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.09(P=0.28))						
Test for subgroup differences: Chi ² =0	.22, df=1	. (P=0.97), I ² =0%					
			Fa	vours control	-20 -10 0 10 20	Favours trea	atment

Study or subgroup	Her	bal drugs	No in	tervention	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI
2.3.1 Yishen Zhuanggu mixture ver	sus no t	reatment (6 mo	nths)				
Gong L 2001	46	10.9 (7.2)	17	11.9 (9.9)		100%	-1[-6.15,4.15]
Subtotal ***	46		17			100%	-1[-6.15,4.15]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.38(P=0.7)							
2.3.2 Shengu capsule versus no tre	atment	(6 months)					
Gong L 2001	17	6.8 (6.1)	17	11.9 (9.9)		100%	-5.1[-10.63,0.43]
Subtotal ***	17	0.0 (0.1)	17	11.5 (5.5)		100%	-5.1[-10.63,0.43]
Heterogeneity: Not applicable							[,]
Test for overall effect: Z=1.81(P=0.07							
2.3.3 Huoluo Gukang pills versus n	o treatm	ient (6 months)					
Zhang YS 2003	81	9.1 (3.4)	55	6.4 (4.8)		100%	2.7[1.23,4.17]
Subtotal ***	81		55		•	100%	2.7[1.23,4.17]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.6(P=0)							
2.3.4 Gushukang granule versus no	treatm	ent (6 months)					
Zhang YS 2003	74	9.9 (4.1)	55	6.4 (4.8)		100%	3.5[1.92,5.08]
Subtotal ***	74		55		◆	100%	3.5[1.92,5.08]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.35(P<0.00	01)						
2.3.5 Shigu yin versus no treatmer	t (6 mor	iths)					
Zhang YP 2007	40	4.6 (2.5)	40	3.4 (2.2)	+	100%	1.2[0.17,2.23]
Subtotal ***	40		40		•	100%	1.2[0.17,2.23]
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P<0.0001); I ² =100%					
Test for overall effect: Z=2.28(P=0.02)						
Test for subgroup differences: Chi ² =1	4.25, df=	1 (P=0.01), I ² =71	.93%				
			Fa	vours control	-10 -5 0 5 10	Favours tre	atment

Analysis 2.3. Comparison 2 Chinese herbal medicines versus no intervention, Outcome 3 Bone Gla protein (BGP).

Comparison 3. Chinese herbal medicines versus western medicine

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 New fractures	1	142	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.1 Kanggusong granule versus Caltrate (9 months)	1	71	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
1.2 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Risk Ratio (M-H, Fixed, 95% Cl)	0.0 [0.0, 0.0]
2 Bone mineral density (BMD)	51		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.1 Kanggusong granule versus ipriflavone plus Caltrate (BMD of lumbar spine, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.05, 0.05]
2.2 Kanggusong granule versus Caltrate (BMD of lumbar spine, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [-0.02, 0.10]
2.3 Kanggusong capsule versus Caltrate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.02, 0.11]
2.4 Strong Bone capsule versus Caltrate (BMD of lumbar spine, 3 months)	1	105	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.08, 0.06]
2.5 Qianggu capsule versus active vitamin D3 (BMD of lumbar spine, 6 months)	1	54	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [-0.01, 0.09]
2.6 Qianggu capsule versus alendronate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.04, 0.05]
2.7 Herba epimedii prescription versus vit- amin D plus Caltrate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.03 [-0.00, 0.06]
2.8 Bushen Shengsui principle versus con- jugated oestrogens plus medroxyproges- terone (BMD of lumbar spine, 6 months)	1	66	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.12, 0.12]
2.9 Bushen Qianggutang versus Caltrate (BMD of lumbar spine, 3 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	0.09 [0.01, 0.17]
2.10 Bushen Jianpi Migu prescription versus Caltrate (BMD of lumbar spine, 3 months)	1	150	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.03, 0.09]
2.11 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (BMD of lum- bar spine, 6 months)	1	141	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.01, 0.05]
2.12 Bushen Huoxue capsules versus Cal- trate and Rocalirol (BMD of lumbar spine, 12 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.05, 0.09]
2.13 Bushen Zhuanggu tang versus alen- dronate sodium tablets (BMD of lumbar spine, 3 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [0.01, 0.07]
2.14 Bushenjianpi Zhuangguyin versus Cal- trate and calcitonin (BMD of lumbar spine, 12 weeks)	1	100	Mean Difference (IV, Ran- dom, 95% CI)	0.16 [0.10, 0.22]
2.15 Jiawei Bushen Zhuangjintang versus calcium granule (BMD of lumbar spine, 3 months)	1	90	Mean Difference (IV, Ran- dom, 95% CI)	0.10 [0.05, 0.15]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.16 Gukang oral liquid versus alendronate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.03, 0.05]
2.17 Kidney-tonifying herbs versus nilestri- ol (BMD of lumbar spine, 6 months)	1	46	Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.09, 0.05]
2.18 Kidney-tonifying herbs versus calcium (BMD of lumbar spine, 6 months)	1	46	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.04, 0.08]
2.19 Yishen Yanggan mixture versus cal- cium gluconate (BMD of lumbar spine, 6 months)	1	110	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [0.01, 0.07]
2.20 Yinyanghuo versus conjugated oestro- gens (BMD of lumbar spine, 3 to 6 months)	1	25	Mean Difference (IV, Ran- dom, 95% CI)	0.03 [-0.04, 0.10]
2.21 Shenyao capsules versus Caltrate (BMD of lumbar spine, 6 months)	1	100	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.05, 0.05]
2.22 Guli powder versus Caltrate (BMD of lumbar spine, 3 months, male)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.01, 0.05]
2.23 Guli powder versus Caltrate (BMD of lumbar spine, 3 months, female)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [-0.07, 0.15]
2.24 Gushen Yijing tang versus Caltrate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [-0.02, 0.14]
2.25 Bugu Shengsui capsule versus vita- min D2 plus calcium tablet (BMD of lumbar spine, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.12 [-0.01, 0.26]
2.26 Huangqi Sanxian tang versus nilestriol (BMD of lumbar spine, 3 months)	1	50	Mean Difference (IV, Ran- dom, 95% CI)	0.00 [-0.03, 0.04]
2.27 Zishen Gukang pill versus Caltrate plus vitamin D (BMD of lumbar spine, 3 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.00 [-0.05, 0.04]
2.28 Xianling Gusong capsules versus Cal- trate (BMD of lumbar spine, 6 months)	1	43	Mean Difference (IV, Ran- dom, 95% CI)	-0.03 [-0.08, 0.02]
2.29 Jianshenfang granule versus alen- dronate sodium (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.09 [-0.03, 0.21]
2.30 Jiangu recipe versus alendronate sodium tablets (BMD of lumbar spine, 12 months)	1	120	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.00, 0.04]
2.31 Gukang decoction versus alendronate sodium tablets (BMD of lumbar spine, 4 months)	1	83	Mean Difference (IV, Ran- dom, 95% CI)	-0.00 [-0.03, 0.03]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.32 Gumiling granule versus bicarbonate calcium chewable (BMD of lumbar spine, 6 months)	1	25	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [-0.02, 0.09]
2.33 Gujian capsule versus alfacalcidol (BMD of lumbar spine, 6 months)	1	65	Mean Difference (IV, Ran- dom, 95% CI)	0.14 [0.03, 0.26]
2.34 Xianlinggubao capsule versus alen- dronate (BMD of lumbar spine, 6 months)	1	104	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.02, 0.02]
2.35 Erxian soup versus Caltrate (BMD of lumbar spine, 6 months)	1	58	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.02, 0.11]
2.36 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of lumbar spine, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.25 [0.11, 0.39]
2.37 Gukang oral liquid versus calcium glu- conate (BMD of radius, 6 months)	1	61	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [0.01, 0.04]
2.38 Herba epimedii prescription versus vitamin D plus Caltrate (BMD of radius, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.07 [0.04, 0.11]
2.39 Bushen Yigu soft extract versus Alfa- calcidol (BMD of radius, 3 months)	1	74	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.02, 0.04]
2.40 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of radius, 6 months)	1	50	Mean Difference (IV, Ran- dom, 95% CI)	0.08 [-0.12, 0.28]
2.41 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of radius, 6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [-0.02, 0.11]
2.42 Liuwei Dihuang pills versus calcium (BMD of radius, 12 months)	1	42	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [0.03, 0.05]
2.43 Gukang oral liquid versus calcium glu- conate (BMD of ulna, 6 months)	1	61	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.02, 0.02]
2.44 Bushen Yigu soft extract versus Alfa- calcidol (BMD of ulna, 3 months)	1	74	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.01, 0.05]
2.45 Bugu Shengsui capsule versus vita- min D2 plus calcium tablet (BMD of ulna, 6 months)	1	50	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [-0.01, 0.13]
2.46 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of ulna, 6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.05 [-0.00, 0.11]
2.47 Liuwei Dihuang pills versus calcium (BMD of ulna, 12 months)	1	42	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [0.01, 0.03]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.48 Kanggusong granule versus ipri- flavone plus Caltrate (BMD of femoral neck, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.04, 0.02]
2.49 Kanggusong granule versus Caltrate (BMD of femoral neck, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.03, 0.05]
2.50 Herba epimedii prescription versus vitamin D plus Caltrate (BMD of femoral neck, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.02, 0.10]
2.51 Bushen Shengsui principle versus con- jugated oestrogens plus medroxyproges- terone (BMD of femoral neck, 6 months)	1	66	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.11, 0.09]
2.52 Kidney-tonifying herbs versus nilestri- ol (BMD of femoral neck, 6 months)	1	46	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.02, 0.06]
2.53 Kidney-tonifying herbs versus calcium (BMD of femoral neck, 6 months)	1	46	Mean Difference (IV, Ran- dom, 95% CI)	0.05 [0.01, 0.09]
2.54 Gumikang capsule versus calcium glu- conate (BMD of femoral neck, 6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.04, 0.08]
2.55 Yanghuo Sanzi tang versus Caltrate (BMD of femoral neck, 6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.05 [0.02, 0.08]
2.56 Qianggu soft extract versus calcium gluconate (BMD of femoral neck, 6 months)	1	99	Mean Difference (IV, Ran- dom, 95% CI)	0.07 [0.02, 0.12]
2.57 Qianggu capsules versus oestradiol valerate (BMD of femoral neck, 6 months)	1	90	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.02, 0.06]
2.58 Qianggu paste versus calcium glu- conate tablets (BMD of femoral neck, 6 months)	1	123	Mean Difference (IV, Ran- dom, 95% CI)	0.07 [0.03, 0.11]
2.59 Qianggu capsule versus active vitamin D3 (BMD of femoral neck, 6 months)	1	54	Mean Difference (IV, Ran- dom, 95% CI)	0.03 [-0.01, 0.07]
2.60 Shigu yin versus Caltrate (BMD of femoral neck, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.03 [-0.01, 0.07]
2.61 Jiangu capsule versus Caltrate (BMD of femoral neck, 12 months)	1	125	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [0.03, 0.06]
2.62 Gujian capsule versus alfacalcidol (BMD of femoral neck, 6 months)	1	65	Mean Difference (IV, Ran- dom, 95% CI)	0.08 [0.03, 0.14]
2.63 Bushenhuoxue capsules versus Cal- trate and Rocalirol (BMD of femoral neck, 12 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.06, 0.10]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.64 Bushenjianpi Zhuangguyin versus Cal- trate and calcitonin (BMD of femoral neck, 12 weeks)	1	100	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.00, 0.12]
2.65 Bugu Shengsui capsule versus vita- min D2 plus calcium tablet (BMD of femoral neck, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.09 [-0.05, 0.23]
2.66 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of femoral neck, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.07 [-0.06, 0.20]
2.67 Kanggusong granule versus ipri- flavone plus Caltrate (BMD of Ward's, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	-0.03 [-0.07, 0.01]
2.68 Kanggusong granule versus Caltrate (BMD of Ward's, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.04, 0.04]
2.69 Kidney-tonifying herbs versus nilestri- ol (BMD of Ward's, 6 months)	1	46	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.02, 0.10]
2.70 Kidney-tonifying herbs versus calcium (BMD of Ward's, 6 months)	1	46	Mean Difference (IV, Ran- dom, 95% CI)	0.10 [0.06, 0.14]
2.71 Gujian capsule versus alfacalcidol (BMD of Ward's, 6 months)	1	65	Mean Difference (IV, Ran- dom, 95% CI)	0.08 [0.01, 0.15]
2.72 Qianggu capsule versus alendronate (BMD of Ward's, 6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.02, 0.03]
2.73 Xianlinggubao capsule versus alen- dronate (BMD of Ward's, 6 months)	1	104	Mean Difference (IV, Ran- dom, 95% CI)	-0.00 [-0.02, 0.02]
2.74 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of Ward's, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.07 [-0.05, 0.19]
2.75 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of Ward's, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.10 [-0.01, 0.22]
2.76 Kanggusong granule versus ipri- flavone plus Caltrate (BMD of trochanter, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.05, 0.03]
2.77 Kanggusong granule versus Caltrate (BMD of trochanter, 9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	0.03 [-0.00, 0.06]
2.78 Gujian capsule versus alfacalcidol (BMD of trochanter, 6 months)	1	65	Mean Difference (IV, Ran- dom, 95% CI)	0.14 [0.07, 0.20]
2.79 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (BMD of trochanter, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.11 [-0.04, 0.27]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.80 Shangke Jiegu tablet versus vitamin D2 plus calcium tablet (BMD of trochanter, 6 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.19 [0.04, 0.33]
2.81 Gushukang granule versus Calcium carbonate with vitamin D chewable tablets (BMD of hip bone, 6 months)	1	39	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.02, 0.06]
2.82 Guli powder versus Caltrate (BMD of hip bone, 3 months, male)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.04, 0.04]
2.83 Guli powder versus Caltrate (BMD of hip bone, 3 months, female)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	0.03 [-0.05, 0.11]
2.84 TPF capsule versus calcium granule (BMD of distal radius, 6 months)	1	120	Mean Difference (IV, Ran- dom, 95% CI)	0.20 [0.17, 0.23]
2.85 Jiawei Zhuangyao Jianshen tang ver- sus compound calcium amino acid chelate capsules (BMD of calcaneus, 3 months)	1	58	Mean Difference (IV, Ran- dom, 95% CI)	0.06 [0.01, 0.11]
2.86 Liuwei Dihuang pills versus Caltrate (BMD of lumbar spine, 6 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	0.05 [0.03, 0.07]
2.87 Bushen Jianpi Jingu decoction versus calcitonin (BMD of lumbar spine, 3 months)	1	75	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.09, 0.13]
2.88 Bushen Jianpi Jingu decoction versus calcitonin (BMD of femoral neck, 3 months)	1	75	Mean Difference (IV, Ran- dom, 95% CI)	0.05 [-0.02, 0.12]
2.89 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (BMD of lumbar spine, 6 months)	1	64	Mean Difference (IV, Ran- dom, 95% CI)	0.05 [0.03, 0.07]
2.90 Kangshu Jiangu granule versus Cal- trate (BMD of femoral neck, 6 months)	1	76	Mean Difference (IV, Ran- dom, 95% CI)	0.08 [0.01, 0.15]
2.91 Kangshu Jiangu granule versus Cal- trate (BMD of lumbar spine, 6 months)	1	76	Mean Difference (IV, Ran- dom, 95% CI)	0.11 [0.01, 0.21]
2.92 Bushen Tianjing Huoxue therapy ver- sus Caltrate and calcitriol soft capsule (BMD of lumbar spine, 6 months)	1	61	Mean Difference (IV, Ran- dom, 95% CI)	0.04 [-0.00, 0.07]
3 T score in BMD measurement	2	330	Std. Mean Difference (IV, Random, 95% CI)	0.11 [-0.12, 0.34]
3.1 Jingujian granule versus Caltrate (T score, 3 months)	1	120	Std. Mean Difference (IV, Random, 95% CI)	0.03 [-0.35, 0.41]
3.2 Jingujian granule versus Caltrate (T score, 3 months)	1	210	Std. Mean Difference (IV, Random, 95% CI)	0.16 [-0.12, 0.45]
4 Symptoms including pain, muscle fatigue and limited mobility	12		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
4.1 Jiawei Bushen Zhuangjintang versus calcium granule (3 months)	1	90	Risk Ratio (M-H, Fixed, 95% CI)	1.68 [1.28, 2.19]
4.2 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Risk Ratio (M-H, Fixed, 95% CI)	1.86 [1.24, 2.80]
4.3 Kanggusong granule versus ipriflavone (3 months)	1	60	Risk Ratio (M-H, Fixed, 95% CI)	1.6 [1.07, 2.39]
4.4 Yishen Yanggan mixture versus calcium gluconate (6 months)	1	110	Risk Ratio (M-H, Fixed, 95% CI)	1.70 [1.28, 2.25]
4.5 Yinyanghuo versus conjugated oestro- gens (3 to 6 months)	1	25	Risk Ratio (M-H, Fixed, 95% Cl)	0.96 [0.72, 1.28]
4.6 Gumiling granule versus bicarbonate calcium chewable (6 months)	1	25	Risk Ratio (M-H, Fixed, 95% Cl)	4.26 [1.43, 12.72]
4.7 Jiawei Zhuangyao Jianshen tang ver- sus compound calcium amino acid chelate capsules (3 months)	1	58	Risk Ratio (M-H, Fixed, 95% CI)	1.25 [0.94, 1.66]
4.8 Zishen Gukang pill versus Caltrate plus vitamin D (3 months)	1	60	Risk Ratio (M-H, Fixed, 95% Cl)	1.27 [1.01, 1.61]
4.9 Xianling Gusong capsules versus Cal- trate (3 months)	1	43	Risk Ratio (M-H, Fixed, 95% Cl)	1.57 [1.03, 2.39]
4.10 Kanggusong capsule versus Caltrate (6 months)	1	80	Risk Ratio (M-H, Fixed, 95% Cl)	1.51 [1.12, 2.04]
4.11 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Risk Ratio (M-H, Fixed, 95% Cl)	1.65 [1.31, 2.08]
4.12 Jingujian granule versus Caltrate (3 months)	1	100	Risk Ratio (M-H, Fixed, 95% Cl)	3.15 [1.89, 5.26]
5 Oestradiol (E2)	25		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
5.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	12.17 [8.27, 16.07]
5.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	11.0 [6.97, 15.03]
5.3 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Ran- dom, 95% CI)	10.46 [4.29, 16.63]
5.4 Bushen Shengsui principle versus con- jugated oestrogens plus medroxyproges- terone (6 months)	1	66	Mean Difference (IV, Ran- dom, 95% CI)	4.0 [-3.92, 11.92]
5.5 Bushen Qiangshen pill versus Caltrate (3 months)	1	30	Mean Difference (IV, Ran- dom, 95% CI)	6.71 [-2.28, 15.70]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
5.6 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Mean Difference (IV, Ran- dom, 95% CI)	4.20 [0.89, 7.51]
5.7 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	3.90 [-6.64, 14.44]
5.8 Gumikang capsule versus calcium glu- conate (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	3.5 [1.14, 5.86]
5.9 Bushen Yigu soft extract versus Alfacal- cidol (3 months)	1	74	Mean Difference (IV, Ran- dom, 95% CI)	76.29 [31.19, 121.39]
5.10 Kanggusong granule versus ipri- flavone (3 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	4.18 [-13.85, 22.21]
5.11 Yanghuo Sanzi tang versus Caltrate (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	23.07 [17.83, 28.31]
5.12 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	3.90 [-9.01, 16.81]
5.13 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	13.98 [3.90, 24.06]
5.14 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Ran- dom, 95% CI)	3.15 [0.28, 6.02]
5.15 Prescription for tonifying kidney ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	14.00 [3.68, 24.32]
5.16 Kidney meridian sticking versus ipri- flavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	11.99 [1.15, 22.83]
5.17 Urinary bladder meridian sticking ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	17.99 [7.65, 28.33]
5.18 Huangqi Sanxian tang versus nilestriol (3 months)	1	50	Mean Difference (IV, Ran- dom, 95% CI)	-32.97 [-39.42, -26.52]
5.19 Gukang oral liquid versus alendronate sodium tablets (6 months)	1	70	Mean Difference (IV, Ran- dom, 95% CI)	5.09 [2.81, 7.37]
5.20 Gukang decoction versus alendronate sodium tablets (4 months)	1	83	Mean Difference (IV, Ran- dom, 95% CI)	-0.65 [-9.04, 7.74]
5.21 Jianshenfang granule versus alen- dronate sodium (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	5.83 [4.21, 7.45]
5.22 Jiangu recipe versus alendronate sodium tablets (6 months)	1	120	Mean Difference (IV, Ran- dom, 95% CI)	5.82 [3.69, 7.95]
5.23 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Mean Difference (IV, Ran- dom, 95% Cl)	10.75 [8.55, 12.95]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
5.24 Bushen Zhuanggu tang versus alen- dronate sodium tablets (3 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	5.37 [2.07, 8.67]
5.25 Bushen Huoxue capsule versus Cal- trate and Rocalirol (12 months)	1	59	Mean Difference (IV, Ran- dom, 95% CI)	2.13 [0.42, 3.84]
5.26 Jingujian granule versus Caltrate (3 months)	1	210	Mean Difference (IV, Ran- dom, 95% CI)	4.85 [4.56, 5.14]
5.27 Qianggu paste versus calcium glu- conate tablets (6 months)	1	123	Mean Difference (IV, Ran- dom, 95% CI)	4.20 [1.79, 6.61]
5.28 Tongbu Qianggutang versus calcium plus vitamin D3 (female, 3 months)	1	18	Mean Difference (IV, Ran- dom, 95% CI)	5.03 [-8.01, 18.07]
5.29 Tongbu Qianggutang versus calcium plus vitamin D3 (male, 3 months)	1	22	Mean Difference (IV, Ran- dom, 95% CI)	1.89 [-17.98, 21.77]
5.30 Gujian capsule versus alfacalcidol (6 months)	1	58	Mean Difference (IV, Ran- dom, 95% CI)	22.35 [-10.51, 55.21]
5.31 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Ran- dom, 95% CI)	8.78 [0.92, 16.64]
6 Serum calcium (Ca)	22		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
6.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	-0.09 [-0.17, -0.01]
6.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Ran- dom, 95% CI)	-0.03 [-0.11, 0.05]
6.3 Gushukang granule versus Calcium car- bonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.10, 0.06]
6.4 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Ran- dom, 95% CI)	-0.13 [-0.22, -0.04]
6.5 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Mean Difference (IV, Ran- dom, 95% CI)	-0.03 [-0.05, -0.01]
6.6 Gumikang capsule versus calcium glu- conate (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	1.40 [1.39, 1.41]
6.7 Bushen Jianpi Migu prescription versus Caltrate (3 months)	1	150	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.05, 0.07]
6.8 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Ran- dom, 95% Cl)	0.10 [0.03, 0.17]
6.9 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Ran- dom, 95% CI)	0.10 [-0.05, 0.25]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
6.10 Yinyanghuo versus conjugated oestro- gens (3 to 6 months)	1	25	Mean Difference (IV, Ran- dom, 95% CI)	0.54 [0.23, 0.85]
6.11 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.07, 0.03]
6.12 Shenyao capsules versus Caltrate (6 months)	1	100	Mean Difference (IV, Ran- dom, 95% CI)	0.02 [-0.08, 0.12]
6.13 Guli powder versus Caltrate (3 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.09 [0.02, 0.16]
6.14 Prescription for tonifying kidney ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.0 [-0.05, 0.05]
6.15 Kidney meridian sticking versus ipri- flavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.06, 0.04]
6.16 Urinary bladder meridian sticking ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.06, 0.04]
6.17 Gushen Yijing tang versus Caltrate (6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.23 [0.11, 0.35]
6.18 Gukang oral liquid versus alendronate sodium tablets (6 months)	1	70	Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.06, 0.02]
6.19 Qianggu capsule versus active vitamin D3 (6 months)	1	54	Mean Difference (IV, Ran- dom, 95% CI)	0.01 [-0.06, 0.08]
6.20 Jiangu capsule versus Caltrate (12 months)	1	125	Mean Difference (IV, Ran- dom, 95% CI)	-0.06 [-0.11, -0.01]
6.21 Bushen Yangxue tang versus calcium gluconate (6 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	0.13 [-0.00, 0.26]
6.22 Bushenjianpi Zhuangguyin versus Cal- trate and calcitonin (12 weeks)	1	100	Mean Difference (IV, Ran- dom, 95% CI)	0.74 [0.66, 0.82]
6.23 Erxian soup versus Caltrate (6 months)	1	58	Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.25, 0.21]
6.24 Qianggu paste versus calcium glu- conate tablets (6 months)	1	123	Mean Difference (IV, Ran- dom, 95% CI)	-0.03 [-0.06, -0.00]
6.25 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	-0.02 [-0.10, 0.06]
6.26 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-0.05, 0.03]
7 Phosphorus (P)	17		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
7.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	0.06 [-0.03, 0.15]
7.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.29, 0.27]
7.3 Gushukang granule versus Calcium car- bonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.09, 0.11]
7.4 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Fixed, 95% CI)	-0.12 [-0.21, -0.03]
7.5 Bushen Jianpi Migu prescription versus Caltrate (3 months)	1	150	Mean Difference (IV, Fixed, 95% CI)	0.03 [-0.02, 0.08]
7.6 Kanggusong granule versus ipriflavone (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.20, 0.06]
7.7 Yinyanghuo versus conjugated oestro- gens (3 to 6 months)	1	25	Mean Difference (IV, Fixed, 95% CI)	0.13 [-0.13, 0.39]
7.8 Shenyao capsules versus Caltrate (6 months)	1	100	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.08, 0.06]
7.9 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.13, 0.11]
7.10 Guli powder versus Caltrate (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.05 [-0.13, 0.03]
7.11 Prescription for tonifying kidney ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.04 [-0.15, 0.07]
7.12 Kidney meridian sticking versus ipri- flavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.13, 0.11]
7.13 Urinary bladder meridian sticking ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.13, 0.11]
7.14 Gushen Yijing tang versus Caltrate (6 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	0.04 [-0.09, 0.17]
7.15 Qianggu capsule versus active vitamin D3 (6 months)	1	54	Mean Difference (IV, Fixed, 95% CI)	0.02 [-0.05, 0.09]
7.16 Jiangu capsule versus Caltrate (12 months)	1	125	Mean Difference (IV, Fixed, 95% CI)	0.09 [-0.20, 0.38]
7.17 Bushenzhuanggu decoction versus al- endronate sodium tablets (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.24 [0.10, 0.38]
7.18 Bushenjianpi Zhuangguyin versus Cal- trate and calcitonin (12 weeks)	1	100	Mean Difference (IV, Fixed, 95% CI)	-0.37 [-0.48, -0.26]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
7.19 Erxian soup versus Caltrate (6 months)	1	58	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.20, 0.14]
7.20 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.12, 0.10]
7.21 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.15, 0.15]
8 Alkaline phosphatase (ALP)	32		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Kanggusong granule versus ipriflavone plus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	1.69 [0.79, 2.59]
8.2 Kanggusong granule versus Caltrate (9 months)	1	71	Mean Difference (IV, Fixed, 95% CI)	1.28 [0.30, 2.26]
8.3 Gushukang granule versus Calcium car- bonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Fixed, 95% CI)	-0.5 [-1.70, 0.70]
8.4 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Fixed, 95% CI)	-0.07 [-0.25, 0.11]
8.5 Bushen Qiangshen pill versus Caltrate (3 months)	1	30	Mean Difference (IV, Fixed, 95% CI)	0.27 [-1.27, 1.81]
8.6 Qianggu soft extract versus calcium gluconate (6 months)	1	99	Mean Difference (IV, Fixed, 95% CI)	3.60 [2.62, 4.58]
8.7 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-1.06 [-2.54, 0.42]
8.8 Gumikang capsule versus calcium glu- conate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	3.41 [2.84, 3.98]
8.9 Bushen Jianpi Migu prescription versus Caltrate (3 months)	1	150	Mean Difference (IV, Fixed, 95% CI)	0.10 [0.01, 0.19]
8.10 Kanggusong granule versus ipri- flavone (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.13 [-0.07, 0.33]
8.11 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Fixed, 95% CI)	-0.29 [-1.67, 1.09]
8.12 Liuwei Dihuang pills versus calcium (12 months)	1	42	Mean Difference (IV, Fixed, 95% CI)	0.55 [-0.12, 1.22]
8.13 TPF capsule versus calcium granule (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	3.84 [2.53, 5.15]
8.14 Yinyanghuo versus conjugated oestro- gens (3 to 6 months)	1	25	Mean Difference (IV, Fixed, 95% CI)	-7.0 [-11.17, -2.83]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
8.15 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-1.05 [-2.86, 0.76]
8.16 Shenyao capsules versus Caltrate (6 months)	1	100	Mean Difference (IV, Fixed, 95% CI)	-2.40 [-3.58, -1.22]
8.17 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Fixed, 95% CI)	-2.94 [-4.34, -1.54]
8.18 Guli powder versus Caltrate (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.30 [-2.97, 3.57]
8.19 Huangqi Sanxian tang versus nilestriol (3 months)	1	50	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-1.14, 1.08]
8.20 Gushen Yijing tang versus Caltrate (6 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	2.17 [0.73, 3.61]
8.21 Gukang oral liquid versus alendronate sodium Tablets	1	70	Mean Difference (IV, Fixed, 95% CI)	0.48 [-0.34, 1.30]
8.22 Qianggu capsule versus active vitamin D3 (6 months)	1	54	Mean Difference (IV, Fixed, 95% CI)	0.71 [-1.17, 2.59]
8.23 Jiangu capsule versus Caltrate (12 months)	1	125	Mean Difference (IV, Fixed, 95% CI)	2.04 [1.32, 2.76]
8.24 Jianshenfang granule versus alen- dronate sodium tablets (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.33 [-2.79, 3.45]
8.25 Jingujian granule versus Caltrate (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	0.53 [-0.69, 1.75]
8.26 Jianshenfang granule versus alen- dronate sodium tablets (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.33 [-2.78, 3.44]
8.27 Bushen Zhuanggu tang versus alen- dronate sodium tablets (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-0.11 [-0.99, 0.77]
8.28 Bushenjianpi Zhuangguyin versus Cal- trate and calcitonin (12 weeks)	1	100	Mean Difference (IV, Fixed, 95% CI)	-0.82 [-2.83, 1.19]
8.29 Jingujian granule versus Caltrate (3 months)	1	210	Mean Difference (IV, Fixed, 95% CI)	2.40 [2.21, 2.59]
8.30 Erxian soup versus Caltrate (6 months)	1	58	Mean Difference (IV, Fixed, 95% CI)	0.0 [-0.87, 0.87]
8.31 Qianggu paste versus calcium glu- conate tablets (6 months)	1	123	Mean Difference (IV, Fixed, 95% CI)	3.60 [2.86, 4.34]
8.32 Bushen Yangxue tang versus calcium gluconate (6 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	2.62 [0.84, 4.40]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
8.33 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	0.18 [-1.08, 1.44]
8.34 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	0.91 [0.15, 1.67]
9 Bone Gla protein (BGP)	14		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only
9.1 Bushen Jianpi Huoxue recipe versus al- endronate sodium tablets (6 months)	1	141	Mean Difference (IV, Ran- dom, 95% CI)	-2.13 [-2.74, -1.52]
9.2 Acupoint sticking of Migudan versus oyster shell calcium chewable tablets (3 months)	1	96	Mean Difference (IV, Ran- dom, 95% CI)	1.55 [1.24, 1.86]
9.3 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.10 [-0.93, 0.73]
9.4 Gusong recipe versus alendronate sodi- um tablets (5 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	-0.10 [-1.11, 0.91]
9.5 Yanghuo Sanzi tang versus Caltrate (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	2.71 [-0.30, 5.72]
9.6 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Ran- dom, 95% CI)	-0.49 [-2.17, 1.19]
9.7 Shigu yin versus Caltrate (6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	0.80 [-0.34, 1.94]
9.8 Jingujian granule versus Caltrate (3 months)	1	120	Mean Difference (IV, Ran- dom, 95% CI)	2.53 [-0.38, 5.44]
9.9 Jianshenfang granule versus alen- dronate sodium (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.49 [-1.59, 2.57]
9.10 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Mean Difference (IV, Ran- dom, 95% CI)	1.81 [-0.31, 3.93]
9.11 Bushen Huoxue capsules versus Cal- trate and Rocalirol (12 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.93 [0.35, 1.51]
9.12 Kanggusong capsule versus Caltrate (6 months)	1	80	Mean Difference (IV, Ran- dom, 95% CI)	1.78 [0.40, 3.16]
9.13 Liuwei Dihuang pills versus calcium (12 months)	1	42	Mean Difference (IV, Ran- dom, 95% CI)	17.9 [12.43, 23.37]
9.14 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	-1.50 [-5.07, 2.08]
10 Interleukin-6 (IL-6)	7		Mean Difference (IV, Fixed, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
10.1 Bushen Jianpi Huoxue recipe versus alendronate sodium tablets (6 months)	1	141	Mean Difference (IV, Fixed, 95% CI)	-5.72 [-14.05, 2.61]
10.2 Gukang oral liquid versus alendronate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-3.5 [-15.93, 8.93]
10.3 Yanghuo Sanzi tang versus Caltrate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-20.29 [-35.67, -4.91]
10.4 Jianshenfang granule versus alen- dronate sodium (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-12.56 [-29.26, 4.14]
10.5 Jiangu recipe versus alendronate sodium tablets (12 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-19.99 [-30.92, -9.06]
10.6 Bushen Huoxue capsules versus Cal- trate and Rocalirol (12 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-18.70 [-34.16, -3.24]
10.7 Gusong recipe versus alendronate sodium tablets (5 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-3.5 [-18.72, 11.72]
11 Parathyroid hormone (PTH)	6		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
11.1 Prescription for tonifying kidney ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-13.0 [-41.67, 15.67]
11.2 Kidney meridian sticking versus ipri- flavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-13.01 [-41.95, 15.93]
11.3 Urinary bladder meridian sticking ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-3.01 [-31.44, 25.42]
11.4 Kanggusong granule versus ipri- flavone (3 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	11.81 [-14.64, 38.26]
11.5 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Fixed, 95% CI)	-10.63 [-140.92, 119.66]
11.6 TPF capsule versus calcium granule (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-254.0 [-399.06, -108.94]
11.7 Gujian capsule versus alfacalcidol (6 months)	1	48	Mean Difference (IV, Fixed, 95% CI)	-22.57 [-60.92, 15.78]
11.8 Gushukang granule versus ipriflavone (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-3.02 [-30.91, 24.87]
11.9 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	-2.06 [-6.74, 2.62]
12 Computed tomography (CT)	8		Mean Difference (IV, Ran- dom, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
12.1 Prescription for tonifying kidney ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	0.96 [-3.71, 5.63]
12.2 Kidney meridian sticking versus ipri- flavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-1.01 [-5.44, 3.42]
12.3 Urinary bladder meridian sticking ver- sus ipriflavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-4.68, 4.66]
12.4 Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (6 months)	1	44	Mean Difference (IV, Ran- dom, 95% CI)	15.93 [-24.16, 56.02]
12.5 Strong Bone capsule versus Caltrate (3 months)	1	105	Mean Difference (IV, Ran- dom, 95% CI)	16.25 [10.43, 22.07]
12.6 Jingujian granule versus Caltrate (3 months)	1	210	Mean Difference (IV, Ran- dom, 95% CI)	21.98 [17.01, 26.95]
12.7 TPF capsule versus Calcium granule (6 months)	1	120	Mean Difference (IV, Ran- dom, 95% CI)	17.71 [11.53, 23.89]
12.8 Tongbu Qianggutang versus calcium plus vitamin D3 (3 months)	1	40	Mean Difference (IV, Ran- dom, 95% CI)	-6.18 [-12.89, 0.52]
12.9 Gujian capsule versus alfacalcidol (6 months)	1	57	Mean Difference (IV, Ran- dom, 95% CI)	-12.77 [-70.92, 45.38]
12.10 Gushukang granule versus ipri- flavone (6 months)	1	60	Mean Difference (IV, Ran- dom, 95% CI)	-0.01 [-4.44, 4.42]
12.11 Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets (6 months)	1	64	Mean Difference (IV, Ran- dom, 95% CI)	0.11 [-0.04, 0.26]

Analysis 3.1. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 1 New fractures.

Study or subgroup	Herbal drugs	West medicine		Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H	I, Fixed, 95% CI		M-H, Fixed, 95% CI
3.1.1 Kanggusong granule versus	Caltrate (9 months))				
An SJ 2000	0/31	0/40				Not estimable
Subtotal (95% CI)	31	40				Not estimable
Total events: 0 (Herbal drugs), 0 (We	est medicine)					
Heterogeneity: Not applicable						
Test for overall effect: Not applicabl	e					
3.1.2 Kanggusong granule versus	ipriflavone plus Ca	ltrate (9 months)				
An SJ 2000	0/31	0/40				Not estimable
Subtotal (95% CI)	31	40				Not estimable
Total events: 0 (Herbal drugs), 0 (We	est medicine)					
Heterogeneity: Not applicable						
		Favours treatment	0.001 0.1	1 10	¹⁰⁰⁰ Favours control	

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herbal drugs	West medicine		Risk Ratio				Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI					M-H, Fixed, 95% CI	
Test for overall effect: Not applicable									
Total (95% CI)	62	80							Not estimable
Total events: 0 (Herbal drugs), 0 (Wes	t medicine)								
Heterogeneity: Not applicable									
Test for overall effect: Not applicable									
Test for subgroup differences: Not ap	plicable								
		Favours treatment	0.001	0.1	1	10	1000	Favours control	

Analysis 3.2. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 2 Bone mineral density (BMD).

Study or subgroup	Herb	al drugs	West	medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
3.2.1 Kanggusong granule versu spine, 9 months)	ıs ipriflavon	e plus Caltrate	(BMD of l	umbar			
An SJ 2000	31	1 (0.1)	40	1 (0.1)		100%	0[-0.05,0.05]
Subtotal ***	31		40		+	100%	0[-0.05,0.05]
Heterogeneity: Not applicable							
Test for overall effect: Not applica	ble						
3.2.2 Kanggusong granule versu	us Caltrate (I	BMD of lumbar	spine, 9 n	nonths)			
An SJ 2000	31	1 (0.1)	40	0.9 (0.1)		100%	0.04[-0.02,0.1]
Subtotal ***	31		40		•	100%	0.04[-0.02,0.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.4(P=0.1	L6)						
3.2.3 Kanggusong capsule versu	ıs Caltrate (I	3MD of lumbar	spine, 6 n	nonths)			
Wei RY 2011	48	0.7 (0.1)	32	0.7 (0.1)		100%	0.06[0.02,0.11]
Subtotal ***	48		32			100%	0.06[0.02,0.11]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.64(P=0	.01)						
3.2.4 Strong Bone capsule versu	ıs Caltrate (I	3MD of lumbar	spine, 3 n	nonths)			
Cui TH 1999	74	0.8 (0.2)	31	0.8 (0.2)		100%	-0.01[-0.08,0.06]
Subtotal ***	74		31		-	100%	-0.01[-0.08,0.06]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.29(P=0	.77)						
3.2.5 Qianggu capsule versus ac months)	tive vitamin	D3 (BMD of lu	mbar spin	ie, 6			
Wang J 2007	28	0.8 (0.1)	26	0.8 (0.1)	+	100%	0.04[-0.01,0.09]
Subtotal ***	28		26			100%	0.04[-0.01,0.09]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.54(P=0	.12)						
		BMD of lumbar	spine, 6 r	nonths)			
3.2.6 Qianggu capsule versus al	endronate (I						
3.2.6 Qianggu capsule versus al Xu H 2010	endronate (I 40	0.7 (0.1)	40	0.7 (0.1)		100%	0.01[-0.04,0.05]
		0.7 (0.1)	40 40	0.7 (0.1)	₩	100% 100%	0.01[-0.04,0.05] 0.01[-0.04,0.05]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her N	bal drugs Mean(SD)	West N	medicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Test for overall effect: Z=0.27(P=0.79)		mean(5D)	N				Kundoni, 55 /0 Cr
3.2.7 Herba epimedii prescription v	versus v	itamin D plus C	altrate (F	MD of lum-			
bar spine, 6 months)	101303 0	italiili b plus ci					
Dong YF 2004	40	0.8 (0.1)	40	0.7 (0.1)		100%	0.03[-0,0.0
Subtotal ***	40		40		◆	100%	0.03[-0,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.75(P=0.08))						
3.2.8 Bushen Shengsui principle ve yprogesterone (BMD of lumbar spi			gens plu	s medrox-			
Liao L 2004	32	0.9 (0.3)	34	0.9 (0.2)		100%	0[-0.12,0.1
Subtotal ***	32		34			100%	0[-0.12,0.1
Heterogeneity: Not applicable							
Test for overall effect: Not applicable	!						
3.2.9 Bushen Qianggutang versus C	Caltrate	(BMD of lumbar	r spine, 3	months)			
Qi ZX 1998	20	0.8 (0.2)	20	0.7 (0.1)		100%	0.09[0.01,0.1
Subtotal ***	20		20			100%	0.09[0.01,0.1
Heterogeneity: Not applicable							·
Test for overall effect: Z=2.3(P=0.02)							
3.2.10 Bushen Jianpi Migu prescrip	otion ver	rsus Caltrate (Bl	MD of lun	ıbar spine, 3			
months) Wang ZK 2004	83	0.8 (0.1)	67	0.7 (0.1)		100%	0.06[0.03,0.0
Subtotal ***	83	0.0 (0.1)	67	0.7 (0.1)		100%	0.06[0.03,0.0
Heterogeneity: Not applicable	03		07			100%	0.00[0.03,0.0
Test for overall effect: Z=4.59(P<0.000	01)						
	01)						
3.2.11 Bushen Jianpi Huoxue recip lumbar spine, 6 months)	e versus	alendronate so	odium tal	olets (BMD of			
He MT 2007	71	0.7 (0.1)	70	0.7 (0.1)		100%	0.02[-0.01,0.0
Subtotal ***	71		70		◆	100%	0.02[-0.01,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.18(P=0.24))						
3.2.12 Bushen Huoxue capsules ver	rsus Cal	trate and Rocali	irol (BMD	of lumbar			
spine, 12 months)		- ()		- ()	-		
Zhang XJ 2008	30	1 (0.1)	30	1 (0.1)		100%	0.02[-0.05,0.0
Subtotal ***	30		30			100%	0.02[-0.05,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.57(P=0.57))						
3.2.13 Bushen Zhuanggu tang versi bar spine, 3 months)	us alend	lronate sodium	tablets (I	BMD of lum-			
Ling JY 2008	30	0.7 (0.1)	30	0.7 (0.1)		100%	0.04[0.01,0.0
Subtotal ***	30		30		•	100%	0.04[0.01,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=2.81(P=0.01))						
3.2.14 Bushenjianpi Zhuangguyin v bar spine, 12 weeks)	ersus C	altrate and calc	itonin (B	MD of lum-			
	versus C	altrate and calc 1 (0.1)	50	MD of lum- 0.8 (0.2)		100%	0.16[0.1,0.2

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her N	rbal drugs Mean(SD)	West N	t medicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Heterogeneity: Not applicable							
Test for overall effect: Z=5.1(P<0.000	1)						
3.2.15 Jiawei Bushen Zhuangjintar	ng versu	ıs calcium granu	ıle (BMD	oflumbar			
spine, 3 months) Lv ZH 2002	48	0.8 (0.2)	42	0.7 (0.1)		100%	0.1[0.05.0.1]
Subtotal ***	40 48	0.8 (0.2)	42 42	0.7 (0.1)		100%	0.1[0.05,0.1] 0.1[0.05,0.1]
Heterogeneity: Not applicable	40		42			100%	0.1[0.05,0.13
Test for overall effect: Z=3.63(P=0)							
3.2.16 Gukang oral liquid versus al	endrona	ate (BMD of lum	bar spine	e, 6 months)			
Shao M 2003	30	0.7 (0.1)	30	0.7 (0.1)		100%	0.01[-0.03,0.0
Subtotal ***	30	(11)	30			100%	0.01[-0.03,0.0!
Heterogeneity: Not applicable							- ,
Test for overall effect: Z=0.48(P=0.63)						
3.2.17 Kidney-tonifying herbs vers	us niles	triol (BMD of lur	nbar spiı	ne, 6			
months)							
Song XW 2000	23	0.9 (0.1)	23	0.9 (0.1)		100%	-0.02[-0.09,0.05
Subtotal ***	23		23			100%	-0.02[-0.09,0.0!
Heterogeneity: Not applicable Test for overall effect: Z=0.59(P=0.56)						
				6			
3.2.18 Kidney-tonifying herbs vers			-			100%	0.02[.0.04.0.0
Song XW 2000 Subtotal ***	23 23	0.9 (0.1)	23 23	0.9 (0.1)		100%	0.02[-0.04,0.03
	23		23			100%	0.02[-0.04,0.08
Heterogeneity: Not applicable Test for overall effect: Z=0.71(P=0.48)						
3.2.19 Yishen Yanggan mixture ver	sus calc	ium gluconate (BMD of l	umbar spine,			
6 months)							
Xu W 2005	60	0.7 (0.1)	50	0.7 (0.1)		100%	0.04[0.01,0.07
Subtotal ***	60		50		•	100%	0.04[0.01,0.07
Heterogeneity: Not applicable							
Test for overall effect: Z=2.98(P=0)							
3.2.20 Yinyanghuo versus conjugat months)	ted oest	rogens (BMD of	lumbar s	pine, 3 to 6			
Zhao LN 2003	15	0.7 (0.1)	10	0.7 (0.1)		100%	0.03[-0.04,0.
Subtotal ***	15		10		-	100%	0.03[-0.04,0.1
Heterogeneity: Not applicable							
Test for overall effect: Z=0.83(P=0.41)						
3.2.21 Shenyao capsules versus Ca	ltrate (I	BMD of lumbar s	pine, 6 n	nonths)			
Chen NQ 2006	50	0.9 (0.1)	50	0.9 (0.1)	-	100%	0[-0.05,0.0
Subtotal ***	50		50		+	100%	0[-0.05,0.05
Heterogeneity: Not applicable							
	5						
Test for overall effect: Not applicable		f lumbar spine,	3 month	s, male)			
Test for overall effect: Not applicable 3.2.22 Guli powder versus Caltrate Lan ZX 2006		f lumbar spine, 0.9 (0)	3 month 15	s, male) 0.9 (0)	=	100%	0.02[-0.01,0.05
Heterogeneity: Not applicable Test for overall effect: Not applicable 3.2.22 Guli powder versus Caltrate Lan ZX 2006 Subtotal ***	e (BMD o				●	100% 100%	0.02[-0.01,0.0 0.02[-0.01,0.0

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
,	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% CI
Test for overall effect: Z=1.55(P=0.12)							
3.2.23 Guli powder versus Caltrate							
Lan ZX 2006	15	0.8 (0.2)	15	0.7 (0.2)		100%	0.04[-0.07,0.15]
Subtotal ***	15		15			100%	0.04[-0.07,0.15]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.73(P=0.47)							
3.2.24 Gushen Yijing tang versus Ca	ltrato (I	RMD of lumbar o	nine En	onths)			
	39		41	0.9 (0.2)		100%	0.06[0.02 0.14]
Zhong RQ 2007 Subtotal ***	39 39	1 (0.2)	41 41	0.9 (0.2)		100%	0.06[-0.02,0.14] 0.06[-0.02,0.14]
Heterogeneity: Not applicable	35		71			10070	0.00[-0.02,0.14]
Test for overall effect: Z=1.39(P=0.16)							
3.2.25 Bugu Shengsui capsule versu lumbar spine, 6 months)	ıs vitam	nin D2 plus calci	um table	t (BMD of			
Xie YM 1997	20	1.1 (0.2)	10	1 (0.2)	+	100%	0.12[-0.01,0.26]
Subtotal ***	20		10			100%	0.12[-0.01,0.26]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.76(P=0.08)							
3.2.26 Huangqi Sanxian tang versus	nilestr	iol (BMD of lum	bar spine	, 3 months)			
Zhou ZK 2006	30	0.9 (0.1)	20	0.9 (0.1)		100%	0[-0.03,0.04]
Subtotal ***	30		20		•	100%	0[-0.03,0.04]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.11(P=0.91)							
3.2.27 Zishen Gukang pill versus Ca 3 months)	ltrate p	lus vitamin D (B	MD of lui	nbar spine,			
Huang ZJ 2008	30	0.7 (0.1)	30	0.7 (0.1)		100%	-0[-0.05,0.04]
Subtotal ***	30		30			100%	-0[-0.05,0.04]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.05(P=0.96)							
3.2.28 Xianling Gusong capsules ver months)	rsus Cal	trate (BMD of lu	mbar spi	ine, 6			
Li ZY 2006	21	0.6 (0.1)	22	0.6 (0.1)		100%	-0.03[-0.08,0.02]
Subtotal ***	21		22		-	100%	-0.03[-0.08,0.02]
Heterogeneity: Tau ² =0; Chi ² =0, df=0(F	<0.0001	l); l ² =100%					
Test for overall effect: Z=1.08(P=0.28)							
3.2.29 Jianshenfang granule versus 6 months)	alendr	onate sodium (E	3MD of lu	mbar spine,			
Li BL 2007	30	0.8 (0.3)	30	0.7 (0.2)		100%	0.09[-0.03,0.21]
Subtotal ***	30		30	()		100%	0.09[-0.03,0.21]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.48(P=0.14)							
3.2.30 Jiangu recipe versus alendro 12 months)	nate so	dium tablets (B	MD of lur	nbar spine,			
Qiu RB 2008	60	0.6 (0.1)	60	0.6 (0.1)	-+-	100%	0.02[-0,0.04]
Subtotal ***	60		60		•	100%	0.02[-0,0.04]
Heterogeneity: Not applicable							
			Fa	vours control	-0.2 -0.1 0 0.1 0.2	Favours trea	atment

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
Test for overall effect: Z=1.83(P=0.07)							
3.2.31 Gukang decoction versus ale	ndrona	te sodium table	ets (BMD o	of lumbar			
spine, 4 months)						1000/	
Chen X 2008	42	0.7 (0.1)	41	0.7 (0.1)		100%	-0[-0.03,0.03
Subtotal ***	42		41		•	100%	-0[-0.03,0.03
Heterogeneity: Not applicable							
Test for overall effect: Z=0.14(P=0.89)							
3.2.32 Gumiling granule versus bica spine, 6 months)	rbonat	e calcium chew	able (BM	D of lumbar			
Gang PH 2001	15	0.9 (0.1)	10	0.9 (0.1)	-	100%	0.04[-0.02,0.09
Subtotal ***	15	0.0 (0.2)	10	010 (012)	-	100%	0.04[-0.02,0.09
Heterogeneity: Not applicable	15		10			10070	0.04[-0.02,0.0
Test for overall effect: Z=1.32(P=0.19)							
2 2 22 Culler annula uarra alfa ad	-:			- math -)			
3.2.33 Gujian capsule versus alfacal	ciaol (i 34						0 14[0 02 0 2
Meng XD 2003 Subtotal ***	34 34	1.1 (0.3)	31 31	1 (0.1)		100%	0.14[0.03,0.26
	34		31			100%	0.14[0.03,0.26
Heterogeneity: Not applicable							
Test for overall effect: Z=2.46(P=0.01)							
3.2.34 Xianlinggubao capsule versu: months)	s alend	ronate (BMD of	lumbar s	pine, 6			
Xu M 2009	52	0.7 (0.1)	52	0.7 (0.1)		100%	0[-0.02,0.02
Subtotal ***	52		52		→	100%	0[-0.02,0.02
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
3.2.35 Erxian soup versus Caltrate (BMD of	lumbar spine. (5 months)			
Wu JZ 2010	30	0.6 (0.1)	28	0.5 (0.1)		100%	0.06[0.02,0.1]
Subtotal ***	30	0.0 (0.1)	28	0.5 (0.1)		100%	0.06[0.02,0.11
Heterogeneity: Not applicable	30		20			100%	0.00[0.02,0.11
Test for overall effect: Z=2.67(P=0.01)							
3.2.36 Shangke Jiegu tablet versus v bar spine, 6 months)	/itamir	n D2 plus calciui	n tablet (BMD of lum-			
Yuan YN 2000	20	1.2 (0.2)	10	1 (0.2)		100%	0.25[0.11,0.39
Subtotal ***	20		10			100%	0.25[0.11,0.39
Heterogeneity: Not applicable							
Test for overall effect: Z=3.55(P=0)							
3.2.37 Gukang oral liquid versus cal	cium g	luconate (BMD o	of radius,	6 months)			
Chen JP 1999	36	0.6 (0)	25	0.5 (0)	+	100%	0.02[0.01,0.04
Subtotal ***	36		25		•	100%	0.02[0.01,0.04
Heterogeneity: Not applicable							·
Test for overall effect: Z=3.99(P<0.000	1)						
3.2.38 Herba epimedii prescription	versus	vitamin D plus (Caltrate (BMD of ra-			
dius, 6 months)	40	0.4 (0.1)	40	0.2 (0.1)		1000/	0.0750.04.0.0
Dong YF 2004	40	0.4 (0.1)	40	0.3 (0.1)		100%	0.07[0.04,0.1]
Subtotal ***	40		40		•	100%	0.07[0.04,0.11
Heterogeneity: Not applicable							

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

		bal drugs		medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% CI
Test for overall effect: Z=4.07(P<0.00	01)						
3.2.39 Bushen Yigu soft extract ver	sus Alfa	calcidol (BMD o	f radius, 3	3 months)	<u> </u>		
Wang XY 2000	37	0.6 (0.1)	37	0.6 (0.1)		100%	0.01[-0.02,0.0
Subtotal ***	37		37		•	100%	0.01[-0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.65(P=0.52))						
3.2.40 Bugu Shengsui capsule vers dius, 6 months)	us vitam	iin D2 plus calci	um table	t (BMD of ra-			
Xie YM 1997	30	0.5 (0.1)	20	0.4 (0.4)		- 100%	0.08[-0.12,0.2
Subtotal ***	30		20			100%	0.08[-0.12,0.2
Heterogeneity: Not applicable							
Test for overall effect: Z=0.81(P=0.42))						
3.2.41 Shangke Jiegu tablet versus dius, 6 months)	vitamin	D2 plus calciur	n tablet (BMD of ra-			
Yuan YN 2000	30	0.6 (0.1)	30	0.5 (0.1)		100%	0.04[-0.02,0.1
Subtotal ***	30		30	/		100%	0.04[-0.02,0.1
Heterogeneity: Not applicable					-		,
Test for overall effect: Z=1.33(P=0.18))						
3.2.42 Liuwei Dihuang pills versus	calcium	(BMD of radius,	12 mont	hs)			
Zhang J 2003	24	0 (0)	18	0 (0)	+	100%	0.04[0.03,0.0
Subtotal ***	24		18		•	100%	0.04[0.03,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=8.36(P<0.00	01)						
3.2.43 Gukang oral liquid versus ca	lcium gl	uconate (BMD o	of ulna, 6	months)			
Chen JP 1999	36	0.1 (0)	25	0.1 (0)	+	100%	0[-0.02,0.0
Subtotal ***	36		25		•	100%	0[-0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
3.2.44 Bushen Yigu soft extract ver	sus Alfa	calcidol (BMD o	fulna, 3 r	nonths)			
Wang XY 2000	37	0.6 (0.1)	37	0.6 (0.1)		100%	0.02[-0.01,0.0
Subtotal ***	37		37		•	100%	0.02[-0.01,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.04(P=0.3)							
3.2.45 Bugu Shengsui capsule vers	us vitam	iin D2 plus calci	um table	t (BMD of ul-			
3.2.45 Bugu Shengsui capsule vers na, 6 months)		-			 - 122	100%	0.06[-0.01.0.1
3.2.45 Bugu Shengsui capsule vers na, 6 months) Xie YM 1997	30	iin D2 plus calci 0.5 (0.1)	20	t (BMD of ul-		100% 100%	
3.2.45 Bugu Shengsui capsule vers na, 6 months) Xie YM 1997 Subtotal ***		-			■	100% 100%	
3.2.45 Bugu Shengsui capsule vers na, 6 months) Xie YM 1997 Subtotal *** Heterogeneity: Not applicable	30	-	20		*		
3.2.45 Bugu Shengsui capsule vers na, 6 months) Xie YM 1997 Subtotal *** Heterogeneity: Not applicable	30	-	20		•		
3.2.45 Bugu Shengsui capsule verse na, 6 months) Xie YM 1997 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=1.7(P=0.09) 3.2.46 Shangke Jiegu tablet versus	30 30	0.5 (0.1)	20 20	0.4 (0.1)			
3.2.45 Bugu Shengsui capsule verse na, 6 months) Xie YM 1997 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=1.7(P=0.09) 3.2.46 Shangke Jiegu tablet versus na, 6 months)	30 30	0.5 (0.1)	20 20	0.4 (0.1)	₩ ◆		0.06[-0.01,0.1
Test for overall effect: Z=1.04(P=0.3) 3.2.45 Bugu Shengsui capsule versi na, 6 months) Xie YM 1997 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=1.7(P=0.09) 3.2.46 Shangke Jiegu tablet versus na, 6 months) Yuan YN 2000 Subtotal ***	30 30 vitamin	0.5 (0.1) D2 plus calciur	20 20 n tablet (0.4 (0.1) BMD of ul-		100%	0.06[-0.01,0.1 0.06[-0.01,0.1 0.05[-0,0.1 0.05[-0,0.1
 3.2.45 Bugu Shengsui capsule verse na, 6 months) Xie YM 1997 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=1.7(P=0.09) 3.2.46 Shangke Jiegu tablet versus na, 6 months) Yuan YN 2000 	30 30 vitamin 30 30	0.5 (0.1) D2 plus calciur 0.5 (0.1)	20 20 n tablet (30	0.4 (0.1) BMD of ul-	■ ◆	100%	0.06[-0.01,0.1 0.05[-0,0.1

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herb N	al drugs Mean(SD)	West I N	medicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
3.2.47 Liuwei Dihuang pills versu	ıs calcium (BMD of ulna, 1	2 months)				
Zhang J 2003	24	0.1 (0)	18	0 (0)	+	100%	0.02[0.01,0.0
Subtotal ***	24		18		•	100%	0.02[0.01,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=3.89(P<0.0	0001)						
3.2.48 Kanggusong granule versı neck, 9 months)	us ipriflavo	ne plus Caltrat	e (BMD of	femoral			
An SJ 2000	31	0.7 (0.1)	40	0.7 (0.1)	-	100%	-0.01[-0.04,0.0
Subtotal ***	31		40			100%	-0.01[-0.04,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.56(P=0.5	57)						
3.2.49 Kanggusong granule versi	us Caltrata	(BMD of femor	al nack 9	months)			
An SJ 2000	31	0.7 (0.1)	40	0.7 (0.1)		100%	0.01[-0.03,0.0
Subtotal ***	31	0.7 (0.1)	40 40	0.7 (0.1)		100%	0.01[-0.03,0.0
	31		40			100%	0.01[-0.03,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.5(P=0.62	2)						
3.2.50 Herba epimedii prescriptio femoral neck, 6 months)	on versus v	itamin D plus (Caltrate (E	MD of			
Dong YF 2004	40	0.8 (0.1)	40	0.8 (0.1)		100%	0.06[0.02,0
Subtotal ***	40	()	40			100%	0.06[0.02,0
Heterogeneity: Not applicable	10		10		•	20070	0100[0102;0
Test for overall effect: Z=3.35(P=0)							
3.2.51 Bushen Shengsui principle progesterone (BMD of femoral r iao L 2004			ogens plus 34	s medrox- 0.9 (0.2)		100%	-0.01[-0.11,0.0
Subtotal ***	32		34			100%	-0.01[-0.11,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.2(P=0.84	1)						
3.2.52 Kidney-tonifying herbs ve months)	rsus nilestr	iol (BMD of fer	noral necl	s , 6			
Song XW 2000	23	0.7 (0.1)	23	0.7 (0.1)	—	100%	0.02[-0.02,0.0
Subtotal ***	23	()	23	()	-	100%	0.02[-0.02,0.0
Heterogeneity: Not applicable					•		[,
Test for overall effect: Z=0.9(P=0.37	7)						
3.2.53 Kidney-tonifying herbs ve	rsus calciu	m (BMD of fem	oral neck.	6 months)			
Song XW 2000	23	0.7 (0.1)	23	0.6 (0.1)		100%	0.05[0.01,0.0
Subtotal ***	23	(5.1)	23	(0/		100%	0.05[0.01,0.0
	23					20070	0.0010.01,0.0
Heterogeneity: Not applicable Test for overall effect: Z=2.79(P=0.0	01)						
Heterogeneity: Not applicable Test for overall effect: Z=2.79(P=0.0 3.2.54 Gumikang capsule versus		iconate (BMD c	of femoral	neck, 6			
Heterogeneity: Not applicable Test for overall effect: Z=2.79(P=0.0 3.2.54 Gumikang capsule versus months)	calcium glı					100%	0.02[-0.04.0.0
Heterogeneity: Not applicable Test for overall effect: Z=2.79(P=0.0 3.2.54 Gumikang capsule versus months) Wang CC 2005	calcium glu 32	u conate (BMD c 0.6 (0.1)	28	neck, 6 0.6 (0.1)	-	100% 100%	0.02[-0.04,0.0
Heterogeneity: Not applicable Test for overall effect: Z=2.79(P=0.0 3.2.54 Gumikang capsule versus months)	calcium glı				-	100% 100%	0.02[-0.04,0.0 0.02[-0.04,0.0

Chinese herbal medicines for treating osteoporosis (Review)



		Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% CI
3.2.55 Yanghuo Sanzi tang versus	Caltrate (BMD of femora	l neck, 6 i	months)			
Qiu RB 2004	30	0.7 (0.1)	30	0.6 (0.1)		100%	0.05[0.02,0.08
Subtotal ***	30		30		\bullet	100%	0.05[0.02,0.08
Heterogeneity: Not applicable							
Test for overall effect: Z=3.23(P=0)							
3.2.56 Qianggu soft extract versus months)	s calcium	gluconate (BMI	D of femo	ral neck, 6			
Peng T 2002	78	0.6 (0.1)	21	0.6 (0.1)		100%	0.07[0.02,0.12
Subtotal ***	78		21			100%	0.07[0.02,0.12
Heterogeneity: Not applicable							
Test for overall effect: Z=2.59(P=0.02	1)						
3.2.57 Qianggu capsules versus of	estradiol	valerate (BMD o	of femora	l neck, 6			
months)	40	07/01)	40	0.7 (0.1)		1000/	0.00.000.000
Ruan XY 2006	48	0.7 (0.1)	42	0.7 (0.1)		100%	0.02[-0.02,0.06
Subtotal ***	48		42			100%	0.02[-0.02,0.06
Heterogeneity: Not applicable							
Test for overall effect: Z=1.05(P=0.29	9)						
3.2.58 Qianggu paste versus calciu months)	um glucoi	nate tablets (BN	ID of fem	oral neck, 6			
Wang H 2007	75	0.6 (0.1)	48	0.6 (0.1)		100%	0.07[0.03,0.1
Subtotal ***	75	· · ·	48	. ,		100%	0.07[0.03,0.1]
Heterogeneity: Not applicable					•		
Test for overall effect: Z=3.44(P=0)							
3.2.59 Qianggu capsule versus act months)	ive vitam	in D3 (BMD of f	emoral no	eck, 6			
Wang J 2007	28	0.7 (0.1)	26	0.7 (0.1)		100%	0.03[-0.01,0.0
Subtotal ***	28	011 (012)	26	011 (012)	_	100%	0.03[-0.01,0.0]
Heterogeneity: Not applicable	20		20		•	20070	0.000[0.002,010
	7)						
Test for overall effect: Z=1.37(P=0.17	()						
3.2.60 Shigu yin versus Caltrate (E			•	()			
Zhang YP 2007	40	0.7 (0.1)	40	0.7 (0.1)		100%	0.03[-0.01,0.0]
Subtotal ***	40		40			100%	0.03[-0.01,0.07
Heterogeneity: Tau ² =0; Chi ² =0, df=0); I ² =100%					
Test for overall effect: Z=1.33(P=0.18	3)						
3.2.61 Jiangu capsule versus Caltı							
Wang YZ 2008	63	0.7 (0)	62	0.7 (0.1)		100%	0.04[0.03,0.0
Subtotal ***	63		62		•	100%	0.04[0.03,0.06
Heterogeneity: Tau²=0; Chi²=0, df=0	(P<0.0001); I ² =100%					
Test for overall effect: Z=4.93(P<0.00	001)						
3.2.62 Gujian capsule versus alfac	alcidol (B	MD of femoral	neck, 6 m	onths)			
Meng XD 2003	34	0.8 (0.1)	31	0.7 (0.1)	- -	100%	0.08[0.03,0.1
Subtotal ***	34		31		•	100%	0.08[0.03,0.14
Heterogeneity: Not applicable							
Test for overall effect: Z=3.11(P=0)							

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup		al drugs		medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% Cl
3.2.63 Bushenhuoxue capsules v neck, 12 months)	ersus Caltr	ate and Rocali	rol (BMD o	of femoral			
Zhang XJ 2008	30	0.8 (0.2)	30	0.7 (0.2)		100%	0.02[-0.06,0.
Subtotal ***	30		30			100%	0.02[-0.06,0.
Heterogeneity: Not applicable							- ,
Test for overall effect: Z=0.48(P=0.6	53)						
3.2.64 Bushenjianpi Zhuangguyii	1 versus Ca	ltrate and calc	itonin (Bl	MD of			
femoral neck, 12 weeks) Zhang XG 2011	50	0.9 (0.2)	50	0.9 (0.1)		100%	0.06[0,0.1]
Subtotal ***	50	0.5 (0.2)	50	0.5 (0.1)		100%	0.06[0,0.1
Heterogeneity: Tau²=0; Chi²=0, df≕		12-1000%	50			100%	0.06[0,0.1
Test for overall effect: Z=2.07(P=0.0		,1 -100 %					
3.2.65 Bugu Shengsui capsule ve	rsus vitami	in D2 plus calci	um table	t (BMD of			
femoral neck, 6 months)		-					
Xie YM 1997	20	0.9 (0.1)	10	0.8 (0.2)		100%	0.09[-0.05,0.2
Subtotal ***	20		10			100%	0.09[-0.05,0.2
Heterogeneity: Not applicable							
Test for overall effect: Z=1.31(P=0.1	19)						
3.2.66 Shangke Jiegu tablet vers femoral neck, 6 months)	us vitamin	D2 plus calciur	n tablet (BMD of			
Yuan YN 2000	20	0.9 (0.1)	10	0.8 (0.2)		100%	0.07[-0.06,0.
Subtotal ***	20		10			100%	0.07[-0.06,0.
Heterogeneity: Not applicable							
Test for overall effect: Z=1.01(P=0.3	31)						
3.2.67 Kanggusong granule versu months)	ıs ipriflavo	ne plus Caltrat	e (BMD o	f Ward's, 9			
An SJ 2000	31	0.6 (0.1)	40	0.6 (0.1)		100%	-0.03[-0.07,0.0
Subtotal ***	31		40		•	100%	-0.03[-0.07,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.4(P=0.16	5)						
3.2.68 Kanggusong granule versi	ıs Caltrate	(BMD of Ward'	s, 9 mont	hs)			
An SJ 2000	31	0.6 (0.1)	40	0.6 (0.1)		100%	0[-0.04,0.0
Subtotal ***	31		40		•	100%	0[-0.04,0.04
Heterogeneity: Not applicable							
Test for overall effect: Not applicab	ole						
3.2.69 Kidney-tonifying herbs ve	rsus nilestı	riol (BMD of Wa	rd's, 6 m	onths)			
Song XW 2000	23	0.6 (0.1)	23	0.5 (0.1)		100%	0.06[0.02,0.
Subtotal ***	23		23		•	100%	0.06[0.02,0.
Heterogeneity: Tau ² =0; Chi ² =0, df=	0(P<0.0001)	; I ² =100%					
Test for overall effect: Z=2.91(P=0)							
3.2.70 Kidney-tonifying herbs ve	rsus calciu		d's, 6 mo	nths)			
Song XW 2000	23	0.6 (0.1)	23	0.5 (0.1)		100%	0.1[0.06,0.1
Subtotal ***	23		23		•	100%	0.1[0.06,0.1
the formation of the state of the following the state of							
Heterogeneity: Not applicable Test for overall effect: Z=5.58(P<0.0	001)						

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Herba N	al drugs Mean(SD)	West r N	nedicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
3.2.71 Gujian capsule versus alfacal	idol (BN	AD of Ward's, 6	6 months)				
Meng XD 2003	34	0.7 (0.2)	31	0.6 (0.1)		100%	0.08[0.01,0.15
Subtotal ***	34		31		-	100%	0.08[0.01,0.15
Heterogeneity: Not applicable							
Test for overall effect: Z=2.2(P=0.03)							
3.2.72 Qianggu capsule versus alend	ronate	(BMD of Ward's	s, 6 month	s)			
Xu H 2010	40	0.4 (0.1)	40	0.4 (0.1)	<u> </u>	100%	0.01[-0.02,0.03
Subtotal ***	40		40		•	100%	0.01[-0.02,0.03
Heterogeneity: Not applicable							
Test for overall effect: Z=0.63(P=0.53)							
3.2.73 Xianlinggubao capsule versus	alendro	onate (BMD of	Ward's, 6 I	months)			
Xu M 2009	52	0.4 (0.1)	52	0.4 (0.1)	<u> </u>	100%	-0[-0.02,0.02
Subtotal ***	52		52		•	100%	-0[-0.02,0.02
Heterogeneity: Not applicable							
Test for overall effect: Z=0.1(P=0.92)							
3.2.74 Bugu Shengsui capsule versu: Ward's, 6 months)	s vitami	n D2 plus calci	um tablet	(BMD of			
Xie YM 1997	20	0.7 (0.1)	10	0.6 (0.2)		100%	0.07[-0.05,0.19
Subtotal ***	20		10			100%	0.07[-0.05,0.19
Heterogeneity: Not applicable							
Test for overall effect: Z=1.11(P=0.27)							
3.2.75 Shangke Jiegu tablet versus v Ward's, 6 months) Yuan YN 2000	20	0.7 (0.1)	10	0.6 (0.2)		100%	0.1[-0.01,0.2
Subtotal ***	20		10			100%	0.1[-0.01,0.22
Heterogeneity: Not applicable							
Test for overall effect: Z=1.73(P=0.08)							
3.2.76 Kanggusong granule versus ij 9 months)	oriflavoı	ne plus Caltrat	e (BMD of	trochanter,			
An SJ 2000	31	0.7 (0.1)	40	0.7 (0.1)		100%	-0.01[-0.05,0.03
Subtotal ***	31		40		+	100%	-0.01[-0.05,0.03
Heterogeneity: Not applicable							
Test for overall effect: Z=0.52(P=0.6)							
3.2.77 Kanggusong granule versus C	altrate (BMD of trocha	inter, 9 mo	onths)			
An SJ 2000	31	0.7 (0.1)	40	0.6 (0.1)		100%	0.03[-0,0.0
Subtotal ***	31		40		•	100%	0.03[-0,0.06
Heterogeneity: Not applicable							
Test for overall effect: Z=1.68(P=0.09)							
3.2.78 Gujian capsule versus alfacal					_		
Meng XD 2003	34	0.8 (0.2)	31	0.6 (0.1)		100%	0.14[0.07,0.2
Subtotal ***	34		31		-	100%	0.14[0.07,0.2
Heterogeneity: Not applicable							
Test for overall effect: Z=3.95(P<0.000)	L)						
3.2.79 Bugu Shengsui capsule versus	vitami	n D2 nlus calci	um tablet	(BMD of			

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
Xie YM 1997	20	0.8 (0.2)	10	0.6 (0.2)		- 100%	0.11[-0.04,0.2]
Subtotal ***	20		10			100%	0.11[-0.04,0.2]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.42(P=0.16)							
3.2.80 Shangke Jiegu tablet versus v trochanter, 6 months)	/itamin	D2 plus calciur	n tablet (BMD of			
Yuan YN 2000	20	0.8 (0.2)	10	0.6 (0.2)		100%	0.19[0.04,0.3]
Subtotal ***	20	0.0 (0.2)	10	0.0 (0.2)		100%	0.19[0.04,0.3
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P·)· I ² =100%	10			100/0	0.15[0.04,0.5
Test for overall effect: Z=2.53(P=0.01)	-0.0001	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
3.2.81 Gushukang granule versus Ca tablets (BMD of hip bone, 6 months)		arbonate with	vitamin	D chewable			
Chen ZX 2002	20	0.6 (0.1)	19	0.6 (0.1)		100%	0.02[-0.02,0.0
Subtotal ***	20		19		•	100%	0.02[-0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.93(P=0.35)							
3.2.82 Guli powder versus Caltrate (BMD of	hin bone 3 mo	nths ma	le)			
Lan ZX 2006	15	0.8 (0.1)	15	0.8 (0.1)		100%	0[-0.04,0.0
Subtotal ***	15	0.0 (0.1)	15	0.0 (0.1)		100%	0[-0.04,0.0
Heterogeneity: Not applicable	15		15			10070	0[-0.04,0.0
Test for overall effect: Not applicable							
3.2.83 Guli powder versus Caltrate (
Lan ZX 2006	15	0.7 (0.1)	15	0.7 (0.1)		100%	0.03[-0.05,0.1
Subtotal ***	15		15			100%	0.03[-0.05,0.1
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P·	<0.0001); I ² =100%					
Test for overall effect: Z=0.71(P=0.48)							
3.2.84 TPF capsule versus calcium g	ranule	(BMD of distal r	adius, 6	months)			
Zhang YL 1996	60	0.8 (0.1)	60	0.6 (0.1)		100%	0.2[0.17,0.2
Subtotal ***	60		60		•	100%	0.2[0.17,0.2
Heterogeneity: Not applicable							
Test for overall effect: Z=12.17(P<0.000	01)						
3.2.85 Jiawei Zhuangyao Jianshen t chelate capsules (BMD of calcaneus,			calcium	amino acid			
He N 2006	29	0.7 (0.1)	29	0.6 (0.1)	- <mark></mark> -	100%	0.06[0.01,0.1
Subtotal ***	29		29			100%	0.06[0.01,0.1
Heterogeneity: Not applicable	-		-		-		
Test for overall effect: Z=2.54(P=0.01)							
3.2.86 Liuwei Dihuang pills versus C						1000/	
Ma C 2011	35	0.9 (0.1)	36	0.9 (0)		100%	0.05[0.03,0.0
Subtotal ***	35		36			100%	0.05[0.03,0.0
Heterogeneity: Not applicable	• •						
Test for overall effect: Z=4.12(P<0.000)	L)						
3.2.87 Bushen Jianpi Jingu decoctio 3 months)	n versı	ıs calcitonin (BN	MD of lun	nbar spine,			
				6			
Mao YF 2011	39	1 (0.2)	36	1 (0.3)		100%	0.02[-0.09,0.1

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
, , ,	N	Mean(SD)	N	Mean(SD)	Random, 95% CI	U	Random, 95% CI
Subtotal ***	39		36			100%	0.02[-0.09,0.13]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.35(P=0.73)							
3.2.88 Bushen Jianpi Jingu decoctio months)	on versi	us calcitonin (BN	MD of fen	noral neck, 3			
Mao YF 2011	39	0.7 (0.2)	36	0.7 (0.1)		100%	0.05[-0.02,0.12]
Subtotal ***	39		36		•	100%	0.05[-0.02,0.12]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.48(P=0.14)							
3.2.89 Radix rehmanniae preparata ate tablets (BMD of lumbar spine, 6			rsus calc	ium carbon-			
Ou L 2011	32	1 (0.1)	32	0.9 (0)		100%	0.05[0.03,0.07]
Subtotal ***	32		32		•	100%	0.05[0.03,0.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.22(P<0.000)1)						
3.2.90 Kangshu Jiangu granule vers months)						100%	
Shi CD 2012	40	0.8 (0.2)	36	0.7 (0.1)		100%	0.08[0.01,0.15]
Subtotal ***	40		36			100%	0.08[0.01,0.15]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.16(P=0.03)							
3.2.91 Kangshu Jiangu granule vers months)	sus Calt	rate (BMD of lun	nbar spiı	ne, 6			
Shi CD 2012	40	1 (0.1)	36	0.9 (0.3)	——————————————————————————————————————	100%	0.11[0.01,0.21]
Subtotal ***	40		36			100%	0.11[0.01,0.21]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.19(P=0.03)							
3.2.92 Bushen Tianjing Huoxue the sule (BMD of lumbar spine, 6 month		rsus Caltrate an	d calcitri	iol soft cap-			
Zhu HJ 2011	31	0.7 (0.1)	30	0.7 (0.1)		100%	0.04[-0,0.07]
Subtotal ***	31		30		•	100%	0.04[-0,0.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.87(P=0.06)							
			Fa	vours control	-0.2 -0.1 0 0.1 0.2	Favours trea	atment

Analysis 3.3. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 3 T score in BMD measurement.

Study or subgroup	Herbal drugs		West	tmedicine		Std.	Mean Differe	nce		Weight S	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Ra	ndom, 95%	CI			Random, 95% CI
3.3.1 Jingujian granule versus Cal	trate (T s	score, 3 months)									
Li YH 2008	80	-3.1 (1.8)	40	-3.1 (1.6)						36.43%	0.03[-0.35,0.41]
Subtotal ***	80		40							36.43%	0.03[-0.35,0.41]
Heterogeneity: Not applicable											
Test for overall effect: Z=0.15(P=0.88	3)										
			Favo	urs treatment	-100	-50	0	50	100	Favours contr	ol

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her	bal drugs	West	medicine		Std. M	lean Difference		Weight 9	Std. Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Ran	idom, 95% Cl			Random, 95% Cl
3.3.2 Jingujian granule ve	rsus Caltrate (T s	score, 3 months)								
Li YH 2010	140	-3.1 (0.1)	70	-3.1 (0.3)					63.57%	0.16[-0.12,0.45]
Subtotal ***	140		70						63.57%	0.16[-0.12,0.45]
Heterogeneity: Not applical	ble									
Test for overall effect: Z=1.1	.1(P=0.27)									
Total ***	220		110						100%	0.11[-0.12,0.34]
Heterogeneity: Tau ² =0; Chi ²	² =0.3, df=1(P=0.58); I ² =0%								
Test for overall effect: Z=0.9	98(P=0.33)									
Test for subgroup difference	es: Chi²=0.3, df=1	(P=0.58), I ² =0%								
			Favo	urs treatment	-100	-50	0 50	100	Favours contr	ol

Analysis 3.4. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 4 Symptoms including pain, muscle fatigue and limited mobility.

Study or subgroup	Herbal drugs	West medicine	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% CI
3.4.1 Jiawei Bushen Zhuangjintar	ıg versus calcium gr	anule (3 months)			
Lv ZH 2002	46/48	24/42		100%	1.68[1.28,2.19]
Subtotal (95% CI)	48	42	•	100%	1.68[1.28,2.19]
Total events: 46 (Herbal drugs), 24 (West medicine)				
Heterogeneity: Tau ² =0; Chi ² =0, df=0	(P<0.0001); I ² =100%				
Test for overall effect: Z=3.77(P=0)					
3.4.2 Qianggu soft extract versus	calcium aluconato (f months)			
Peng T 2002	76/78	11/21		100%	1.86[1.24,2.8]
-	78/18	11/21 21		100% 100%	
Subtotal (95% CI)		21		100%	1.86[1.24,2.8]
Total events: 76 (Herbal drugs), 11 (west medicine)				
Heterogeneity: Not applicable Test for overall effect: Z=2.97(P=0)					
Test for overall effect: Z=2.97(P=0)					
3.4.3 Kanggusong granule versus	ipriflavone (3 mont	hs)			
Wu MS 2001	24/30	15/30		100%	1.6[1.07,2.39]
Subtotal (95% CI)	30	30	•	100%	1.6[1.07,2.39]
Total events: 24 (Herbal drugs), 15 (West medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2.3(P=0.02))				
3.4.4 Yishen Yanggan mixture ver	sus calcium glucona	te (6 months)			
Xu W 2005	53/60	26/50		100%	1.7[1.28,2.25]
Subtotal (95% CI)	60	50	•	100%	1.7[1.28,2.25]
Total events: 53 (Herbal drugs), 26 (West medicine)				- / -
Heterogeneity: Not applicable					
Test for overall effect: Z=3.69(P=0)					
3.4.5 Yinyanghuo versus conjugat	ed oestrogens (3 to	6 months)			
Zhao LN 2003	13/15	9/10	<mark>.</mark> ←	100%	0.96[0.72,1.28]
Subtotal (95% CI)	15	10	+	100%	0.96[0.72,1.28]
Total events: 13 (Herbal drugs), 9 (V	Vest medicine)				
		Favours treatment	0.01 0.1 1 10	¹⁰⁰ Favours control	

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Herbal drugs n/N	West medicine n/N	Risk Ratio M-H, Fixed, 95% CI	Weight	Risk Ratio M-H, Fixed, 95% Cl
Heterogeneity: Not applicable					
Test for overall effect: Z=0.26(P	=0.8)				
3.4.6 Gumiling granule versus months)	s bicarbonate calcium ch	ewable (6			
Gang PH 2001	15/15	2/10		100%	4.26[1.43,12.72
Subtotal (95% CI)	15	10	-	100%	4.26[1.43,12.72
Total events: 15 (Herbal drugs),	, 2 (West medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2.6(P=	0.01)				
3.4.7 Jiawei Zhuangyao Jians amino acid chelate capsules (Ind calcium			
He N 2006	25/29	20/29		100%	1.25[0.94,1.66
Subtotal (95% CI)	29	29	•	100%	1.25[0.94,1.66
Total events: 25 (Herbal drugs),	, 20 (West medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=1.54(P	=0.12)				
3.4.8 Zishen Gukang pill versu	us Caltrate plus vitamin	D (3 months)			
Huang ZJ 2008	28/30	22/30	+	100%	1.27[1.01,1.6]
Subtotal (95% CI)	30	30	◆	100%	1.27[1.01,1.61
Total events: 28 (Herbal drugs),	, 22 (West medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2(P=0.	05)				
3.4.9 Xianling Gusong capsule					
Li ZY 2006	18/21	12/22		100%	1.57[1.03,2.39
Subtotal (95% CI)	21	22	-	100%	1.57[1.03,2.39
Total events: 18 (Herbal drugs),					
Heterogeneity: Tau ² =0; Chi ² =0,					
Test for overall effect: Z=2.11(P	=0.03)				
3.4.10 Kanggusong capsule ve					
Wei RY 2011	43/48	19/32		100%	1.51[1.12,2.04
Subtotal (95% CI)	48	32	•	100%	1.51[1.12,2.04
Total events: 43 (Herbal drugs), Heterogeneity: Tau ² =0; Chi ² =0,					
Test for overall effect: Z=2.67(P					
3.4.11 Jiangu recipe versus al	endronate sodium table	ts (12 months)			
Qiu RB 2008	56/60	34/60		100%	1.65[1.31,2.08
Subtotal (95% CI)	60	60	•	100% 100%	1.65[1.31,2.08
Total events: 56 (Herbal drugs).					,
Heterogeneity: Not applicable	, ,,				
Test for overall effect: Z=4.23(P	<0.0001)				
3.4.12 Jingujian granule versu	us Caltrate (3 months)				
Li YH 2008	52/60	11/40		100%	3.15[1.89,5.2
Subtotal (95% CI)	60	40	•	100%	3.15[1.89,5.26
Total events: 52 (Herbal drugs),	, 11 (West medicine)				
Heterogeneity: Not applicable					

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herbal drugs n/N	West medicine n/N			Risk Ratio Fixed, 959			Weight	Risk Ratio M-H, Fixed, 95% Cl
Test for overall effect: Z=4.39(P<	•	1/1		M-H	, FIXEd, 95	/0 CI			M-11, FIA20, 55% CI
Test for subgroup differences: Ch	i ² =27.44, df=1 (P=0), I ² =	59.91%				i.	L		
		Favours treatment	0.01	0.1	1	10	100	Favours control	

Analysis 3.5. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 5 Oestradiol (E2).

Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% CI	-	Random, 95% CI
3.5.1 Kanggusong granule versus i	priflavo	ne plus Caltrate	(9 mont	hs)			
An SJ 2000	31	32.5 (10.3)	40	20.4 (4.6)		100%	12.17[8.27,16.07]
Subtotal ***	31		40			100%	12.17[8.27,16.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=6.12(P<0.00	01)						
3.5.2 Kanggusong granule versus (Caltrate	(9 months)					
An SJ 2000	31	32.5 (10.3)	40	21.5 (5.6)		100%	11[6.97,15.03]
Subtotal ***	31		40		•	100%	11[6.97,15.03]
Heterogeneity: Not applicable							
Test for overall effect: Z=5.36(P<0.00	01)						
3.5.3 Strong Bone capsule versus (altrate ((3 months)					
Cui TH 1999	74	44.2 (19.4)	31	33.7 (12.2)		100%	10.46[4.29,16.63]
Subtotal ***	74		31		-	100%	10.46[4.29,16.63]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.32(P=0)							
3.5.4 Bushen Shengsui principle ve yprogesterone (6 months)	ersus cor	ijugated oestro	gens plus	s medrox-			
Liao L 2004	32	25.2 (19.3)	34	21.2 (12.6)		100%	4[-3.92,11.92]
Subtotal ***	32		34		-	100%	4[-3.92,11.92]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.99(P=0.32)						
3.5.5 Bushen Qiangshen pill versus	s Caltrat	e (3 months)					
Mu G 2001a	15	21.9 (13.2)	15	15.2 (11.9)		100%	6.71[-2.28,15.7]
Subtotal ***	15		15			100%	6.71[-2.28,15.7]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.46(P=0.14)						
3.5.6 Qianggu soft extract versus c	alcium g	luconate (6 mo	nths)				
Peng T 2002	78	21.1 (5.9)	21	16.9 (7.1)		100%	4.2[0.89,7.51]
Subtotal ***	78		21		•	100%	4.2[0.89,7.51]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.49(P=0.01)						
3.5.7 Gukang oral liquid versus ale	ndronat	e (6 months)					
Shao M 2003	30	64 (19.9)	30	60.1 (21.8)		100%	3.9[-6.64,14.44]
Subtotal ***	30		30			100%	3.9[-6.64,14.44]
Heterogeneity: Not applicable							

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her N	bal drugs Mean(SD)	Wes ^t N	t medicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Test for overall effect: Z=0.72(P=0.47)							
3.5.8 Gumikang capsule versus cal	cium glu	uconate (6 mont	:hs)				
Wang CC 2005	32	20.7 (3.8)	28	17.2 (5.3)	-+-	100%	3.5[1.14,5.8
Subtotal ***	32		28		•	100%	3.5[1.14,5.8
Heterogeneity: Not applicable							
Test for overall effect: Z=2.9(P=0)							
3.5.9 Bushen Yigu soft extract vers	us Alfac	alcidol (3 monti	ıs)				
Wang XY 2000	37	169.5 (68.9)	37	93.2 (121.8)		100%	76.29[31.19,121.3
Subtotal ***	37		37	()		- 100%	76.29[31.19,121.3
Heterogeneity: Not applicable	5.		51			20070	10125[52125,22215
Test for overall effect: Z=3.32(P=0)							
3.5.10 Kanggusong granule versus	ipriflav	one (3 months)					
Wu MS 2001	30	158.4 (40.3)	30	154.2 (30.2)		100%	4.18[-13.85,22.2
Subtotal ***	30		30			100%	4.18[-13.85,22.2
Heterogeneity: Not applicable							
Test for overall effect: Z=0.45(P=0.65)							
3.5.11 Yanghuo Sanzi tang versus C	altrate	(6 months)					
Qiu RB 2004	30	48.9 (11.5)	30	25.8 (9.1)		100%	23.07[17.83,28.3
Subtotal ***	30	1010 (1110)	30	2010 (012)		100%	23.07[17.83,28.3
Heterogeneity: Not applicable	50		50			- 100/0	23.01[11.03,20.3
Test for overall effect: Z=8.64(P<0.00)	01)						
3.5.12 Gusong recipe versus alendı	onate s	odium tablets (!	5 months	5)			
Xiao W 2008	20	64 (19.9)	20	60.1 (21.8)		100%	3.9[-9.01,16.8
Subtotal ***	20		20	Υ Υ		100%	3.9[-9.01,16.8
Heterogeneity: Not applicable							
Test for overall effect: Z=0.59(P=0.55)							
3.5.13 Gushukang granule versus i	oriflavo	ne (6 months)					
Wu MS 2007	30	152.3 (19.1)	30	138.4 (20.7)		100%	13.98[3.9,24.0
Subtotal ***	30		30			100%	13.98[3.9,24.0
Heterogeneity: Tau ² =0; Chi ² =0, df=0(1): $l^2 = 100\%$					
Test for overall effect: Z=2.72(P=0.01)		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
3.5.14 Bushen Jianpi Huoxue recip	e versu:	s alendronate so	odium tal	blets (6			
months)					' 		
He MT 2007	71	41.6 (8.2)	70	38.4 (9.2)		100%	3.15[0.28,6.0
Subtotal ***	71		70		•	100%	3.15[0.28,6.0
Heterogeneity: Not applicable							
Test for overall effect: Z=2.15(P=0.03)							
3.5.15 Prescription for tonifying ki	dney ve	rsus ipriflavone	(6 mont	hs)			
Vu MS 2007	30	152.4 (20.1)	30	138.4 (20.7)		100%	14[3.68,24.3
Subtotal ***	30		30			100%	14[3.68,24.3
Heterogeneity: Tau ² =0; Chi ² =0, df=0(I	o<0.000	1); I ² =100%					
Test for overall effect: Z=2.66(P=0.01)							
3.5.16 Kidney meridian sticking ve		iflavono (6 mon	••••				

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her N	bal drugs Mean(SD)	West N	medicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Wu MS 2007	30	150.3 (22.1)	30	138.4 (20.7)		100%	11.99[1.15,22.83
Subtotal ***	30		30			100%	11.99[1.15,22.83
Heterogeneity: Not applicable							- /
Test for overall effect: Z=2.17(P=0.03)							
3.5.17 Urinary bladder meridian stic	king v	ersus ipriflavon	e (6 mon	ths)			
Wu MS 2007	30	156.3 (20.2)	30	138.4 (20.7)		- 100%	17.99[7.65,28.33
Subtotal ***	30		30			- 100%	17.99[7.65,28.33
Heterogeneity: Not applicable							
Test for overall effect: Z=3.41(P=0)							
3.5.18 Huangqi Sanxian tang versus	nilestr	iol (3 months)		_			
Zhou ZK 2006	30	19.7 (2)	20	52.7 (14.6)		100%	-32.97[-39.42,-26.52
Subtotal ***	30		20			100%	-32.97[-39.42,-26.52
Heterogeneity: Not applicable							
Test for overall effect: Z=10.01(P<0.000	01)						
3.5.19 Gukang oral liquid versus ale	ndrona	ite sodium table	ets (6 mo	nths)			
Wang JM 2008	33	44.3 (5.5)	37	39.2 (4.1)		100%	5.09[2.81,7.37
Subtotal ***	33		37		•	100%	5.09[2.81,7.37
Heterogeneity: Not applicable							
Test for overall effect: Z=4.38(P<0.000)	L)						
3.5.20 Gukang decoction versus aler	ndrona	te sodium table	ts (4 mo	nths)			
Chen X 2008	42	39.6 (18.6)	41	40.2 (20.3)		100%	-0.65[-9.04,7.74
Subtotal ***	42		41		-	100%	-0.65[-9.04,7.74
Heterogeneity: Not applicable							
Test for overall effect: Z=0.15(P=0.88)							
3.5.21 Jianshenfang granule versus	alendr	onate sodium (6	6 months	;)			
Li BL 2007	30	17.3 (3.3)	30	11.5 (3.2)	+	100%	5.83[4.21,7.45
Subtotal ***	30		30		•	100%	5.83[4.21,7.45
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P·		L); I ² =100%					
Test for overall effect: Z=7.03(P<0.000)	L)						
3.5.22 Jiangu recipe versus alendro							
Qiu RB 2008	60	21.7 (6.2)	60	15.9 (5.7)		100%	5.82[3.69,7.95
Subtotal ***	60		60		•	100%	5.82[3.69,7.95
Heterogeneity: Not applicable Test for overall effect: Z=5.36(P<0.000)	L)						
3.5.23 Jiangu recipe versus alendro						1000/	
Qiu RB 2008	60	26.6 (6.7)	60	15.8 (5.6)		100%	10.75[8.55,12.95
Subtotal ***	60		60			100%	10.75[8.55,12.95
Heterogeneity: Not applicable Test for overall effect: Z=9.57(P<0.000)	L)						
3.5.24 Bushen Zhuanggu tang versu	- مماد م	Ironate codium	tablete /'	a months)			
Ling JY 2008	30 atend	30.2 (6.6)	30	24.8 (6.5)		100%	5.37[2.07,8.6]
Subtotal ***	30 30	50.2 (0.0)	30 30	27.0 (0.3)		100% 100%	5.37[2.07,8.67
	50		50			100%	5.57[2.07,8.67
Heterogeneity: Not applicable							

Chinese herbal medicines for treating osteoporosis (Review)



Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Study or subgroup	Herbal drugs		West	tmedicine	Mean Difference		Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)		, 95% CI		Random, 95% Cl
						,		,
3.5.25 Bushen Huoxue capsule ver	sus Calt	rate and Rocalir	ol (12 m	onths)				
Zhang XJ 2008	29	10.9 (3.2)	30	8.8 (3.5)		+	100%	2.13[0.42,3.84]
Subtotal ***	29		30			◆	100%	2.13[0.42,3.84]
Heterogeneity: Not applicable								
Test for overall effect: Z=2.44(P=0.01))							
3.5.26 Jingujian granule versus Ca	ltrate (3	months)						
Li YH 2010	140	12.2 (1.4)	70	7.4 (0.8)		- F	100%	4.85[4.56,5.14]
Subtotal ***	140		70			1	100%	4.85[4.56,5.14]
Heterogeneity: Not applicable								
Test for overall effect: Z=32.58(P<0.0	001)							
3.5.27 Qianggu paste versus calciu	m gluco	nate tablets (6 r	months)					
Wang H 2007	75	16.1 (5.9)	48	11.9 (7.1)		-+-	100%	4.2[1.79,6.61]
Subtotal ***	75		48			•	100%	4.2[1.79,6.61]
Heterogeneity: Not applicable								
Test for overall effect: Z=3.41(P=0)								
3.5.28 Tongbu Qianggutang versus	calciun	n plus vitamin D	3 (femal	e, 3 months)				
Zhou LZ 2001	14	40.9 (17.7)	4	35.9 (9.4)			100%	5.03[-8.01,18.07]
Subtotal ***	14		4				100%	5.03[-8.01,18.07]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.76(P=0.45))							
3.5.29 Tongbu Qianggutang versus	calciun	n plus vitamin D	3 (male,	3 months)				
Zhou LZ 2001	16	54.1 (34.9)	6	52.3 (12.7)		•	100%	1.89[-17.98,21.77]
Subtotal ***	16		6				100%	1.89[-17.98,21.77]
Heterogeneity: Not applicable								
Test for overall effect: Z=0.19(P=0.85))							
3.5.30 Gujian capsule versus alfaca	lcidol (e	5 months)						
Meng XD 2003	31	78.6 (73.2)	27	56.2 (54)			100%	22.35[-10.51,55.21]
Subtotal ***	31		27				100%	22.35[-10.51,55.21]
Heterogeneity: Not applicable								
Test for overall effect: Z=1.33(P=0.18))							
3.5.31 Radix rehmanniae preparat ate tablets (6 months)	a and Ra	ıdix astragali ve	ersus calo	ium carbon-				
Ou L 2011	32	67.1 (17.9)	32	58.4 (14)			100%	8.78[0.92,16.64]
Subtotal ***	32	01.1 (11.3)	32	55.1 (17)			100%	8.78[0.92,16.64]
Heterogeneity: Not applicable	52		32				100 /0	0.10[0.02,20.04]
Test for overall effect: Z=2.19(P=0.03))							
	/) 10 20		

Analysis 3.6. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 6 Serum calcium (Ca).

Study or subgroup		bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI
3.6.1 Kanggusong granule versus ip		-					
An SJ 2000	31	2.4 (0.2)	40	2.5 (0.2)		100%	-0.09[-0.17,-0.01]
Subtotal ***	31		40		•	100%	-0.09[-0.17,-0.01]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.14(P=0.03)							
3.6.2 Kanggusong granule versus Ca	altrate	(9 months)					
An SJ 2000	31	2.4 (0.2)	40	2.4 (0.2)		100%	-0.03[-0.11,0.05]
Subtotal ***	31		40		•	100%	-0.03[-0.11,0.05]
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P	< 0.0001	L); I ² =100%					
Test for overall effect: Z=0.75(P=0.45)							
3.6.3 Gushukang granule versus Cal tablets (6 months)	cium c	arbonate with v	itamin D o	hewable			
Chen ZX 2002	20	2.4 (0.1)	19	2.4 (0.1)		100%	-0.02[-0.1,0.06]
Subtotal ***	20		19		•	100%	-0.02[-0.1,0.06]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.46(P=0.64)							
3.6.4 Strong Bone capsule versus Ca	altrate	(3 months)					
Cui TH 1999	74	2.2 (0.2)	31	2.4 (0.2)	-+-	100%	-0.13[-0.22,-0.04]
Subtotal ***	74		31		•	100%	-0.13[-0.22,-0.04]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.74(P=0.01)							
3.6.5 Qianggu soft extract versus ca	lcium g	gluconate (6 mo	nths)				
Peng T 2002	78	2.7 (0)	21	2.8 (0.1)	+	100%	-0.03[-0.05,-0.01]
Subtotal ***	78		21		•	100%	-0.03[-0.05,-0.01]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.54(P=0.01)							
3.6.6 Gumikang capsule versus calc	ium glu	iconate (6 mont	hs)				
Wang CC 2005	32	3.7 (0)	28	2.3 (0)		100%	1.4[1.39,1.41]
Subtotal ***	32		28			100%	1.4[1.39,1.41]
Heterogeneity: Not applicable							
Test for overall effect: Z=541.01(P<0.0	001)						
3.6.7 Bushen Jianpi Migu prescripti	on vers	us Caltrate (3 m	onths)				
Wang ZK 2004	83	2.3 (0.2)	67	2.3 (0.2)	+	100%	0.01[-0.05,0.07]
Subtotal ***	83		67		•	100%	0.01[-0.05,0.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.34(P=0.73)							
3.6.8 Kanggusong granule versus ip	riflavo	ne (3 months)					
Wu MS 2001	30	2.4 (0.2)	30	2.3 (0.1)	+	100%	0.1[0.03,0.17]
Subtotal ***	30		30		•	100%	0.1[0.03,0.17]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.76(P=0.01)							
3.6.9 Bugu Shengsui capsule versus	vitami	n D2 plus calciu	m tablet (6 months)			
				rs treatment -1	-0.5 0 0.5	¹ Favours cor	

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her N	bal drugs Mean(SD)	N	medicine Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Xie YM 1997	26	2.4 (0.2)	18	2.3 (0.3)		100%	0.1[-0.05,0.25
Subtotal ***	26	2.4 (0.2)	18	2.5 (0.5)		100%	0.1[-0.05,0.25
Heterogeneity: Not applicable	20		10			100%	0.1[-0.03,0.2.
o , , , ,							
Test for overall effect: Z=1.29(P=0.2)							
3.6.10 Yinyanghuo versus conjugate	ed oest	rogens (3 to 6 m	onths)				
Zhao LN 2003	15	2.8 (0.6)	10	2.3 (0.2)		100%	0.54[0.23,0.85
Subtotal ***	15		10			100%	0.54[0.23,0.85
Heterogeneity: Not applicable							
Test for overall effect: Z=3.47(P=0)							
3.6.11 Gushukang granule versus ip	oriflavo	ne (6 months)					
Wu MS 2007	30	2.3 (0.1)	30	2.4 (0.1)	+	100%	-0.02[-0.07,0.03
Subtotal ***	30		30		•	100%	-0.02[-0.07,0.03
Heterogeneity: Not applicable							
Test for overall effect: Z=0.77(P=0.44)							
3.6.12 Shenyao capsules versus Cal	trate (6	months)					
Chen NQ 2006	50	2.5 (0.3)	50	2.5 (0.2)	<u></u>	100%	0.02[-0.08,0.12
Subtotal ***	50		50			100%	0.02[-0.08,0.12
Heterogeneity: Not applicable							
Test for overall effect: Z=0.4(P=0.69)							
3.6.13 Guli powder versus Caltrate	(3 mont	ths)					
Lan ZX 2006	30	2.3 (0.1)	30	2.2 (0.1)	+	100%	0.09[0.02,0.16
Subtotal ***	30		30		•	100%	0.09[0.02,0.16
Heterogeneity: Not applicable							
Test for overall effect: Z=2.49(P=0.01)							
3.6.14 Prescription for tonifying kid	lney ve	rsus ipriflavone	(6 monti	hs)			
Wu MS 2007	30	2.4 (0.1)	30	2.4 (0.1)	+	100%	0[-0.05,0.05
Subtotal ***	30		30		•	100%	0[-0.05,0.05
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
3.6.15 Kidney meridian sticking ver	sus inri	flavone (6 mon	ths)				
Wu MS 2007	30	2.3 (0.1)	30	2.4 (0.1)	+	100%	-0.01[-0.06,0.04
Subtotal ***	30	210 (012)	30	211 (012)	•	100%	-0.01[-0.06,0.04
Heterogeneity: Not applicable	•••						[,
Test for overall effect: Z=0.37(P=0.72)							
3.6.16 Urinary bladder meridian sti	cking v	ersus ipriflavon	e (6 mon	ths)			
Wu MS 2007	30	2.3 (0.1)	30	2.4 (0.1)		100%	-0.01[-0.06,0.04
Subtotal ***	30 30	2.3 (0.1)	30 30	2.7 (0.1)		100% 100%	-0.01[-0.06,0.04
Heterogeneity: Not applicable	50		30		•	100 /0	-0.01[-0.00,0.04
Test for overall effect: Z=0.39(P=0.7)							
3.6.17 Gushen Yijing tang versus Ca	ltrate (6 months)					
Zhong RQ 2007	39	2.5 (0.3)	41	2.3 (0.2)		100%	0.23[0.11,0.3
Subtotal ***	39 39	2.3 (0.3)	41 41	2.3 (0.2)		100% 100%	0.23[0.11,0.35
	22		41		-	10070	0.23[0.11,0.33
Heterogeneity: Not applicable					J. J		

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Herb	al drugs	West	nedicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% CI		Random, 95% Cl
3.6.18 Gukang oral liquid versus al							
Wang JM 2008	33	2.4 (0.1)	37	2.4 (0.1)		100%	-0.02[-0.06,0.02]
Subtotal ***	33		37		•	100%	-0.02[-0.06,0.02]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.96(P=0.34)							
3.6.19 Qianggu capsule versus acti	ve vitami	n D3 (6 month	5)				
Wang J 2007	28	2.3 (0.1)	26	2.3 (0.1)	+	100%	0.01[-0.06,0.08]
Subtotal ***	28		26		•	100%	0.01[-0.06,0.08]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.29(P=0.77)							
3.6.20 Jiangu capsule versus Caltra	te (12 m	onths)					
Wang YZ 2008	63	2.3 (0.1)	62	2.3 (0.2)	+	100%	-0.06[-0.11,-0.01]
Subtotal ***	63		62		•	100%	-0.06[-0.11,-0.01]
Heterogeneity: Not applicable							,,
Test for overall effect: Z=2.39(P=0.02)							
3.6.21 Bushen Yangxue tang versus	calcium	gluconate (6 n	nonths)				
Zhan ML 2007	20	2.3 (0.3)	20	2.1 (0.2)	—	100%	0.13[-0,0.26]
Subtotal ***	20	210 (010)	20	212 (012)	-	100%	0.13[-0,0.26]
Heterogeneity: Not applicable	-•				•		0.20[0,0.20]
Test for overall effect: Z=1.96(P=0.05)							
,							
3.6.22 Bushenjianpi Zhuangguyin v	ersus Cal				_		
Zhang XG 2011	50	3.9 (0.2)	50	3.2 (0.2)		100%	0.74[0.66,0.82]
Subtotal ***	50		50		•	100%	0.74[0.66,0.82]
Heterogeneity: Not applicable							
Test for overall effect: Z=17.62(P<0.00	001)						
3.6.23 Erxian soup versus Caltrate	(6 month	s)					
Wu JZ 2010	30	2.2 (0.5)	28	2.2 (0.4)		100%	-0.02[-0.25,0.21]
Subtotal ***	30		28		\bullet	100%	-0.02[-0.25,0.21]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.17(P=0.86)							
3.6.24 Qianggu paste versus calciu	n glucon	ate tablets (6 n	nonths)				
Wang H 2007	75	2.7 (0)	48	2.8 (0.1)	+	100%	-0.03[-0.06,-0]
Subtotal ***	75		48		•	100%	-0.03[-0.06,-0]
Heterogeneity: Tau ² =0; Chi ² =0, df=0(H	P<0.0001)	; I ² =100%					
Test for overall effect: Z=2.21(P=0.03)							
3.6.25 Tongbu Qianggutang versus	calcium	plus vitamin D	3 (3 mont	hs)			
Zhou LZ 2001	30	2.4 (0.1)	10	2.4 (0.1)		100%	-0.02[-0.1,0.06]
Subtotal ***	30		10		•	100%	-0.02[-0.1,0.06]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.43(P=0.67)							
3.6.26 Radix rehmanniae preparata	a and Rad	lix astragali ve	rsus calci	um carbon-			
ate tablets (6 months)				/- `			
Ou L 2011	32	2.5 (0.1)	32	2.5 (0.1)	+	100%	-0.01[-0.05,0.03]

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herbal drugs		West medicine			Mean Difference				Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Ran	dom, 95	% CI			Random, 95% Cl
Subtotal ***	32		32				•			100%	-0.01[-0.05,0.03]
Heterogeneity: Not applicable											
Test for overall effect: Z=0.47(P=0.64)											
			Favou	irs treatment	-1	-0.5	0	0.5	1	Favours contro	

Analysis 3.7. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 7 Phosphorus (P).

Study or subgroup	Herb	al drugs	West	medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
3.7.1 Kanggusong granule versus	ipriflavon	e plus Caltrate	(9 month	is)			
An SJ 2000	31	1.2 (0.2)	40	1.2 (0.2)		100%	0.06[-0.03,0.15]
Subtotal ***	31		40		•	100%	0.06[-0.03,0.15]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.24(P=0.2	1)						
3.7.2 Kanggusong granule versus	Caltrate (9 months)					
An SJ 2000	31	1.2 (0.2)	40	1.2 (0.9)		100%	-0.01[-0.29,0.27]
Subtotal ***	31		40			100%	-0.01[-0.29,0.27]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.07(P=0.9	4)						
3.7.3 Gushukang granule versus (tablets (6 months)	Calcium ca	rbonate with v	itamin D	chewable			
Chen ZX 2002	20	1.1 (0.2)	19	1.1 (0.1)	-	100%	0.01[-0.09,0.11]
Subtotal ***	20	()	19			100%	0.01[-0.09,0.11]
Heterogeneity: Not applicable					Ĭ		
Test for overall effect: Z=0.2(P=0.84)						
3.7.4 Strong Bone capsule versus	Caltrate (3	3 months)					
Cui TH 1999	74	1 (0.1)	31	1.1 (0.3)		100%	-0.12[-0.21,-0.03]
Subtotal ***	74		31		\bullet	100%	-0.12[-0.21,-0.03]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.55(P=0.0	1)						
3.7.5 Bushen Jianpi Migu prescrip	otion versu	ıs Caltrate (3 m	onths)				
Wang ZK 2004	83	1.3 (0.2)	67	1.2 (0.1)	<u> </u>	100%	0.03[-0.02,0.08]
Subtotal ***	83		67		•	100%	0.03[-0.02,0.08]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.07(P=0.2	8)						
3.7.6 Kanggusong granule versus	ipriflavon	e (3 months)					
Wu MS 2001	30	1.4 (0.3)	30	1.4 (0.3)		100%	-0.07[-0.2,0.06]
Subtotal ***	30		30		-	100%	-0.07[-0.2,0.06]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.02(P=0.3	1)						
3.7.7 Yinyanghuo versus conjuga	ted oestro	gens (3 to 6 mo	nths)				
Zhao LN 2003	15	1.8 (0.3)	10	1.7 (0.3)		100%	0.13[-0.13,0.39]
Subtotal ***	15		10			100%	0.13[-0.13,0.39]

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her N	bal drugs Mean(SD)	West N	medicine Mean(SD)	Mean Difference Fixed, 95% Cl	Weight	Mean Difference Fixed, 95% CI
Heterogeneity: Not applicable		mean(5D)		Mean(5D)			11,200,357,001
Test for overall effect: Z=0.98(P=0.33)							
3.7.8 Shenyao capsules versus Caltr	ate (6 i	months)					
Chen NQ 2006	50	1.3 (0.2)	50	1.3 (0.2)		100%	-0.01[-0.08,0.0
Subtotal ***	50		50			100%	-0.01[-0.08,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.28(P=0.78)							
3.7.9 Gushukang granule versus ipri	flavon	e (6 months)					
Wu MS 2007	30	1.3 (0.3)	30	1.3 (0.2)		100%	-0.01[-0.13,0.1
Subtotal ***	30		30		$\overline{\bullet}$	100%	-0.01[-0.13,0.1
Heterogeneity: Not applicable							
Test for overall effect: Z=0.16(P=0.87)							
3.7.10 Guli powder versus Caltrate (3 mon	ths)					
Lan ZX 2006	30	1.3 (0.2)	30	1.4 (0.1)		100%	-0.05[-0.13,0.0
Subtotal ***	30		30		•	100%	-0.05[-0.13,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.24(P=0.21)							
3.7.11 Prescription for tonifying kid	ney ve	rsus ipriflavone	(6 mont	hs)			
Wu MS 2007	30	1.2 (0.2)	30	1.3 (0.2)		100%	-0.04[-0.15,0.0
Subtotal ***	30		30		•	100%	-0.04[-0.15,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.7(P=0.48)							
3.7.12 Kidney meridian sticking ver	sus ipri	iflavone (6 mon	ths)				
Wu MS 2007	30	1.3 (0.2)	30	1.3 (0.2)		100%	-0.01[-0.13,0.1
Subtotal ***	30		30		•	100%	-0.01[-0.13,0.1
Heterogeneity: Not applicable							
Test for overall effect: Z=0.16(P=0.87)							
3.7.13 Urinary bladder meridian stic	king v	ersus ipriflavon	e (6 mon	ths)			
Wu MS 2007	30	1.3 (0.2)	30	1.3 (0.2)		100%	-0.01[-0.13,0.1
Subtotal ***	30		30		•	100%	-0.01[-0.13,0.1
Heterogeneity: Not applicable Test for overall effect: Z=0.16(P=0.87)							
3.7.14 Gushen Yijing tang versus Cal	trate (6 months)					
Zhong RQ 2007	39	1.1 (0.2)	41	1.1 (0.4)		100%	0.04[-0.09,0.1
Subtotal ***	39		41		$\overline{\bullet}$	100%	0.04[-0.09,0.1
Heterogeneity: Not applicable							
Test for overall effect: Z=0.62(P=0.53)							
3.7.15 Qianggu capsule versus activ	e vitan	nin D3 (6 month	s)				
Wang J 2007	28	1.1 (0.1)	26	1.1 (0.2)		100%	0.02[-0.05,0.0
Subtotal ***	28		26		+	100%	0.02[-0.05,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.56(P=0.58)							
3.7.16 Jiangu capsule versus Caltra	te (12 n	nonths)					
			Fa	vours control	-0.5 -0.25 0 0.25 0.5	Favours trea	atment

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her	bal drugs	West	tmedicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% CI	-	Fixed, 95% CI
Wang YZ 2008	63	1.4 (0.8)	62	1.3 (0.9)		100%	0.09[-0.2,0.38]
Subtotal ***	63		62			100%	0.09[-0.2,0.38]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.6(P=0.55)							
3.7.17 Bushenzhuanggu decoction months)	versus a	alendronate sod	ium tabl	lets (3			
Ling JY 2008	30	1 (0.2)	30	0.7 (0.3)		100%	0.24[0.1,0.38]
Subtotal ***	30		30		•	100%	0.24[0.1,0.38]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.29(P=0)							
3.7.18 Bushenjianpi Zhuangguyin v	ersus C	altrate and calc	itonin (1	2 weeks)			
Zhang XG 2011	50	0.6 (0.2)	50	1 (0.3)		100%	-0.37[-0.48,-0.26]
Subtotal ***	50		50		$\overline{\bullet}$	100%	-0.37[-0.48,-0.26]
Heterogeneity: Not applicable							
Test for overall effect: Z=6.78(P<0.000)1)						
3.7.19 Erxian soup versus Caltrate	(6 mont	hs)					
Wu JZ 2010	30	1.1 (0.3)	28	1.1 (0.4)		100%	-0.03[-0.2,0.14]
Subtotal ***	30		28		-	100%	-0.03[-0.2,0.14]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.34(P=0.73)							
3.7.20 Tongbu Qianggutang versus	calcium	n plus vitamin D	3 (3 mon	ths)			
Zhou LZ 2001	30	1.2 (0.2)	10	1.2 (0.2)		100%	-0.01[-0.12,0.1]
Subtotal ***	30		10		—	100%	-0.01[-0.12,0.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.18(P=0.86)							
3.7.21 Radix rehmanniae preparata ate tablets (6 months)	a and Ra	ıdix astragali ve	rsus calo	ium carbon-			
Ou L 2011	32	1.3 (0.4)	32	1.3 (0.2)		100%	0[-0.15,0.15]
Subtotal ***	32		32		+	100%	0[-0.15,0.15]
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
Test for subgroup differences: Chi ² =6	9.8, df=1	L (P<0.0001), I ² =7	1.35%				
			Fa	vours control	-0.5 -0.25 0 0.25 0.5	Favours tre	atment

Analysis 3.8. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 8 Alkaline phosphatase (ALP).

Study or subgroup	Her	bal drugs	West	medicine		Mea	an Difference		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Fiz	xed, 95% CI			Fixed, 95% CI
3.8.1 Kanggusong granule ve	ersus ipriflavoi	ne plus Caltrate	(9 mont	hs)						
An SJ 2000	31	13.2 (2)	40	11.5 (1.8)					100%	1.69[0.79,2.59]
Subtotal ***	31		40				•		100%	1.69[0.79,2.59]
Heterogeneity: Tau ² =0; Chi ² =0	, df=0(P<0.0001	.); I²=100%								
Test for overall effect: Z=3.68(P=0)									
			Fa	vours control	-10	-5	0 5	10	Favours treatme	ent

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Herb	al drugs	West	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
3.8.2 Kanggusong granule versus	Caltrate (9 months)					
An SJ 2000	31	13.2 (2)	40	11.9 (2.2)		100%	1.28[0.3,2.26
Subtotal ***	31		40		•	100%	1.28[0.3,2.26
Heterogeneity: Not applicable							
Test for overall effect: Z=2.56(P=0.01	L)						
3.8.3 Gushukang granule versus C tablets (6 months)	alcium ca	rbonate with v	itamin D	chewable			
Chen ZX 2002	20	8.2 (1.8)	19	8.7 (2)		100%	-0.5[-1.7,0.7
Subtotal ***	20		19			100%	-0.5[-1.7,0.7
Heterogeneity: Not applicable							
Test for overall effect: Z=0.81(P=0.42	2)						
3.8.4 Strong Bone capsule versus	Caltrate (3	8 months)					
Cui TH 1999	74	1.4 (0.3)	31	1.4 (0.5)	+	100%	-0.07[-0.25,0.1]
Subtotal ***	74	()	31	····/	•	100%	-0.07[-0.25,0.11
Heterogeneity: Not applicable							·····
Test for overall effect: Z=0.78(P=0.44	ł)						
3.8.5 Bushen Qiangshen pill versu	s Caltrate	(3 months)					
Mu G 2001a	15	4.5 (1.8)	15	4.3 (2.4)		100%	0.27[-1.27,1.8
Subtotal ***	15	. ,	15		-	100%	0.27[-1.27,1.8
Heterogeneity: Not applicable					-		- /
Test for overall effect: Z=0.34(P=0.73	3)						
3.8.6 Qianggu soft extract versus o	-			(-)			
Peng T 2002	78	11 (2.1)	21	7.4 (2)		100%	3.6[2.62,4.5
Subtotal ***	78		21		•	100%	3.6[2.62,4.5
Heterogeneity: Not applicable							
Test for overall effect: Z=7.2(P<0.000)1)						
3.8.7 Gukang oral liquid versus ale	endronate	(6 months)					
Shao M 2003	30	19.5 (3.1)	30	20.6 (2.7)		100%	-1.06[-2.54,0.4
Subtotal ***	30		30		•	100%	-1.06[-2.54,0.42
Heterogeneity: Not applicable							
Test for overall effect: Z=1.41(P=0.16	5)						
3.8.8 Gumikang capsule versus ca	lcium gluo	onate (6 mont	hs)				
Wang CC 2005	32	10.5 (1.6)	28	7.1 (0.2)		100%	3.41[2.84,3.98
Subtotal ***	32		28		•	100%	3.41[2.84,3.98
Heterogeneity: Not applicable							
Test for overall effect: Z=11.75(P<0.0	0001)						
3.8.9 Bushen Jianpi Migu prescrip	tion versu	s Caltrate (3 m	onths)				
Wang ZK 2004	83	1.2 (0.3)	67	1.1 (0.3)	+	100%	0.1[0.01,0.1
Subtotal ***	83		67			100%	0.1[0.01,0.19
Heterogeneity: Not applicable							
Test for overall effect: Z=2.07(P=0.04	t)						
3.8.10 Kanggusong granule versus	s ipriflavo	ne (3 months)					
Wu MS 2001	30	1.6 (0.4)	30	1.5 (0.4)	+	100%	0.13[-0.07,0.3]
Subtotal ***	30		30			100%	0.13[-0.07,0.33

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	N	bal drugs Mean(SD)	N	medicine Mean(SD)	Mean Difference Fixed, 95% Cl	Weight	Mean Difference Fixed, 95% Cl
Heterogeneity: Not applicable							
Test for overall effect: Z=1.25(P=0.2	1)						
3.8.11 Bugu Shengsui capsule ver	sus vitan	nin D2 plus calci	um table	t (6 months)			
Xie YM 1997	26	4.1 (1.8)	18	4.4 (2.6)		100%	-0.29[-1.67,1.09
Subtotal ***	26	. ,	18			100%	-0.29[-1.67,1.09
Heterogeneity: Not applicable							
Test for overall effect: Z=0.41(P=0.6	8)						
3.8.12 Liuwei Dihuang pills versu	s calcium	(12 months)					
Zhang J 2003	24	2.2 (1.4)	18	1.7 (0.8)		100%	0.55[-0.12,1.22
Subtotal ***	24	. ,	18		•	100%	0.55[-0.12,1.22
Heterogeneity: Not applicable					•		
Test for overall effect: Z=1.6(P=0.11)						
3.8.13 TPF capsule versus calciun	ı granule	(6 months)					
Zhang YL 1996	60	12 (3.8)	60	8.1 (3.5)		100%	3.84[2.53,5.1
Subtotal ***	60	, <i>i</i>	60			100%	3.84[2.53,5.1
Heterogeneity: Tau ² =0; Chi ² =0, df=0		L); ² =100%			-		······································
Test for overall effect: Z=5.76(P<0.0		-,,					
3.8.14 Yinyanghuo versus conjug	ated oest	rogens (3 to 6 m	onths)				
Zhao LN 2003	15	20.8 (6.3)	10	27.8 (4.3)		100%	-7[-11.17,-2.8
Subtotal ***	15		10			100%	-7[-11.17,-2.8
Heterogeneity: Not applicable							
Test for overall effect: Z=3.29(P=0)							
3.8.15 Gusong recipe versus alen	dronate s	odium tablets (!	5 months)			
Xiao W 2008	20	19.5 (3.1)	20	20.6 (2.7)		100%	-1.05[-2.86,0.7
Subtotal ***	20		20		\bullet	100%	-1.05[-2.86,0.76
Heterogeneity: Not applicable							
Test for overall effect: Z=1.14(P=0.2	6)						
3.8.16 Shenyao capsules versus C	altrate (6	i months)					
Chen NQ 2006	50	12.2 (2.9)	50	14.6 (3.1)		100%	-2.4[-3.58,-1.2
Subtotal ***	50		50		\bullet	100%	-2.4[-3.58,-1.22
Heterogeneity: Not applicable							
Test for overall effect: Z=3.99(P<0.0	001)						
3.8.17 Bushen Jianpi Huoxue reci	pe versus	alendronate so	dium tal	olets (6			
months)							
He MT 2007	71	11.7 (3.9)	70	14.7 (4.5)		100%	-2.94[-4.34,-1.54
Subtotal ***	71		70		-	100%	-2.94[-4.34,-1.54
Heterogeneity: Not applicable Test for overall effect: Z=4.12(P<0.0	001)						
3.8.18 Guli powder versus Caltrat	o /2 mor	the)					
-			20	15 4 (6 2)		1000/	
Lan ZX 2006	30	15.7 (6.7)	30	15.4 (6.2)		100%	0.3[-2.97,3.5]
Subtotal ***	30		30			100%	0.3[-2.97,3.57
Heterogeneity: Not applicable Test for overall effect: Z=0.18(P=0.8	6)						

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Her N	bal drugs Mean(SD)	West N	medicine Mean(SD)	Mean Difference Fixed, 95% Cl	Weight	Mean Difference Fixed, 95% CI
3.8.19 Huangqi Sanxian tang versu							
Zhou ZK 2006	30	11.6 (1.7)	20	11.6 (2.1)		100%	-0.03[-1.14,1.0
Subtotal ***	30		20			100%	-0.03[-1.14,1.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.05(P=0.96))						
3.8.20 Gushen Yijing tang versus Ca	altrate ((5 months)					
Zhong RQ 2007	39	13.2 (3.6)	41	11.1 (3)		100%	2.17[0.73,3.6
Subtotal ***	39		41			100%	2.17[0.73,3.6
Heterogeneity: Not applicable Test for overall effect: Z=2.95(P=0)							
3.8.21 Gukang oral liquid versus al	endrona	te sodium Table	ets				
Wang JM 2008	33	14.3 (1.9)	37	13.8 (1.6)		100%	0.48[-0.34,1.
Subtotal ***	33		37		•	100%	0.48[-0.34,1.3
Heterogeneity: Not applicable Test for overall effect: Z=1.15(P=0.25))						
3.8.22 Qianggu capsule versus acti	ve vitam	in D3 (6 months	5)				
Wang J 2007	28	12.1 (3.2)	26	11.4 (3.8)		100%	0.71[-1.17,2.5
Subtotal ***	28		26		-	100%	0.71[-1.17,2.5
Heterogeneity: Not applicable							
Test for overall effect: Z=0.74(P=0.46))						
3.8.23 Jiangu capsule versus Caltra	ate (12 n	nonths)					
Wang YZ 2008	63	12.6 (2)	62	10.6 (2.1)		100%	2.04[1.32,2.7
Subtotal ***	63		62		•	100%	2.04[1.32,2.7
Heterogeneity: Not applicable Test for overall effect: Z=5.58(P<0.000	01)						
3.8.24 Jianshenfang granule versu							
Li BL 2007	30	16.6 (6.5)	30	16.3 (5.8)		100%	0.33[-2.79,3.4
Subtotal ***	30		30			100%	0.33[-2.79,3.4
Heterogeneity: Not applicable							
Test for overall effect: Z=0.21(P=0.84)							
3.8.25 Jingujian granule versus Cal						1000/	
Li YH 2008	80	12.2 (3.1)	40	11.7 (3.3)		100%	0.53[-0.69,1.7
Subtotal ***	80		40			100%	0.53[-0.69,1.7
Heterogeneity: Not applicable Test for overall effect: Z=0.85(P=0.4)							
3.8.26 Jianshenfang granule versu	s alendr	onate sodium +=	blets (A	months)			
Li BL 2007	30	16.7 (6.5)	30	16.3 (5.8)		100%	0.33[-2.78,3.4
Subtotal ***	30	_3.1 (3.3)	30	(0.0)		100%	0.33[-2.78,3.4
Heterogeneity: Tau ² =0; Chi ² =0, df=0(I): $l^2 = 100\%$				20070	0.001 2.10,0.4
Test for overall effect: Z=0.21(P=0.84)		,,00,0					
3.8.27 Bushen Zhuanggu tang versi	us alend	ronate sodium (tablets (i	3 months)			
Ling JY 2008	30	11.6 (1.5)	30	11.7 (1.9)		100%	-0.11[-0.99,0.7
Subtotal ***	30		30			100%	-0.11[-0.99,0.7]
Heterogeneity: Not applicable							

Chinese herbal medicines for treating osteoporosis (Review)



Trusted evidence. Informed decisions. Better health.

Study or subgroup		bal drugs		medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Fixed, 95% Cl		Fixed, 95% Cl
Test for overall effect: Z=0.25(P=0.81)							
3.8.28 Bushenjianpi Zhuangguyin v	ersus C	altrate and calc	itonin (1 [.]	weeks)			
Zhang XG 2011	50	14.9 (5)	50	15.8 (5.2)		100%	-0.82[-2.83,1.19]
Subtotal ***	50	11.5 (5)	50	10.0 (0.2)		100%	-0.82[-2.83,1.19]
Heterogeneity: Not applicable							[,]
Test for overall effect: Z=0.8(P=0.42)							
3.8.29 Jingujian granule versus Cal	trate (3	months)					
Li YH 2010	140	14.8 (0.5)	70	12.4 (0.8)	+	100%	2.4[2.21,2.59]
Subtotal ***	140		70		•	100%	2.4[2.21,2.59]
Heterogeneity: Not applicable							
Test for overall effect: Z=24.65(P<0.00	001)						
2.0.20 Emilian annu comus California	(C	h.a.\					
3.8.30 Erxian soup versus Caltrate	30		20	1E 1 (1 C)		1000/	0[0 22 0 27]
Wu JZ 2010		15.1 (1.8)	28	15.1 (1.6)		100%	0[-0.87,0.87]
Subtotal ***	30		28			100%	0[-0.87,0.87]
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
3.8.31 Qianggu paste versus calciu	n gluco	nate tablets (6 r	nonths)				
Wang H 2007	75	11 (2.1)	48	7.4 (2)		100%	3.6[2.86,4.34]
Subtotal ***	75		48		•	100%	3.6[2.86,4.34]
Heterogeneity: Not applicable							
Test for overall effect: Z=9.53(P<0.000	01)						
3.8.32 Bushen Yangxue tang versus	calcium	n gluconate (6 n	nonths)				
Zhan ML 2007	20	10.7 (3.7)	20	8.1 (1.7)		100%	2.62[0.84,4.4]
Subtotal ***	20	10.1 (0.1)	20	0.1 (1.1)		100%	2.62[0.84,4.4]
Heterogeneity: Not applicable]
Test for overall effect: Z=2.88(P=0)							
3.8.33 Tongbu Qianggutang versus	calcium	ı plus vitamin D	3 (3 mon	ths)			
Zhou LZ 2001	30	11.7 (2.3)	10	11.6 (1.6)		100%	0.18[-1.08,1.44]
Subtotal ***	30		10		+	100%	0.18[-1.08,1.44]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.28(P=0.78)							
3.8.34 Radix rehmanniae preparata	and Ra	dix astragali ve	rsus calc	ium carbon-			
ate tablets (6 months)							
Ou L 2011	32	13 (1.5)	32	12.1 (1.6)		100%	0.91[0.15,1.67]
Subtotal ***	32		32		◆	100%	0.91[0.15,1.67]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.34(P=0.02)							
Test for subgroup differences: Chi ² =8	48.34, d	=1 (P<0.0001), I ²	=96.11%				
			Fa	vours control	-10 -5 0 5	¹⁰ Favours trea	atment

Trusted evidence. Informed decisions. Better health.

Study or subgroup	пен	oal drugs	west	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
3.9.1 Bushen Jianpi Huoxue recip nonths)	e versus a	lendronate soc	lium tabl	ets (6			
He MT 2007	71	4.6 (1.8)	70	6.7 (1.9)		100%	-2.13[-2.74,-1.5
Subtotal ***	71	1.0 (1.0)	70	0.1 (1.3)		100%	-2.13[-2.74,-1.52
Heterogeneity: Not applicable	11		10		•	100 /0	-2.15[-2.14,-1.5
Test for overall effect: Z=6.86(P<0.0	001)						
	001)						
3.9.2 Acupoint sticking of Miguda tablets (3 months)	n versus o	yster shell calc	ium chev	vable			
Ku YL 2007	48	7.7 (0.9)	48	6.1 (0.7)	+	100%	1.55[1.24,1.8
Subtotal ***	48		48		•	100%	1.55[1.24,1.8
Heterogeneity: Not applicable							
Test for overall effect: Z=9.87(P<0.0	001)						
3.9.3 Gukang oral liquid versus al	ondronate	(6 months)					
Shao M 2003	30	6.5 (1.8)	30	6.6 (1.5)		100%	-0.1[-0.93,0.7]
Subtotal ***	30	0.0 (1.0)	30	0.0 (1.3)		100%	-0.1[-0.93,0.73
Heterogeneity: Not applicable	50		50			100 /0	-0.1[-0.55,0.1]
Test for overall effect: Z=0.24(P=0.8	1)						
	-)						
3.9.4 Gusong recipe versus alendi	ronate sod	lium tablets (5	months)				
Kiao W 2008	20	6.5 (1.8)	20	6.6 (1.5)		100%	-0.1[-1.11,0.9
Subtotal ***	20		20		+	100%	-0.1[-1.11,0.9
Heterogeneity: Not applicable							
Test for overall effect: Z=0.19(P=0.8	5)						
3.9.5 Yanghuo Sanzi tang versus (Caltrate (6	months)					
Qiu RB 2004	30	10.9 (6.4)	30	8.2 (5.5)	_	100%	2.71[-0.3,5.7
Subtotal ***	30		30			100%	2.71[-0.3,5.7
Heterogeneity: Not applicable							
Test for overall effect: Z=1.76(P=0.0	8)						
3.9.6 Strong Bone capsule versus	Caltrate (3 months)					
Cui TH 1999	74	5.4 (4)	31	5.9 (4)		100%	-0.49[-2.17,1.1
Subtotal ***	74		31		-	100%	-0.49[-2.17,1.19
Heterogeneity: Tau ² =0; Chi ² =0, df=0): ² =100%					
Test for overall effect: Z=0.57(P=0.5							
3.9.7 Shigu yin versus Caltrate (6	months)						
Zhang YP 2007	40	4.6 (2.5)	40	3.8 (2.7)		100%	0.8[-0.34,1.9
Subtotal ***	40 40	r.u (2.J)	40 40	0.0 (2.1)		100% 100%	0.8[-0.34,1.9
Heterogeneity: Not applicable	U.		ντ			100 /0	0.0[-0.34,1.3
Test for overall effect: Z=1.38(P=0.1	7)						
3.9.8 Jingujian granule versus Ca	-						
_i YH 2008	80	20.6 (8.9)	40	18 (7)		100%	2.53[-0.38,5.4
Subtotal ***	80		40			100%	2.53[-0.38,5.4
Heterogeneity: Not applicable							
Test for overall effect: Z=1.7(P=0.09)						

Analysis 3.9. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 9 Bone Gla protein (BGP).

Chinese herbal medicines for treating osteoporosis (Review)



_

Trusted evidence. Informed decisions. Better health.

Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl	-	Random, 95% CI
Li BL 2007	30	9.6 (5.2)	30	9.1 (2.7)	— <u>—</u>	100%	0.49[-1.59,2.57]
Subtotal ***	30		30			100%	0.49[-1.59,2.57]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.46(P=0.64)							
3.9.10 Jiangu recipe versus alendro		-					
Qiu RB 2008	60	10 (6.3)	60	8.2 (5.5)		100%	1.81[-0.31,3.93]
Subtotal ***	60		60			100%	1.81[-0.31,3.93]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.67(P=0.09)							
3.9.11 Bushen Huoxue capsules ver	sus Cal	trate and Rocali	rol (12 m	ionths)			
Zhang XJ 2008	30	5.9 (1.1)	30	4.9 (1.2)		100%	0.93[0.35,1.51]
Subtotal ***	30		30		•	100%	0.93[0.35,1.51]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.13(P=0)							
3.9.12 Kanggusong capsule versus	Caltrate	e (6 months)					
Wei RY 2011	48	7.7 (3.2)	32	5.9 (3)	——————————————————————————————————————	100%	1.78[0.4,3.16]
Subtotal ***	48		32		-	100%	1.78[0.4,3.16]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.54(P=0.01)							
3.9.13 Liuwei Dihuang pills versus o							
Zhang J 2003	24	34 (10.2)	18	16.1 (7.9)		100%	17.9[12.43,23.37]
Subtotal ***	24		18			100%	17.9[12.43,23.37]
Heterogeneity: Not applicable							
Test for overall effect: Z=6.41(P<0.000	1)						
3.9.14 Tongbu Qianggutang versus	calcium	n plus vitamin D	3 (3 mon	ths)			
Zhou LZ 2001	30	7.5 (4.2)	10	9 (5.2)		100%	-1.5[-5.07,2.08]
Subtotal ***	30		10			100%	-1.5[-5.07,2.08]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.82(P=0.41)							
			Fa	vours control	-5 -2.5 0 2.5 5	Favours tre	atment

Analysis 3.10. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 10 Interleukin-6 (IL-6).

Study or subgroup	Herl	oal drugs	West	medicine		Mean Di	fference		Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Fixed,	95% CI			Fixed, 95% CI
3.10.1 Bushen Jianpi Huoxue rec months)	ipe versus	alendronate so	dium tab	lets (6						
He MT 2007	71	68.2 (24.6)	70	74 (25.8)			-		100%	-5.72[-14.05,2.61]
Subtotal ***	71		70			•	•		100%	-5.72[-14.05,2.61]
Heterogeneity: Not applicable										
Test for overall effect: Z=1.35(P=0.1	L8)									
3.10.2 Gukang oral liquid versus	alendrona	te (6 months)								
Shao M 2003	30	69.6 (21.9)	30	73.1 (26.9)	1		- ,		100%	-3.5[-15.93,8.93]
			Favoi	urs treatment	-50	-25) 25	50	Favours contro	l

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her	bal drugs	Wes	t medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% Cl		Fixed, 95% CI
Subtotal ***	30		30		-	100%	-3.5[-15.93,8.93
Heterogeneity: Not applicable							
Test for overall effect: Z=0.55(P=0.58)							
3.10.3 Yanghuo Sanzi tang versus C	altrate	(6 months)					
Qiu RB 2004	30	98.2 (29.5)	30	118.5 (31.3)		100%	-20.29[-35.67,-4.91
Subtotal ***	30		30		•	100%	-20.29[-35.67,-4.91
Heterogeneity: Not applicable							
Test for overall effect: Z=2.59(P=0.01)							
3.10.4 Jianshenfang granule versu	s alendr	onate sodium (6 month	5)			
Li BL 2007	30	81.9 (34)	30	94.4 (32)		100%	-12.56[-29.26,4.14
Subtotal ***	30		30			100%	-12.56[-29.26,4.14
Heterogeneity: Not applicable							
Test for overall effect: Z=1.47(P=0.14)							
3.10.5 Jiangu recipe versus alendro	onate so	dium tablets (1	2 month	s)			
Qiu RB 2008	60	98.5 (29.9)	60	118.5 (31.2)		100%	-19.99[-30.92,-9.06
Subtotal ***	60		60		\bullet	100%	-19.99[-30.92,-9.06
Heterogeneity: Not applicable							
Test for overall effect: Z=3.58(P=0)							
3.10.6 Bushen Huoxue capsules ver	rsus Cali	rate and Rocali	irol (12 n	nonths)			
Zhang XJ 2008	30	107.5 (24.5)	30	126.2 (35.6)		100%	-18.7[-34.16,-3.24
Subtotal ***	30		30		\bullet	100%	-18.7[-34.16,-3.24
Heterogeneity: Not applicable							
Test for overall effect: Z=2.37(P=0.02)							
3.10.7 Gusong recipe versus alendr	onate s	odium tablets (!	5 month	5)			
Xiao W 2008	20	69.6 (21.9)	20	73.1 (26.9)		100%	-3.5[-18.72,11.72
Subtotal ***	20		20		-	100%	-3.5[-18.72,11.72
Heterogeneity: Not applicable							
Test for overall effect: Z=0.45(P=0.65)							
Test for subgroup differences: Chi ² =8		(P-0.18) 12-32	270%				

Analysis 3.11. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 11 Parathyroid hormone (PTH).

Study or subgroup	Her	bal drugs	West	medicine		Меа	n Differenc	e	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)		Fix	ced, 95% CI			Fixed, 95% CI
3.11.1 Prescription for tonifying	kidney ve	rsus ipriflavone	(6 mont	hs)						
Wu MS 2007	30	312.4 (59.1)	30	325.4 (54.1)					100%	-13[-41.67,15.67]
Subtotal ***	30		30				•		100%	-13[-41.67,15.67]
Heterogeneity: Not applicable										
Test for overall effect: Z=0.89(P=0.3	37)									
3.11.2 Kidney meridian sticking v	versus ipr	iflavone (6 mont	hs)							
Wu MS 2007	30	312.3 (60.1)	30	325.4 (54.1)					100%	-13.01[-41.95,15.93]
			Favo	urs treatment	-200	-100	0 1	.00 200	Favours contr	ol

Chinese herbal medicines for treating osteoporosis (Review)

Cochrane Library

Trusted evidence. Informed decisions. Better health.

Study or subgroup		bal drugs		medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	N	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
Subtotal ***	30		30		•	100%	-13.01[-41.95,15.9
Heterogeneity: Not applicable							
Test for overall effect: Z=0.88(P=0.38)							
3.11.3 Urinary bladder meridian stie	king v	ersus ipriflavon	e (6 mon	ths)			
Wu MS 2007	30	322.3 (58.2)	30	325.4 (54.1)		100%	-3.01[-31.44,25.42
Subtotal ***	30		30		•	100%	-3.01[-31.44,25.42
Heterogeneity: Not applicable							
Test for overall effect: Z=0.21(P=0.84)							
3.11.4 Kanggusong granule versus i	priflav	one (3 months)					
Wu MS 2001	30	324.2 (45.4)	30	312.4 (58.4)	<u> </u>	100%	11.81[-14.64,38.2
Subtotal ***	30		30		•	100%	11.81[-14.64,38.26
Heterogeneity: Not applicable							
Test for overall effect: Z=0.88(P=0.38)							
3.11.5 Bugu Shengsui capsule versu	s vitan	nin D2 plus calci	um table	t (6 months)			
Xie YM 1997	26	539.2 (221.4)	18	549.9 (213.5)		100%	-10.63[-140.92,119.66
Subtotal ***	26		18	× ,		100%	-10.63[-140.92,119.66
Heterogeneity: Not applicable							
Test for overall effect: Z=0.16(P=0.87)							
3.11.6 TPF capsule versus calcium g	ranule	(6 months)					
Zhang YL 1996	60	569 (372)	60	823 (436.2)		100%	-254[-399.06,-108.94
Subtotal ***	60		60			100%	-254[-399.06,-108.94
Heterogeneity: Not applicable							
Test for overall effect: Z=3.43(P=0)							
3.11.7 Gujian capsule versus alfacal	cidol (e	5 months)					
Meng XD 2003	26	129.1 (48.7)	22	151.7 (80.1)		100%	-22.57[-60.92,15.78
Subtotal ***	26		22		-	100%	-22.57[-60.92,15.78
Heterogeneity: Not applicable							
Test for overall effect: Z=1.15(P=0.25)							
3.11.8 Gushukang granule versus ip	riflavo	ne (6 months)					
Wu MS 2007	30	322.3 (56.1)	30	325.4 (54.1)		100%	-3.02[-30.91,24.8]
Subtotal ***	30		30		₹	100%	-3.02[-30.91,24.87
Heterogeneity: Not applicable							
Test for overall effect: Z=0.21(P=0.83)							
3.11.9 Radix rehmanniae preparata	and Ra	ıdix astragali ve	rsus calo	ium carbon-			
ate tablets (6 months) Ou L 2011	32	22.1 (9.4)	32	24.2 (9.7)	4	100%	-2.06[-6.74,2.6
Subtotal ***	32 32	22.1 (3.4)	32 32	27.2 (3.1)		100% 100%	-2.06[-6.74,2.6
Heterogeneity: Not applicable	32		32			10070	-2.00[-0.17,2.0
Test for overall effect: Z=0.86(P=0.39)							
Test for subgroup differences: Chi ² =14	70 46	-1 (D=0.0C) 12-45	00/				



Analysis 3.12. Comparison 3 Chinese herbal medicines versus western medicine, Outcome 12 Computed tomography (CT).

Study or subgroup	Heri	oal drugs	West	medicine	Mean Difference	Weight	Mean Difference
Study of Subgroup	N	Mean(SD)	N	Mean(SD)	Random, 95% CI	Weight	Random, 95% Cl
3.12.1 Prescription for tonifying							
Wu MS 2007	30	74.2 (9.2)	30	73.3 (9.2)	+	100%	0.96[-3.71,5.63]
Subtotal ***	30		30		•	100%	0.96[-3.71,5.63]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.4(P=0.69))						
·							
3.12.2 Kidney meridian sticking v	versus ipri	flavone (6 mont	:hs)				
Wu MS 2007	30	72.3 (8.2)	30	73.3 (9.2)	+	100%	-1.01[-5.44,3.42]
Subtotal ***	30		30		•	100%	-1.01[-5.44,3.42]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.45(P=0.6	55)						
3.12.3 Urinary bladder meridian	sticking ve	ersus ipriflavon	e (6 mon	ths)			
Wu MS 2007	30	73.3 (9.2)	30	73.3 (9.2)	+	100%	-0.01[-4.68,4.66]
Subtotal ***	30		30		→	100%	-0.01[-4.68,4.66]
Heterogeneity: Not applicable							
Test for overall effect: Z=0(P=1)							
3.12.4 Bugu Shengsui capsule vei	rsus vitam	in D2 plus calci	um table	t (6 months)			
Xie YM 1997	26	48.4 (60.5)	18	32.5 (70.7)		100%	15.93[-24.16,56.02]
Subtotal ***	26		18			100%	15.93[-24.16,56.02]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.78(P=0.4	4)						
3.12.5 Strong Bone capsule versu							
Cui TH 1999	74	26.8 (25.2)	31	10.5 (2.9)		100%	16.25[10.43,22.07]
Subtotal ***	74		31		•	100%	16.25[10.43,22.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=5.47(P<0.0	001)						
3.12.6 Jingujian granule versus C	altrate (3	months)					
Li YH 2010	140	63.2 (23.8)	70	41.2 (13)	+	100%	21.98[17.01,26.95]
Subtotal ***	140		70		•	100%	21.98[17.01,26.95]
Heterogeneity: Not applicable							
Test for overall effect: Z=8.66(P<0.0	0001)						
3.12.7 TPF capsule versus Calciur	n granule	(6 months)					
Zhang YL 1996	60	48.6 (18.3)	60	30.9 (16.2)		100%	17.71[11.53,23.89]
Subtotal ***	60		60		•	100%	17.71[11.53,23.89]
Heterogeneity: Not applicable							,
Test for overall effect: Z=5.61(P<0.0	0001)						
3.12.8 Tongbu Qianggutang vers						4000/	c 10 ¹ co co c
Zhou LZ 2001	30	11.2 (8.1)	10	17.4 (9.7)		100%	-6.18[-12.89,0.52]
Subtotal ***	30		10			100%	-6.18[-12.89,0.52]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.81(P=0.0	11)						
3.12.9 Gujian capsule versus alfa	calcidol (6	months)					
-			Favoi	urs treatment -1	00 -50 0 50	100 Favours cor	ntrol

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% CI
Meng XD 2003	31	142.7 (103)	26	155.5 (118.3)		100%	-12.77[-70.92,45.38]
Subtotal ***	31		26			100%	-12.77[-70.92,45.38]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.43(P=0.6	7)						
3.12.10 Gushukang granule versu	ıs ipriflavo	one (6 months)					
Wu MS 2007	30	73.3 (8.3)	30	73.3 (9.2)	+	100%	-0.01[-4.44,4.42]
Subtotal ***	30		30		•	100%	-0.01[-4.44,4.42]
Heterogeneity: Not applicable							
Test for overall effect: Z=0(P=1)							
3.12.11 Radix rehmanniae prepar bonate tablets (6 months)	rata and R	adix astragali v	ersus cal	cium car-			
Ou L 2011	32	1.9 (0.4)	32	1.8 (0.2)		100%	0.11[-0.04,0.26]
Subtotal ***	32		32			100%	0.11[-0.04,0.26]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.49(P=0.1	4)						
Test for subgroup differences: Chi ² =	=139.23, di	f=1 (P<0.0001), I ²	=92.82%				
			Favoi	Irs treatment -1	.00 -50 0 50	100 Favours cor	ntrol

Comparison 4. Chinese herbal medicines plus western medicine versus western medicine

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
1 New fractures	5		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
1.1 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Risk Ratio (M-H, Fixed, 95% CI)	0.06 [0.00, 1.00]
1.2 Xianlinggubao capsule (low-dose) plus cal- cium and vitamin D versus placebo plus calci- um and vitamin D (12 months)	1	120	Risk Ratio (M-H, Fixed, 95% Cl)	0.33 [0.01, 8.02]
1.3 Xianlinggubao capsule (high-dose) plus cal- cium and vitamin D versus placebo plus calci- um and vitamin D (12 months)	1	116	Risk Ratio (M-H, Fixed, 95% CI)	0.36 [0.01, 8.58]
1.4 Bushen Zhuanggu granules plus calcium and vitamin D versus placebo granules plus calcium and vitamin D (5 years)	1	155	Risk Ratio (M-H, Fixed, 95% CI)	0.44 [0.13, 1.43]
1.5 Kanggusong soup plus Caltrate versus Cal- trate (3 months)	1	75	Risk Ratio (M-H, Fixed, 95% Cl)	0.22 [0.01, 5.34]
1.6 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Risk Ratio (M-H, Fixed, 95% CI)	0.0 [0.0, 0.0]
2 Bone mineral density (BMD)	43		Mean Difference (IV, Random, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.1 Gushen decoction plus Caltrate and Alfacal- cidol versus Caltrate and Alfacalcidol (BMD of lumbar spine, 6 months)	1	64	Mean Difference (IV, Random, 95% CI)	0.06 [0.01, 0.11]
2.2 Jiarong tablet plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	0.04 [-0.05, 0.14]
2.3 Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus cal- citonin (BMD of lumbar spine, 8 months)	1	45	Mean Difference (IV, Random, 95% CI)	0.14 [0.08, 0.20]
2.4 Zhuanggu capsule plus Caltrate versus Cal- trate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [0.00, 0.02]
2.5 Antai capsule plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.04 [-0.00, 0.08]
2.6 Bushen Zhuanggutang plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.14 [0.06, 0.22]
2.7 Zishen prescription plus Caltrate and cal- citonin versus Caltrate plus calcitonin (BMD of lumbar spine, 8 months)	1	45	Mean Difference (IV, Random, 95% CI)	0.14 [0.08, 0.20]
2.8 Guilu Erxiantang plus calcium carbonate tablet versus calcium carbonate tablet (BMD of lumbar spine, 6 months)	1	85	Mean Difference (IV, Random, 95% CI)	0.03 [-0.03, 0.09]
2.9 Guben Zhuanggu capsules plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.03 [0.01, 0.05]
2.10 Migu tablet plus Caltrate versus Caltrate (BMD of Lumbar spine, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.08 [0.07, 0.09]
2.11 Shugan zishen huoxue tang plus Caltrate and alendronate sodium versus Caltrate plus alendronate sodium (BMD of lumbar spine, 6 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.12 [0.08, 0.16]
2.12 Bushen Yangxue tang plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.13 Bushen Kangsong pill plus calcium car- bonate tablets versus calcium carbonate tablets (BMD of lumbar spine, 6 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.04]
2.14 Gusongbao granule plus compound cal- cium amino acid chelate capsule versus place- bo granule plus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.07, 0.05]
2.15 Qianggu capsule plus alendronate versus alendronate (BMD of lumbar spine, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.08 [0.03, 0.12]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.16 Xianlinggubao capsule plus Caltrate ver- sus Caltrate (BMD of lumbar spine, 12 months)	1	68	Mean Difference (IV, Random, 95% CI)	0.30 [0.25, 0.35]
2.17 Xianlinggubao capsule plus salmon cal- citonin and Caltrate versus salmon calcitonin plus Caltrate (BMD of lumbar spine, 3 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.03 [-0.03, 0.09]
2.18 Xianlinggubao capsule plus alendronate versus alendronate (BMD of lumbar spine, 6 months)	1	104	Mean Difference (IV, Random, 95% CI)	0.06 [0.03, 0.09]
2.19 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vita- min D3 and calcium amino acid chelate (BMD of lumbar spine, 48 weeks)	1	112	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.06]
2.20 Xianlinggubao capsule plus Caltrate ver- sus Caltrate (BMD of lumbar spine, 12 months)	1	136	Mean Difference (IV, Random, 95% CI)	0.31 [0.28, 0.34]
2.21 Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.18 [0.14, 0.22]
2.22 Jiangu granule plus compound calci- um amino acid chelate capsule versus place- bo granule plus compound calcium amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	0.04 [-0.02, 0.10]
2.23 Jinwugutong capsules plus calcium versus placebo plus calcium (BMD of lumbar spine, 6 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.11 [0.07, 0.15]
2.24 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of lumbar spine, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.25 Chinese medicine Bushenhuoxue recipe plus conventional western medicine versus conventional western medicine (BMD of lum- bar spine, 3 months)	1	57	Mean Difference (IV, Random, 95% CI)	0.16 [0.09, 0.22]
2.26 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of lumbar spine, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.27 Shengsuiyin recipe plus Caltrate versus Caltrate (BMD of Lumbar spine, 12 months)	1	144	Mean Difference (IV, Random, 95% CI)	0.31 [0.28, 0.34]
2.28 Yigu capsule plus calcium versus placebo plus calcium (BMD of lumbar spine, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.08 [0.04, 0.12]
2.29 Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus ta-	1	120	Mean Difference (IV, Random, 95% CI)	0.10 [0.06, 0.14]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
moxifen and Caltrate (BMD of lumbar spine, 3 months)				
2.30 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (BMD of lumbar spine, 12 months)	1	90	Mean Difference (IV, Random, 95% CI)	0.01 [-0.04, 0.06]
2.31 Migu tablet plus compound calcium amino acid chelate capsule versus compound calci- um amino acid chelate capsule (BMD of lumbar spine, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.17 [0.14, 0.20]
2.32 Huangqi plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	36	Mean Difference (IV, Random, 95% CI)	0.06 [0.01, 0.11]
2.33 Jiarong tablet plus Caltrate versus Cal- trate (BMD of femoral neck, 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	0.09 [0.02, 0.15]
2.34 Antai capsule plus Caltrate versus Caltrate (BMD of femoral neck, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.35 Xianlinggubao capsule plus Caltrate ver- sus Caltrate (BMD of femoral neck, 12 months)	1	68	Mean Difference (IV, Random, 95% CI)	0.3 [0.25, 0.35]
2.36 Guben Zhuanggu capsules plus Cal- trate versus Caltrate (BMD of femoral neck, 6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.02]
2.37 Migu tablet plus Caltrate versus Caltrate (BMD of femoral neck, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.09 [0.08, 0.10]
2.38 Qianggu capsules plus oestradiol valer- ate versus oestradiol valerate (BMD of femoral neck, 6 months)	1	88	Mean Difference (IV, Random, 95% CI)	0.03 [-0.01, 0.07]
2.39 Chinese medicine Bushenhuoxue recipe plus conventional western medicine ver- sus conventional western medicine (BMD of femoral neck, 3 months)	1	57	Mean Difference (IV, Random, 95% CI)	0.17 [0.12, 0.23]
2.40 Heche Dazao pill plus oyster shell calci- um chewable tablets versus oyster shell calci- um chewable tablets (BMD of femoral neck, 3 months)	1	114	Mean Difference (IV, Random, 95% CI)	0.04 [0.00, 0.07]
2.41 Xianlinggubao capsule plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of femoral neck, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.26 [0.22, 0.30]
2.42 Huangqi plus Caltrate versus Caltrate (BMD of femoral neck, 6 months)	1	36	Mean Difference (IV, Random, 95% CI)	0.07 [0.03, 0.11]
2.43 Gusongbao granule plus compound cal- cium amino acid chelate capsule versus place- bo granule plus compound calcium amino	1	96	Mean Difference (IV, Random, 95% CI)	0.01 [-0.03, 0.05]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
acid chelate capsule (BMD of femoral neck, 6 months)				
2.44 Jiangu granule plus compound calci- um amino acid chelate capsule versus place- bo granule plus compound calcium amino acid chelate capsule (BMD of femoral neck, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.07, 0.03]
2.45 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of femoral neck, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
2.46 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of femoral neck, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.47 Yigu capsule plus calcium versus placebo plus calcium (BMD of femoral neck, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.04 [0.01, 0.07]
2.48 Migu tablet plus compound calcium amino acid chelate capsule versus compound calcium amino acid chelate capsule (BMD of femoral neck, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.24 [0.21, 0.27]
2.49 Antai capsule plus Caltrate versus Caltrate (BMD of Ward's, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.50 Migu tablet plus Caltrate versus Caltrate (BMD of Ward's, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.09 [0.08, 0.10]
2.51 Qianggu capsule plus alendronate versus alendronate (BMD of Ward's, 6 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.07]
2.52 Xianlinggubao capsule plus alendronate versus alendronate (BMD of Ward's, 6 months)	1	104	Mean Difference (IV, Random, 95% CI)	0.04 [0.02, 0.06]
2.53 Gusongbao granule plus compound cal- cium amino acid chelate capsule versus place- bo granule plus compound calcium amino acid chelate capsule (BMD of Ward's, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.06, 0.04]
2.54 Xianlinggubao capsule plus compound calcium amino acid chelate capsules versus compound calcium amino acid chelate cap- sules (BMD of Ward's, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.23 [0.19, 0.27]
2.55 Migu tablet plus compound calcium amino acid chelate capsules versus compound cal- cium amino acid chelate capsules (BMD of Ward's, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.28 [0.24, 0.32]
2.56 Jiangu granule plus compound calcium amino acid chelate capsule versus placebo granule plus compound calcium amino acid chelate capsule (BMD of Ward's, 6 months)	1	96	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.06, 0.04]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.57 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of Ward's, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.04]
2.58 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of Ward's, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.59 Yigu capsule plus calcium versus placebo plus calcium (BMD of Ward's, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.04 [0.00, 0.08]
2.60 Antai capsule plus Caltrate versus Caltrate (BMD of trochanter, 6 months)	1	128	Mean Difference (IV, Random, 95% CI)	0.03 [0.00, 0.06]
2.61 Migu tablet plus Caltrate versus Caltrate (BMD of trochanter, 12 months)	1	44	Mean Difference (IV, Random, 95% CI)	0.15 [0.14, 0.16]
2.62 Xuduanzhuanggu capsule plus calcium tablet versus placebo plus calcium tablet (BMD of trochanter, 6 months)	1	480	Mean Difference (IV, Random, 95% CI)	0.0 [-0.02, 0.02]
2.63 Migu tablet plus compound calcium amino acid chelate capsules versus compound cal- cium amino acid chelate capsules (BMD of trochanter, 6 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.12 [0.07, 0.17]
2.64 Xianlinggubao capsule plus compound calcium amino acid chelate capsules versus compound calcium amino acid chelate cap- sules (BMD of trochanter, 6 months)	1	106	Mean Difference (IV, Random, 95% CI)	0.13 [0.08, 0.18]
2.65 Gusongbao granule plus calcium tablet versus placebo plus calcium tablet (BMD of trochanter, 6 months)	1	240	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.66 Yigu capsule plus calcium versus placebo plus calcium (BMD of trochanter, 6 months)	1	140	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.06]
2.67 Gushukang granule plus Calcium carbon- ate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets (BMD of hip bone, 6 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.15 [0.11, 0.19]
2.68 Jinwugutong capsules plus calcium ver- sus placebo plus calcium (BMD of hip bone, 6 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.01 [-0.02, 0.04]
2.69 Gengnian Anyi tablet plus Caltrate versus Caltrate (BMD of distal radius, 6 months)	1	42	Mean Difference (IV, Random, 95% CI)	0.01 [-0.06, 0.08]
2.70 Shangke Yishen Zhuanggu pill plus Cal- trate and calcitonin versus Caltrate and calci- tonin (BMD of lumbar spine, 3 months)	1	300	Mean Difference (IV, Random, 95% CI)	0.04 [0.03, 0.05]
2.71 Bushenhuoxue therapy plus calcium car- bonate tablets and alfacalcidol versus calci-	1	80	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.04, 0.02]

Chinese herbal medicines for treating osteoporosis (Review)



Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
um carbonate tablets and alfacalcidol (BMD of lumbar spine, 3 months)				
2.72 Gukang tablet plus oyster shell calcium chewable tablets and vitamin A and D capsules versus oyster shell calcium chewable tablets and vitamin A and D capsules (BMD of lumbar spine, for 3 months)	1	80	Mean Difference (IV, Random, 95% CI)	0.24 [0.14, 0.34]
2.73 Liuwei Dihuang pills plus Caltrate versus Caltrate (BMD of lumbar spine, 6 months)	1	72	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.08]
2.74 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (BMD of lumbar spine,3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.02 [-0.01, 0.05]
2.75 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (BMD of femoral neck, 3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.01 [-0.01, 0.03]
2.76 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calci- tonin and calcium carbonate tablet (BMD of trochanter, 3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.02 [0.01, 0.04]
2.77 Yishen Zhuanggu decoction plus calcitriol soft capsule versus calcitriol soft capsule (BMD of lumbar spine, 3 months)	1	100	Mean Difference (IV, Random, 95% CI)	0.02 [-0.00, 0.05]
2.78 Hugu capsule plus Caltrate versus placebo capsule plus Caltrate (BMD of lumbar spine, 6 months)	1	122	Mean Difference (IV, Random, 95% CI)	0.03 [-0.00, 0.06]
2.79 Hugu capsule plus Caltrate versus place- bo capsule plus Caltrate (BMD of Ward's, 6 months)	1	122	Mean Difference (IV, Random, 95% CI)	0.05 [0.02, 0.08]
2.80 Bushen Qianggu Huoxue therapy plus cal- cium and cod liver oil versus calcium and cod liver oil (BMD of lumbar spine, 3 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.05 [-0.01, 0.11]
2.81 Bushen Qianggu Huoxue therapy plus cal- cium and cod liver oil versus calcium and cod liver oil (BMD of femoral neck, 3 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.02 [-0.02, 0.05]
2.82 Bushen Qianggu Huoxue therapy plus cal- cium and cod liver oil versus calcium and cod liver oil (BMD of Ward's, 3 months)	1	84	Mean Difference (IV, Random, 95% CI)	0.04 [0.02, 0.07]
2.83 Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus cal- cium and vitamin D (BMD of lumbar spine, 12 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.0 [-0.04, 0.04]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
2.84 Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus cal- cium and vitamin D (BMD of lumbar spine, 12 months)	1	116	Mean Difference (IV, Random, 95% CI)	0.0 [-0.03, 0.03]
2.85 Xianlinggubao capsule (low-dose) plus calcium and vitamin D versus placebo plus cal- cium and vitamin D (BMD of femoral neck, 12 months)	1	120	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.86 Xianlinggubao capsule (high-dose) plus calcium and vitamin D versus placebo plus cal- cium and vitamin D (BMD of femoral neck, 12 months)	1	116	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.05, 0.03]
2.87 Bushen Zhuanggu granules plus calcium and vitamin D versus placebo granules plus calcium and vitamin D (BMD of distal radius, 5 years)	1	155	Mean Difference (IV, Random, 95% CI)	0.10 [0.09, 0.10]
3 T score in BMD measurement	1	67	Mean Difference (IV, Fixed, 95% CI)	0.91 [0.57, 1.25]
3.1 Erxian Yanggu decoction plus alendronate sodium tablets versus alendronate sodium tablets (T score, 6 months)	1	67	Mean Difference (IV, Fixed, 95% CI)	0.91 [0.57, 1.25]
4 Quality of life	1	80	Mean Difference (IV, Fixed, 95% CI)	5.30 [3.67, 6.93]
4.1 Bushenhuoxue therapy plus calcium car- bonate tablets and alfacalcidol versus calcium carbonate tablets and alfacalcidol (3 months)	1	80	Mean Difference (IV, Fixed, 95% CI)	5.30 [3.67, 6.93]
5 Symptoms including pain, muscle fatigue and limited mobility	4		Risk Ratio (M-H, Fixed, 95% CI)	Subtotals only
5.1 Heche Dazao pill plus oyster shell calcium chewable tablets versus oyster shell calcium chewable tablets (3 months)	1	114	Risk Ratio (M-H, Fixed, 95% CI)	1.15 [1.01, 1.30]
5.2 Xianlinggubao capsule plus salmon calci- tonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Risk Ratio (M-H, Fixed, 95% CI)	1.33 [1.09, 1.61]
5.3 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	82	Risk Ratio (M-H, Fixed, 95% CI)	1.01 [0.91, 1.12]
5.4 Kanggusong soup plus Caltrate versus Cal- trate (3 months)	1	75	Risk Ratio (M-H, Fixed, 95% Cl)	1.48 [1.09, 2.02]
6 Oestradiol (E2)	9		Mean Difference (IV, Random, 95% CI)	Subtotals only

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
6.1 Gushen decoction plus Caltrate and Al- facalcidol versus Caltrate and Alfacalcidol (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	4.54 [0.47, 8.61]
6.2 Ziyin Bushen Zhuanggu prescription plus Caltrate and Calcitonin versus Caltrate plus Calcitonin (8 months)	1	45	Mean Difference (IV, Random, 95% CI)	23.21 [14.46, 31.96]
6.3 Zhuanggu capsule plus Caltrate versus Cal- trate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	4.06 [2.56, 5.56]
6.4 Bushen Qiangshen pill plus Caltrate versus Caltrate (3 months)	1	40	Mean Difference (IV, Random, 95% CI)	7.60 [-0.51, 15.71]
6.5 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Random, 95% CI)	11.0 [8.14, 13.86]
6.6 Zishen prescription plus Caltrate and calci- tonin versus Caltrate plus calcitonin (8 months)	1	45	Mean Difference (IV, Random, 95% CI)	23.21 [14.46, 31.96]
6.7 Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Cal- trate plus alendronate sodium tablets (6 months)	1	42	Mean Difference (IV, Random, 95% CI)	26.99 [18.44, 35.54]
6.8 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Random, 95% CI)	6.04 [4.61, 7.47]
6.9 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Random, 95% CI)	40.85 [33.61, 48.09]
7 Serum calcium (Ca)	12		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Gushen decoction plus Caltrate and Al- facalcidol versus Caltrate and Alfacalcidol (6 months)	1	64	Mean Difference (IV, Random, 95% CI)	0.05 [-0.02, 0.12]
7.2 Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calci- um carbonate with vitamin D chewable tablets (6 months)	1	42	Mean Difference (IV, Random, 95% CI)	-0.01 [-0.09, 0.07]
7.3 Zhuanggu capsule plus Caltrate versus Cal- trate (6 months)	1	60	Mean Difference (IV, Random, 95% CI)	0.01 [-0.07, 0.09]
7.4 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Random, 95% CI)	-0.03 [-0.09, 0.03]
7.5 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Random, 95% CI)	-0.05 [-0.11, 0.01]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
7.6 Xianlinggubao capsule plus salmon calci- tonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Random, 95% CI)	0.03 [-0.09, 0.15]
7.7 Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.37 [0.32, 0.42]
7.8 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Random, 95% CI)	-0.07 [-0.13, -0.01]
7.9 Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus ta- moxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	0.37 [0.32, 0.42]
7.10 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.10, 0.06]
7.11 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Random, 95% CI)	0.28 [0.11, 0.45]
7.12 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (3 months)	1	120	Mean Difference (IV, Random, 95% CI)	-0.02 [-0.06, 0.02]
8 Phosphorus (P)	10		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
8.1 Gushen decoction plus Caltrate and Al- facalcidol versus Caltrate and Alfacalcidol (6 months)	1	64	Mean Difference (IV, Fixed, 95% CI)	-0.13 [-0.27, 0.01]
8.2 Gushukang granule plus Calcium carbonate with vitamin D chewable tabletsl versus Calci- um carbonate with vitamin D chewable tablets (6 months)	1	42	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.11, 0.07]
8.3 Zhuanggu capsule plus Caltrate versus Cal- trate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.06, 0.08]
8.4 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Fixed, 95% CI)	-0.01 [-0.23, 0.21]
8.5 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.09, 0.05]
8.6 Xianlinggubao capsule plus salmon calci- tonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Fixed, 95% CI)	0.01 [-0.12, 0.14]
8.7 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	-0.03 [-0.08, 0.02]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
8.8 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Mean Difference (IV, Fixed, 95% CI)	-0.02 [-0.08, 0.04]
8.9 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Fixed, 95% CI)	0.31 [0.14, 0.48]
8.10 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	0.06 [-0.22, 0.34]
9 Alkaline phosphatase (ALP)	15		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
9.1 Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calci- um carbonate with vitamin D chewable tablets (6 months)	1	39	Mean Difference (IV, Fixed, 95% CI)	-0.5 [-1.70, 0.70]
9.2 Zhuanggu capsule plus Caltrate versus Cal- trate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	0.0 [-1.55, 1.55]
9.3 Bushen Qiangshen pill plus Caltrate versus Caltrate (3 months)	1	40	Mean Difference (IV, Fixed, 95% CI)	-0.31 [-1.72, 1.10]
9.4 Xianlinggubao capsule plus salmon calci- tonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Fixed, 95% CI)	-0.99 [-1.52, -0.46]
9.5 Antai capsule plus Caltrate versus Caltrate (6 months)	1	128	Mean Difference (IV, Fixed, 95% CI)	1.28 [0.55, 2.01]
9.6 Traditional Chinese capsule plus calcium gluconate versus calcium gluconate (9 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	1.77 [1.20, 2.34]
9.7 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	1.01 [-0.04, 2.06]
9.8 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	1.73 [0.71, 2.75]
9.9 Chinese medicine (combination of 10 herbs) plus tamoxifen and Caltrate versus ta- moxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	-0.26 [-1.64, 1.12]
9.10 Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin versus calcitonin (12 months)	1	90	Mean Difference (IV, Fixed, 95% CI)	0.08 [-0.54, 0.70]
9.11 Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	3.54 [1.68, 5.40]
9.12 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Fixed, 95% CI)	0.82 [0.63, 1.01]

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici- pants	Statistical method	Effect size
9.13 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Fixed, 95% CI)	10.48 [9.81, 11.15]
9.14 Kanggusong soup plus Caltrate versus Cal- trate (3 months)	1	75	Mean Difference (IV, Fixed, 95% CI)	-1.61 [-3.17, -0.05]
9.15 Yiyuanjiangu decoction plus calcitonin and calcium carbonate tablet versus calcitonin and calcium carbonate tablet (3 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	0.31 [-0.48, 1.10]
10 Bone Gla protein (BGP)	8		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
10.1 Zhuanggu capsule plus Caltrate versus Caltrate (6 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	-2.3 [-4.07, -0.53]
10.2 Traditional Chinese capsule plus calcium gluconate versus calcium gluconate (9 months)	1	60	Mean Difference (IV, Fixed, 95% CI)	1.23 [0.88, 1.58]
10.3 Xianlinggubao capsule plus salmon cal- citonin and Caltrate versus salmon calcitonin plus Caltrate (3 months)	1	107	Mean Difference (IV, Fixed, 95% CI)	0.56 [-0.30, 1.42]
10.4 Yigu capsule plus calcium versus placebo plus calcium (6 months)	1	140	Mean Difference (IV, Fixed, 95% CI)	2.60 [1.66, 3.54]
10.5 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Fixed, 95% CI)	6.24 [5.69, 6.79]
10.6 Xianlinggubao capsule plus Caltrate ver- sus Caltrate (12 months)	1	68	Mean Difference (IV, Fixed, 95% CI)	1.85 [0.87, 2.83]
10.7 Jinwugutong capsules plus calcium versus placebo plus calcium (6 months)	1	120	Mean Difference (IV, Fixed, 95% CI)	2.47 [1.44, 3.50]
10.8 Huangqi plus Caltrate versus Caltrate (6 months)	1	36	Mean Difference (IV, Fixed, 95% CI)	0.63 [0.50, 0.76]
11 Interleukin-6 (IL-6)	3		Mean Difference (IV, Fixed, 95% CI)	Subtotals only
11.1 Erxian Yanggu decoction plus alendronate sodium tablets versus alendronate sodium tablets (6 months)	1	67	Mean Difference (IV, Fixed, 95% CI)	-16.18 [-19.62, -12.74]
11.2 Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate (48 weeks)	1	112	Mean Difference (IV, Fixed, 95% CI)	-133.3 [-139.94, -126.66]
11.3 Kanggusong soup plus Caltrate versus Cal- trate (3 months)	1	75	Mean Difference (IV, Fixed, 95% CI)	-16.32 [-31.60, -1.04]

Chinese herbal medicines for treating osteoporosis (Review)

Analysis 4.1. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 1 New fractures.

Study or subgroup	Herbal drugs	West medicine	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% CI		M-H, Fixed, 95% Cl
4.1.1 Yigu capsule plus calcium ve months)	ersus placebo plus c	alcium (6			
Zhang RH 2004	0/70	8/70 -		100%	0.06[0,1]
Subtotal (95% CI)	70	70 -		100%	0.06[0,1]
Total events: 0 (Herbal drugs), 8 (We	est medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=1.96(P=0.0	5)				
4.1.2 Xianlinggubao capsule (low- versus placebo plus calcium and v					
Zhu HM 2012	0/60	1/60		100%	0.33[0.01,8.02]
Subtotal (95% CI)	60	60		100%	0.33[0.01,8.02]
Total events: 0 (Herbal drugs), 1 (We	est medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.68(P=0.5))				
4.1.3 Xianlinggubao capsule (high versus placebo plus calcium and v					
Zhu HM 2012	0/56	1/60	_	100%	0.36[0.01,8.58]
Subtotal (95% CI)	56	60		100%	0.36[0.01,8.58]
Total events: 0 (Herbal drugs), 1 (We	est medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.64(P=0.53	3)				
4.1.4 Bushen Zhuanggu granules placebo granules plus calcium and					
Deng WM 2012	4/88	7/67	- <mark></mark> +	100%	0.44[0.13,1.43]
Subtotal (95% CI)	88	67		100%	0.44[0.13,1.43]
Total events: 4 (Herbal drugs), 7 (We	est medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=1.37(P=0.1	7)				
4.1.5 Kanggusong soup plus Caltr	ate versus Caltrate	(3 months)			
Li ZP 2011	0/45	1/30		100%	0.22[0.01,5.34]
Subtotal (95% CI)	45	30		100%	0.22[0.01,5.34]
Total events: 0 (Herbal drugs), 1 (We	est medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.92(P=0.36	6)				
4.1.6 Zhuangguqiangjin tablet and versus calcitonin (12 months)	d Shujinbogu tablet	plus calcitonin			
Zhang ZF 2011	0/48	0/42			Not estimable
Subtotal (95% CI)	48	42			Not estimable
Total events: 0 (Herbal drugs), 0 (We	est medicine)				
Heterogeneity: Not applicable					
Test for overall effect: Not applicabl	le				
Test for subgroup differences: Chi ² =	=1.68, df=1 (P=0.79), I	² =0%			
		Favours treatment 0.001	0.1 1 10 10	⁰⁰⁰ Favours control	

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



Analysis 4.2. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 2 Bone mineral density (BMD).

Study or subgroup	Herbalı	olus drugs	р	rugs	Mean Difference	Weight	Mean Difference
study of subgroup	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl	neight	Random, 95% CI
4.2.1 Gushen decoction plus Cal calcidol (BMD of lumbar spine, 6							
Chen FS 2001	32	0.6 (0.1)	32	0.5 (0.1)		100%	0.06[0.01,0.11]
Subtotal ***	32		32		•	100%	0.06[0.01,0.11]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.17(P=0	0.03)						
4.2.2 Jiarong tablet plus Caltrat months)	te versus Cali	trate (BMD of l	umbar sp	ine, 6			
Chen YQ 2001	20	1 (0.2)	21	0.9 (0.1)		100%	0.04[-0.05,0.14]
Subtotal ***	20		21		-	100%	0.04[-0.05,0.14]
Heterogeneity: Tau ² =0; Chi ² =0, df	f=0(P<0.0001);	l ² =100%					
Test for overall effect: Z=0.89(P=0).37)						
4.2.3 Ziyin Bushen Zhuanggu pr Caltrate plus calcitonin (BMD of			d calciton	in versus			
Li HW 2004	25	1 (0.1)	20	0.9 (0.1)		100%	0.14[0.08,0.2]
Subtotal ***	25		20		•	100%	0.14[0.08,0.2]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.88(P<0	0.0001)						
4.2.4 Zhuanggu capsule plus Ca months)	ltrate versus	Caltrate (BMD	of lumba	r spine, 6			
Li SL 2004	30	0.7 (0)	30	0.7 (0)	+	100%	0.01[0,0.02]
Subtotal ***	30		30		•	100%	0.01[0,0.02]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.45(P=0).01)						
4.2.5 Antai capsule plus Caltrate months)	e versus Calt	rate (BMD of lu	ımbar spi	ne, 6			
Wang SW 2003	65	1 (0.1)	63	0.9 (0.1)		100%	0.04[-0,0.08]
Subtotal ***	65		63		•	100%	0.04[-0,0.08]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.88(P=0	0.06)						
4.2.6 Bushen Zhuanggutang plu spine, 6 months)	us Caltrate ve	rsus Caltrate (BMD of lu	mbar			
Ye AN 1998	31	1.1 (0.1)	29	1 (0.2)		100%	0.14[0.06,0.22]
Subtotal ***	31		29			100%	0.14[0.06,0.22]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.31(P=0))						
4.2.7 Zishen prescription plus C tonin (BMD of lumbar spine, 8 m		alcitonin vers	us Caltrat	e plus calci-			
Zhao G 2002	25	1 (0.1)	20	0.9 (0.1)		100%	0.14[0.08,0.2]
Subtotal ***	25		20			100%	0.14[0.08,0.2]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.88(P<0	0.0001)						
4.2.8 Guilu Erxiantang plus calc		te tablet versu	ıs calcium	carbonate			
tablet (BMD of lumbar chine & r							
tablet (BMD of lumbar spine, 6 r Zhou XT 2001	45	0.8 (0.1)	40	0.8 (0.2)		100%	0.03[-0.03,0.09]

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba N	l plus drugs Mean(SD)	N	Drugs Mean(SD)		Difference m, 95% Cl	Weight	Mean Difference Random, 95% Cl
Subtotal ***	45		40			•	100%	0.03[-0.03,0.09
Heterogeneity: Not applicable								- ,
Test for overall effect: Z=1.13(P=0.26)							
4.2.9 Guben Zhuanggu capsules pl	us Caltra	ate versus Caltra	ate (BMD	oflumbar				
spine, 6 months)								
Zou JJ 2005	30	0.7 (0)	30	0.6 (0)		+	100%	0.03[0.01,0.0
Subtotal ***	30		30			•	100%	0.03[0.01,0.0
Heterogeneity: Not applicable								
Test for overall effect: Z=3.87(P=0)								
4.2.10 Migu tablet plus Caltrate ve months)	rsus Cal	trate (BMD of Lu	ımbar sp	ine, 12				
Xie J 2004	24	0.9 (0)	20	0.8 (0)		+	100%	0.08[0.07,0.0
Subtotal ***	24		20			•	100%	0.08[0.07,0.0
Heterogeneity: Not applicable								- ,
Test for overall effect: Z=17.19(P<0.0	001)							
4.2.11 Shugan zishen huoxue tang sus Caltrate plus alendronate sodi								
Han XL 2007	25	1 (0.1)	17	0.8 (0)			100%	0.12[0.08,0.1
Subtotal ***	25		17			•	100%	0.12[0.08,0.1
Heterogeneity: Not applicable								
Test for overall effect: Z=6.61(P<0.00	01)							
4.2.12 Bushen Yangxue tang plus C spine, 6 months) He XQ 2006	Caltrate	versus Caltrate	(BMD of I	umbar 0.9 (0.1)		-	100%	0.02[-0.02,0.0
Subtotal ***	32		28			•	100%	0.02[-0.02,0.0
Heterogeneity: Not applicable						•		
Test for overall effect: Z=1.1(P=0.27)								
4.2.13 Bushen Kangsong pill plus c	alcium	carbonate table	ts versus	calcium car-				
bonate tablets (BMD of lumbar spi	ne, 6 mo	onths)						
Guo JH 2008	42	0.9 (0.1)	42	0.9 (0.1)			100%	0.01[-0.03,0.0
Subtotal ***	42		42			♦	100%	0.01[-0.03,0.0
Heterogeneity: Not applicable								
Test for overall effect: Z=0.44(P=0.66)							
4.2.14 Gusongbao granule plus con versus placebo granule plus comp (BMD of lumbar spine, 6 months)					_			
Xiong YH 2008	48	0.8 (0.2)	48	0.8 (0.2)	-		100%	-0.01[-0.07,0.0
Subtotal ***	48		48		•	•	100%	-0.01[-0.07,0.0
Heterogeneity: Not applicable								
Test for overall effect: Z=0.29(P=0.77)							
4.2.15 Qianggu capsule plus alend spine, 6 months)	ronate v	ersus alendrona	ate (BMD	of lumbar				
Xu H 2010	40	0.8 (0.1)	40	0.7 (0.1)			100%	0.08[0.03,0.1
Subtotal ***	40		40			•	100%	0.08[0.03,0.1
Heterogeneity: Not applicable								
Test for overall effect: Z=3.36(P=0)								
					<u> </u>			
			Fa	vours control	-0.5 -0.25	0 0.25	0.5 Favours trea	tment

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup		plus drugs		rugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% Cl
4.2.16 Xianlinggubao capsule plus spine, 12 months)	s Caltrate \	ersus Caltrate	e (BMD of l	umbar			
Wu W 2005	34	0.8 (0.1)	34	0.5 (0.1)		100%	0.3[0.25,0.35]
Subtotal ***	34		34			100%	0.3[0.25,0.35]
Heterogeneity: Not applicable							
Test for overall effect: Z=11.2(P<0.00	001)						
4.2.17 Xianlinggubao capsule plus salmon calcitonin plus Caltrate (B				ersus			
Dong Y 2010	54	0.9 (0.2)	53	0.9 (0.1)		100%	0.03[-0.03,0.09]
Subtotal ***	54		53			100%	0.03[-0.03,0.09]
Heterogeneity: Not applicable							- / -
Test for overall effect: Z=0.96(P=0.34	4)						
4.2.18 Xianlinggubao capsule plus lumbar spine, 6 months)	s alendron	ate versus aler	ndronate (BMD of			
Xu M 2009	52	0.8 (0.1)	52	0.7 (0.1)	+	100%	0.06[0.03,0.09]
Subtotal ***	52	. •	52		•	100%	0.06[0.03,0.09]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.25(P<0.00	001)						
4.2.19 Xianlinggubao capsule plus versus vitamin D3 and calcium an weeks)							
Zhang XZ 2004	62	0.6 (0.1)	50	0.6 (0.1)	<u> </u>	100%	0.01[-0.03,0.06]
Subtotal ***	62	. ,	50			100%	0.01[-0.03,0.06]
Heterogeneity: Not applicable							- , -
Test for overall effect: Z=0.52(P=0.6	1)						
4.2.20 Xianlinggubao capsule plus spine, 12 months)	s Caltrate v	ersus Caltrate	e (BMD of l	umbar			
Qiu ZX 2010	67	0.8 (0.1)	69	0.5 (0.1)		← 100%	0.31[0.28,0.34]
Subtotal ***	67	()	69			♦ 100%	0.31[0.28,0.34]
Heterogeneity: Not applicable						•	
Test for overall effect: Z=18.72(P<0.0	0001)						
4.2.21 Xianlinggubao capsule plus sule versus compound calcium an spine, 6 months)							
Dai Y 2007	53	0.9 (0.1)	53	0.7 (0.1)		100%	0.18[0.14,0.22]
Subtotal ***	53		53			100%	0.18[0.14,0.22]
Heterogeneity: Not applicable							[,]
Test for overall effect: Z=9.74(P<0.00	001)						
4.2.22 Jiangu granule plus compo sus placebo granule plus compou				•			
of lumbar spine, 6 months)		0.0 (0.0)					0.045.0.00
Xiong YH 2008	48	0.8 (0.2)	48	0.8 (0.2)		100%	0.04[-0.02,0.1]
Subtotal ***	48		48		-	100%	0.04[-0.02,0.1]
Heterogeneity: Not applicable	2)						
Test for overall effect: Z=1.22(P=0.22	2)						
4.2.23 Jinwugutong capsules plus lumbar spine, 6 months)	s calcium v	ersus placebo	plus calci	um (BMD of			
Zheng WK 2007	60	1 (0.1)	60	0.8 (0.1)	⊢	100%	0.11[0.07,0.15]

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba N	l plus drugs Mean(SD)	N	Drugs Mean(SD)	Mean Diffe Random, 9		Weight	Mean Difference Random, 95% Cl
Subtotal ***	60		60		,	•	100%	0.11[0.07,0.1!
Heterogeneity: Tau ² =0; Chi ² =0, df=0): l ² =100%				•		0.112[0101;012
Test for overall effect: Z=5.58(P<0.00		.,,. 20070						
	,01)							
4.2.24 Xuduanzhuanggu capsule p um tablet (BMD of lumbar spine, 6			ıs placeb	o plus calci-				
Zhan HS 2009	360	0.9 (0.2)	120	0.9 (0.2)	+		100%	0.02[-0.01,0.05
Subtotal ***	360		120		•	•	100%	0.02[-0.01,0.05
Heterogeneity: Not applicable								
Test for overall effect: Z=1.17(P=0.24	1)							
4.2.25 Chinese medicine Bushenh								
icine versus conventional westerr					1		1000/	
Cao GY 2010	30	1.2 (0.1)	27	1 (0.1)			100%	0.16[0.09,0.22
Subtotal ***	30		27			-	100%	0.16[0.09,0.22
Heterogeneity: Not applicable								
Test for overall effect: Z=4.77(P<0.00	001)							
4.2.26 Gusongbao granule plus ca tablet (BMD of lumbar spine, 6 mo		olet versus plac	ebo plus	calcium				
Zhan HS 2009	120	0.8 (0.2)	120	0.9 (0.2)			100%	-0.01[-0.05,0.03
Subtotal ***	120		120		•		100%	-0.01[-0.05,0.03
Heterogeneity: Not applicable								
Test for overall effect: Z=0.45(P=0.65	5)							
4.2.27 Shengsuiyin recipe plus Ca 12 months)	ltrate ver	sus Caltrate (B	MD of Lui	nbar spine,				
Jian QQ 2010	73	0.8 (0.1)	71	0.5 (0.1)		+-	100%	0.31[0.28,0.34
Subtotal ***	73		71			•	100%	0.31[0.28,0.34
Heterogeneity: Tau ² =0; Chi ² =0, df=0	(P<0.0001	.); l ² =100%						- ,
Test for overall effect: Z=19.29(P<0.0								
4.2.28 Yigu capsule plus calcium v	ersus pla	cebo plus calci	um (BMD	of lumbar				
spine, 6 months) Zhang RH 2004	70	0.9 (0.1)	70	0.8 (0.1)			100%	0.08[0.04,0.12
Subtotal ***	70 70	0.9 (0.1)	70 70	0.0 (0.1)			100%	0.08[0.04,0.12
Heterogeneity: Not applicable	10		10			▼	10070	0.00[0.04,0.12
Test for overall effect: Z=4.11(P<0.00	001)							
4.2.29 Chinese medicine (combina versus tamoxifen and Caltrate (Bl	4D of lum	ibar spine, 3 m	onths)			_		
Cao W 2010	60	0.8 (0.1)	60	0.7 (0.1)			100%	0.1[0.06,0.14
Subtotal ***	60		60			◆	100%	0.1[0.06,0.14
Heterogeneity: Not applicable								
Test for overall effect: Z=4.76(P<0.00	001)							
4.2.30 Zhuangguqiangjin tablet ar calcitonin (BMD of lumbar spine, 1	-	•	is calcito	nin versus				
Zhang ZF 2011	48	0.8 (0.1)	42	0.8 (0.1)	-		100%	0.01[-0.04,0.0
Subtotal ***	48		42			•	100%	0.01[-0.04,0.06
Heterogeneity: Not applicable								-
Test for overall effect: Z=0.34(P=0.73	3)							

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herbal	plus drugs	I	Drugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Random, 95% Cl		Random, 95% Cl
4.2.31 Migu tablet plus compour sus compound calcium amino ac months)							
Dai Y 2007	54	0.9 (0.1)	53	0.7 (0.1)		100%	0.17[0.14,0.2
Subtotal ***	54		53		•	100%	0.17[0.14,0.2
Heterogeneity: Not applicable							
Test for overall effect: Z=10.89(P<0	0.0001)						
4.2.32 Huangqi plus Caltrate ver	sus Caltrat	e (BMD of lumb	ar spine,	6 months)			
Yang B 2007	18	0.8 (0.1)	18	0.7 (0.1)	-+-	100%	0.06[0.01,0.1]
Subtotal ***	18		18		•	100%	0.06[0.01,0.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.57(P=0.	01)						
4.2.33 Jiarong tablet plus Caltra	te versus C	altrate (BMD of	f femoral	neck, 6			
months)	20	0.9 (0.1)	21	07(01)		1000/	0.00[0.02.0.1]
Chen YQ 2001 Subtotal ***	20 20	0.8 (0.1)	21 21	0.7 (0.1)		100% 100%	0.09[0.02,0.15
	20		21			100%	0.09[0.02,0.1
Heterogeneity: Not applicable	01)						
Test for overall effect: Z=2.53(P=0.	01)						
4.2.34 Antai capsule plus Caltrat months)	e versus Ca	ltrate (BMD of	femoral	neck, 6			
Wang SW 2003	65	0.7 (0.1)	63	0.7 (0.1)	+	100%	0.01[-0.02,0.04
Subtotal ***	65		63		•	100%	0.01[-0.02,0.04
Heterogeneity: Not applicable							
Test for overall effect: Z=0.65(P=0.	51)						
4.2.35 Xianlinggubao capsule pl neck, 12 months)	us Caltrate	versus Caltrate	e (BMD of	femoral			
Wu W 2005	34	0.7 (0.1)	34	0.4 (0.1)		100%	0.3[0.25,0.3
Subtotal ***	34	0.1 (0.1)	34	0.1(0.1)		100%	0.3[0.25,0.35
Heterogeneity: Not applicable					•	20070	0.5[0.20,0.00
Test for overall effect: Z=13(P<0.00	001)						
	,01)						
4.2.36 Guben Zhuanggu capsule: neck, 6 months)	s plus Caltr	ate versus Calt	rate (BM	D of femoral			
Zou JJ 2005	30	0.6 (0)	30	0.6 (0)	+	100%	0.01[-0.01,0.02
Subtotal ***	30		30		•	100%	0.01[-0.01,0.02
Heterogeneity: Tau ² =0; Chi ² =0, df=	0(P<0.0001); I ² =100%					
Test for overall effect: Z=0.97(P=0.	33)						
4.2.37 Migu tablet plus Caltrate months)	versus Calt	rate (BMD of fe	moral ne	ck, 12			
Xie J 2004	24	0.8 (0)	20	0.7 (0)	+	100%	0.09[0.08,0.1
Subtotal ***	24 24	0.0 (0)	20	(0)	●	100%	0.09[0.08,0.1
Heterogeneity: Not applicable	-7		20		· ·	20070	0.00[0.00,0.1
Test for overall effect: Z=11.87(P<0).0001)						
4.2.38 Qianggu capsules plus oe		erate versus o	estradiol	valerate			
(BMD of femoral neck, 6 months)		<i>a</i> = <i>t</i> = 1	<u>.</u> .				
Ruan XY 2006	46	0.7 (0.1)	42	0.7 (0.1)		100%	0.03[-0.01,0.0]
Subtotal ***	46		42		•	100%	0.03[-0.01,0.07
Heterogeneity: Not applicable							

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba N	l plus drugs Mean(SD)	N	Drugs Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Test for overall effect: Z=1.47(P=0.14)		Mean(SD)	N	Mean(SD)	Random, 95% CI		Random, 95% CI
4.2.39 Chinese medicine Bushenhu icine versus conventional western	medicin	e (BMD of femo	ral neck,	3 months)			
Cao GY 2010	30	1.2 (0.1)	27	1 (0.1)		100%	0.17[0.12,0.2
Subtotal ***	30		27		•	100%	0.17[0.12,0.2
Heterogeneity: Not applicable							
Test for overall effect: Z=5.91(P<0.000	01)						
4.2.40 Heche Dazao pill plus oyster ter shell calcium chewable tablets				•			
Chen XL 2010	57	0.6 (0.1)	57	0.6 (0.1)		100%	0.04[0,0.0
Subtotal ***	57		57		•	100%	0.04[0,0.0
Heterogeneity: Tau ² =0; Chi ² =0, df=0(I	P<0.0001	L); I ² =100%					
Test for overall effect: Z=2.18(P=0.03)							
4.2.41 Xianlinggubao capsule plus sule versus compound calcium ami neck, 6 months)							
Dai Y 2007	53	0.8 (0.1)	53	0.6 (0.1)		100%	0.26[0.22,0.
Subtotal ***	53	. ,	53		•	100%	0.26[0.22,0.
Heterogeneity: Not applicable							- ,
Test for overall effect: Z=11.54(P<0.00	001)						
4.2.42 Huangqi plus Caltrate versu							
/ang B 2007	18	0.7 (0.1)	18	0.6 (0.1)		100%	0.07[0.03,0.1
Subtotal ***	18		18		•	100%	0.07[0.03,0.1
Heterogeneity: Not applicable Test for overall effect: Z=3.22(P=0)							
4.2.43 Gusongbao granule plus con versus placebo granule plus compo							
(BMD of femoral neck, 6 months)					-	1000/	
Xiong YH 2008	48	0.7 (0.1)	48	0.7 (0.1)		100%	0.01[-0.03,0.0
Subtotal ***	48		48		•	100%	0.01[-0.03,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.44(P=0.66)							
4.2.44 Jiangu granule plus compou sus placebo granule plus compoun of femoral neck, 6 months)							
Xiong YH 2008	48	0.7 (0.1)	48	0.7 (0.1)		100%	-0.02[-0.07,0.0
Subtotal ***	48		48		•	100%	-0.02[-0.07,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.84(P=0.4)							
4.2.45 Xuduanzhuanggu capsule pl um tablet (BMD of femoral neck, 6 i			s placeb	o plus calci-			
Zhan HS 2009	360	0.7 (0.1)	120	0.7 (0.1)	+	100%	0.01[-0.01,0.0
Subtotal ***	360		120	N 7	•	100%	0.01[-0.01,0.0
Heterogeneity: Not applicable					ľ		
Test for overall effect: Z=0.86(P=0.39)							
4.2.46 Gusongbao granule plus calo tablet (BMD of femoral neck, 6 mor		olet versus place	ebo plus	calcium			

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba N	l plus drugs Mean(SD)	N	Drugs Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
Zhan HS 2009	120	0.7 (0.1)	120	0.7 (0.1)	+	100%	0[-0.03,0.03
Subtotal ***	120		120		•	100%	0[-0.03,0.0
Heterogeneity: Not applicable							
Test for overall effect: Not applicable							
4.2.47 Yigu capsule plus calcium ve	rsus pla	acebo plus calcii	ım (BMD	of femoral			
neck, 6 months)	1545 pt	icebo plus culen		orientorut			
Zhang RH 2004	70	0.7 (0.1)	70	0.7 (0.1)	+	100%	0.04[0.01,0.0
Subtotal ***	70		70		•	100%	0.04[0.01,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=2.46(P=0.01)							
4.2.48 Migu tablet plus compound (sus compound calcium amino acid months)							
Dai Y 2007	54	0.8 (0.1)	53	0.6 (0.1)		100%	0.24[0.21,0.2
Subtotal ***	54		53	•	•	100%	0.24[0.21,0.2]
Heterogeneity: Not applicable							- ,**
Test for overall effect: Z=13.69(P<0.00	001)						
4.2.49 Antai capsule plus Caltrate v	versus C	altrate (BMD of	Ward's, (5 months)			
Wang SW 2003	65	0.6 (0.1)	63	0.6 (0.1)		100%	0[-0.03,0.0
Subtotal ***	65		63		•	100%	0[-0.03,0.0
Heterogeneity: Not applicable							- /
Test for overall effect: Not applicable							
4.2.50 Migu tablet plus Caltrate ver	sus Cal	trate (BMD of W	ard's. 12	months)			
Xie J 2004	24	0.6 (0)	20	0.5 (0)	+	100%	0.09[0.08,0.
Subtotal ***	24		20		•	100%	0.09[0.08,0.
Heterogeneity: Not applicable							
Test for overall effect: Z=19.34(P<0.00	001)						
4.2.51 Qianggu capsule plus alendr	onate v	ersus alendrona	ate (BMD	of Ward's, 6			
months)			•				
Xu H 2010	40	0.5 (0.1)	40	0.4 (0.1)	+	100%	0.05[0.02,0.0
Subtotal ***	40		40		•	100%	0.05[0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=3.71(P=0)							
4.2.52 Xianlinggubao capsule plus a Ward's, 6 months)	alendro	nate versus aler	ndronate	(BMD of			
Xu M 2009	52	0.5 (0.1)	52	0.4 (0.1)	+	100%	0.04[0.02,0.0
Subtotal ***	52		52		•	100%	0.04[0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=3.82(P=0)							
4.2.53 Gusongbao granule plus con versus placebo granule plus compo (BMD of Ward's, 6 months)							
Xiong YH 2008	48	0.5 (0.1)	48	0.6 (0.1)	+	100%	-0.01[-0.06,0.0
Subtotal ***	48		48		◆	100%	-0.01[-0.06,0.04
Heterogeneity: Not applicable							
Test for overall effect: Z=0.42(P=0.67)							

Chinese herbal medicines for treating osteoporosis (Review)



	N	plus drugs Mean(SD)	D N	rugs Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% Cl
4 2 E4 Vianlinggubao canculo							Kandoni, 55% Ci
4.2.54 Xianlinggubao capsule sules versus compound calciı months)					I		
Dai Y 2007	53	0.6 (0.1)	53	0.4 (0.1)		100%	0.23[0.19,0.2
Subtotal ***	53	(,	53			100%	0.23[0.19,0.2
Heterogeneity: Not applicable			55		· · ·	20070	0120[0120;012
Test for overall effect: Z=10.72(
	1 -0.0001)						
4.2.55 Migu tablet plus comp compound calcium amino aci			-				
Dai Y 2007	54	0.7 (0.1)	53	0.4 (0.1)		100%	0.28[0.24,0.3
Subtotal ***	54		53		•	100%	0.28[0.24,0.3
Heterogeneity: Not applicable							
Test for overall effect: Z=13.78(P<0.0001)						
4.2.56 Jiangu granule plus co sus placebo granule plus com of Ward's, 6 months)							
Xiong YH 2008	48	0.5 (0.1)	48	0.6 (0.1)	-	100%	-0.01[-0.06,0.0
Subtotal ***	48		48			100%	-0.01[-0.06,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.41(P	'=0.68)						
4.2.57 Xuduanzhuanggu caps um tablet (BMD of Ward's, 6 n		m tablet versu	s placebo	plus calci-			
Zhan HS 2009	360	0.6 (0.1)	120	0.5 (0.1)	+	100%	0.02[-0,0.0
Subtotal ***	360		120		•	100%	0.02[-0,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.61(P	'=0.11)						
4.2.58 Gusongbao granule plu tablet (BMD of Ward's, 6 mon		et versus place	bo plus c	alcium			
Zhan HS 2009	120	0.6 (0.1)	120	0.5 (0.1)	+	100%	0.01[-0.02,0.0
		. ,	120		▲	1000/	0.01[-0.02,0.0
Subtotal ***	120				ľ	100%	
	120					100%	
Heterogeneity: Not applicable						100%	
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P	P=0.54)	aha pluc calci	m (PMD c	fWard's 6		100%	
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci	P=0.54)	ebo plus calcii	ım (BMD o	f Ward's, 6		100%	
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months)	P=0.54)	ebo plus calcio 0.6 (0.1)	ım (BMD c 70	f Ward's, 6 0.5 (0.1)		100%	0.04[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004	9=0.54) Jum versus plac	-			•		0.04[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal ***	2=0.54) um versus plac 70 70	-	70		•	100%	0.04[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable	P=0.54) um versus plac 70 70	-	70		⊷	100%	0.04[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt	P=0.54) um versus plac 70 70 P=0.03)	0.6 (0.1)	70 70	0.5 (0.1)	★	100%	0.04[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months)	P=0.54) um versus plac 70 70 P=0.03)	0.6 (0.1)	70 70	0.5 (0.1)	±= ◆	100%	
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months) Wang SW 2003	P=0.54) ium versus plac 70 70 P=0.03) trate versus Cal	0.6 (0.1)	70 70 trochante	0.5 (0.1) r, 6		100% 100%	0.04[0,0.0 0.04[0,0.0 0.03[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months) Wang SW 2003 Subtotal ***	P=0.54) ium versus plac 70 70 P=0.03) trate versus Cal 65 65	0.6 (0.1)	70 70 trochante	0.5 (0.1) r, 6	++= ◆ 1	100% 100% 100%	0.04[0,0.0 0.04[0,0.0 0.03[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months) Wang SW 2003 Subtotal *** Heterogeneity: Not applicable	P=0.54) um versus plac 70 70 P=0.03) trate versus Cal 65 65	0.6 (0.1)	70 70 trochante	0.5 (0.1) r, 6	*	100% 100% 100%	0.04[0,0.0 0.04[0,0.0 0.03[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months) Wang SW 2003 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.21(P	P=0.54) 100 versus plac 70 70 70 P=0.03) trate versus Cal 65 65 9=0.03)	0.6 (0.1)	70 70 trochante 63 63	0.5 (0.1) r, 6 0.6 (0.1)		100% 100% 100%	0.04[0,0.0 0.04[0,0.0 0.03[0,0.0
Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months) Wang SW 2003 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.21(P 4.2.61 Migu tablet plus Caltra	P=0.54) ium versus plac 70 70 2=0.03) trate versus Cal 65 65 9=0.03) ate versus Caltr	0.6 (0.1) Itrate (BMD of 0.7 (0.1)	70 70 trochante 63 63 ochanter,	0.5 (0.1) r, 6 0.6 (0.1) 12 months)		100% 100% 100% 100%	0.04[0,0.0 0.04[0,0.0 0.03[0,0.0 0.03[0,0.0
Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.62(P 4.2.59 Yigu capsule plus calci months) Zhang RH 2004 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.15(P 4.2.60 Antai capsule plus Calt months) Wang SW 2003 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=2.21(P 4.2.61 Migu tablet plus Caltra Xie J 2004 Subtotal ***	P=0.54) 100 versus plac 70 70 70 P=0.03) trate versus Cal 65 65 9=0.03)	0.6 (0.1)	70 70 trochante 63 63	0.5 (0.1) r, 6 0.6 (0.1)		100% 100% 100%	0.04[0,0.0 0.04[0,0.0

Chinese herbal medicines for treating osteoporosis (Review)



Trusted evidence. Informed decisions. Better health.

Cochrane Database of Systematic Reviews

Study or subgroup		plus drugs		Drugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% Cl		Random, 95% CI
Test for overall effect: Z=24.77(P<0.0	001)						
4.2.62 Xuduanzhuanggu capsule p um tablet (BMD of trochanter, 6 mo		m tablet versu	is placeb	o plus calci-			
Zhan HS 2009	360	0.6 (0.1)	120	0.6 (0.1)	+	100%	0[-0.02,0.0
Subtotal ***	360	0.0 (0.1)	120	0.0 (0.1)		100%	0[-0.02,0.0
	300		120		T	100%	0[-0.02,0.0
Heterogeneity: Not applicable Test for overall effect: Not applicable							
4.2.63 Migu tablet plus compound compound calcium amino acid che							
Dai Y 2007	54	0.7 (0.1)	53	0.5 (0.2)		100%	0.12[0.07,0.]
Subtotal ***	54		53		•	100%	0.12[0.07,0.1
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P<0.0001)	; l ² =100%					
est for overall effect: Z=4.38(P<0.00	01)						
I.2.64 Xianlinggubao capsule plus	compoun	d calcium ami	no acid	chelate			
capsules versus compound calciun trochanter, 6 months)					1		
Dai Y 2007	53	0.7 (0.1)	53	0.5 (0.2)		100%	0.13[0.08,0.
		0.7 (0.1)		0.5 (0.2)			
Subtotal ***	53		53			100%	0.13[0.08,0.
leterogeneity: Not applicable							
Test for overall effect: Z=5.42(P<0.00	01)						
1.2.65 Gusongbao granule plus cal ablet (BMD of trochanter, 6 month		et versus place	ebo plus	calcium			
Zhan HS 2009	120	0.6 (0.1)	120	0.6 (0.1)	+	100%	0[-0.03,0.
Subtotal ***	120		120		•	100%	0[-0.03,0.
Heterogeneity: Not applicable							
Test for overall effect: Not applicable	•						
1.2.66 Yigu capsule plus calcium ve rochanter, 6 months)	ersus plac	ebo plus calci	um (BMI) of			
Zhang RH 2004	70	0.6 (0.1)	70	0.6 (0.1)		100%	0.02[-0.02,0.
Subtotal ***	70		70		•	100%	0.02[-0.02,0.
Heterogeneity: Not applicable							
Test for overall effect: Z=1.08(P=0.28)						
4.2.67 Gushukang granule plus Cal tablets versus Calcium carbonate v bone, 6 months)							
Chen ZX 2002	23	0.8 (0.1)	19	0.6 (0.1)		100%	0.15[0.11,0.
Subtotal ***	23		19	. •		100%	0.15[0.11,0.
Heterogeneity: Not applicable							- , , ,
Test for overall effect: Z=6.75(P<0.00	01)						
I.2.68 Jinwugutong capsules plus nip bone, 6 months)	calcium v	ersus placebo	plus cal	cium (BMD of			
Zheng WK 2007	60	0.7 (0.1)	60	0.7 (0.1)	+	100%	0.01[-0.02,0.
Subtotal ***	60		60		•	100%	0.01[-0.02,0.0
leterogeneity: Not applicable							
Test for overall effect: Z=0.8(P=0.42)							
4.2.69 Gengnian Anyi tablet plus Ca 5 months)	altrate ve	rsus Caltrate (BMD of	distal radius,			

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba N	l plus drugs Mean(SD)	N	Drugs Mean(SD)	Mean Difference Random, 95% Cl	Weight	Mean Difference Random, 95% CI
Fan HX 2004	22	0.5 (0.1)	20	0.5 (0.2)		100%	0.01[-0.06,0.0
Subtotal ***	22		20	(,		100%	0.01[-0.06,0.0
Heterogeneity: Not applicable			20			10070	0.01[-0.00,0.0
Test for overall effect: Z=0.26(P=0.79))						
4.2.70 Shangke Yishen Zhuanggu p	ill plus (Caltrate and cal	citonin v	ersus Cal-			
trate and calcitonin (BMD of lumba							
Hu J 2012	155	0.7 (0.1)	145	0.7 (0.1)	+	100%	0.04[0.03,0.0
Subtotal ***	155		145		•	100%	0.04[0.03,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=6.35(P<0.00	01)						
4.2.71 Bushenhuoxue therapy plus dol versus calcium carbonate table months)							
Liang DB 2012	40	0.8 (0.1)	40	0.8 (0.1)		100%	-0.01[-0.04,0.0
Subtotal ***	40		40		•	100%	-0.01[-0.04,0.03
Heterogeneity: Not applicable							
Test for overall effect: Z=0.59(P=0.55))						
4.2.72 Gukang tablet plus oyster sl and D capsules versus oyster shell D capsules (BMD of lumbar spine, f	calcium	chewable table					
Liu JM 2012	40	1 (0.2)	40	0.8 (0.2)		100%	0.24[0.14,0.3
Subtotal ***	40		40		•	100%	0.24[0.14,0.3
Heterogeneity: Not applicable							
Test for overall effect: Z=4.78(P<0.00	01)						
4.2.73 Liuwei Dihuang pills plus Ca 6 months)	ltrate v	ersus Caltrate (I	3MD of lu	mbar spine,			
Ma C 2011	36	0.9 (0.1)	36	0.9 (0)	+	100%	0.05[0.02,0.0
Subtotal ***	36		36		•	100%	0.05[0.02,0.03
Heterogeneity: Tau ² =0; Chi ² =0, df=0(P<0.000	1); I ² =100%					
Test for overall effect: Z=3.72(P=0)							
4.2.74 Yiyuanjiangu decoction plus versus calcitonin and calcium carb months)							
Ma CZ 2011	60	1 (0.1)	60	1 (0.1)	+-	100%	0.02[-0.01,0.0
Subtotal ***	60		60		◆	100%	0.02[-0.01,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.3(P=0.19)							
4.2.75 Yiyuanjiangu decoction plus versus calcitonin and calcium carb months)							
Ma CZ 2011	60	0.7 (0.1)	60	0.7 (0.1)	+	100%	0.01[-0.01,0.0
Subtotal ***	60		60		•	100%	0.01[-0.01,0.0]
Heterogeneity: Tau ² =0; Chi ² =0, df=0(1): ² =100%			ľ		,,,,,,
Test for overall effect: Z=1.41(P=0.16)		-,,, 100/0					
4.2.76 Yiyuanjiangu decoction plus							
versus calcitonin and calcillim care							
		0.7 (0)	60	0.7 (0)	+	100%	0 02[0 01 0 0
versus calcitonin and calcium carb Ma CZ 2011 Subtotal ***	60 60	0.7 (0)	60 60	0.7 (0)	+ ▲	100% 100%	0.02[0.01,0.0 0.02[0.01,0.0

Chinese herbal medicines for treating osteoporosis (Review)



Cochrane Database of Systematic Reviews

Study or subgroup	Herba N	l plus drugs Mean(SD)	N	Drugs Mean(SD)	Mean Difference Random, 95% CI	Weight	Mean Difference Random, 95% Cl
Heterogeneity: Not applicable							
Test for overall effect: Z=2.83(P=0)							
4.2.77 Yishen Zhuanggu decoction soft capsule (BMD of lumbar spine,			ule versu	s calcitriol			
Ma YJ 2011	50	0.7 (0.1)	50	0.7 (0.1)	+	100%	0.02[-0,0.0
Subtotal ***	50	()	50			100%	0.02[-0,0.0
Heterogeneity: Tau ² =0; Chi ² =0, df=0(I		1): $l^2 = 100\%$			•		010_[0,010
Test for overall effect: Z=1.89(P=0.06)							
4.2.78 Hugu capsule plus Caltrate v	/ersus p	lacebo capsule	plus Calt	rate (BMD of			
lumbar spine, 6 months)	C1	0.0 (0.1)	C1	0.0 (0.1)		1000/	0.001.0.0
Wang XD 2011	61	0.8 (0.1)	61	0.8 (0.1)		100%	0.03[-0,0.0
Subtotal ***	61		61			100%	0.03[-0,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.74(P=0.08)							
4.2.79 Hugu capsule plus Caltrate v Ward's, 6 months)	/ersus p	lacebo capsule	plus Calt	rate (BMD of			
Wang XD 2011	61	0.7 (0.1)	61	0.6 (0.1)	+	100%	0.05[0.02,0.0
Subtotal ***	61		61		•	100%	0.05[0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=2.9(P=0)							
4.2.80 Bushen Qianggu Huoxue the calcium and cod liver oil (BMD of lu		pine, 3 months)	cod liver 42			100%	
Tang ZA 2012		0.9 (0.1)		0.8 (0.1)			0.05[-0.01,0.1
Subtotal ***	42		42			100%	0.05[-0.01,0.1
Heterogeneity: Not applicable Test for overall effect: Z=1.65(P=0.1)							
4.2.81 Bushen Qianggu Huoxue the	rapy pl	us calcium and o	od liver	oil versus			
calcium and cod liver oil (BMD of fe							
Tang ZA 2012	42	0.7 (0.1)	42	0.7 (0.1)	+	100%	0.02[-0.02,0.0
Subtotal ***	42		42		•	100%	0.02[-0.02,0.0
Heterogeneity: Not applicable							
Test for overall effect: Z=0.95(P=0.34))						
4.2.82 Bushen Qianggu Huoxue the calcium and cod liver oil (BMD of W			cod liver	oil versus			
Tang ZA 2012	42	0.6 (0.1)	42	0.6 (0.1)	+	100%	0.04[0.02,0.0
Subtotal ***	42		42		•	100%	0.04[0.02,0.0
Heterogeneity: Not applicable							·
Test for overall effect: Z=3.09(P=0)							
4.2.83 Xianlinggubao capsule (low- placebo plus calcium and vitamin [
Zhu HM 2012	60	0.8 (0.1)	60	0.8 (0.1)	1	100%	0[-0.04,0.0
Subtotal ***	60	0.0 (0.1)	60		-	100%	0[-0.04,0.04
Heterogeneity: Not applicable					Ť	100/0	01-010-010
Test for overall effect: Not applicable							
4.2.84 Xianlinggubao capsule (high placebo plus calcium and vitamin [

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba	l plus drugs		rugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% CI		Random, 95% CI
Zhu HM 2012	56	0.8 (0.1)	60	0.8 (0.1)	<u> </u>	100%	0[-0.03,0.03]
Subtotal ***	56		60		•	100%	0[-0.03,0.03]
Heterogeneity: Not applicable							
Test for overall effect: Not applicab	le						
4.2.85 Xianlinggubao capsule (lov placebo plus calcium and vitamin							
Zhu HM 2012	60	0.6 (0.1)	60	0.6 (0.1)		100%	-0.01[-0.05,0.03]
Subtotal ***	60		60			100%	-0.01[-0.05,0.03]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.55(P=0.5	8)						
4.2.86 Xianlinggubao capsule (hig placebo plus calcium and vitamin							
Zhu HM 2012	56	0.6 (0.1)	60	0.6 (0.1)		100%	-0.01[-0.05,0.03]
Subtotal ***	56		60			100%	-0.01[-0.05,0.03]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.54(P=0.5	9)						
4.2.87 Bushen Zhuanggu granules granules plus calcium and vitami				s placebo			
Deng WM 2012	88	0.3 (0)	67	0.2 (0)		100%	0.1[0.09,0.1]
Subtotal ***	88		67		•	100%	0.1[0.09,0.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=31.02(P<0.	0001)						
			Fav	/ours control -	0.5 -0.25 0 0.25	0.5 Favours trea	atment

Analysis 4.3. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 3 T score in BMD measurement.

Study or subgroup	Herba	l plus drugs	I	Drugs		Меа	n Difference	We	eight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)		Fix	ced, 95% CI			Fixed, 95% CI
4.3.1 Erxian Yanggu decoctio dronate sodium tablets (T sc			ablets ver	sus alen-						
Huang JW 2008	34	-2 (0.7)	33	-2.9 (0.8)			1	1	L00%	0.91[0.57,1.25]
Subtotal ***	34		33					1	.00%	0.91[0.57,1.25]
Heterogeneity: Not applicable	2									
Test for overall effect: Z=5.19(P<0.0001)									
Total ***	34		33					1	.00%	0.91[0.57,1.25]
Heterogeneity: Not applicable	2									
Test for overall effect: Z=5.19(F	P<0.0001)									
			Favoi	urs treatment	-100	-50	0 50	100 Fav	ours control	



Analysis 4.4. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 4 Quality of life.

Study or subgroup	Herba	l plus drugs	0	rugs	Ме	an Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	F	ixed, 95% CI		Fixed, 95% CI
4.4.1 Bushenhuoxue therapy plu versus calcium carbonate tablet				acalcidol				
Liang DB 2012	40	56.1 (3.9)	40	50.8 (3.5)		+	100%	5.3[3.67,6.93]
Subtotal ***	40		40			•	100%	5.3[3.67,6.93]
Heterogeneity: Not applicable								
Test for overall effect: Z=6.37(P<0.	0001)							
Total ***	40		40			•	100%	5.3[3.67,6.93]
Heterogeneity: Not applicable								
Test for overall effect: Z=6.37(P<0.	0001)							
			Favou	rs treatment -100	-50	0 50	¹⁰⁰ Favours cont	rol

Analysis 4.5. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 5 Symptoms including pain, muscle fatigue and limited mobility.

Study or subgroup	Experimental	Control	Risk Ratio	Weight	Risk Ratio
	n/N	n/N	M-H, Fixed, 95% Cl		M-H, Fixed, 95% CI
4.5.1 Heche Dazao pill plus oyster sus oyster shell calcium chewable		ole tablets ver-			
Chen XL 2010	55/57	48/57	+	100%	1.15[1.01,1.3]
Subtotal (95% CI)	57	57	◆	100%	1.15[1.01,1.3]
Total events: 55 (Experimental), 48	(Control)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2.17(P=0.03	3)				
4.5.2 Xianlinggubao capsule plus sus salmon calcitonin plus Caltrat		l Caltrate ver-			
Dong Y 2010	50/54	37/53	+	100%	1.33[1.09,1.61]
Subtotal (95% CI)	54	53	♦	100%	1.33[1.09,1.61]
Total events: 50 (Experimental), 37	(Control)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2.88(P=0)					
4.5.3 Zhuangguqiangjin tablet an versus calcitonin (12 months)	d Shujinbogu tablet p	lus calcitonin			
Zhang ZF 2011	43/45	35/37	+	100%	1.01[0.91,1.12]
Subtotal (95% CI)	45	37	+	100%	1.01[0.91,1.12]
Total events: 43 (Experimental), 35	(Control)				
Heterogeneity: Not applicable					
Test for overall effect: Z=0.2(P=0.84))				
4.5.4 Kanggusong soup plus Caltr	ate versus Caltrate (3	months)			
Li ZP 2011	40/45	18/30		100%	1.48[1.09,2.02]
Subtotal (95% CI)	45	30	•	100%	1.48[1.09,2.02]
Total events: 40 (Experimental), 18	(Control)				
Heterogeneity: Not applicable					
Test for overall effect: Z=2.49(P=0.0	1)				
Test for subgroup differences: Chi ² =	=10.32, df=1 (P=0.02), I ²	=70.94%			
	Fi	avours treatment 0.01	0.1 1 10	¹⁰⁰ Favours control	

Chinese herbal medicines for treating osteoporosis (Review)

Analysis 4.6. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 6 Oestradiol (E2).

Study or subgroup	Herbal pl	us drugs		Drugs	Mean Difference	Weight	Mean Difference
	-	Mean(SD)	N	Mean(SD)	Random, 95% Cl	8	Random, 95% Cl
4.6.1 Gushen decoction plus Ca calcidol (6 months)							,
Chen FS 2001	32	43.7 (8.2)	32	39.1 (8.4)		100%	4.54[0.47,8.61]
Subtotal ***	32		32			100%	4.54[0.47,8.61]
Heterogeneity: Not applicable					•		
Test for overall effect: Z=2.19(P=0).03)						
	,						
4.6.2 Ziyin Bushen Zhuanggu pı Caltrate plus Calcitonin (8 mon		s Caltrate an	d Calcito	nin versus			
Li HW 2004	25	52.4 (16.1)	20	29.2 (13.9)		- 100%	23.21[14.46,31.96]
Subtotal ***	25		20		-	- 100%	23.21[14.46,31.96]
Heterogeneity: Not applicable							
Test for overall effect: Z=5.2(P<0.0	0001)						
4 C 2 7kuun eeu aanula alua Ca		- I turata (C					
4.6.3 Zhuanggu capsule plus Ca		-	-	17.2 (2)		1000/	
Li SL 2004 Subtotal ***	30 30	21.2 (2.9)	30 30	17.2 (3)		100% 100%	4.06[2.56,5.56]
	30		30			100%	4.06[2.56,5.56]
Heterogeneity: Not applicable Test for overall effect: Z=5.32(P<0	0001)						
4.6.4 Bushen Qiangshen pill plu							
Mu G 2001	20	22.6 (14.2)	20	15 (11.9)		100%	7.6[-0.51,15.71]
Subtotal ***	20		20			100%	7.6[-0.51,15.71]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.84(P=0).07)						
4.6.5 Antai capsule plus Caltrat	e versus Caltra	ite (6 months	;)				
Wang SW 2003	65	32.5 (10.3)	63	21.5 (5.6)		100%	11[8.14,13.86]
Subtotal ***	65		63		•	100%	11[8.14,13.86]
Heterogeneity: Not applicable							
Test for overall effect: Z=7.53(P<0	0.0001)						
4.6.6 Zishen prescription plus C tonin (8 months)	altrate and cal	lcitonin versı	us Caltra	te plus calci-			
Zhao G 2002	25	52.4 (16.1)	20	29.2 (13.9)		- 100%	23.21[14.46,31.96]
Subtotal ***	25		20		-	100%	23.21[14.46,31.96]
Heterogeneity: Not applicable							
Test for overall effect: Z=5.2(P<0.0	0001)						
4.6.7 Shugan zishen huoxue tar versus Caltrate plus alendronat				lium tablets			
Han XL 2007		58.6 (15.5)	17	31.6 (12.7)		100%	26.99[18.44,35.54]
Subtotal ***	25		17			100%	26.99[18.44,35.54]
Heterogeneity: Not applicable							-
Test for overall effect: Z=6.18(P<0	0.0001)						
4.6.8 Xianlinggubao capsule plu versus vitamin D3 and calcium a				d chelate			
	62		KS) 50	31 8 (3 7)		1000%	6 04[4 61 7 47]
Zhang XZ 2004	62	37.9 (4)	50	31.8 (3.7)		100%	6.04[4.61,7.47]

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba	l plus drugs	D	rugs	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% Cl
Subtotal ***	62		50		•	100%	6.04[4.61,7.47]
Heterogeneity: Not applicable							
Test for overall effect: Z=8.31(P<0.0	0001)						
4.6.9 Yigu capsule plus calcium v	ersus plac	ebo plus calciur	n (6 mont	:hs)			
Zhang RH 2004	70	- 64.5 (30.5)	70	23.6 (5)		100%	40.85[33.61,48.09]
Subtotal ***	70		70			100%	40.85[33.61,48.09]
Heterogeneity: Not applicable							
Test for overall effect: Z=11.06(P<0	.0001)						
			Fav	ours control	-20 -10 0 10	20 Favours tre	atment

Analysis 4.7. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 7 Serum calcium (Ca).

Study or subgroup	Herbal	plus drugs	D	rugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	N	Mean(SD)	Random, 95% CI		Random, 95% CI
4.7.1 Gushen decoction plus Caltra calcidol (6 months)	ite and A	facalcidol vers	us Caltrat	e and Alfa-			
Chen FS 2001	32	2.2 (0.2)	32	2.2 (0.1)		100%	0.05[-0.02,0.12]
Subtotal ***	32		32		-	100%	0.05[-0.02,0.12]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.35(P=0.18)						
4.7.2 Gushukang granule plus Calc tablets versus Calcium carbonate v							
Chen ZX 2002	23	2.4 (0.1)	19	2.4 (0.1)		100%	-0.01[-0.09,0.07]
Subtotal ***	23		19		-	100%	-0.01[-0.09,0.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.25(P=0.81)						
4.7.3 Zhuanggu capsule plus Caltra	ate versu	s Caltrate (6 mo	onths)				
Li SL 2004	30	2.5 (0.2)	30	2.5 (0.2)	— <u>—</u> —	100%	0.01[-0.07,0.09]
Subtotal ***	30		30		-	100%	0.01[-0.07,0.09]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.23(P=0.81)						
4.7.4 Antai capsule plus Caltrate vo	ersus Cal	trate (6 months	5)				
Wang SW 2003	65	2.4 (0.2)	63	2.4 (0.2)		100%	-0.03[-0.09,0.03]
Subtotal ***	65		63			100%	-0.03[-0.09,0.03]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.03(P=0.31)						
4.7.5 Jinwugutong capsules plus c months)	alcium vo	ersus placebo p	lus calciu	m (6			
Zheng WK 2007	60	2.3 (0.2)	60	2.3 (0.2)		100%	-0.05[-0.11,0.01]
Subtotal ***	60		60		•	100%	-0.05[-0.11,0.01]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.66(P=0.1)							
4.7.6 Xianlinggubao capsule plus s calcitonin plus Caltrate (3 months)		lcitonin and Ca	ltrate ver	sus salmon			
			Fav	ours control	-0.4 -0.2 0 0.2	^{0.4} Favours tre	atment

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup		l plus drugs	I	Drugs	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Random, 95% CI		Random, 95% CI
Dong Y 2010	54	2.4 (0.3)	53	2.3 (0.3)		100%	0.03[-0.09,0.15
Subtotal ***	54		53			100%	0.03[-0.09,0.15
Heterogeneity: Not applicable							
Test for overall effect: Z=0.48(P=0.63)						
4.7.7 Bushenyiqihuoxue soup plus and Caltrate (3 months)	tamoxif	en and Caltrate	versus t	amoxifen			
Zhang DS 2011	60	2.5 (0.2)	60	2.1 (0.2)		100%	0.37[0.32,0.42
Subtotal ***	60		60			100%	0.37[0.32,0.42
Heterogeneity: Not applicable							
Test for overall effect: Z=13.51(P<0.0	001)						
4.7.8 Yigu capsule plus calcium vei	sus plac	ebo plus calciu	m (6 mon	ths)			
Zhang RH 2004	70	2.3 (0.2)	70	2.4 (0.2)		100%	-0.07[-0.13,-0.01
Subtotal ***	70		70		$\overline{\bullet}$	100%	-0.07[-0.13,-0.01
Heterogeneity: Not applicable							
Test for overall effect: Z=2.37(P=0.02)						
4.7.9 Chinese medicine (combinati versus tamoxifen and Caltrate (3 n		herbs) plus tan	noxifen a	nd Caltrate			
Cao W 2010	60	2.5 (0.2)	60	2.1 (0.2)		100%	0.37[0.32,0.42
Subtotal ***	60		60			100%	0.37[0.32,0.42
Heterogeneity: Not applicable							
Test for overall effect: Z=13.51(P<0.0	001)						
4.7.10 Zhuangguqiangjin tablet an calcitonin (12 months)	d Shujin	bogu tablet plu	s calcitor	nin versus			
Zhang ZF 2011	48	2.2 (0.2)	42	2.2 (0.2)		100%	-0.02[-0.1,0.06
Subtotal ***	48		42		$\overline{\bullet}$	100%	-0.02[-0.1,0.06
Heterogeneity: Not applicable							
Test for overall effect: Z=0.51(P=0.61)						
4.7.11 Huangqi plus Caltrate versu	s Caltra	te (6 months)					
Yang B 2007	18	2.6 (0.3)	18	2.3 (0.3)		100%	0.28[0.11,0.45
Subtotal ***	18		18			100%	0.28[0.11,0.45
Heterogeneity: Not applicable							
Test for overall effect: Z=3.23(P=0)							
4.7.12 Yiyuanjiangu decoction plus versus calcitonin and calcium carb				te tablet			
Ma CZ 2011	60	2.3 (0.1)	60	2.3 (0.1)		100%	-0.02[-0.06,0.02
Subtotal ***	60	,	60	()		100%	-0.02[-0.06,0.02
Heterogeneity: Not applicable					•	100 /0	0.02[-0.00,0.07
Test for overall effect: Z=0.99(P=0.32	`						
		1 (D -0.0001) -2	00.010/				
Test for subgroup differences: Chi ² =3	827.4, df=	=1 (P<0.0001), I ² =	96.64%				



Analysis 4.8. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 8 Phosphorus (P).

Study or subgroup	Herbal	plus drugs	р	rugs	Mean Difference	Weight	Mean Difference
Study of Subgroup	N	Mean(SD)	N	Mean(SD)	Fixed, 95% Cl	Weight	Fixed, 95% Cl
4.8.1 Gushen decoction plus Ca calcidol (6 months)							
Chen FS 2001	32	1.6 (0.3)	32	1.8 (0.3)		100%	-0.13[-0.27,0.01]
Subtotal ***	32		32		\bullet	100%	-0.13[-0.27,0.01]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.86(P=0	0.06)						
4.8.2 Gushukang granule plus (tabletsl versus Calcium carbon							
Chen ZX 2002	23	1.1 (0.2)	19	1.1 (0.1)		100%	-0.02[-0.11,0.07]
Subtotal ***	23		19		•	100%	-0.02[-0.11,0.07]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.45(P=0	0.65)						
4.8.3 Zhuanggu capsule plus Ca	altrate versus	Caltrate (6 mo	onths)				
Li SL 2004	30	1.3 (0.1)	30	1.3 (0.2)		100%	0.01[-0.06,0.08]
Subtotal ***	30		30		•	100%	0.01[-0.06,0.08]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.27(P=0	0.79)						
4.8.4 Antai capsule plus Caltrat	te versus Calt	rate (6 months	5)				
Wang SW 2003	65	1.2 (0.2)	63	1.2 (0.9)		100%	-0.01[-0.23,0.21]
Subtotal ***	65		63			100%	-0.01[-0.23,0.21]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.09(P=0	0.93)						
4.8.5 Jinwugutong capsules plu months)	us calcium ve	rsus placebo p	lus calciu	m (6			
Zheng WK 2007	60	1.2 (0.2)	60	1.2 (0.2)		100%	-0.02[-0.09,0.05]
Subtotal ***	60		60		•	100%	-0.02[-0.09,0.05]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.53(P=0	0.59)						
4.8.6 Xianlinggubao capsule pl		citonin and Ca	ltrate ver	sus salmon			
calcitonin plus Caltrate (3 mon			50			1000/	
Dong Y 2010	54	1.6 (0.2)	53	1.6 (0.4)		100%	0.01[-0.12,0.14]
Subtotal ***	54		53			100%	0.01[-0.12,0.14]
Heterogeneity: Not applicable	>						
Test for overall effect: Z=0.16(P=0	0.88)						
4.8.7 Yigu capsule plus calcium		•	•	-			_
Zhang RH 2004	70	1.2 (0.2)	70	1.3 (0.1)	-	100%	-0.03[-0.08,0.02]
Subtotal ***	70		70		•	100%	-0.03[-0.08,0.02]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.21(P=0	0.23)						
4.8.8 Zhuangguqiangjin tablet citonin (12 months)	and Shujinbo	gu tablet plus	calcitonin	versus cal-			
Zhang ZF 2011	48	1.1 (0.1)	42	1.1 (0.1)	-+	100%	-0.02[-0.08,0.04]
Subtotal ***	48		42		•	100%	-0.02[-0.08,0.04]
Subtotat					1		

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba	l plus drugs	1	Drugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI	-	Fixed, 95% CI
Test for overall effect: Z=0.68(P=0.5	5)						
	-						
4.8.9 Huangqi plus Caltrate versi	us Caltrate	e (6 months)					
Yang B 2007	18	2.8 (0.3)	18	2.5 (0.2)		100%	0.31[0.14,0.48]
Subtotal ***	18		18		-	100%	0.31[0.14,0.48]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.63(P=0)							
4.8.10 Yiyuanjiangu decoction pl versus calcitonin and calcium ca				te tablet			
Ma CZ 2011	60	1.4 (0.8)	60	1.3 (0.8)		100%	0.06[-0.22,0.34]
Subtotal ***	60		60			100%	0.06[-0.22,0.34]
Heterogeneity: Tau ² =0; Chi ² =0, df=	0(P<0.0001	.); I ² =100%					
Test for overall effect: Z=0.42(P=0.6	67)						
Test for subgroup differences: Chi ²	² =18.44, df=	1 (P=0.03), I ² =51	.2%				
			Favo	urs treatment	-0.5 -0.25 0 0.25 0.5	Favours cor	trol

Analysis 4.9. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 9 Alkaline phosphatase (ALP).

Study or subgroup	Herba	l plus drugs	I	Drugs	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
4.9.1 Gushukang granule plus Ca tablets versus Calcium carbonate							
Chen ZX 2002	20	8.2 (1.8)	19	8.7 (2)		100%	-0.5[-1.7,0.7]
Subtotal ***	20		19		•	100%	-0.5[-1.7,0.7]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.81(P=0.4	2)						
4.9.2 Zhuanggu capsule plus Calt	rate versı	ıs Caltrate (6 m	onths)				
Li SL 2004	30	11.5 (3.2)	30	11.5 (3)		100%	0[-1.55,1.55]
Subtotal ***	30		30		\bullet	100%	0[-1.55,1.55]
Heterogeneity: Not applicable							
Test for overall effect: Not applicab	le						
4.9.3 Bushen Qiangshen pill plus	Caltrate v	ersus Caltrate (3 month	s)			
Mu G 2001	20	3.9 (2)	20	4.3 (2.6)		100%	-0.31[-1.72,1.1]
Subtotal ***	20		20		-	100%	-0.31[-1.72,1.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.43(P=0.6	7)						
4.9.4 Xianlinggubao capsule plus calcitonin plus Caltrate (3 month		alcitonin and Ca	altrate ve	rsus salmon			
Dong Y 2010	54	15.1 (1.4)	53	16.1 (1.4)	-+-	100%	-0.99[-1.52,-0.46]
Subtotal ***	54		53		•	100%	-0.99[-1.52,-0.46]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.64(P=0)							
4.9.5 Antai capsule plus Caltrate	versus Ca	ltrate (6 month	s)				
Wang SW 2003	65	13.2 (2)	63	11.9 (2.2)		100%	1.28[0.55,2.01]
			Fa	vours control	-5 -2.5 0 2.5 5	Favours tre	atment

Chinese herbal medicines for treating osteoporosis (Review)



	N	l plus drugs Mean(SD)	N	Drugs Mean(SD)	Mean Difference Fixed, 95% Cl	Weight	Mean Difference Fixed, 95% CI
Subtotal ***	65	/	63	<u> </u>	•	100%	1.28[0.55,2.0]
Heterogeneity: Not applicable							- , **
Test for overall effect: Z=3.44(P=0)							
4.9.6 Traditional Chinese capsule conate (9 months)	plus calci	um gluconate v	ersus ca	lcium glu-			
Miu JQ 2008	30	14.7 (1.4)	30	12.9 (0.8)		100%	1.77[1.2,2.3
Subtotal ***	30		30		•	100%	1.77[1.2,2.34
Heterogeneity: Not applicable							
Test for overall effect: Z=6.08(P<0.00	001)						
4.9.7 Jinwugutong capsules plus o months)	calcium v	ersus placebo p	lus calcii	ım (6			
Zheng WK 2007	60	11.8 (3.3)	60	10.8 (2.5)		100%	1.01[-0.04,2.0
Subtotal ***	60		60		•	100%	1.01[-0.04,2.0
Heterogeneity: Not applicable							
Test for overall effect: Z=1.89(P=0.06	6)						
4.9.8 Yigu capsule plus calcium ve	ersus place	ebo plus calciu	n (6 mon	ths)			
Zhang RH 2004	70	11.7 (3.6)	70	10 (2.5)		100%	1.73[0.71,2.7
Subtotal ***	70		70		\mathbf{A}	100%	1.73[0.71,2.7
Heterogeneity: Tau²=0; Chi²=0, df=0	(P<0.0001); I ² =100%					- /
Test for overall effect: Z=3.32(P=0)							
Cao W 2010	60	13.6 (3.4)	60	13.9 (4.3)		100%	
versus tamoxifen and Caltrate (3 i Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71	60 60	13.6 (3.4)	60 60	13.9 (4.3)	•	100% 100%	
Cao W 2010 Subtotal *** Heterogeneity: Not applicable	60 60 1)		60		•		
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.7) 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months)	60 60 1) nd Shujini	bogu tablet plu:	60 s calcitor	in versus	•	100%	-0.26[-1.64,1.1
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011	60 60 1)		60				- 0.26[-1.64,1.1 0.08[-0.54,0.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal ***	60 60 1) nd Shujini	bogu tablet plu:	60 s calcitor	in versus		100%	- 0.26[-1.64,1.1 0.08[-0.54,0.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable	60 60 1) 48 48	bogu tablet plu:	60 s calcitor 42	in versus		100%	- 0.26[-1.64,1.1 0.08[-0.54,0.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal ***	60 60 1) 48 48	bogu tablet plu:	60 s calcitor 42	in versus		100%	- 0.26[-1.64,1.1 0.08[-0.54,0.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable	60 60 1) 48 48 48	bogu tablet plus 12.9 (1.5)	60 s calcitor 42 42	iin versus 12.8 (1.5)		100%	- 0.26[-1.64,1.1 0.08[-0.54,0.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu	60 60 1) 48 48 48	bogu tablet plus 12.9 (1.5)	60 s calcitor 42 42	iin versus 12.8 (1.5)		100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup pluand Caltrate (3 months)	60 60 1) 48 48 48 0) us tamoxi	bogu tablet plu 12.9 (1.5) fen and Caltrat	60 s calcitor 42 42 e versus	iin versus 12.8 (1.5) tamoxifen		100% 100% 100%	-0.26[-1.64,1.1 -0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5. 3.54[1.68,5.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011	60 60 1) 48 48 48 0) us tamoxi 60	bogu tablet plu 12.9 (1.5) fen and Caltrat	60 s calcitor 42 42 e versus 60	iin versus 12.8 (1.5) tamoxifen		100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.7) 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal ***	60 60 1) 48 48 48 0) us tamoxi 60	bogu tablet plu 12.9 (1.5) fen and Caltrat	60 s calcitor 42 42 e versus 60	iin versus 12.8 (1.5) tamoxifen		100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=3.72(P=0)	60 60 1) 48 48 9 us tamoxi 60 60	bogu tablet plu: 12.9 (1.5) fen and Caltrat 20.5 (5.5)	60 s calcitor 42 42 e versus 60	iin versus 12.8 (1.5) tamoxifen		100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable	60 60 1) 48 48 9 us tamoxi 60 60	bogu tablet plu: 12.9 (1.5) fen and Caltrat 20.5 (5.5)	60 s calcitor 42 42 e versus 60	iin versus 12.8 (1.5) tamoxifen		100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=3.72(P=0) 4.9.12 Huangqi plus Caltrate versu	60 60 1) 48 48 48 0 us tamoxi 60 60 60 us Caltrat	bogu tablet plus 12.9 (1.5) fen and Caltrat 20.5 (5.5)	60 s calcitor 42 42 e versus 60 60	in versus 12.8 (1.5) tamoxifen 17 (4.9)		100% 100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5. 3.54[1.68,5. 0.82[0.63,1.0
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.7) 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=3.72(P=0) 4.9.12 Huangqi plus Caltrate versu Yang B 2007 Subtotal ***	60 60 1) 48 48 48 0 us tamoxi 60 60 0 us Caltrat 18	bogu tablet plus 12.9 (1.5) fen and Caltrat 20.5 (5.5)	60 s calcitor 42 42 e versus 60 60 18	in versus 12.8 (1.5) tamoxifen 17 (4.9)		100% 100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5. 3.54[1.68,5. 0.82[0.63,1.0
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=3.72(P=0) 4.9.12 Huangqi plus Caltrate versu Yang B 2007	60 60 1) 48 48 48 0 us tamoxi 60 60 us Caltrat 18 18	bogu tablet plus 12.9 (1.5) fen and Caltrat 20.5 (5.5)	60 s calcitor 42 42 e versus 60 60 18	in versus 12.8 (1.5) tamoxifen 17 (4.9)		100% 100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5. 3.54[1.68,5.
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.7) 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=3.72(P=0) 4.9.12 Huangqi plus Caltrate versu Yang B 2007 Subtotal *** Heterogeneity: Not applicable	60 60 1) 48 48 48) us tamoxi 60 60 60 us Caltrat 18 18 18	bogu tablet plu: 12.9 (1.5) fen and Caltrat 20.5 (5.5) te (6 months) 3.3 (0.3)	60 s calcitor 42 42 e versus 60 60 18 18 18	in versus 12.8 (1.5) tamoxifen 17 (4.9) 2.5 (0.3)		100% 100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0. 0.08[-0.54,0. 3.54[1.68,5. 3.54[1.68,5. 0.82[0.63,1.0
Cao W 2010 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.37(P=0.71 4.9.10 Zhuangguqiangjin tablet ar calcitonin (12 months) Zhang ZF 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=0.25(P=0.8) 4.9.11 Bushenyiqihuoxue soup plu and Caltrate (3 months) Zhang DS 2011 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=3.72(P=0) 4.9.12 Huangqi plus Caltrate versu Yang B 2007 Subtotal *** Heterogeneity: Not applicable Test for overall effect: Z=8.48(P<0.00	60 60 1) nd Shujini 48 48 48 00 60 60 60 60 80 18 18 18 2001) 5 vitamin	bogu tablet plu: 12.9 (1.5) fen and Caltrat 20.5 (5.5) ce (6 months) 3.3 (0.3)	60 s calcitor 42 42 e versus 60 60 18 18 18 18	in versus 12.8 (1.5) tamoxifen 17 (4.9) 2.5 (0.3)		100% 100% 100% 100%	-0.26[-1.64,1.1 0.08[-0.54,0 0.08[-0.54,0. 3.54[1.68,5 3.54[1.68,5. 0.82[0.63,1.0

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Herba	l plus drugs	1	Drugs	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
Subtotal ***	62		50			100%	10.48[9.81,11.15]
Heterogeneity: Not applicable							
Test for overall effect: Z=30.43(P<0	.0001)						
4.9.14 Kanggusong soup plus Cal	ltrate vers	us Caltrate (3 m	onths)				
Li ZP 2011	45	15.3 (3)	30	17 (3.6)		100%	-1.61[-3.17,-0.05]
Subtotal ***	45		30		-	100%	-1.61[-3.17,-0.05]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.03(P=0.0	04)						
4.9.15 Yiyuanjiangu decoction pl versus calcitonin and calcium ca				te tablet			
Ma CZ 2011	60	12.7 (2.2)	60	12.4 (2.2)		100%	0.31[-0.48,1.1]
Subtotal ***	60		60		•	100%	0.31[-0.48,1.1]
Heterogeneity: Not applicable							
Test for overall effect: Z=0.77(P=0.4	44)						
Test for subgroup differences: Chi ²	=865.15, df	f=1 (P<0.0001), I ²	=98.38%				
			Fa	vours control	-5 -2.5 0 2.5 5	Favours tre	atment

Analysis 4.10. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 10 Bone Gla protein (BGP).

Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
4.10.1 Zhuanggu capsule plus Calt	rate vers	sus Caltrate (6 m	nonths)				
Li SL 2004	30	6.9 (4)	30	9.2 (2.9)		100%	-2.3[-4.07,-0.53]
Subtotal ***	30		30		•	100%	-2.3[-4.07,-0.53]
Heterogeneity: Not applicable							
Test for overall effect: Z=2.55(P=0.01)						
4.10.2 Traditional Chinese capsule conate (9 months)	plus cal	cium gluconate	versus c	alcium glu-			
Miu JQ 2008	30	7.8 (0.7)	30	6.6 (0.7)	+	100%	1.23[0.88,1.58]
Subtotal ***	30		30		♦	100%	1.23[0.88,1.58]
Heterogeneity: Not applicable							
Test for overall effect: Z=6.9(P<0.000	1)						
4.10.3 Xianlinggubao capsule plus salmon calcitonin plus Caltrate (3			altrate v	ersus			
Dong Y 2010	54	5.8 (2.5)	53	5.2 (2)	-+-	100%	0.56[-0.3,1.42]
Subtotal ***	54		53		•	100%	0.56[-0.3,1.42]
Heterogeneity: Not applicable							
Test for overall effect: Z=1.28(P=0.2)							
4.10.4 Yigu capsule plus calcium ve	ersus pla	cebo plus calciu	ım (6 mo	nths)			
Zhang RH 2004	70	10.1 (3.8)	70	7.5 (1.4)		100%	2.6[1.66,3.54]
Subtotal ***	70		70		\bullet	100%	2.6[1.66,3.54]
Heterogeneity: Not applicable							
Test for overall effect: Z=5.39(P<0.00	01)						
			Favo	urs treatment	10 -5 0 5	¹⁰ Favours cor	ntrol

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Her	bal drugs	West	medicine	Mean Difference	Weight	Mean Difference
	Ν	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI	_	Fixed, 95% CI
4.10.5 Xianlinggubao capsule plus versus vitamin D3 and calcium an				cid chelate			
Zhang XZ 2004	62	18.5 (1.1)	50	12.2 (1.7)		100%	6.24[5.69,6.79]
Subtotal ***	62		50		•	100%	6.24[5.69,6.79]
Heterogeneity: Not applicable							
Test for overall effect: Z=22.41(P<0.0	0001)						
4.10.6 Xianlinggubao capsule plus	s Caltrate	e versus Caltrate	e (12 mor	iths)			
Wu W 2005	34	7.2 (2.5)	34	5.4 (1.4)		100%	1.85[0.87,2.83]
Subtotal ***	34		34		•	100%	1.85[0.87,2.83]
Heterogeneity: Not applicable							
Test for overall effect: Z=3.71(P=0)							
4.10.7 Jinwugutong capsules plus months)	calcium	versus placebo	plus calc	ium (6			
Zheng WK 2007	60	10 (3.3)	60	7.5 (2.4)		100%	2.47[1.44,3.5]
Subtotal ***	60		60		•	100%	2.47[1.44,3.5]
Heterogeneity: Not applicable							
Test for overall effect: Z=4.71(P<0.00	001)						
4.10.8 Huangqi plus Caltrate vers	us Caltra	te (6 months)					
Yang B 2007	18	2.2 (0.2)	18	1.6 (0.2)		100%	0.63[0.5,0.76]
Subtotal ***	18		18		+	100%	0.63[0.5,0.76]
Heterogeneity: Not applicable							
Test for overall effect: Z=9.44(P<0.00	001)						
Test for subgroup differences: Chi ² =	422.89, d	f=1 (P<0.0001), I ²	=98.34%				
			Favo	urs treatment	-10 -5 0 5 1	¹⁰ Favours cor	ntrol

Analysis 4.11. Comparison 4 Chinese herbal medicines plus western medicine versus western medicine, Outcome 11 Interleukin-6 (IL-6).

Study or subgroup	Exp	erimental	C	Control	Mean Difference	Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI		Fixed, 95% CI
4.11.1 Erxian Yanggu decoction dronate sodium tablets (6 montl		ronate sodium t	ablets v	ersus alen-			
Huang JW 2008	34	125.8 (7.5)	33	141.9 (6.8)		100%	-16.18[-19.62,-12.74]
Subtotal ***	34		33			100%	-16.18[-19.62,-12.74]
Heterogeneity: Not applicable							
Test for overall effect: Z=9.23(P<0.	0001)						
4.11.2 Xianlinggubao capsule plu versus vitamin D3 and calcium a				cid chelate			
Zhang XZ 2004	62	95.1 (20.3)	50	228.4 (15.5)	- +	100%	-133.3[-139.94,-126.66]
Subtotal ***	62		50		•	100%	-133.3[-139.94,-126.66]
Heterogeneity: Not applicable							
Test for overall effect: Z=39.36(P <c< td=""><td>.0001)</td><td></td><td></td><td></td><td></td><td></td><td></td></c<>	.0001)						
4.11.3 Kanggusong soup plus Ca	trate vers	us Caltrate (3 m	onths)				
Li ZP 2011	45	75.6 (35.2)	30	92 (31.6)	+	100%	-16.32[-31.6,-1.04]
Subtotal ***	45		30		•	100%	-16.32[-31.6,-1.04]
Heterogeneity: Not applicable							
			Favo	urs treatment	-500 -250 0 250 500	Favours co	ntrol

Chinese herbal medicines for treating osteoporosis (Review)



Study or subgroup	Expe	erimental	c	Control	Mean Difference		Weight	Mean Difference
	N	Mean(SD)	Ν	Mean(SD)	Fixed, 95% CI			Fixed, 95% CI
Test for overall effect: Z=2.09(F	P=0.04)							
Test for subgroup differences:	Chi ² =952.68, di	f=1 (P<0.0001), l ⁱ	²=99.79%					
			Favo	urs treatment	-500 -250 0 250	500	Favours contro	ol

ADDITIONAL TABLES

Name of herbs	Preparation	English names (Latin names) of the composition	Study ID	
Kanggusong gran- Granule ule		Chinese herbal medicine manufactured by Hebei Handan phar- maceutical factory, which is composed of prepared rhizome of adhesive rehmannia (Radix rehmanniae preparata), Dioscorea batatas (Rhizoma dioscoreae), Cuscuta seed (Semen cuscutae), Epimedium (Herba epimedii), etc.	An SJ 2000; Wu MS 2001	
Bushenhuoxue recipe	Decoction	Herbal mixture composed of deer horn glue (Colla cornus cervi), prepared rhizome of adhesive rehmannia (Radix rehmanniae preparata), Epimedium (Herba epimedii), Cuscu- ta seed (Semen cuscutae), Psoralea corylifolia (Fructus pso- raleae), Eucommia bark (Cortex eucommiae), membranous milk vetch root (Radix astragali), Danshen root (Radix salvi- ae miltiorrhizae), Rhizoma corydalis (Rhizoma corydalis), For- tune's drynaria rhizome (Rhizoma drynariae), Liquorice root (Radix glycyrrhizae), Frankincense (olibanum), Myrrh (Com- miphora molmol), Dragon's bones (Os Draconis) and oyster shell (Concha ostreae)	Cao GY 2010	
Chinese medicine (combinations of 10 herbs)	Decoction	Herbal mixture composed of Psoralea corylifolia (Fructus psoraleae), Fortune's drynaria rhizome (Rhizoma drynariae), Glossy privet fruit (Fructus ligustri lucidi), Epimedium (Herba epimedii), liquorice root (Radix glycyrrhizae), Szechuan lovage rhizome (Rhizoma chuanxiong), Chinese angelica (Radix angel- icae sinensis), Himalayan teasel root (Radix dipsaci), Ground beetle (Eupolyphaga seu steleophaga) and liquorice root (Radix glycyrrhizae)	Cao W 2010	
Gushen decoction	Decoction	Herbal mixture composed of 6 herbs: Epimedium (Herba epimedii), King Solomon's seal rhizome (Rhizoma polygonati), Barbary wolfberry fruit (Fructus lycii), human placenta (Pla- centa hominis), Rehmanniae radix preparata and clematis root (Radix clematidis)	Chen FS 2001	
Gukang oral liquid	Oral liquid	Herbal mixture manufactured by affiliated orthopedics hospital of Guangzhou University of Traditional Chinese Medicine. It is a combined medicine composed of Epimedium (Herba epimedii), desert-living cistanche (Herba cistanches), liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), etc.	Chen JP 1999; Shao M 2003; Wang JM 2008	
Shenyao capsules	Capsule	Chinese patent herbal medicine composed of Red leaves to kidney (Trachelos permum jasminoides Lem. Var. heterophyl- lum Tsiang), White leaves to kidney (euonymus fortunei Hand. Mazz), Cotton kidney (Urena procumbens L), Litchi kidney (Ag- rimonia pilosa Ledeb Var japonica Nakai), Dragon buds kidney	Chen NQ 2006	

Chinese herbal medicines for treating osteoporosis (Review)



Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

(Salvia substolonifera Stib), Fagopyrum esculentum kidney

Beoralea conflicita [Fuctus péoraleae], Rehmaniae radi: preparata, Danshen root (Radix salviae militorrhizae), descri- living cistanche (Herba cistanches), liquorice root (Radix gly- cyrrhizae), Chinese angelica (Radix angelicae sinensis), white peory root (Radix peoniae aldix), Cuscuta seed (Semen cuscu- tae), Chinese date (Fructus jujubae), etc. Chen XL 2 Heche Dazao pill Decoction Herbal mixture composed of human placenta (Placenta ho- minis), Rehmanniae radix preparata, Radix aspraagi, Radix ophiopogonis (Radix ophiopogonis), Eucommia bark (Cortex eucomniae), two-tooth achyranthes root (Radix gdy- cyrrhizae), Posrelae conflicito (Fructus poraleae), Dioscorea batatas (Rhizoma dioscoreae) and Wolfiporia cocos (Poria) Chen YL 2 Jiarong tablet Tablet Chinese patent herbal medicine composed of Epimedium (Her- ba epimedii), Rehmanniae radix preparata), fuciorice root (Radix gdy- cyrrhizae), Doscorea batatas (Rhizoma dioscoreae) and Wolfiporia cocos (Poria) Chen YQ 2 Gushukang granule Granule Chinese patent herbal medicine composed of Epimedium (Her- ba epimedii), Rehmanniae radix preparata), fucror: ture's drynaria rhizome (Rhizoma drynariae), etc. Cui TH 19: 2003 Strong Bone cap- sule Capsule Herbal mixture composed of den homania bark (Cort- spatholobus stem (Caulis spatholobi), etc. Cui TH 19: 2010; Qiu Wu W 200 2009; Zhu 2004; Zhu 2004; Zhu 2004; Zhu 2004; Zhu Cui TH 19: 2010; Qiu Wu W 200 2009; Zhu 2004; Zhu Cui TH 19: 2010; Qiu Wu W 200 2009; Zhu 2010; Qiu Wu W 200 2009; Zhu 2010; Qiu Wu W 200 2009; Zhu Cui TH 19: 2010; Qiu Wu W 200 2009; Zhu 2010; Qiu Wu W 200 2009; Zhu			(Salvia substoionifera Stib), Fagopyrum esculentum kidney (Fagopyrum cymosum Meisn), etc.	
minis), Rehmanniae radix preparata, Radix asparagi, Radix ophiopogonis (Radix ophiopogonis), Eucommia bark (Cortex eucommiae), two-tooth achyranthes root (Radix achyranthis bidentatae), Amur cork tree bark (Cortex phellodendri), totroise shell (Carapax et plastrum testudinis), liquorice root (Radix gly- cyrrhizae), Psoralea corylifolia (Fructus psoraleae), Dioscorea batatas (Rhizoma dioscoreae) and Wolfiporia cocos (Poria)Chen YQ 2Jiarong tabletTabletChinese patent herbal medicine manufactured by XI'an Boai Medicine limited companyChen ZX 2 Medicine limited companyChen ZX 2 Ms 2003Gushukang granuleGranuleChinese patent herbal medicine composed of Epimedium (Her- ba epimedii), Rehmanniae radix preparata, liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), For- tune's drynaria rhizome (Rhizoma drynariae), etc.Chen ZX 2 Ms 2003Strong Bone cap- suleCapsuleHerbal mixture composed of deer horn glue (Colla cornus cervi), desert-living cistanche (Herba cistanches), prepared rhi- zone of rehmannia (Radix rehmanniae preparata), tortoise shell (Carapax et plastrum testudinis), Lucommia bark (Corr- tex eucommiae), bitter orange (Fructus aurantii), Suberect spatholobus stem (Caulis spatholobi), etc.Cui TH 192 2010; Qiu WU W 2007 2010; Qiu WU W 2007 2010; Qiu WU W 2007 2004Migu tabletTabletThe medicine was developed by Union Hospital of Tongji Med- ical College and composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2004Migu tabletTabletThe medicine composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2004Migu table	Gukang dection	Decoction	Psoralea corylifolia (Fructus psoraleae), Rehmanniae radix preparata, Danshen root (Radix salviae miltiorrhizae), desert- living cistanche (Herba cistanches), liquorice root (Radix gly- cyrrhizae), Chinese angelica (Radix angelicae sinensis), white peony root (Radix paeoniae alba), Cuscuta seed (Semen cuscu-	Chen X 2008
Medicine limited companyGushukang granuleGranuleChinese patent herbal medicine composed of Epimedium (Her- ba epimedii), Rehmanniae radix preparata, liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), For- tune's drynaria rhizome (Rhizoma drynariae), etc.Chen ZX 2 MS 2007; i 2003Strong Bone cap- suleCapsuleHerbal mixture composed of deer horn glue (Colla cornus cervi), desert-living cistanch (Herba cistanches), prepared rhi- zome of rehmannia (Radix rehmanniae preparata), tortoise shell (Carapax et plastrum testudinis), Eucommia bark (Cor- tex eucommiae), bitter orange (Furcutus aurantii), SuberectCui TH 19: 2003Xianlinggubao cap- suleCapsuleChinese patent herbal medicine composed of Epimedium (Her- ba epimedii), Himalayan teasel root (Radix dipsaci), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2010; Qiu Wu W 2002 2009; Zha 2004; ZhuMigu tabletTabletThe medicine was developed by Union Hospital of Tongji Med- ical College and composed of Epimedium (Herba epimedii), Eu- commia bark (Cortex eucommiae), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2004Herba epimedii pre- scriptionDecoctionHerbal mixture composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cor- tex eucommiae), oyster shell (Concha ostreae), common monkshood mother root, processed radix aconiti (Radix aconiti preparata), Kunezoff monkshood root (Radix aconiti kusnezof- fii), Chinese angelica (Radix angelicae sinensis) and Szechuan lovage rhizome (Rhizoma chuanxiong)Dong YF 2 Soralea composition was Rehmanniae radix preparata, Dioscorea battas (Rhizoma disocoreae), Eucommia bark, Cortex eucomm	Heche Dazao pill	Decoction	minis), Rehmanniae radix preparata, Radix asparagi, Radix ophiopogonis (Radix ophiopogonis), Eucommia bark (Cortex eucommiae), two-tooth achyranthes root (Radix achyranthis bidentatae), Amur cork tree bark (Cortex phellodendri), tortoise shell (Carapax et plastrum testudinis), liquorice root (Radix gly- cyrrhizae), Psoralea corylifolia (Fructus psoraleae), Dioscorea	Chen XL 2010
ba epimedii), Rehmanniae radix preparata, liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), For- tune's drynaria rhizome (Rhizoma drynariae), etc.MS 2007; i 2003Strong Bone cap- suleCapsuleHerbal mixture composed of deer horn glue (Colla cornus cervi), desert-living cistanche (Herba cistanches), prepared rhi- zome of rehmannia (Radix rehmanniae preparata), tortoise shell (Carapax et plastrum testudinis), Eucommia bark (Cor- tex eucommiae), bitter orange (Fructus aurantii), Suberect spatholobus stem (Caulis spatholobi), etc.Cui TH 193Xianlinggubao cap- suleCapsuleChinese patent herbal medicine composed of Epimedium (Her- ba epimedii), Himalayan teasel root (Radix dipsaci), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2010; Qiu Wu W 200 2009; Zha 	Jiarong tablet	Tablet		Chen YQ 2001
sulecervi), desert-living cistanche (Herba cistanches), prepared rhi- zome of rehmannia (Radix rehmanniae preparata), tortoise shell (Carapax et plastrum testudinis), Eucommia bark (Cor- tex eucommiae), bitter orange (Fructus aurantii), Suberect spatholobus stem (Caulis spatholobi), etc.Dai Y 2007 2010; Qiu Wu W 200 2009; Zha 2009; Zha 2009; Zha 2009; Zha 2009; Zha 2009; Zha 2004 (Radix dipsaci), Psoralea dical College and composed of Epimedium (Her- ba epimedii), Himalayan teasel root (Radix dipsaci), Psoralea a corylifolia (Fructus psoraleae), etc.Dai Y 2007 2010; Qiu Wu W 200 2009; Zha 2004; ZhuMigu tabletTabletThe medicine was developed by Union Hospital of Tongji Med- ical College and composed of Epimedium (Herba epimedii), Eu- commia bark (Cortex eucommiae), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2004Herba epimedii pre- scriptionDecoctionHerbal mixture composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cor- tex eucommiae), oyster shell (Concha ostreae), common monkshood mother root, processed radix aconiti (Radix aconiti preparata), Kusnezoff monkshood root (Radix aconiti kusnezof- fii), Chinese angelica (Radix angelicae sinensis) and Szechuan lovage rhizome (Rhizoma chuanxiong)Dong YF 2Gengnian Anyi tabletTabletChinese patent herbal medicine company. The main composition was Rehmanniae radix preparata, Dioscorea batatas (Rhizoma dioscorea), Eucommia bark (Cortex eucommiae), desert-livingFan HX 20	Gushukang granule	Granule	ba epimedii), Rehmanniae radix preparata, liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), For-	Chen ZX 2002; Wu MS 2007; Zhang YS 2003
suleba epimedii), Himalayan teasel root (Radix dipsaci), Psoralea corylifolia (Fructus psoraleae), etc.2010; Qiu Wu W 200 2009; Zha 2004; ZhuMigu tabletTabletThe medicine was developed by Union Hospital of Tongji Med- ical College and composed of Epimedium (Herba epimedii), Eu- commia bark (Cortex eucommiae), Psoralea corylifolia (Fructus psoraleae), etc.Dai Y 2007 2004Herba epimedii pre- scriptionDecoctionHerbal mixture composed of Epimedium (Herba epimedii), 		Capsule	cervi), desert-living cistanche (Herba cistanches), prepared rhi- zome of rehmannia (Radix rehmanniae preparata), tortoise shell (Carapax et plastrum testudinis), Eucommia bark (Cor- tex eucommiae), bitter orange (Fructus aurantii), Suberect	Cui TH 1999
ical College and composed of Epimedium (Herba epimedii), Eu- commia bark (Cortex eucommiae), Psoralea corylifolia (Fructus psoraleae), etc.2004Herba epimedii pre- scriptionDecoctionHerbal mixture composed of Epimedium (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cor- tex eucommiae), oyster shell (Concha ostreae), common monkshood mother root, processed radix aconiti (Radix aconiti preparata), Kusnezoff monkshood root (Radix aconiti kusnezof- fii), Chinese angelica (Radix angelicae sinensis) and Szechuan lovage rhizome (Rhizoma chuanxiong)Dong YF 2Gengnian Anyi 		Capsule	ba epimedii), Himalayan teasel root (Radix dipsaci), Psoralea	Dai Y 2007; Dong Y 2010; Qiu ZX 2010; Wu W 2005; Xu M 2009; Zhang XZ 2004; Zhu HM 2012
scription Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cortex eucommiae), oyster shell (Concha ostreae), common monkshood mother root, processed radix aconiti (Radix aconiti preparata), Kusnezoff monkshood root (Radix aconiti kusnezoffii), Chinese angelica (Radix angelicae sinensis) and Szechuan lovage rhizome (Rhizoma chuanxiong) Gengnian Anyi Tablet Chinese patent herbal medicine manufactured by Hubei tra-tablet Chinese patent herbal medicine company. The main composition was Rehmanniae radix preparata, Dioscorea batatas (Rhizoma dioscoreae), Eucommia bark (Cortex eucommiae), desert-living	Migu tablet	Tablet	ical College and composed of Epimedium (Herba epimedii), Eu- commia bark (Cortex eucommiae), Psoralea corylifolia (Fructus	Dai Y 2007; Xie J 2004
tablet ditional Chinese medicine company. The main composition was Rehmanniae radix preparata, Dioscorea batatas (Rhizoma dioscoreae), Eucommia bark (Cortex eucommiae), desert-living		Decoction	Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cor- tex eucommiae), oyster shell (Concha ostreae), common monkshood mother root, processed radix aconiti (Radix aconiti preparata), Kusnezoff monkshood root (Radix aconiti kusnezof- fii), Chinese angelica (Radix angelicae sinensis) and Szechuan	Dong YF 2004
		Tablet	ditional Chinese medicine company. The main composition was Rehmanniae radix preparata, Dioscorea batatas (Rhizoma dioscoreae), Eucommia bark (Cortex eucommiae), desert-living	Fan HX 2004

Chinese herbal medicines for treating osteoporosis (Review)



Gumiling granule	Granule	Self developed herbal mixture (no details on composition)	Gang PH 2001
Shengu capsule	Capsule	Chinese patent medicine manufactured by Beijing Tianjiu Med- icine limited company. The main composition was oyster shell (Concha ostreae)	Gong L 2001
Yishen Zhuanggu mixture	Decoction	Chinese patented medicine manufactured by Beijing Xuan- wu hospital. It is a combined medicine composed of Psoralea corylifolia (Fructus psoraleae), Radix codonopsis pilosulae (Radix codonopsis), Fortune's drynaria rhizome (Rhizoma dry- nariae), Rehmanniae radix preparata, liquorice root (Radix gly- cyrrhizae), etc.	Gong L 2001
Bushen Kangsong pill	Pill	Chinese patent medicine manufactured by the People's Lib- eration Army General Hospital of Nanjing Military Region. It is composed of Rehmanniae radix preparata, Chinese taxillus twig (Herba taxilli), Dioscorea batatas (Rhizoma dioscoreae), common macrocarpium fruit (Fructus corni), Barbary wolfberry fruit (Fructus lycii), hairy antler (Corn Cervi Pantotrichum), Hi- malayan teasel root (Radix dipsaci), Psoralea corylifolia (Fruc- tus psoraleae), Eucommia bark (Cortex eucommiae), Epimedi- um (Herba epimedii), desert-living cistanche (Herba cistanch- es), two-tooth achyranthes root (Radix achyranthis bidentatae), Cuscuta seed (Semen cuscutae), cassia bark (Cortex cinnamo- mi), Chinese angelica (Radix angelicae sinensis), liquorice root (Radix glycyrrhizae), Dragon's bones (Os Draconis), oyster shell (Concha ostreae), hawthorn fruit (Fructus crataegi), liquorice root (Radix glycyrrhizae), etc.	Guo JH 2008
Shugan zishen huoxue tang	Decoction	Herbal mixture composed of Chinese thorowax root (Radix bu- pleuri), white peony root (Radix paeoniae alba), Nutgrass galin- gale rhizome (Rhizoma cyperi), bitter orange (Fructus auran- tii), Pinellia tuber (Rhizoma pinelliae), Wolfiporia cocos (Poria), prepared rhizome of adhesive rehmannia (Radix rehmanniae preparata), common macrocarpium fruit (Fructus corni), tor- toise shell (Carapax et plastrum testudinis), East Asian tree fern rhizome (Rhizoma cibotii), Fructus chaenomelis (Chaenome- les speciosa Nakai), prepared frankincense (olibanum), Myrrh preparata (Commiphora molmol) and Szechuan lovage rhi- zome (Rhizoma chuanxiong)	Han XL 2007
Bushen Jianpi Huoxue recipe	Decoction	Herbal mixture composed of Psoralea corylifolia (Fructus pso- raleae), Epimedium (Herba epimedii), desert-living cistanche (Herba cistanches), Rehmanniae radix preparata, white peony root (Radix paeoniae alba), liquorice root (Radix glycyrrhizae), Cuscuta seed (Semen cuscutae), Danshen root (Radix salviae miltiorrhizae), Chinese angelica (Radix angelicae sinensis) and Chinese date (Fructus jujubae)	He MT 2007
Jiawei Zhuangyao Jianshen tang	Decoction	Herbal mixture composed of East Asian tree fern rhizome (Rhi- zoma cibotii), Cherokee rose fruit (Fructus rosae laevigatae), Chinese taxillus twig (Herba taxilli), suberect spatholobus stem (Caulis spatholobi), Philippine flemingia root (Moghania philip- pinensis li.), beautiful millettia root (Millettia speciosa champ), Cuscuta seed (Semen cuscutae), glossy privet fruit (Fructus ligustri lucidi), Rhizoma corydalis (Rhizoma corydalis), Chi- nese angelica (Radix angelicae sinensis), red peony root (Radix paeoniae rubra) and largehead atractylodes rhizome (Rhizoma atractylodis macrocephalae)	He N 2006

Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

Chinese herbal medicines for treating osteoporosis (Review)

Bushen Yangxue tang	Decoction	Herbal mixture composed of medicinal Indian mulberry root (Radix morindae officinalis), Epimedium (Herba epimedii), Cherokee rose fruit (Fructus rosae laevigatae), Barbary wolfber- ry fruit (Fructus lycii), Chinese date (Fructus jujubae), Chinese angelica (Radix angelicae sinensis), white peony root (Radix paeoniae alba) and tuber fleece flower root (Radix polygoni multiflori), etc.	He XQ 2006; Zhan ML 2007
Shangke Yishen Zhuanggu pill	Pill	Herbal mixture composed of Rehmanniae radix preparata, Chi- nese angelica (Radix angelicae sinensis), two-tooth achyran- thes root (Radix achyranthis bidentatae), Sanqi (Radix noto- ginseng), Wolfiporia cocos (Poria), Danshen root (Radix salvi- ae miltiorrhizae), common macrocarpium fruit (Fructus corni), Szechuan lovage rhizome (Rhizoma chuanxiong), membranous milk vetch root (Radix astragali), etc.	Hu J 2012
Erxian Yanggu tang	Decoction	Herbal mixture composed of medicinal Indian mulberry root (Radix morindae officinalis), common curculigo rhizome (Rhi- zoma curculiginis), Epimedium (Herba epimedii), Barbary wolf- berry fruit (Fructus lycii), Eucommia bark (Cortex eucommi- ae), Fortune's drynaria rhizome (Rhizoma drynariae), Amur cork tree bark (Cortex phellodendri), common anemarrhena rhizome (Rhizoma anemarrhenae), deer horn glue (Colla cor- nus cervi), tortoise shell glue (Colla carapacis et plastri testu- dinis), paniculate swallow wort root (Radix Cynanchi Panicu- lati), white peony root (Radix paeoniae alba), Chinese angelica (Radix angelicae sinensis), Radix astragali preparata and bitter orange (Fructus aurantii)	Huang JW 2008
Zishen Gukang pill	Pill	Chinese patent medicine manufactured by the Traditional Chi- nese Medicine Hospital of Henan province pharmacy. It is com- posed of Epimedium (Herba epimedii), Chinese angelica (Radix angelicae sinensis), prepared rhizome of adhesive rehmannia (Radix rehmanniae preparata), Psoralea corylifolia (Fructus psoraleae), common macrocarpium fruit (Fructus corni), two- tooth achyranthes root (Radix achyranthis bidentatae), etc.	Huang ZJ 2008
Shengsuiyin	Decoction	Herbal mixture composed of medicinal Indian mulberry root (Radix morindae officinalis), Chinese taxillus twig (Herba taxilli), Cuscuta seed (Semen cuscutae), tortoise shell glue (Colla cara- pacis et plastri testudinis), Epimedium (Herba epimedii), com- mon macrocarpium fruit (Fructus corni), Radix codonopsis pilo- sulae (Radix codonopsis), Dioscorea batatas (Rhizoma dioscore- ae), Wolfiporia cocos (Poria) and glossy privet fruit (Fructus ligustri lucidi)	Jian QQ 2010
Guli powder	Powder	Chinese patent medicine manufactured by drug manufacto- ry of the research institute of traditional Chinese medicine of Sichuan province. It is composed of Radix codonopsis pilosu- lae (Radix codonopsis), large head atractylodes rhizome (Rhi- zoma atractylodis macrocephalae), Wolfiporia cocos (Poria), Radix angelicae (Radix angelicae dahuricae), Epimedium (Her- ba epimedii), common cnidium fruit (Fructus cnidii), Psoralea fruits (Fructus psoraleae), Rehmanniae radix preparata, two- tooth achyranthes root (Radix achyranthis bidentatae), etc.	Lan ZX 2006
Jianshenfang gran- ule	Granule	Chinese patent medicine manufactured by Guangzhou Yuex- iu District Orthopedic Hospital. It is composed of Himalayan teasel root (Radix dipsaci), clematis root (Radix clematidis),	Li BL 2007

Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

Chinese herbal medicines for treating osteoporosis (Review)



		Cherokee rose fruit (Fructus rosae laevigatae), East Asian tree fern rhizome (Rhizoma cibotii), Philippine flemingia root (Moghania philippinensis li.), two-tooth achyranthes root (Radix achyranthis bidentatae), etc.	
Ziyin Bushen Zhuanggu prescrip- tion	Decoction	Investigator-prescribed herbal mixture composed of Eucom- mia bark (Cortex eucommiae), Rehmanniae radix preparata, deer horn glue (Colla cornus cervi), liquorice root (Radix gly- cyrrhizae), Chinese angelica (Radix angelicae sinensis), Rhi- zoma corydalis (Rhizoma corydalis), two-tooth achyranthes root (Radix achyranthis bidentatae), Danshen root (Radix salvi- ae miltiorrhizae), Psoralea corylifolia (Fructus psoraleae), Wolfi- poria cocos (Poria), etc.	Li HW 2004
Zhuanggu capsule	Capsule	Herbal mixture composed of Epimedium (Herba epimedii), common cnidium fruit (Fructus cnidii), human placenta (Pla- centa hominis), liquorice root (Radix glycyrrhizae), Sanqi (Radix notoginseng), etc.	Li SL 2004
Jingujian granule	Granule	Chinese patent medicine manufactured by Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine pharmacy. It is composed of Fortune's drynaria rhizome (Rhizoma drynari- ae), Eucommia bark (Cortex eucommiae), Szechuan lovage rhi- zome (Rhizoma chuanxiong), large head atractylodes rhizome (Rhizoma atractylodis macrocephalae), Manchurian wild ginger (Herba asari), etc.	Li YH 2008
Jingujian granule (1,2,3)	Granule	Jingujian granule 1: Rehmanniae radix preparata, common macrocarpium fruit (Fructus corni), Cuscuta seed (Semen cus- cutae), tortoise shell (Carapax et plastrum testudinis), two- tooth achyranthes root (Radix achyranthis bidentatae), For- tune's drynaria rhizome (Rhizoma drynariae), Eucommia bark (Cortex eucommiae), etc. Jingujian granule 2: Psoralea corylifolia (Fructus psoraleae), Eucommia bark (Cortex eucommiae), two-tooth achyranthes root (Radix achyranthis bidentatae), Radix codonopsis pilosu- lae (Radix codonopsis), large-head atractylodes rhizome (Rhi- zoma atractylodis macrocephalae), etc. Jingujian granule 3: Eucommia bark (Cortex eucommiae), For- tune's drynaria rhizome (Rhizoma drynariae), Medicinal cyathu- la root (Radix cyathulae), two-tooth achyranthes root (Radix achyranthis bidentatae), Manchurian wild ginger (Herba asari), large-head atractylodes rhizome (Rhizoma atractylodis macro- cephalae), Szechuan lovage rhizome (Rhizoma chuanxiong)	Li YH 2010
Kanggusong soup	Decoction	Herbal mixture composed of Rehmanniae radix preparata 18 g, Barbary wolfberry fruit (Fructus lycii) 9 g, Epimedium (Her- ba epimedii) 18 g, Himalayan teasel root (Radix dipsaci) 9 g, membranous milk vetch root (Radix astragali) 9 g, Wolfiporia cocos (Poria) 9 g, Danshen root (Radix salviae miltiorrhizae) 18 g, Radix puerariae (Radix puerariae) 9 g, suberect spatholobus stem (Caulis spatholobi) 18 g, etc.	Li ZP 2011
Xianling Gusong capsule	Capsule	The capsule included Epimedium (Herba epimedii), common curculigo rhizome (Rhizoma curculiginis), medicinal Indian mulberry root (Radix morindae officinalis), ginseng (Radix gin- seng), Chinese angelica (Radix angelicae sinensis), human pla- centa (Placenta hominis) and common anemarrhena rhizome (Rhizoma anemarrhenae).	Li ZY 2006

Chinese herbal medicines for treating osteoporosis (Review)

Cochrane

Librarv

Bushenhuoxue therapy	Decoction	Herbal mixture composed of Rehmanniae radix preparata 24 g, Epimedium (Herba epimedii) 18 g, membranous milk vetch root (Radix astragali) 15 g, common macrocarpium fruit (Fruc- tus corni) 12 g, Dioscorea batatas (Rhizoma dioscoreae) 12 g, Eucommia bark (Cortex eucommiae) 12g, Danshen root (Radix salviae miltiorrhizae) 12 g, tree peony bark (Cortex moutan) 9 g, Wolfiporia cocos (Poria) 9 g, oriental water plantain rhizome (Rhizoma alismatis) 9 g, safflower (Flos carthami) 9 g, Sanqi (Radix notoginseng) 3 g	Liang DB 2012
Bushen Shengsui principle	Decoction	Investigator-prescribed herbal mixture composed of Psoralea corylifolia (Fructus psoraleae), Epimedium (Herba epimedii), Eucommia bark (Cortex eucommiae) and glossy privet fruit (Fructus ligustri lucidi)	Liao L 2004
Migu decoction	Decoction	Self developed herbal mixture (no details on composition)	Lin W 2000
Bushen Zhuanggu tang	Decoction	Herbal mixture composed of East Asian tree fern rhizome (Rhi- zoma cibotii), Himalayan teasel root (Radix dipsaci), medici- nal Indian mulberry root (Radix morindae officinalis), Epimedi- um (Herba epimedii), Psoralea corylifolia (Fructus psoraleae), liquorice root (Radix glycyrrhizae), white peony root (Radix paeoniae alba), Chinese angelica (Radix angelicae sinensis), Szechuan lovage rhizome (Rhizoma chuanxiong), safflower (Flos carthami) and two-tooth achyranthes root (Radix achyran- this bidentatae)	Ling JY 2008
Gukang tablet	Tablet	Chinese patent medicine manufactured by Laiyang biological chemical pharmaceutical factory. It is composed of Rehman- niae radix preparata, Epimedium (Herba epimedii), suberect spatholobus stem (Caulis spatholobi), Chinese Pyrola Herb (Herba Pyrolae), Eucommia bark (Cortex eucommiae), medi- cinal Indian mulberry root (Radix morindae officinalis), com- mon curculigo rhizome (Rhizoma curculiginis), desert-living cis- tanche (Herba cistanches), two-tooth achyranthes root (Radix achyranthis bidentatae), Chinese angelica (Radix angelicae sinensis), safflower (Flos carthami), etc.	Liu JM 2012
Jiawei Bushen Zhuangjintang	Decoction	Investigator-prescribed herbal formulation composed of Rehmanniae radix preparata, Chinese angelica (Radix angelicae sinensis), two-tooth achyranthes root (Radix achyranthis biden- tatae), Asiatic cornelian cherry fruit (Fructus corni), Wolfiporia cocos (Poria), Himalayan teasel root (Radix dipsaci), Eucommia bark (Cortex eucommiae), white peony root (Radix paeoniae al- ba), green tangerine peel (Pericarpium citri reticulatae viride), Slenderstyle acanthopanax bark (Cortex acanthopanacis), hairy antler (Corn Cervi Pantotrichum), etc.	Lv ZH 2002
Yiyuanjiangu de- coction	Decoction	Herbal mixture composed of Rehmanniae radix preparata 15 g, Psoralea corylifolia (Fructus psoraleae) 15 g, Epimedium (Herba epimedii) 10 g, Radix angelicae pubescentis 10 g, Barbary wolf- berry fruit (Fructus lycii) 10 g, East Asian tree fern rhizome (Rhi- zoma cibotii) 10 g, Chinese angelica (Radix angelicae sinensis) 10 g, membranous milk vetch root (Radix astragali) 20 g, two- tooth achyranthes root (Radix achyranthis bidentatae) 20 g, Chinese taxillus twig (Herba taxilli) 20 g, Himalayan teasel root (Radix dipsaci) 12 g, etc.	Ma CZ 2011

Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. Cochrane

Library

Yishen Zhuanggu decoction	Decoction	Herbal mixture composed of Rehmanniae radix preparata 24 g, Fortune's drynaria rhizome (Rhizoma drynariae) 20g, Hi- malayan teasel root (Radix dipsaci) 20 g, Epimedium (Her- ba epimedii) 30 g, Chinese angelica (Radix angelicae sinen- sis) 15 g, white peony root (Radix paeoniae alba) 10 g, Eucom- mia bark (Cortex eucommiae) 20 g, Chinese taxillus twig (Her- ba taxilli) 30g, membranous milk vetch root (Radix astragali) 30g, Dioscorea batatas (Rhizoma dioscoreae) 2 0g, tuber fleece flower root (Radix polygoni multiflori) 20 g and Cuscuta seed (Semen cuscutae) 15 g	Ma YJ 2011
Bushen Jianpi Jin- gu decoction	Decoction	Herbal mixture composed of Rehmanniae radix preparata 20 g, Dioscorea batatas (Rhizoma dioscoreae) 15 g, common macro- carpium fruit (Fructus corni) 12 g, Barbary wolfberry fruit (Fruc- tus lycii) 12 g, Eucommia bark (Cortex eucommiae) 15 g, Pso- ralea corylifolia (Fructus psoraleae) 15 g, Fortune's drynar- ia rhizome (Rhizoma drynariae) 15 g, Radix codonopsis pilo- sulae (Radix codonopsis) 20 g, membranous milk vetch root (Radix astragali) 20 g, large-head atractylodes rhizome (Rhi- zoma atractylodis macrocephalae) 10 g, Wolfiporia cocos (Po- ria) 10 g and liquorice root (Radix glycyrrhizae) 10 g	Mao YF 2011
Gujian capsule	Capsule	Developed by Xiyuan hospital of China academy of TCM (no de- tails on composition)	Meng XD 2003
Traditional Chinese capsule	Capsule	The capsule included Epimedium (Herba epimedii), Fortune's drynaria rhizome (Rhizoma drynariae), liquorice root (Radix gly- cyrrhizae), King Solomon's seal rhizome (Rhizoma polygonati), Radix puerariae (Radix puerariae), Rhizoma corydalis (Rhizoma corydalis), etc.	Miu JQ 2008
Bushen Qiangshen pill	Pill	Chinese patented medicine composed of ginseng (Radix gin- seng), hairy antler (Cornu cervi pantotrichum), desert-living cis- tanche (Herba cistanches), liquorice root (Radix glycyrrhizae), Barbary wolfberry fruit (Fructus lycii), etc.	Mu G 2001; Mu G 2001a
Radix rehmanni- ae preparata and Radix astragali	Decoction	Herbal mixture composed of Rehmanniae radix preparata 30 g, membranous milk vetch root (Radix astragali) 30 g, etc.	Ou L 2011
Qianggu soft ex- tract	Slurry	Herbal mixture composed of medicinal Indian mulberry root (Radix morindae officinalis), Cuscuta seed (Semen cuscutae), liquorice root (Radix glycyrrhizae), Chinese angelica (Radix an- gelicae sinensis), etc.	Peng T 2002
Bushen Qianggutang	Decoction	Investigator-prescribed formula composed of Himalayan teasel root (Radix dipsaci), Cuscuta seed (Semen cuscutae), Psoralea corylifolia (Fructus psoraleae), Fortune's drynaria rhizome (Rhi- zoma drynariae), common macrocarpium fruit (Fructus corni), Barbary wolfberry fruit (Fructus lycii), glossy privet fruit (Fruc- tus ligustri lucidi), Dioscorea batatas (Rhizoma dioscoreae), Wolfiporia cocos (Poria), etc.	Qi ZX 1998
Yanghuo Sanzi tang	Decoction	Herbal mixture composed of Epimedium (Herba epimedii), Fructus Schisandrae (Fructus schisandrae chinensis), common macrocarpium fruit (Fructus corni), Psoralea corylifolia (Fruc- tus psoraleae), mulberry fruit (Fructus mori), Barbary wolfber- ry fruit (Fructus lycii), oyster shell (Concha ostreae), prepared	Qiu RB 2004

 Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

Chinese herbal medicines for treating osteoporosis (Review)



Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

fleece flower root (Radix polygoni multiflori preparata) and red

		ginseng (Radix ginseng rubra)	
Jiangu recipe	Decoction	Herbal mixture composed of Epimedium (Herba epimedii), medicinal Indian mulberry root (Radix morindae officinalis), common cnidium fruit (Fructus cnidii), liquorice root (Radix glycyrrhizae), Fortune's drynaria rhizome (Rhizoma drynari- ae), deer horn glue (Colla cornus cervi), hawthorn fruit (Fructus crataegi), common macrocarpium fruit (Fructus corni) and Pso- ralea corylifolia (Fructus psoraleae)	Qiu RB 2008
Qianggu capsule	Capsule	Chinese patent medicine manufactured by Beijing Qihuang Pharmaceutical Limited Company; the main composition was Fortune's drynaria rhizome (Rhizoma drynariae)	Ruan XY 2006; Wang J 2007; Xu H 2010
Kangshu Jiangu granule	Granule	Chinese patent medicine manufactured by Shanxi college of traditional Chinese medicine pharmaceutical factory. It is com- posed of Epimedium (Herba epimedii) 20 g, Eucommia bark (Cortex eucommiae) 15 g, two-tooth achyranthes root (Radix achyranthis bidentatae) 15 g, Danshen root (Radix salviae mil- tiorrhizae) 15 g, large-head atractylodes rhizome (Rhizoma atractylodis macrocephalae) 12 g, etc.	Shi CD 2012
Kidney-tonifying herbs	Granule	Herbal mixture composed of Epimedium (Herba epimedii), desert-living cistanche (Herba cistanches), Psoralea corylifo- lia (Fructus psoraleae), tuber fleece flower root (Radix polygo- ni multiflori), Chinese angelica (Radix angelicae sinensis), saf- flower (Flos carthami), common aucklandia root (Radix auck- landiae), etc.	Song XW 2000
Bushen Qianggu Huoxue therapy	Decoction	Herbal mixture composed of Psoralea corylifolia (Fructus pso- raleae) 15 g, Fortune's drynaria rhizome (Rhizoma drynariae) 10 g, Eucommia bark (Cortex eucommiae) 15 g, Epimedium (Her- ba epimedii) 10 g, Barbary wolfberry fruit (Fructus lycii) 15 g, Rehmanniae radix preparata 15 g, desert-living cistanche (Her- ba cistanches) 10 g, deer horn glue (Colla cornus cervi) 10 g, medicinal Indian mulberry root (Radix morindae officinalis) 10 g, Cuscuta seed (Semen cuscutae) 15 g, East Asian tree fern rhi- zome (Rhizoma cibotii) 10 g, Himalayan teasel root (Radix dip- saci) 10 g, Sanqi (Radix notoginseng) 10 g, Danshen root (Radix salviae miltiorrhizae) 10 g, suberect spatholobus stem (Caulis spatholobi) 15 g, etc.	Tang ZA 2012
Gumikang capsule	Capsule	Herbal mixture composed of human placenta (Placenta homin- is), hairy antler (Cornu cervi pantotrichum), etc.	Wang CC 2005
Qianggu paste	Paste	Chinese patent medicine manufactured by Affiliated Hospital of Wuhan University of Technology pharmacy, composed of flat stem milk vetch seed (Semen astragali complanati), Psoralea corylifolia (Fructus psoraleae), Epimedium (Herba epimedii), Chinese angelica (Radix angelicae sinensis), liquorice root (Radix glycyrrhizae), etc.	Wang H 2007
Antai capsule	Capsule	Chinese herbal medicine manufactured by the medicine re- search institute of Fourth Military Medical University.	Wang SW 2003
Hugu capsule	Capsule	Chinese patent medicine manufactured by Dongguan Super Success Pharmaceutical Co., Ltd. It is composed of tuber fleece	Wang XD 2011

Chinese herbal medicines for treating osteoporosis (Review)

		epimedii), Rehmanniae radix preparata, etc.	
Bushen Yigu soft ex- tract	Oral liquid	Herbal mixture composed of prepared rhizome of adhesive rehmannia (Radix rehmanniae preparata), Epimedium (Herba epimedii), large-head atractylodes rhizome (Rhizoma atracty- lodis macrocephalae), oriental water plantain rhizome (Rhi- zoma alismatis), etc.	Wang XY 2000
Jiangu capsule	Capsule	Chinese patent medicine manufactured by Affiliated Hospital of Luohe Medical College pharmacy, composed of liquorice root (Radix glycyrrhizae), Danshen root (Radix salviae miltiorrhizae), Szechuan lovage rhizome (Rhizoma chuanxiong), Cuscuta seed (Semen cuscutae), Asiatic cornelian cherry fruit (Fructus corni), Dragon's bones (Os Draconis), oyster shell (Concha ostreae) and medicinal Indian mulberry root (Radix morindae officinalis)	Wang YZ 2008
Bushen Jianpi Migu prescription	Decoction	Investigator-prescribed herbal formulation composed of liquorice root (Radix glycyrrhizae), Cuscuta seed (Semen cus- cutae), Epimedium (Herba epimedii), Asiatic cornelian cher- ry fruit (Fructus corni), Dragon's bones (Os Draconis), oyster shell (Concha ostreae), deer horn glue (Colla cornus cervi), Rehmanniae radix preparata, desert-living cistanche (Herba cistanches), Eucommia bark (Cortex eucommiae), suberect spatholobus stem (Caulis spatholobi), medicinal Indian mulber- ry root (Radix morindae officinalis), Szechuan lovage rhizome (Rhizoma chuanxiong), liquorice root (Radix glycyrrhizae)	Wang ZK 2004
Kanggusong cap- sule (self devel- oped)	Capsule	Manufactured by the First Attached Hospital of Hebei North- ern Institute, composed of Epimedium (Herba epimedii), Hi- malayan teasel root (Radix dipsaci), Rehmanniae radix prepara- ta, Barbary wolfberry fruit (Fructus lycii), liquorice root (Radix glycyrrhizae), Wolfiporia cocos (Poria), Danshen root (Radix salviae miltiorrhizae), Radix puerariae (Radix puerariae) and suberect spatholobus stem (Caulis spatholobi)	Wei RY 2011
Erxian soup	Liquid	Herbal mixture composed of common curculigo rhizome (Rhi- zoma curculiginis), Epimedium (Herba epimedii), medicinal In- dian mulberry root (Radix morindae officinalis), Chinese angel- ica (Radix angelicae sinensis), common anemarrhena rhizome (Rhizoma anemarrhenae), Amur cork tree bark (Cortex phel- lodendri)	Wu JZ 2010
Urinary bladder meridian sticking	Patch	Herbal mixture composed of Rehmannia root (Radix rehmanni- ae), Epimedium (Herba epimedii), Dioscorea batatas (Rhizoma dioscoreae), Danshen root (Radix salviae miltiorrhizae), For- tune's drynaria rhizome (Rhizoma drynariae), Radix angelicae pubescentis, etc.	Wu MS 2007
Kidney meridian sticking	Patch	Herbal mixture composed of Rehmannia root (Radix rehmanni- ae), Epimedium (Herba epimedii), Dioscorea batatas (Rhizoma dioscoreae), Danshen root (Radix salviae miltiorrhizae), For- tune's drynaria rhizome (Rhizoma drynariae), Radix angelicae pubescentis, etc.	Wu MS 2007
Prescription for tonifying kidney	Pill	Herbal mixture composed of Rehmannia root (Radix rehmanni- ae), Epimedium (Herba epimedii), Dioscorea batatas (Rhizoma dioscoreae), Danshen root (Radix salviae miltiorrhizae), For-	Wu MS 2007

Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

Chinese herbal medicines for treating osteoporosis (Review)



Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued) tune's drynaria rhizome (Rhizoma drynariae). Radix angelicae

		tune's drynaria rhizome (Rhizoma drynariae), Radix angelicae pubescentis, etc.	
Gusong fang	Decoction	Herbal mixture composed of nutmeg, Chinese angelica (Radix angelicae sinensis), liquorice root (Radix glycyrrhizae), Psoralea corylifolia (Fructus psoraleae), Epimedium (Herba epimedii), desert-living cistanche (Herba cistanches), etc.	Xiao W 2008
Bugu Shengsui cap- sule	Capsule	Herbal mixture composed of Psoralea corylifolia (Fructus pso- raleae), East Asian tree fern rhizome (Rhizoma cibotii), Sanqi (Radix notoginseng), ginseng (Radix ginseng), etc.	Xie YM 1997
Jiangu granule	Granule	Chinese patent medicine manufactured by Ruijin hospital pharmacy, composed of Epimedium (Herba epimedii), Radix codonopsis pilosulae (Radix codonopsis), large-head atracty- lodes rhizome (Rhizoma atractylodis macrocephalae), glossy privet fruit (Fructus ligustri lucidi), etc.	Xiong YH 2008
Gusongbao granule	Granule	Chinese patent medicine composed of Epimedium (Herba epimedii), Rehmanniae radix preparata, oyster shell (Concha ostreae), etc.	Xiong YH 2008; Zhan HS 2009
Yishen Yanggan mixture	Oral liquid	Herbal mixture composed of liquorice root (Radix glycyrrhizae), common macrocarpium fruit (Fructus corni), Epimedium (Her- ba epimedii), desert-living cistanche (Herba cistanches), Pso- ralea corylifolia (Fructus psoraleae), Chinese angelica (Radix angelicae sinensis), etc.	Xu W 2005
Acupoint sticking of Migudan	Patch	Herbal mixture composed of Psoralea corylifolia (Fructus pso- raleae), Fortune's drynaria rhizome (Rhizoma drynariae), Hi- malayan teasel root (Radix dipsaci), Szechuan lovage rhizome (Rhizoma chuanxiong), processed radix aconiti (Radix aconiti preparata), tuberculate Speranskia herb (Garden balsam stem), two-tooth achyranthes root (Radix achyranthis bidentatae), Manchurian wild ginger (Herba asari), etc.	Xu YL 2007
Huangqi	Decoction	Single herb of liquorice root (Radix glycyrrhizae)	Yang B 2007
Bushen Zhuanggutang	Decoction	Investigator-prescribed formula composed of Eucommia bark (Cortex eucommiae), Rehmanniae radix preparata, Fortune's drynaria rhizome (Rhizoma drynariae), Barbary wolfberry fruit (Fructus lycii), Epimedium (Herba epimedii), Radix codonop- sis pilosulae (Radix codonopsis), liquorice root (Radix gly- cyrrhizae), common macrocarpium fruit (Fructus corni) and Sanqi (Radix notoginseng)	Ye AN 1998
Shangke Jiegu tablet	Tablet	Chinese patent herbal medicine composed of Sanqi (Radix no- toginseng), safflower (Flos carthami), frankincense (olibanum), myrrh (Commiphora molmol), ground beetle (Eupolyphaga seu steleophaga), etc.	Yuan YN 2000
Xuduanzhuanggu capsule	Capsule	Chinese patent medicine manufactured by Zhejiang Di'er medi- cine limited company	Zhan HS 2009
Bushenyiqihuoxue soup	Decoction	Herbal mixture composed of Psoralea corylifolia (Fructus psoraleae), Fortune's drynaria rhizome (Rhizoma drynariae), glossy privet fruit (Fructus ligustri lucidi), Epimedium (Her- ba epimedii), liquorice root (Radix glycyrrhizae), white peony root (Radix paeoniae alba), Chinese angelica (Radix angelicae	Zhang DS 2011

Chinese herbal medicines for treating osteoporosis (Review)



		(Eupolyphaga seu steleophaga) and liquorice root (Radix gly- cyrrhizae)	
Liuwei Dihuang pill	Pill	Chinese patent medicine	Ma C 2011; Zhang J 2003
Yigu capsule	Capsule	Herbal mixture composed of Epimedium (Herba epimedii), Bar- bary wolfberry fruit (Fructus lycii), Chinese angelica (Radix an- gelicae sinensis), two-tooth achyranthes root (Radix achyran- this bidentatae), etc.	Zhang RH 2004
Bushenjianpi Zhuangguyin	Decoction	Herbal mixture composed of human placenta (Placenta ho- minis), Dioscorea batatas (Rhizoma dioscoreae), red peony root (Radix paeoniae rubra), white peony root (Radix paeoni- ae alba), Chinese angelica (Radix angelicae sinensis), Radix codonopsis pilosulae (Radix codonopsis), liquorice root (Radix glycyrrhizae), large-head atractylodes rhizome (Rhizoma atractylodis macrocephalae), common macrocarpium fruit (Fructus corni), common cnidium fruit (Fructus cnidii), Chi- nese thorowax root (Radix bupleuri), Eucommia bark (Cortex eucommiae), two-tooth achyranthes root (Radix achyranthis bidentatae), Amur cork tree bark (Cortex phellodendri), tortoise shell (Carapax et plastrum testudinis), liquorice root (Radix gly- cyrrhizae), Psoralea corylifolia (Fructus psoraleae), Wolfiporia cocos (Poria), scorpion, Epimedium (Herba epimedii), Sanqi (Radix notoginseng), leech (Hirudo), etc.	Zhang XG 2011
Bushen Huoxue capsule	Capsule	Herbal mixture composed of Epimedium (Herba epimedii), Eucommia bark (Cortex eucommiae), Himalayan teasel root (Radix dipsaci), deer horn glue (Colla cornus cervi), common macrocarpium fruit (Fructus corni), liquorice root (Radix gly- cyrrhizae), Dioscorea batatas (Rhizoma dioscoreae), Chinese angelica (Radix angelicae sinensis), Safflower (Flos carthami), etc.	Zhang XJ 2008
TPF capsule	Capsule	Chinese herbal medicine composed of cake uterine, Colla corii asini, Corium stomachium galli	Zhang YL 1996
Shigu yin	Liquid	Chinese patent medicine manufactured by Third Affiliated Hospital of Luohe Medical College pharmacy, composed of Rehmanniae radix preparata, East Asian tree fern rhizome (Rhi- zoma cibotii), Epimedium (Herba epimedii), Psoralea corylifo- lia (Fructus psoraleae), oyster shell (Concha ostreae), Dioscorea batatas (Rhizoma dioscoreae), etc.	Zhang YP 2007
Huoluo Gukang pill	Pill	Condensed pill composed of Psoralea corylifolia (Fructus psoraleae), Fortune's drynaria rhizome (Rhizoma drynariae), liquorice root (Radix glycyrrhizae), safflower (Flos carthami), Zedoary (Rhizoma curcumae), deer horn glue (Colla cornus cervi), Lumbricus (Pheretima), etc.	Zhang YS 2003
Zhuangguqiangjin tablet	Tablet	Manufactured by Dongwan Hospital of Traditional Chinese Medicine, composed of Slenderstyle acanthopanax bark (Cor- tex acanthopanacis), deer horn glue (Colla cornus cervi), desert-living cistanche (Herba cistanches), Philippine flemingia root (Moghania philippinensis li.), Eucommia bark (Cortex eu- commiae), Epimedium (Herba epimedii), two-tooth achyran- thes root (Radix achyranthis bidentatae), Radix codonopsis pi- losulae (Radix codonopsis), Chinese angelica (Radix angelicae	Zhang ZF 2011

Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

sinensis), Himalayan teasel root (Radix dipsaci), ground beetle

Chinese herbal medicines for treating osteoporosis (Review)



		sinensis), tortoise shell (Carapax et plastrum testudinis), tuber fleece flower root (Radix polygoni multiflori), Amur cork tree bark (Cortex phellodendri), Cortex lycii radicis (Cortex lycii), in- cised notopterygium rhizome (Rhizoma et radix notopterygii) and Radix angelicae pubescentis	
Shujinbogu tablet	Tablet	Manufactured by Dongwan Hospital of Traditional Chinese Medicine, composed of tree peony bark (Cortex moutan), rhubarb (Radix et rhizoma rhei), two-tooth achyranthes root (Radix achyranthis bidentatae), tuberculate Speranskia herb (Garden balsam stem), Szechuan lovage rhizome (Rhizoma chuanxiong), Chinese angelica (Radix angelicae sinensis), Rehmannia root (Radix rehmanniae), mulberry twig (Ramulus mori), ground beetle (Eupolyphaga seu steleophaga), common cnidium fruit (Fructus cnidii), common aucklandia root (Radix aucklandiae), Fortune's drynaria rhizome (Rhizoma drynariae) and Flos caryophyllata (Flos caryophylli)	Zhang ZF 2011
Zishen prescription	Decoction	Investigator-prescribed formula composed of Rehmanniae radix preparata, common macrocarpium fruit (Fructus corni), Dioscorea batatas (Rhizoma dioscoreae), Wolfiporia cocos (Po- ria), Barbary wolfberry fruit (Fructus lycii), tortoise shell glue (Colla carapacis et plastri testudinis), crude Dragon's bones (Os Draconis) and crude oyster shell (Concha ostreae)	Zhao G 2002
Kanggusong cap- sule	Capsule	Chinese patent medicine manufactured by Shenzhen Sanjiu medicine limited company, composed of hairy antler (Corn Cervi Pantotrichum), Epimedium (Herba epimedii), desert-liv- ing cistanche (Herba cistanches), Psoralea corylifolia (Fructus psoraleae), common cnidium fruit (Fructus cnidii), etc.	Zhao HX 2001
Yinyanghuo	Decoction	Single herb of Epimedium (Herba epimedii)	Zhao LN 2003
Jinwugutong cap- sule	Capsule	Chinese patent medicine manufactured by Guizhou Shen- qi Pharmaceutical limited company, composed of Epimedium (Herba epimedii), two-tooth achyranthes root (Radix achyran- this bidentatae), Cibotium barometz (Rhizoma cibotii), Zaocys dhumnade (Zaocys), Psoralea corylifolia (Fructus psoraleae), etc.	
Gushen Yijing tang	Decoction	Herbal mixture composed of Fortune's drynaria rhizome (Rhi- zoma drynariae), Psoralea corylifolia (Fructus psoraleae), Bar- bary wolfberry fruit (Fructus lycii), liquorice root (Radix gly- cyrrhizae), prepared rhizome of adhesive rehmannia (Radix rehmanniae preparata), white peony root (Radix paeoniae al- ba), glossy privet fruit (Fructus ligustri lucidi), Dioscorea batatas (Rhizoma dioscoreae), Wolfiporia cocos (Poria), Chinese date (Fructus jujubae), etc.	Zhong RQ 2007
Tongbu Qianggutang	Decoction	Herbal mixture composed of Epimedium (Herba epimedii), glossy privet fruit (Fructus ligustri lucidi), liquorice root (Radix glycyrrhizae), Sanqi (Radix notoginseng), wine rhubarb (Radix et rhizoma rhei), etc.	Zhou LZ 2001
Guilu Erxiantang	Decoction	Herbal mixture composed of tortoise shell (Carapax et plastrum testudinis), hairy antler (Corn Cervi Pantotrichum), Epimedi- um (Herba epimedii), clematis root (Radix clematidis), prepared rhizome of adhesive rehmannia (Radix rehmanniae prepara- ta), desert-living cistanche (Herba cistanches), medicinal Indian mulberry root (Radix morindae officinalis), liquorice root (Radix	Zhou XT 2001

Table 1. The preparation and composition of the Chinese herbal medicines in the included trials (Continued)

Chinese herbal medicines for treating osteoporosis (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



		glycyrrhizae), Radix codonopsis pilosulae (Radix codonopsis), Chinese angelica (Radix angelicae sinensis) and safflower (Flos carthami)	
Huangqi Sanxian tang	Decoction	Herbal mixture composed of common curculigo rhizome (Rhi- zoma curculiginis), Epimedium (Herba epimedii), liquorice root (Radix glycyrrhizae), Sanqi (Radix notoginseng), etc.	Zhou ZK 2006
Bushen Tianjing Huoxue therapy	Decoction	Herbal mixture composed of Eucommia bark (Cortex eucom- miae) 15 g, Himalayan teasel root (Radix dipsaci) 15 g, Chinese taxillus twig (Herba taxilli) 10 g, Epimedium (Herba epimedii) 15 g, Psoralea corylifolia (Fructus psoraleae) 15 g, common macro- carpium fruit (Fructus corni) 10 g, Danshen root (Radix salviae miltiorrhizae) 10g, suberect spatholobus stem (Caulis spatholo- bi) 30 g, Fortune's drynaria rhizome (Rhizoma drynariae) 30 g, two-tooth achyranthes root (Radix achyranthis bidentatae) 30 g, membranous milk vetch root (Radix astragali) 30 g, large- head atractylodes rhizome (Rhizoma atractylodis macrocepha- lae) 10 g, Wolfiporia cocos (Poria) 20 g and liquorice root (Radix glycyrrhizae) 5 g	Zhu HJ 2011
Guben Zhuanggu capsule	Capsule	Chinese patent medicine manufactured by Zhejiang Di'er medi-Zou J. cine limited company	
Bushen Zhuanggu Granule granules		Chinese patent medicine manufactured by Yifan Pharmacy Company of Guangdong Province, with the following seven herbal compounds: Epimedium (Herba epimedii), Rehmannia (Rehmannia), Dioscorea batatas (Rhizoma dioscoreae), Cor- nus officinalis (Fructus corni), Cinnamomum cassia (Cortex cin- namomi), Drynaria fortunei (Rhizoma drynariae) and Morinda officinalis (Radix morindae officinalis)	Deng WM 2012

APPENDICES

Appendix 1. MEDLINE search strategy

Database	Time span	Search strategy
MEDLINE	1966 to 2013	1. exp bone diseases, metabolic/
		2. osteoporos#s.tw.
		3. bone density/
		4. bone densit\$.tw.
		5. bone mineral densit\$.tw.
		6. exp bone/ and bones.mp. [mp=title, original title, abstract, name of sub-
		stance word, subject heading word]
		7. bone loss\$.tw.
		8. osteomalacia.tw.
		9. osteodystrophy.tw.
		10. exp bone demineralization, pathologic/
		11. (bone adj demineralization).tw.
		12. osteopenia.tw.
		13. bone mass.tw.
		14. exp densitometry/
		15. densitometry.tw.

Chinese herbal medicines for treating osteoporosis (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



- 16. dexa.tw.
- 17. exp fractures/
- 18. fracture\$.tw.
- 19. or/1-18
- 20. exp Medicine, Herbal/
- 21. exp Plants, Medicinal/
- 22. exp Medicine, Traditional/
- 23. exp Drugs, Chinese Herbal/
- 24. herb\$.tw.
- 25. plant.mp. or plants.tw. [mp=title, original title, abstract, name of sub-
- stance word, subject heading word]
- 26. phytomedicine.tw.
- 27. botanical.tw.28. weed\$.tw.
- 29. algae.tw.
- 30. (fungi or fungus).tw.
- 31. ((traditional or chinese or herbal) adj medicine).tw.
- 32. ((oriental or chinese) adj tradition\$).tw.
- 33. or/20-32
- 34. 19 and 33

Appendix 2. EMBASE search strategy

Database	Time span	Search strategy
EMBASE	1998 to 2013	1. exp OSTEOPOROSIS/
		2. exp Metabolic Bone Disease/
		3. osteoporo\$.tw.
		4. exp Bone Density/
		5. (bone adj2 densit\$).tw.
		6. exp BONE/
		7. bone loss.tw.
		8. osteomalacia.tw.
		9. osteodystrophy.tw.
		10. exp Bone Demineralization/
		11. (bone adj deminerali#ation).tw.
		12. osteopenia.tw.
		13. bone mass.tw.
		14. exp bone densitometry/
		15. densitometry.tw.
		16. dexa.tw.
		17. exp Fracture/
		18. fracture\$.tw.
		19. or/1-18
		20. exp Herbal Medicine/
		21. exp Medicinal Plant/
		22. exp Traditional Medicine/
		23. exp Chinese Medicine/
		24. herb\$.tw.
		25. (plant or plants).tw.
		26. phytomedicine.tw.
		27. botanical.tw.
		28. weed\$.tw.
		29. algae.tw.
		30. (fungi or fungus).tw.
		31. ((traditional or chinese or herbal) adj medicine).tw.



(Continued)

- 32. ((oriental or chinese) adj tradition\$).tw.
- 33. or/20-32
- 34. 19 and 33
- 35. random\$.ti,ab.
- 36. factorial\$.ti,ab.
- 37. (crossover\$ or cross over\$ or cross-over\$).ti,ab.
- 38. placebo\$.ti,ab.
- 39. (doubl\$ adj blind\$).ti,ab.
- 40. (singl\$ adj blind\$).ti,ab.
- 41. assign\$.ti,ab.
- 42. allocat\$.ti,ab.
- 43. volunteer\$.ti,ab.
- 44. crossover procedure.sh.
- 45. double blind procedure.sh.
- 46. randomized controlled trial.sh.
- 47. single blind procedure.sh.
- 48. or/35-47
- 49. exp animal/ or nonhuman/ or exp animal experiment/
- 50. exp human/
- 51. 49 and 50
- 52. 49 not 51
- 53. 48 not 52
- 54. 34 and 53

Appendix 3. CENTRAL search strategy

Database Time span	Search strategy
CENTRAL in The Cochrane Library Issue 12, 2012	Search strategy #1 MeSH descriptor Osteoporosis explode all trees in MeSH products #2 MeSH descriptor Bone Diseases, Metabolic explode all trees in MeSH products #3 osteoporo* in All Fields in all products #4 MeSH descriptor Bone Density explode all trees in MeSH products #5 bone near/j2 densit* in All Fields in all products #6 MeSH descriptor Bone and Bones explode all trees in MeSH products #7 bone loss in All Fields in all products #8 osteomalacia in All Fields in all products #9 osteodystrophy in All Fields in all products #10 MeSH descriptor Bone Demineralization, Pathologic explode all trees in MeSH products #11 bone next deminerali* in All Fields in all products #12 osteopenia in All Fields in all products #13 bone mass in All Fields in all products #14 MeSH descriptor Densitometry explode all trees in MeSH products #15 densitometry in All Fields in all products #16 dexa in All Fields in all products #17 MeSH descriptor Fractures, Bone explode all trees in MeSH products #19 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18) #20 MeSH descriptor Medicine, Herbal explode all trees in MeSH products #12 MeSH descriptor Medicine, Herbal explode all trees in MeSH products #13 MeSH descriptor Plants, Medicinal explode all trees in MeSH products #21 MeSH descriptor Plants, Medicinal explode all trees in MeSH products #22 MeSH descriptor Plants, Medicinal explode all trees in MeSH products #24 herb* in All Fields in all products

Chinese herbal medicines for treating osteoporosis (Review)

Copyright @ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



#26 phytomedicine in All Fields in all products
#27 botanical in All Fields in all products
#28 weed* in All Fields in all products
#29 algae in All Fields in all products
#30 fungi or fungus in All Fields in all products
#31 (traditional or chinese or herbal) next medicine in All Fields in all products
#32 (oriental or chinese) next tradition* in All Fields in all products
#33 (#20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32)
#34 (#19 AND #33)

Appendix 4. CBM search strategy

Database	Time span	Search strategy
СВМ	1979 to 2013	1 explode "osteoporosis"/cure of Chinese traditional medicine, the combina- tion of Western and traditional medicine 2 osteoporosis/tw 3 Chinese herbal medicine/tw 4 Chinese traditional medicine/tw 5 2 and (3 or 4) 6 1 or 5

Appendix 5. Effects of interventions on biochemical indicators

Chinese herbal medicines versus placebo (Comparison 01)

Oestradiol (E2) levels

Compared with the placebo group, those treated with Bushen Yigu soft extract after three months treatment had statistically significantly increased serum levels of oestradiol (mean difference (MD) 122.89 pg/ml; 95% confidence interval (CI) 92.97 to 152.81) (Analysis 1.3) (Wang XY 2000).

Chinese herbal medicines versus no intervention (Comparison 02)

Oestradiol (E2) levels

There was no significant difference in levels of serum or urinary oestradiol between Chinese herbal medicines (Bushen Shengsui principle (Analysis 2.2) (Liao L 2004), Yishen Zhuanggu mixture (Analysis 2.2) (Gong L 2001), Huoluo Gukang pills or Gushukang granule (Analysis 2.2) (Zhang YS 2003)) and no intervention after six months treatment.

Bone Gla protein (BGP) levels

Compared with the no intervention group, in those treated with Yishen Zhuanggu mixture or Shengu capsule there were no statistically significant effects on BGP after six months treatment (MD -1.00 μ g/L; 95% CI -6.15 to 4.15 and MD -5.10 μ g/L; 95% CI -10.63 to 0.43, respectively) (Analysis 2.3) (Gong L 2001). Those treated with Huoluo Gukang pills or Gushukang granule had statistically significant increases in BGP after six months treatment (MD 2.70 μ g/L; 95% CI 1.23 to 4.17 and MD 3.50 μ g/L; 95% CI 1.92 to 5.08, respectively) (Analysis 2.3) (Zhang YS 2003). Treatment with Shigu yin also increased BGP after six months treatment (MD 1.20 μ g/L; 95% CI 0.17 to 2.23) (Analysis 2.3) (Zhang YP 2007).

Chinese herbal medicines versus western medicine (Comparison 03)

Oestradiol (E2) levels

Nine trials showed positive effects of herbal treatments on serum or urinary measures of oestradiol when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

• Kanggusong granule versus Caltrate after nine months treatment (MD 11.00 pg/ml; 95% CI 6.97 to 15.03), Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD 12.17 pg/ml; 95% CI 8.27 to 16.07) (Analysis 3.5) (An SJ 2000);



- Strong Bone capsule versus Caltrate after three months treatment (MD 10.46 pg/ml; 95% CI 4.29 to 16.63) (Analysis 3.5) (Cui TH 1999);
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 8.78 pg/ml; 95% CI 0.92 to 16.64) (Analysis 3.5) (Ou L 2011);
- Qianggu soft extract versus calcium gluconate after six months treatment (MD 4.20 pg/ml; 95% CI 0.89 to 7.51) (Analysis 3.5) (Peng T 2002);
- Gumikang capsule versus calcium gluconate after six months treatment (MD 3.50 pg/ml; 95% CI 1.14 to 5.86) (Analysis 3.5) (Wang CC 2005);
- Yanghuo Sanzi tang versus Caltrate after six months treatment (MD 23.06 pg/ml; 95% CI 17.82 to 28.30) (Analysis 3.5) (Qiu RB 2004);
- Jingujian granule versus Caltrate after three months treatment (MD 4.85 pg/ml; 95% CI 4.56 to 5.14) (Analysis 3.5) (Li YH 2010);
- Qianggu paste versus calcium gluconate tablets after six months treatment (MD 4.20 pg/ml; 95% CI 1.79 to 6.61) (Analysis 3.5) (Wang H 2007);
- Bushen Huoxue capsule versus Caltrate plus Rocalirol after 12 months treatment (MD 2.13 pg/ml; 95% CI 0.42 to 3.84) (Analysis 3.5) (Zhang XJ 2008).

However, in the following two trials, Chinese herbal medicines did not show a significant effect:

- Bushen Qiangshen pill versus Caltrate (MD 6.71 pg/ml; 95% CI -2.28 to 15.70) (Analysis 3.5) (Mu G 2001a);
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (female MD 5.03 pg/ml; 95% CI -8.01 to 18.07; male MD 1.89 pg/ml; 95% CI -17.98 to 21.77) (Analysis 3.5) (Zhou LZ 2001).

Seven trials showed a better effect of Chinese herbal medicines when compared with western medicine:

- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets after six months treatment (MD 3.15 pg/ml; 95% CI 0.28 to 6.02) (Analysis 3.5) (He MT 2007);
- prescription for tonifying kidney versus ipriflavone (MD 14.00 pg/ml; 95% CI 3.68 to 24.32), kidney meridian sticking versus ipriflavone (MD 11.99 pg/ml; 95% CI 1.15 to 22.83), urinary bladder meridian sticking versus ipriflavone (MD 17.99 pg/ml; 95% CI 7.65 to 28.33), Gushukang granule versus ipriflavone (MD 13.98 pg/ml; 95% CI 3.90 to 24.06) after six months treatment (Analysis 3.5) (Wu MS 2007);
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD 5.09 pg/ml; 95% CI 2.81 to 7.37) (Analysis 3.5) (Wang JM 2008);
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD 5.83 pg/ml; 95% CI 4.21 to 7.45) (Analysis 3.5) (Li BL 2007);
- Jiangu recipe versus alendronate sodium tablets after 12 months treatment (MD 10.75 pg/ml; 95% CI 8.55 to 12.95) (Analysis 3.5) (Qiu RB 2008);
- Bushen Zhuanggu tang versus alendronate sodium tablets after three months treatment (MD 5.37 pg/ml; 95% CI 2.07 to 8.67) (Analysis 3.5) (Ling JY 2008);
- Bushen Yigu soft extract versus Alfacalcidol after three months treatment (MD 76.29 nmol/L; 95% CI 31.19 to 121.39) (Analysis 3.5) (Wang XY 2000).

However, another five trials found no significant difference between groups in levels of oestradiol:

- Bushen Shengsui principle versus conjugated oestrogens plus medroxyprogesterone after six months treatment (MD 4.00 pg/ml; 95% CI -3.92 to 11.92) (Analysis 3.5) (Liao L 2004);
- Gukang oral liquid versus alendronate after six months treatment (MD 3.90 pg/ml; 95% CI -6.64 to 14.44) (Analysis 3.5) (Shao M 2003);
- Kanggusong granule versus ipriflavone after three months treatment (MD 4.18 pg/ml; 95% CI -13.85 to 22.21) (Analysis 3.5) (Wu MS 2001);
- Gukang decoction versus alendronate sodium tablets after four months treatment (MD -0.65 pg/ml; 95% CI -9.04 to 7.74) (Analysis 3.5) (Chen X 2008);
- Gujian capsule versus alfacalcidol after six months treatment (MD 22.35 pg/ml; 95% CI -10.51 to 55.21) (Analysis 3.5) (Meng XD 2003).

One trial showed a worse effect of Chinese herbal medicine: Huangqi Sanxian tang versus nilestriol after three months treatment (MD -32.97 pg/ml; 95% CI -39.42 to -26.52) (Analysis 3.5) (Zhou ZK 2006).

Serum calcium (Ca) levels

In 12 trials comparing herbal treatments to calcium and vitamin D and, in one case, isoflavone, there were no significant differences between groups in changes in serum calcium:

- Kanggusong granule versus Caltrate after nine months treatment (MD -0.03 mmol/L; 95% CI -0.11 to 0.05) (Analysis 3.6) (An SJ 2000);
- Gushukang granule versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.02 mmol/L; 95% CI -0.10 to 0.06) (Analysis 3.6) (Chen ZX 2002);



- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD -0.01 mmol/L; 95% CI -0.05 to 0.03) (Analysis 3.6) (Ou L 2011);
- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.01 mmol/L; 95% CI -0.05 to 0.07) (Analysis 3.6) (Wang ZK 2004);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD 0.10 mmol/L; 95% CI -0.05 to 0.25) (Analysis 3.6) (Xie YM 1997);
- Shenyao capsules versus Caltrate after six months treatment (MD 0.02 mmol/L; 95% CI -0.08 to 0.12) (Analysis 3.6) (Chen NQ 2006);
- prescription for tonifying kidney versus ipriflavone (MD 0.00 mmol/L; 95% CI -0.05 to 0.05), kidney meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.06 to 0.04), urinary bladder meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.06 to 0.04), Gushukang granule versus ipriflavone (MD -0.02 mmol/L; 95% CI -0.07 to 0.03) after six months treatment (Analysis 3.6) (Wu MS 2007);
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD -0.02 mmol/L; 95% CI -0.06 to 0.02) (Analysis 3.6) (Wang JM 2008);
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.01 mmol/L; 95% CI -0.06 to 0.08) (Analysis 3.6) (Wang J 2007);
- Bushen Yangxue tang versus calcium gluconate after six months treatment (MD 0.13 mmol/L; 95% CI -0.00 to 0.26) (Analysis 3.6) (Zhan ML 2007);
- Erxian soup versus Caltrate after six months treatment (MD -0.02 mmol/L; 95% CI -0.25 to 0.21) (Analysis 3.6) (Wu JZ 2010);
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -0.02 mmol/L; 95% CI -0.10 to 0.06) (Analysis 3.6) (Zhou LZ 2001).

Patients treated with herbal formulae for three to six months showed significantly higher levels of serum calcium in six trials comparing herbal treatment with calcium supplementation, isoflavone supplementation or conjugated hormones:

- Gumikang capsule versus calcium gluconate after six months treatment (MD 1.40 mmol/L; 95% CI 1.39 to 1.41) (Analysis 3.6) (Wang CC 2005);
- Kanggusong granule versus ipriflavone after three months treatment (MD 0.10 mmol/L; 95% CI 0.03 to 0.17) (Analysis 3.6) (Wu MS 2001);
- Yinyanghuo versus conjugated oestrogens after three to six months treatment (MD 0.54 mmol/L; 95% CI 0.23 to 0.85) (Analysis 3.6) (Zhao LN 2003);
- Guli powder versus Caltrate after three months treatment (MD 0.09 mmol/L; 95% CI 0.02 to 0.16) (Analysis 3.6) (Lan ZX 2006);
- Gushen Yijing tang versus Caltrate after six months treatment (MD 0.23 mmol/L; 95% CI 0.11 to 0.35) (Analysis 3.6) (Zhong RQ 2007);
- Bushenjianpi Zhuangguyin versus Caltrate and calcitonin ampoule after 12 weeks (MD 0.74 mmol/L; 95% CI 0.66 to 0.82) (Analysis 3.6) (Zhang XG 2011).

Five trials reported statistically significantly lower levels of serum calcium in the group treated with Chinese herbal medicines compared to supplementation with calcium or calcium and vitamin D and, in one case, isoflavone plus Caltrate:

- Kanggusong granule versus ipriflavone plus Caltrate after nine months treatment (MD -0.09 mmol/L; 95% CI -0.17 to -0.01) (Analysis 3.6) (An SJ 2000);
- Strong Bone capsule versus Caltrate after three months treatment (MD -0.13 mmol/L; 95% CI -0.22 to -0.04) (Analysis 3.6) (Cui TH 1999);
- Qianggu soft extract versus calcium gluconate (MD -0.03 mmol/L; 95% CI -0.05 to -0.01) (Analysis 3.6) (Peng T 2002);
- Qianggu paste versus calcium gluconate tablets after six months treatment (MD -0.03 mmol/L; 95% CI -0.06 to -0.00) (Analysis 3.6) (Wang H 2007);
- Jiangu capsule versus Caltrate after 12 months treatment (MD -0.06 mmol/L; 95% CI -0.11 to -0.01) (Analysis 3.6) (Wang YZ 2008).

Phosphorus (P) levels

Eleven trials showed no significant effects of herbal treatments on phosphorus when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Kanggusong granule versus ipriflavone plus Caltrate (MD 0.06 mmol/L; 95% CI -0.03 to 0.15), Kanggusong granule versus Caltrate (MD -0.01 mmol/L; 95% CI -0.29 to 0.27) after nine months treatment (Analysis 3.7) (An SJ 2000);
- Gushukang granule versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD 0.01 mmol/L; 95% CI -0.09 to 0.11) (Analysis 3.7) (Chen ZX 2002);
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.00 mmol/L; 95% CI -0.15 to 0.15) (Analysis 3.7) (Ou L 2011);
- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.03 mmol/L; 95% CI -0.02 to 0.08) (Analysis 3.7) (Wang ZK 2004);
- Shenyao capsules versus Caltrate after six months treatment (MD -0.01 mmol/L; 95% CI -0.08 to 0.06) (Analysis 3.7) (Chen NQ 2006);
- Guli powder versus Caltrate after three months treatment (MD -0.05 mmol/L; 95% CI -0.13 to 0.03) (Analysis 3.7) (Lan ZX 2006);
- Gushen Yijing tang versus Caltrate after six months treatment (MD 0.04 mmol/L; 95% CI -0.09 to 0.17) (Analysis 3.7) (Zhong RQ 2007);



- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.02 mmol/L; 95% CI -0.05 to 0.09) (Analysis 3.7) (Wang J 2007);
- Jiangu capsule versus Caltrate after 12 months treatment (MD 0.09 mmol/L; 95% CI -0.20 to 0.38) (Analysis 3.7) (Wang YZ 2008);
- Erxian soup versus Caltrate after six months treatment (MD -0.03 mmol/L; 95% CI -0.20 to 0.14) (Analysis 3.7) (Wu JZ 2010);
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -0.01 mmol/L; 95% CI -0.12 to 0.10) (Analysis 3.7) (Zhou LZ 2001).

Three trials found no significant differences between groups for phosphorus when comparing herbal formulae to conventional western medicines:

- Kanggusong granule versus ipriflavone after three months treatment (MD -0.07 mmol/L; 95% CI -0.20 to 0.06) (Analysis 3.7) (Wu MS 2001);
- Yinyanghuo versus conjugated oestrogens after three to six months treatment (MD 0.13 mmol/L; 95% CI -0.13 to 0.39) (Analysis 3.7) (Zhao LN 2003);
- prescription for tonifying kidney versus ipriflavone (MD -0.04 mmol/L; 95% CI -0.15 to 0.07), kidney meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.13 to 0.11), urinary bladder meridian sticking versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.13 to 0.11), Gushukang granule versus ipriflavone (MD -0.01 mmol/L; 95% CI -0.13 to 0.11) after six months treatment (Analysis 3.7) (Wu MS 2007).

One trial showed better effects of Bushen Zhuanggu tang compared to alendronate sodium tablets after three months treatment (MD 0.24 mmol/L; 95% CI 0.10 to 0.38) (Analysis 3.7) (Ling JY 2008).

Two other trials showed worse effects of Chinese herbal medicines:

- Strong Bone capsule compared with Caltrate after three months treatment (MD -0.12 mmol/L; 95% CI -0.21 to -0.03) (Analysis 3.7) (Cui TH 1999);
- Bushenjianpi Zhuangguyin versus Caltrate and calcitonin ampoule after 12 weeks treatment (MD -0.37 mmol/L; 95% CI -0.48 to -0.26) (Analysis 3.7) (Zhang XG 2011).

Alkaline phosphatase (ALP) levels

Eleven trials showed no significant effects of herbal treatments on alkaline phosphatase when compared to calcium supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Gushukang granule versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.50 μmol s⁻¹/L; 95% CI -1.70 to 0.70) (Analysis 3.8) (Chen ZX 2002);
- Strong Bone capsule versus Caltrate after three months treatment (MD -0.07 µmol s⁻¹/L; 95% CI -0.25 to 0.11) (Analysis 3.8) (Cui TH 1999);
- Bushen Qiangshen pill versus Caltrate after three months treatment (MD 0.27 μmol s⁻¹/L; 95% CI -1.27 to 1.81) (Analysis 3.8) (Mu G 2001a);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD -0.29 μmol s⁻¹/L; 95% CI -1.67 to 1.09) (Analysis 3.8) (Xie YM 1997);
- Liuwei Dihuang pills versus calcium after 12 months treatment (MD 0.55 μmol s⁻¹/L; 95% CI -0.12 to 1.22) (Analysis 3.8) (Zhang J 2003);
- Guli powder versus Caltrate after three months treatment (MD 0.30 µmol s⁻¹/L; 95% CI -2.97 to 3.57) (Analysis 3.8) (Lan ZX 2006);
- Qianggu capsule versus active vitamin D3 after six months treatment (MD 0.71 μmol s⁻¹/L; 95% CI -1.17 to 2.59) (Analysis 3.8) (Wang J 2007);
- Jingujian granule versus Caltrate after three months treatment (MD 0.53 μmol s⁻¹/L; 95% CI -0.69 to 1.75) (Analysis 3.8) (Li YH 2008);
- Bushenjianpi Zhuangguyin versus Caltrate and calcitonin ampoule after 12 weeks treatment (MD -0.82 μmol s⁻¹/L; 95% CI -2.83 to 1.19) (Analysis 3.8) (Zhang XG 2011);
- Erxian soup versus Caltrate after six months treatment (MD 0.00 µmol s⁻¹/L; 95% CI -0.87 to 0.87) (Analysis 3.8) (Wu JZ 2010);
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD 0.18 μmol s⁻¹/L; 95% CI -1.08 to 1.44) (Analysis 3.8) (Zhou LZ 2001).

Twelve trials showed better effects of herbal treatments on alkaline phosphatase when compared to calcium supplementation, or calcium combined with vitamin D supplementation, or calcium combined with synthesised isoflavone (ipriflavone):

- Kanggusong granule versus ipriflavone plus Caltrate (MD 1.69 μmol s⁻¹/L; 95% CI 0.79 to 2.59), Kanggusong granule versus Caltrate (MD 1.28 μmol s⁻¹/L; 95% CI 0.30 to 2.26) after nine months treatment (Analysis 3.8) (An SJ 2000);
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.91 μmol s⁻¹/L; 95% CI 0.15 to 1.67) (Analysis 3.8) (Ou L 2011);
- Qianggu soft extract versus calcium gluconate after six months treatment (MD 3.60 μmol s⁻¹/L; 95% CI 2.62 to 4.58) (Analysis 3.8) (Peng T 2002);
- Gumikang capsule versus calcium gluconate after six months treatment (MD 3.41 μmol s⁻¹/L; 95% CI 2.84 to 3.98) (Analysis 3.8) (Wang CC 2005);

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



- Bushen Jianpi Migu prescription versus Caltrate after three months treatment (MD 0.10 μmol s⁻¹/L; 95% CI 0.01 to 0.19) (Analysis 3.8) (Wang ZK 2004);
- Liuwei Dihuang pills versus calcium after six months treatment (MD 0.43 µmol s⁻¹/L; 95% CI 0.11 to 0.75) (Analysis 3.8) (Zhang J 2003);
- TPF capsule versus calcium granule after six months treatment (MD 3.84 µmol s⁻¹/L; 95% CI 2.53 to 5.15) (Analysis 3.8) (Zhang YL 1996);
- Gushen Yijing tang versus Caltrate after six months treatment (MD 2.17 µmol s⁻¹/L; 95% CI 0.73 to 3.61) (Analysis 3.8) (Zhong RQ 2007);
- Jiangu capsule versus Caltrate after 12 months treatment (MD 2.04 μ mol s⁻¹/L; 95% CI 1.32 to 2.76) (Analysis 3.8) (Wang YZ 2008);
- Jingujian granule versus Caltrate after three months treatment (MD 2.40 μmol s⁻¹/L; 95% CI 2.21 to 2.59) (Analysis 3.8) (Li YH 2010);
- Qianggu paste versus calcium gluconate tablets after six months treatment (MD 3.60 μmol s⁻¹/L; 95% CI 2.86 to 4.34) (Analysis 3.8) (Wang H 2007);
- Bushen Yangxue tang versus calcium gluconate after six months treatment (MD 2.62 μmol s⁻¹/L; 95% CI 0.84 to 4.40) (Analysis 3.8) (Zhan ML 2007).

Seven trials showed no significant effects of herbal treatments on alkaline phosphatase when compared to conventional western medicines:

- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD -1.06 μmol s⁻¹/L; 95% CI -2.54 to 0.42) (Analysis 3.8) (Shao M 2003);
- Kanggusong granule versus ipriflavone after three months treatment (MD 0.13 μmol s⁻¹/L; 95% CI -0.07 to 0.33) (Analysis 3.8) (Wu MS 2001);
- Huangqi Sanxian tang versus nilestriol after three months treatment (MD -0.03 µmol s⁻¹/L; 95% CI -1.14 to 1.08) (Analysis 3.8) (Zhou ZK 2006);
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD 0.48 µmol s⁻¹/L; 95% CI -0.34 to 1.30) (Analysis 3.8) (Wang JM 2008);
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD 0.33 μmol s⁻¹/L; 95% CI -2.78 to 3.44) (Analysis 3.8) (Li BL 2007);
- Bushen Zhuanggu tang versus alendronate sodium tablets after three months treatment (MD -0.11 μmol s⁻¹/L; 95% CI -0.99 to 0.77) (Analysis 3.8) (Ling JY 2008);
- Gusong recipe versus alendronate sodium tablets after five months treatment (MD -1.05 μmol s⁻¹/L; 95% CI -2.86 to 0.76) (Analysis 3.8) (Xiao W 2008).

Another three trials showed a worse effect of herbal treatments when compared to calcium supplementation, hormones or alendronate sodium tablets:

- Shenyao capsules versus Caltrate after six months treatment (MD -2.40 μmol s⁻¹/L; 95% CI -3.58 to -1.22) (Analysis 3.8) (Chen NQ 2006);
- Yinyanghuo versus conjugated oestrogens after three to six months treatment (MD -7.00 μmol s⁻¹/L; 95% CI -11.17 to -2.83) (Analysis 3.8) (Zhao LN 2003);
- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets after six months treatment (MD -2.94 μmol s⁻¹/L; 95% CI -4.34 to 1.54) (Analysis 3.8) (He MT 2007).

Bone Gla protein (BGP) levels

One trial found that there was a significant difference in BGP between Chinese herbal and western medicines:

Acupoint sticking of Migudan versus oyster shell calcium chewable tablets after three months treatment (MD 1.55 μg/L; 95% CI 1.24 to 1.86) (Analysis 3.9) (Xu YL 2007).

Three trials showed a statistically significantly better effect on BGP when compared with calcium supplementation:

- Bushen Huoxue capsule versus Caltrate plus Rocalirol after 12 months treatment (MD 0.93 μg/L; 95% CI 0.35 to 1.51) (Analysis 3.9) (Zhang XJ 2008);
- Kanggusong capsule versus Caltrate after six months treatment (MD 1.78 µg/L; 95% CI 0.40 to 3.16) (Analysis 3.9) (Wei RY 2011);
- Liuwei Dihuang pills versus calcium after 12 months treatment (MD 17.90 μg/L; 95% CI 12.43 to 23.37) (Analysis 3.9) (Zhang J 2003).

Three trials showed no significant effects of herbal treatments on BGP when compared to western medicines:

- Gukang oral liquid versus alendronate after six months treatment (MD -0.10 μg/L; 95% CI -0.93 to 0.73) (Analysis 3.9) (Shao M 2003);
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD 0.49 μg/L; 95% CI -1.59 to 2.57) (Analysis 3.9) (Li BL 2007);



Jiangu recipe versus alendronate sodium tablets after 12 months treatment (MD 1.81 μg/L; 95% CI -0.31 to 3.93) (Analysis 3.9) (Qiu RB 2008).

Five trials showed no significant effects of herbal treatments when compared with calcium supplementation:

- Strong Bone capsule versus Caltrate after three months treatment (MD -0.49 μg/L; 95% CI -2.17 to 1.19) (Analysis 3.9) (Cui TH 1999);
- Yanghuo Sanzitang versus Caltrate after six months treatment (MD 2.71 μg/L; 95%CI -0.30 to 5.72) (Analysis 3.9) (Qiu RB 2004);
- Shigu yin versus Caltrate after six months treatment (MD 0.80 μg/L; 95% CI -0.34 to 1.94) (Analysis 3.9) (Zhang YP 2007);
- Jingujian granule versus Caltrate after three months treatment (MD 2.53 μg/L; 95% CI -0.38 to 5.44) (Analysis 3.9) (Li YH 2008);
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -1.50 μg/L; 95% CI -5.07 to 2.08) (Analysis 3.9) (Zhou LZ 2001).

Another trial showed a worse effect of Bushen Jianpi Huoxue recipe when compared to alendronate sodium tablets after six months treatment (MD -2.13 µg/L; 95% CI -2.74 to -1.52) (Analysis 3.9) (He MT 2007).

Interleukin-6 (IL-6) levels

There was no significant difference between herbal drugs and western medicine in interleukin-6 in three trials:

- Bushen Jianpi Huoxue recipe versus alendronate sodium tablets after six months treatment (MD -5.72 pg/ml; 95% CI -14.05 to 2.61) (Analysis 3.10) (He MT 2007);
- Gukang oral liquid versus alendronate sodium tablets after six months treatment (MD -3.50 pg/ml; 95% CI -15.93 to 8.93) (Analysis 3.10) (Shao M 2003);
- Jianshenfang granule versus alendronate sodium tablets after six months treatment (MD -12.56 pg/ml; 95% CI -29.26 to 4.14) (Analysis 3.10) (Li BL 2007).

Three trials showed statistically significantly better effects on interleukin-6:

- Jiangu recipe versus alendronate sodium tablets after 12 months treatment (MD -19.99 pg/ml; 95% CI -30.92 to -9.06) (Analysis 3.10) (Qiu RB 2008);
- Yanghuo Sanzi tang versus Caltrate after six months treatment (MD -20.29 pg/ml; 95% CI -35.67 to -4.91) (Analysis 3.10) (Qiu RB 2004);
- Bushen Huoxue capsule versus Caltrate plus Rocalirol (MD -18.70 pg/ml; 95% CI -34.16 to -3.24) (Analysis 3.10) (Zhang XJ 2008).

Parathyroid hormone (PTH) levels

Four trials showed no significant effects of herbal treatments on PTH when compared to common western medicines:

- prescription for tonifying kidney versus ipriflavone (MD -13.00 μg/L; 95% CI -41.67 to 15.67), kidney meridian sticking versus ipriflavone (MD -13.01 μg/L; 95% CI -41.95 to 15.93), urinary bladder meridian sticking versus ipriflavone (MD -3.01 μg/L; 95% CI -31.44 to 25.42), Gushukang granule versus ipriflavone (MD -3.02 μg/L; 95% CI -30.91 to 24.87) after six months treatment (Analysis 3.11) (Wu MS 2007);
- Kanggusong granule versus ipriflavone after three months treatment (MD 11.81 μg/L; 95% CI -14.64 to 38.26) (Analysis 3.11) (Wu MS 2001);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet after six months treatment (MD -10.63 μg/L; 95% CI -140.92 to 119.66) (Analysis 3.11) (Xie YM 1997);
- Gujian capsule versus alfacalcidol after six months treatment (MD -22.57 pg/ml; 95% CI -60.92 to 15.78) (Analysis 3.11) (Meng XD 2003);
- Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD -2.06 pg/ml; 95% CI -6.74 to 2.62) (Analysis 3.11) (Ou L 2011).

In another trial, TPF capsule showed a better effect than calcium granule after six months treatment (MD -254.00 pg/ml; 95% CI -399.06 to -108.94) (Analysis 3.11) (Zhang YL 1996).

Calcitonin (CT) levels

Five trials showed no significant effects of herbal treatments on calcitonin when compared to common western medicines:

- prescription for tonifying kidney versus ipriflavone (MD 0.96 ng/L; 95% CI -3.71 to 5.63), kidney meridian sticking versus ipriflavone (MD -1.01 ng/L; 95% CI -5.44 to 3.42), urinary bladder meridian sticking versus ipriflavone (MD -0.01 ng/L; 95% CI -4.68 to 4.66), Gushukang granule versus ipriflavone (MD -0.01 ng/L; 95% CI -4.44 to 4.42) after six months treatment (Analysis 3.12) (Wu MS 2007);
- Bugu Shengsui capsule versus vitamin D2 plus calcium tablet (MD 15.93 ng/L; 95% CI -24.16 to 56.02) (Analysis 3.12) (Xie YM 1997);
- Tongbu Qianggutang versus calcium plus vitamin D3 after three months treatment (MD -6.18 ng/L; 95% CI -12.89 to 0.52) (Analysis 3.12) (Zhou LZ 2001);
- Gujian capsule versus alfacalcidol after six months treatment (MD -12.77 ng/L; 95% CI -70.92 to 45.38) (Analysis 3.12) (Meng XD 2003);



Radix rehmanniae preparata and Radix astragali versus calcium carbonate tablets after six months treatment (MD 0.11 ng/L; 95% CI -0.04 to 0.26) (Analysis 3.12) (Ou L 2011).

Three trials showed a statistically significantly better effect on calcitonin when compared with calcium supplementation:

- Strong Bone capsule versus Caltrate after three months treatment (MD 16.25 ng/L; 95% CI 10.43 to 22.07) (Analysis 3.12) (Cui TH 1999);
- Jingujian granule versus Caltrate after three months treatment (MD 21.98 ng/L; 95% CI 17.01 to 26.95) (Analysis 3.12) (Li YH 2010)
- TPF capsule versus calcium granule after six months treatment (MD 17.71 ng/L; 95% CI 11.53 to 23.89) (Analysis 3.12) (Zhang YL 1996).

Chinese herbal medicines plus western medicine versus western medicine (Comparison 04)

Oestradiol (E2) levels

Eight trials showed positive effects of Chinese herbal medicines plus western medicine treatments on E2 when compared to the same western medicines:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol after six months treatment (MD 4.54 pg/ml; 95% CI 0.47 to 8.61) (Analysis 4.6) (Chen FS 2001);
- Shugan zishen huoxue tang plus Caltrate and alendronate sodium tablets versus Caltrate and alendronate sodium tablets after six months treatment (MD 26.99 pg/ml; 95% CI 18.44 to 35.54) (Analysis 4.6) (Han XL 2007);
- Ziyin Bushen Zhuanggu prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin after eight months treatment (MD 23.21 pg/ml; 95% CI 14.46 to 31.96) (Analysis 4.6) (Li HW 2004);
- Zhuanggu capsule plus Caltrate versus Caltrate after six months treatment (MD 4.06 pg/ml; 95% CI 2.56 to 5.56) (Analysis 4.6) (Li SL 2004);
- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD 11.00 pg/ml; 95% CI 8.14 to 13.86) (Analysis 4.6) (Wang SW 2003);
- Zishen prescription plus Caltrate and calcitonin versus Caltrate plus calcitonin (MD 23.21 pg/ml; 95% CI 14.46 to 31.96) (Analysis 4.6) (Zhao G 2002);
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD 6.04 pg/ml; 95% CI 4.61 to 7.47) (Analysis 4.6) (Zhang XZ 2004);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 40.85 pg/ml; 95% CI 33.61 to 48.09) (Analysis 4.6) (Zhang RH 2004).

Compared with Caltrate alone, Bushen Qiangshen pill plus Caltrate did not have significant effect on oestradiol (MD 7.60 pg/ml; 95% CI -0.51 to 15.71) (Analysis 4.6) (Mu G 2001).

Serum calcium (Ca) levels

Three trials showed positive effects of Chinese herbal medicines plus western medicine treatments on calcium when compared to the same western medicines:

- Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 0.37 mmol/L; 95% CI 0.32 to 0.42) (Analysis 4.7) (Zhang DS 2011);
- Chinese medicine (combinations of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 0.37 mmol/L; 95% CI 0.32 to 0.42) (Analysis 4.7) (Cao W 2010);
- Huangqi plus Caltrate versus Caltrate after six months treatment (MD 0.28 mmol/L; 95% CI 0.11 to 0.45) (Analysis 4.7) (Yang B 2007).

While Yigu capsule plus calcium versus placebo plus calcium had a negative effect on calcium after six months treatment (MD -0.07 mmol/L; 95% CI -0.13 to -0.01) (Analysis 4.7) (Zhang RH 2004).

Eight trials did not show positive effects of herbal treatments plus western medicines when compared to the same western medicines:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol after six months treatment (MD 0.05 mmol/L; 95% CI -0.02 to 0.12) (Analysis 4.7) (Chen FS 2001);
- Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.01 mmol/L; 95% CI -0.09 to 0.07) (Analysis 4.7) (Chen ZX 2002);
- Zhuanggu capsule plus Caltrate versus Caltrate after six months treatment (MD 0.01 mmol/L; 95% CI -0.07 to 0.09) (Analysis 4.7) (Li SL 2004);
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD -0.02 mmol/L; 95% CI -0.06 to 0.02) (Analysis 4.7) (Ma CZ 2011);
- Antai capsule plus Caltrate versus Caltrate after six months treatment (MD -0.03 mmol/L; 95% CI -0.09 to 0.03) (Analysis 4.7) (Wang SW 2003);

Copyright $\ensuremath{\mathbb S}$ 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.



- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD -0.05 mmol/L; 95% CI -0.11 to 0.01) (Analysis 4.7) (Zheng WK 2007);
- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.03 mmol/L; 95% CI -0.09 to 0.15) (Analysis 4.7) (Dong Y 2010)
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD -0.02 mmol/L; 95% CI -0.10 to 0.06) (Analysis 4.7) (Zhang ZF 2011).

Phosphorus (P) levels

Nine trials did not show positive effects of herbal treatments plus western medicines when compared to the same western medicines:

- Gushen decoction plus Caltrate and Alfacalcidol versus Caltrate and Alfacalcidol (MD -0.13 mmol/L; 95% CI -0.27 to 0.01) (Analysis 4.8) (Chen FS 2001);
- Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.02 mmol/L; 95% CI -0.11 to 0.07) (Analysis 4.8) (Chen ZX 2002);
- Zhuanggu capsule plus Caltrate versus Caltrate (MD 0.01 mmol/L; 95% CI -0.06 to 0.08) (Analysis 4.8) (Li SL 2004);
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD 0.06 mmol/L; 95% CI -0.22 to 0.34) (Analysis 4.8) (Ma CZ 2011);
- Antai capsule plus Caltrate versus Caltrate (MD -0.01 mmol/L; 95% CI -0.23 to 0.21) (Analysis 4.8) (Wang SW 2003);
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD -0.02 mmol/L; 95% CI -0.09 to 0.05) (Analysis 4.8) (Zheng WK 2007);
- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.01 mmol/L; 95% CI -0.12 to 0.14) (Analysis 4.8) (Dong Y 2010);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD -0.03 mmol/L; 95% CI -0.08 to 0.02) (Analysis 4.8) (Zhang RH 2004);
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD -0.02 mmol/L; 95% CI -0.08 to 0.04) (Analysis 4.8) (Zhang ZF 2011).

Alkaline phosphatase (ALP) levels

Seven trials did not show significant effects of herbal treatments plus western medicines on alkaline phosphatase levels when compared to the same western medicines:

- Gushukang granule plus Calcium carbonate with vitamin D chewable tablets versus Calcium carbonate with vitamin D chewable tablets after six months treatment (MD -0.50 μmol s⁻¹/L; 95% CI -1.70 to 0.70) (Analysis 4.9) (Chen ZX 2002);
- Zhuanggu capsule plus Caltrate versus Caltrate after six months treatment (MD 0.00 μmol s⁻¹/L; 95% CI -1.55 to 1.55) (Analysis 4.9) (Li SL 2004);
- Yiyuanjiangu decoction plus calcitonin ampoule and calcium carbonate tablet versus calcitonin ampoule and calcium carbonate tablet after three months treatment (MD 0.31 μmol s⁻¹/L; 95% CI -0.48 to 1.10) (Analysis 4.9) (Ma CZ 2011);
- Bushen Qiangshen pill plus Caltrate versus Caltrate after three months treatment (MD -0.31 μmol s⁻¹/L; 95% CI -1.72 to 1.10) (Analysis 4.9) (Mu G 2001);
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD 1.01 μmol s⁻¹/L; 95% CI -0.04 to 2.06) (Analysis 4.9) (Zheng WK 2007);
- Chinese medicine (combinations of 10 herbs) plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD -0.26 μmol s⁻¹/L; 95% CI -1.64 to 1.12) (Analysis 4.9) (Cao W 2010);
- Zhuangguqiangjin tablet and Shujinbogu tablet plus calcitonin ampoule versus calcitonin ampoule after 12 months treatment (MD 0.08 μmol s⁻¹/L; 95% CI -0.54 to 0.70) (Analysis 4.9) (Zhang ZF 2011).

Six trials showed that herbal drugs plus western medicine could increase the alkaline phosphatase level when compared with the same western medicine:

- Antai capsule plus Caltrate versus Caltrate regarding alkaline phosphatase before and after six months treatment (MD 1.28 μmol s⁻¹/L; 95% CI 0.55 to 2.01) (Analysis 4.9) (Wang SW 2003);
- Chinese decoction plus calcium gluconate versus calcium gluconate after nine months treatment (MD 1.77 μmol s⁻¹/L; 95% CI 1.20 to 2.34) (Analysis 4.9) (Miu JQ 2008);
- Bushenyiqihuoxue soup plus tamoxifen and Caltrate versus tamoxifen and Caltrate after three months treatment (MD 3.54 μmol s⁻¹/L; 95% CI 1.68 to 5.40) (Analysis 4.9) (Zhang DS 2011);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 1.73 μmol s⁻¹/L; 95% CI 0.71 to 2.75) (Analysis 4.9) (Zhang RH 2004);

Chinese herbal medicines for treating osteoporosis (Review) Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

- Huangqi plus Caltrate versus Caltrate after six months treatment (MD 0.82 μmol s⁻¹/L; 95% Cl 0.63 to 1.01) (Analysis 4.9) (Yang B 2007);
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks (MD 10.48 μmol s⁻¹/L; 95% CI 9.81 to 11.15) (Analysis 4.9) (Zhang XZ 2004).

Two trials showed the opposite effect:

- Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD -0.99 μmol s⁻¹/L; 95% CI -1.52 to -0.46) (Analysis 4.9) (Dong Y 2010);
- Kanggusong soup plus Caltrate versus Caltrate after three months treatment (MD -1.61 μmol s⁻¹/L; 95% CI -3.17 to -0.05) (Analysis 4.9) (Li ZP 2011).

Bone Gla protein (BGP) levels

One trial showed a better effect of herbal drugs plus western medicine:

- Zhuanggu capsule plus Caltrate versus Caltrate (MD -2.30 μg/L; 95% CI -4.07 to -0.53) (Analysis 4.10) (Li SL 2004).

Seven trials showed a worse effect of herbal drugs plus western medicine:

- Traditional Chinese capsule plus calcium gluconate versus calcium gluconate after nine months treatment (MD 1.23 μg/L; 95% CI 0.88 to 1.58) (Analysis 4.10) (Miu JQ 2008);
- Jinwugutong capsule plus calcium versus placebo plus calcium after six months treatment (MD 2.47 μg/L; 95% CI 1.44 to 3.50) (Analysis 4.10) (Zheng WK 2007);
- Yigu capsule plus calcium versus placebo plus calcium after six months treatment (MD 2.60 μg/L; 95% CI 1.66 to 3.54) (Analysis 4.10) (Zhang RH 2004);
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD 6.24 μg/L; 95% CI 5.69 to 6.79) (Analysis 4.10) (Zhang XZ 2004);
- Xianlinggubao capsules plus Caltrate versus Caltrate after 12 months treatment (MD 1.85 μg/L; 95% CI 0.87 to 2.83) (Analysis 4.10) (Wu W 2005);
- Huangqi plus Caltrate versus Caltrate after six months treatment (MD 0.63 μg/L; 95% CI 0.50 to 0.76) (Analysis 4.10) (Yang B 2007).

There was no significant difference between Xianlinggubao capsule plus salmon calcitonin and Caltrate versus salmon calcitonin plus Caltrate after three months treatment (MD 0.56 μ g/L; 95% CI -0.30 to 1.42) (Analysis 4.10) (Dong Y 2010).

Interleukin-6 (IL-6) levels

Three trials showed a better effect of herbal drugs plus western medicine on interleukin-6:

- Erxian Yanggu tang plus alendronate sodium tablets versus alendronate sodium tablets (MD -16.18 pg/ml; 95% CI -19.62 to -12.74) (Analysis 4.11) (Huang JW 2008);
- Kanggusong soup plus Caltrate versus Caltrate after three months treatment (MD -16.32 pg/ml; 95% CI -31.60 to -1.04) (Analysis 4.11) (Li ZP 2011);
- Xianlinggubao capsule plus vitamin D3 and calcium amino acid chelate versus vitamin D3 and calcium amino acid chelate after 48 weeks treatment (MD -133.30 pg/ml; 95% CI -139.94 to -126.66) (Analysis 4.11) (Zhang XZ 2004).

HISTORY

Protocol first published: Issue 3, 2005 Review first published: Issue 3, 2014

Date	Event	Description
26 August 2008	Amended	Converted to new review format. C041-R

CONTRIBUTIONS OF AUTHORS

Y Liu: drafted the protocol, developed the search strategy, selected trials, assessed trial quality, extracted data, performed data analyses and drafted the review.



Y Xia: updated the searches and selected trials, assessed trial quality, extracted data, performed data analyses and co-developed the review.

JP Liu: conceived the study, revised the protocol and the review, provided a methodological perspective and performed data analyses.

DECLARATIONS OF INTEREST

We certify that we have no affiliations with or involvement in any organisation or entity with a direct financial interest in the subject matter of the review (e.g. employment, consultancy, stock ownership, honoraria, expert testimony).

SOURCES OF SUPPORT

Internal sources

- School of Public Health, Shandong University, China.
- Beijing University of Chinese Medicine, China.

External sources

- National Basic Research Program ('973' program, grant number 2006CB504602), China.
- International Science & Technology Cooperation Project (grant number 2009DFA31460), China.
- The Program for Innovative Research Team of Beijing University of Chinese Medicine (no. 2011-CXTD-09), China.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

Chinese diagnostic criteria for osteoporosis were added, besides the WHO criteria, as many trials used the Chinese criteria (these were adapted from the WHO criteria).

INDEX TERMS

Medical Subject Headings (MeSH)

Bone Density Conservation Agents [therapeutic use]; Drugs, Chinese Herbal [*therapeutic use]; Osteoporosis [*drug therapy]; Phytotherapy [*methods]; Randomized Controlled Trials as Topic

MeSH check words

Humans